

[illegible]

[illegible]

additional revenue and avoiding potential business disruption due to the macroeconomic environment and geopolitical instability, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has taken the following steps to capitalize the business:—On April 14, 2023, the Company entered into a sales agreement with AGP, pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to \$5.8 million, to or through AGP, as sales agent (the “AGP 2023 Sales Agreement”). The sale of our shares of common stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the registration statement (the “2023 Registration Statement”) on Form S-3 (File No. 333-271277), filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023. On April 8, 2024, we filed a prospectus supplement to our prospectus dated April 25, 2023 registering the offer and sale of up to \$1,061,478A of shares of our common stock (the “April 2024 Prospectus Supplement”). As of the date the condensed consolidated financial statements were issued, the Company has approximately \$3.7 million available for future sales pursuant to the 2023 Registration Statement, which includes approximately \$1.0A million of remaining availability pursuant to the April 2024 Prospectus Supplement. See Note 7 Stockholders’ Equity, AGP 2023 Sales Agreement, for further discussion. Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company’s ability to continue as a going concern for the next twelveA months from the date these condensed consolidated financial statements were issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern over the next twelveA months from the date of issuance of this Quarterly Report FormA 10-Q.2. SUMMARY OF GAAP ACCOUNTING POLICIESBasis of Presentation. The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to a 1-for-20 reverse stock split which was effected on September 21, 2023, unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements. As of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated financial statements are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for theA year ended DecemberA 31, 2023 contained in our Annual Report on FormA 10-K, filed with the SEC on March 29, 2024. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscalA year 2024.Recently Adopted Accounting Pronouncements.In June 2022, the Financial Accounting Standards Board (the “FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures 10 Table of Contentsfor equity securities subject to contractual sale restrictions. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.In August 2020, the FASB issued ASU 2020-06A “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingA Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.A This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related earnings per share (“EPS”) guidance for both Subtopics. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.Recent Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09A “Income Taxes (Topic 740)”Improvements to Income Tax Disclosures (“ASU 2023-09A”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company’s financial position, results of operations or cash flow.Loss Per Share.Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive to the net loss.The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:ASU 2023-09A “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingA Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.A This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related earnings per share (“EPS”) guidance for both Subtopics. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.Recent Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09A “Income Taxes (Topic 740)”Improvements to Income Tax Disclosures (“ASU 2023-09A”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company’s financial position, results of operations or cash flow.Loss Per Share.Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive to the net loss.The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:ASU 2023-09A “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingA Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.A This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related earnings per share (“EPS”) guidance for both Subtopics. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.Recent Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09A “Income Taxes (Topic 740)”Improvements to Income Tax Disclosures (“ASU 2023-09A”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company’s financial position, results of operations or cash flow.Loss Per Share.Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive to the net loss.The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:ASU 2023-09A “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingA Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.A This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related earnings per share (“EPS”) guidance for both Subtopics. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.Recent Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09A “Income Taxes (Topic 740)”Improvements to Income Tax Disclosures (“ASU 2023-09A”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company’s financial position, results of operations or cash flow.Loss Per Share.Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive to the net loss.The following table summarizes the outstanding securities not included in the computation of diluted net loss

nine months ended September 30, 2024 and 2023, respectively. These costs are primarily related to long-term operating leases for the Company’s facilities and laboratory equipment. Short-term and variable lease costs were less than \$0.1 million for the three and nine months ended September 30, 2024 and 2023, respectively. Finance Lease Costs Finance lease amortization and interest expenses are included in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023. The balances within these accounts are less than \$0.1 million, respectively. 7. STOCKHOLDERS’ EQUITY Common Stock Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance. On December 20, 2018, the Company’s shareholders approved the proposal to authorize the Company’s Board of Directors to, in its discretion, amend the Company’s Third Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 150,000,000 shares to 250,000,000 shares. The Company has not yet implemented this increase. During the three and nine months ended September 30, 2024, the Company issued 12,593 and 50,186A shares of its common stock, respectively, in connection with consulting services of approximately \$0.1 million and \$0.3A million, respectively. At The Market Offering Agreement’s AGP Sales Agreement: On April 2, 2021, the Company entered into a sales agreement with A.G.P./Alliance Global Partners (the AGP), pursuant to which the Company was permitted to offer and sell its common stock, par value \$0.01 per share (the Common Stock), having aggregate sales proceeds of up to \$22.0 million. Shares can be sold either directly to or through AGP as a sales agent (the AGP Sales Agreement), from time to time, in an eat the market offering (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the Shares (the 2021 ATM Offering). The Company is limited in the number of shares it can sell in the 2021 ATM Offering due to the offering limitations currently applicable to the Company under General Instruction I.B.6, of Form S-3 and the Company’s public float as of the applicable date of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the AGP Sales Agreement. The sale of our shares of Common Stock to or through AGP, will be made pursuant to the registration statement (the Registration Statement) on Form S-3 (File No. 333-237445), which was declared effective by the SEC on April 13, 2020, for an aggregate offering price of up to \$50.0 million. A Under the AGP Sales Agreement, Shares were permitted to be sold by any method permitted by law deemed to be an eat the market offering. AGP will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the AGP Sales Agreement, AGP was required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and 16 Table of Contents the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. AGP is not under any obligation to purchase any of the Shares on a principal basis pursuant to the AGP Sales Agreement, except as otherwise agreed by AGP and the Company in writing and expressly set forth in a placement notice. AGP’s obligations to sell the Shares under the AGP Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions. The Company is not obligated to make any sales of Shares under the AGP Sales Agreement and any determination by the Company to do so will be dependent, among other things, on market conditions and the Company’s capital raising needs. A The Company agreed to pay AGP a cash fee of 3.0% of the aggregate gross proceeds from the sale of the Shares on the Company’s behalf pursuant to the AGP Sales Agreement. The AGP Sales Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has provided AGP with customary indemnification and contribution rights. The Company also agreed to reimburse AGP for certain specified expenses, including the expenses of counsel to AGP. During the three and nine months ended September 30, 2023, we received net proceeds of zero and \$0.5 million from the sale of zero and 30,827 shares of common stock through the AGP Sales Agreement. As of the date of issuance of this Quarterly Report on Form 10-Q, we have received an aggregate of \$15.6 million in net proceeds, after issuance costs of approximately \$0.5 million, from the sale of 260,128 shares of common stock pursuant to the AGP Sales Agreement. The offering of the Shares pursuant to the AGP Sales Agreement terminated upon the expiration of the Company’s Registration Statement on Form S-3 (File No. 333-237445). AGP 2023 Sales Agreement: On April 14, 2023, the Company entered into the AGP 2023 Sales Agreement, in an eat the market offering (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the shares of Common Stock. AGP will be entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares of Common Stock pursuant to the AGP 2023 Sales Agreement. The sale of our shares of Common Stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the 2023 Registration Statement on Form S-3 (File No. 333-271277), filed by the Company with the SEC on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023, for an aggregate offering price of up to \$5.8 million. On April 8, 2024, we filed a prospectus supplement (the April 2024 Prospectus Supplement) to our prospectus dated April 25, 2023 registering the offer and sale of up to \$1,061,478A of shares of our common stock. During the three and nine months ended September 30, 2023, we received net proceeds of zero and less than \$1A thousand, respectively, from the sale of zero and 25A shares of common stock, respectively, pursuant to the AGP 2023 Sales Agreement. During the three and nine months ended September 30, 2024, we received net proceeds of zero and \$0.1 million, respectively, from the sale of zero and 11,822 shares of common stock, respectively, pursuant to the AGP 2023 Sales Agreement. We have approximately \$1.0A million of remaining availability pursuant to the 2024 Prospectus Supplement. Registered Direct Offering: On June 8, 2023, the Company, entered into a securities purchase agreement (the Purchase Agreement) with certain institutional investors (the Purchasers), pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the Registered Direct Offering), an aggregate of: (i) 206,250 shares (the Shares) of its common stock, \$0.01 par value (the Common Stock), at a price of \$9.00 per share, and (ii) pre-funded warrants (the Pre-Funded Warrants) to purchase up to 15,972 shares of Common Stock, at a price of \$8.98 per Pre-Funded Warrant. The Company reviewed the provisions of the Pre-Funded Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet 17 Table of Contents date. The Pre-Funded Warrants are immediately exercisable, have an exercise price of \$0.02 per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. All of the Pre-Funded Warrants were exercised during the year ended December 31, 2023 and no Pre-Funded Warrants were outstanding as of September 30, 2024. In a concurrent private placement (the Private Placement) and together with the Registered Direct Offering, (the Offering), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, for no additional consideration, warrants (the RDO Common Warrants) and, together with the Shares and the Pre-Funded Warrants, (the Securities) to purchase up to 444,444 shares of Common Stock. The Company reviewed the provisions of the RDO Common Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of \$12.60 per share, and will expire December 12, 2028. The fair value of the RDO Common Warrants of approximately \$3.5 million at the date of issuance was estimated using the Black-Scholes model which used the following inputs: term of 5 years; risk free rate of 3.89%; volatility of 143%; and share price of \$9.00 per share based on the trading price of the Company’s common stock. The Company allocated \$1.3 million of the issuance proceeds to the RDO Common Warrants based on the relative fair value of the RDO Common Warrants, Common Stock and Pre-Funded Warrants issued in the Offering. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The Registered Direct Offering resulted in gross proceeds to the Company of approximately \$2.0 million. The net proceeds to the Company from the Registered Direct Offering are approximately \$1.8 million, excluding any proceeds that may be received upon the cash exercise of the RDO Common Warrants, after deducting the financial advisor’s fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Registered Direct Offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments and others. A The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions. Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements (the Lock-Up Agreements), agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, during the 90-day period following the closing of the Registered Direct Offering. The Purchase Agreement also requires the Company to use commercially reasonable efforts to file a registration statement with the SEC to register the resale by the Purchasers of the shares of Common Stock issuable upon exercise of the RDO Common Warrants within thirty (30) days of the date of the Purchase Agreement. The Company filed this registration statement on Form S-1 (File No. 333-273172), which was declared effective by the SEC on July 19, 2023. A On June 7, 2023, the Company also entered into a financial advisory agreement (the Financial Advisor Agreement) with A.G.P./Alliance Global Partners (the Financial Advisor). Pursuant to the terms of the Financial Advisor Agreement, the Financial Advisor agreed to use its reasonable best efforts to arrange for the sale of the Securities. The Company paid the Financial Advisor a cash fee of \$140,000 generated from the sale of the Shares and Pre-Funded Warrants. A The Financial Advisor Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Financial Advisor, including for liabilities under the Securities Act of 1933, as amended (the Securities Act), other obligations of the parties, and termination provisions. Pursuant to the Purchase Agreement, the Company has agreed that, subject to certain exceptions, (i) it will not issue any shares of common stock or securities exercisable or convertible into shares of common stock or to file any registration statement or amendment or supplement thereto for a period of ninety (90) days following the closing of the 18 Table of Contents Offering and that (ii) it will not enter into a variable rate transaction for a period of one hundred eighty (180) days following the closing of the Offering. A The Registered Direct Offering was made pursuant to the 2023 Registration Statement, as supplemented by a prospectus supplement dated June 9, 2023. As a result of sales already made under the AGP 2023 Sales Agreement and the Registered Direct Offering, the Company has \$3.7 million of remaining availability under the 2023 Registration Statement. Preferred Stock The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. Series A B Preferred Stock The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A B Convertible Preferred Stock (the Series A B Preferred Stock) with the State of Delaware, which designates 6,900 shares of our preferred stock as Series A B Preferred Stock. The Series A B Preferred Stock has a stated value of \$1 thousand per share and a par value of \$0.01 per share. The Series A B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering consisting of the Company’s Series A B Preferred Stock and warrants. The conversion price of the Series A B Preferred Stock contains a down round feature. The Company will recognize the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation. There were no conversions of Series A B Preferred Stock during the three and nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and December 31, 2023, the Company had 6,900 shares of Series A B Preferred Stock designated and issued and 47 shares of Series A B Preferred Stock outstanding. Based on the stated value of \$1 thousand per share and a conversion price of \$8.00 per share, the outstanding shares of Series B Preferred Stock at September 30, 2024 were convertible into 5,875 shares of common stock. Common Stock Warrants The following represents a summary of the warrants outstanding as of September 30, 2024: 444,444 (1) These warrants were issued in connection with the 2023 registered direct offering and concurrent private placement and are the RDO common warrants discussed below. During the three and nine months ended September 30, 2023, 5,593 and 13,012A warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2018. During the three and nine months ended September 30, 2024, a zero and 15,091A warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2019. RDO Common Warrants. In connection with the Registered Direct Offering and concurrent private placement in June 2023, the Company issued 444,444 RDO Common Warrants to purchase up to 444,444 shares of Common Stock. 19 Table of Contents The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of \$12.60 per share, and will expire December 12, 2028. FAIR VALUE FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements. FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; A and Level 3 Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability. Common Stock Warrant Liabilities. Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated statements of operations. Bridge Note Warrant Liabilities During 2018 and 2019, the Company issued warrants in connection with the issuance of convertible notes. All of these warrants issuances were classified as warrant liabilities (the Bridge Note Warrant Liabilities). The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black Scholes model. During the nine months ended September 30, 2024, the last remaining warrants related to Bridge Note Warrant Liabilities expired and thus at September 30, 2024 there were no warrant liabilities to be valued. As of December 31, 2023, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 0.4 years; volatility rate of 71% to 77%; and risk free rate of 5.33% to 5.40%. During the three and nine months ended September 30, 2024, the changes in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were zero. During the three and nine months ended September 30, 2023, the changes in the fair value of the warrant liabilities were less than \$1 thousand, respectively. EQUITY INCENTIVE PLAN The Company currently issues stock awards under its 2017 Stock Option and Incentive Plan, as amended (the 2017 Plan) which will expire on June 5, 2027. The shares authorized for issuance under the 2017 Plan were 320,699 at September 30, 2024, of which 14,705 were available for future grant. The shares authorized under the 2017 Plan are subject to annual increases on January 1 by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares determined by the Company’s Board of Directors or Compensation Committee. During the nine months ended September 30, 2024, the shares authorized for issuance increased by 71,006 shares. 20 Table of Contents Stock Options. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the condensed consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. During the nine months ended September 30, 2024, the Company granted stock options to purchase up to 75,862 shares of common stock at a weighted average exercise price of \$4.99 per share. These awards have vesting periods of up to four years and had a weighted average grant date fair value of \$4.54. The fair value calculation of options granted during the nine months ended September 30, 2024 used the following assumptions: risk free interest rate of 3.94% to 4.26%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 133% to 139% based on historical volatility of the Company’s common stock over a time that is consistent with the expected life of the option. On August 30, 2024, the Company’s board of directors (the Board) approved a one-time stock option repricing (the Option Repricing), effective August 31, 2024 (the Effective Date). The repricing was undertaken in

and, as permitted by the 2017 Plan, The Option Repricing applies to all Relevant Options (as defined below) granted pursuant to the 2017 Plan to held by employees, including executive officers and non-employee directors of the Board, to the extent such options had an exercise price in excess of \$6.56, the closing price per share of the Company's Common Stock as reported on The Nasdaq Stock Market on August 30, 2024. As of the Effective Date, all such options were repriced such that the exercise price per share was reduced to \$6.56, provided that the original exercise price will apply to stock option exercises during a one year retention period. Under the terms of the Option Repricing, if prior to the first anniversary of the Effective Date (except following a change of control), a Relevant Option is exercised or employment/services are terminated by the Company with cause or voluntarily by the option holder, the option holder will be required to pay the original exercise price of the Relevant Option. If the employment/services of an option holder is terminated by the Company without cause prior to the first anniversary of the Effective Date, the option holder will retain the benefit of the reduced exercise price. The Option Repricing does not change the number of shares, the vesting schedule, or the expiration date of the Relevant Options. As of the Effective Date, approximately 304,000 total outstanding options on the Effective Date, approximately 177,000 were repriced. The Board approved the Option Repricing after careful consideration of various alternatives and the recommendation of the compensation committee of the Board that the repricing was fair, just, and reasonable to the Company and its stockholders. Management determined that the Option Repricing represents a modification of the impacted awards and calculated incremental compensation cost of approximately \$0.5 million resulting from the modification. The incremental expense will be recognized over 1.4 years. As of the Effective Date, the following table summarizes stock option activity under our plans during the nine months ended September 30, 2024:

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620

competitive environment and related market conditions, our ability to comply with the listing requirements of the Nasdaq Capital Market, expected financial and other benefits from our organizational restructuring activities, geopolitical uncertainties including the ongoing Russia and Ukraine conflict and the Israel-Hamas war, actions of governments and regulatory factors affecting our business, projections of future earnings, revenues, synergies, accretion or other financial items, any statements of the plans, strategies and objectives of management for future operations, retaining key employees and other risks as described in our reports filed with the SEC. In some cases these statements are identifiable through the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "target," "can," "could," "may," "should," "will," "would" or the negative of such terms and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons, including those described in Part II, Item 1A, "Risk Factors," of this Quarterly Report on Form 10-Q and our prior filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The following discussion should be read together with our condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q and with the financial statements, related notes and Management's Discussion and Analysis included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which we filed with the Securities and Exchange Commission on March 29, 2024. Results for the three and nine months ended September 30, 2024 are not necessarily indicative of results that may be attained in the future.

Overview

Precipio, Inc., and its subsidiaries, (collectively, "Precipio," "we," "us," "our," "the Company," "Company," "Precipio") is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services aim to deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. We develop innovative technologies in our laboratory where we design, test, validate, and use these products clinically. We believe these technologies improve diagnostic outcomes across various diseases within the hematologic field. We then commercialize these technologies as proprietary products that serve the global laboratory community in furtherance of our mission to eliminate or greatly reduce the prevalence of misdiagnosis. To deliver our strategy, we have structured our organization to develop diagnostic products, including our laboratory and research and development ("R&D") facilities located in New Haven, Connecticut and Omaha, Nebraska, 28 Table of Contents respectively, which house teams that collaborate on the development of new products and services. We operate CLIA laboratories in both New Haven, Connecticut and Omaha, Nebraska where we provide essential blood cancer diagnostics to office-based oncologists in many states nationwide. To deliver on our strategy of mitigating misdiagnoses we rely heavily on our CLIA laboratory to support R&D beta-testing of the products we develop, in a clinical environment. The development of laboratory products involves a qualified facility; highly skilled laboratory staff; and access to viable patient specimens to conduct development and testing. Our CLIA laboratory in New Haven, which is operated by our pathology services division, encapsulates these components, and also generates revenue for us which covers costs associated with operating this laboratory. This structure of utilizing our clinical lab to obtain samples and utilize the equipment and staffing to develop, test and validate our products, significantly reduces the development costs and timeline for our products. This also enables us to accelerate the time to market of new product development and launch. Furthermore, as a clinical laboratory, we are always the first user of every product we develop, which allows us to optimize important laboratory functions such as workflow, inventory management, regulatory and billing issues. As a vendor, this places us as a reputable user of our own products, and we believe gains us significant credibility with existing and prospective customers. Furthermore, because we use our products as part of our day-to-day operations, we are able to deliver a high level of hands-on, experienced support to customers, improving their experience with our products. Our Products Division commercial team generates direct sales and works with our key distributors. Global healthcare distributors, such as ThermoFisher, McKesson, and Cardinal Health, have partnered with us to form the backbone of our go-to-market strategy and enable us to access laboratories around the country that can benefit from using our diagnostic products. Our operating structure promotes the harnessing of our proprietary technology and genetic diagnostic expertise to bring to market our robust pipeline of innovative solutions designed to address the root causes of misdiagnoses. Recent Developments

Change Healthcare ("CHC"), a subsidiary of UnitedHealth Group, suffered a cybersecurity breach in February 2024 which resulted in the temporary shut-down of some of its systems. Precipio uses CHC to process its billings for pathology services. Thus, when CHC shut down its business operations our pathology billings were halted. Our ability to process billings, accept payer remittances, process medical and billing benefit notices, bill secondary insurers, as well as patients, and communicate with commercial payers was severely impacted. Starting shortly after the breach, we redirected a significant amount of our internal resources to manually manufacture the billing services that CHC was no longer delivering. This resulted in billing and cash reimbursement delays during the nine months ended September 30, 2024. Along with the delays in billing and cash reimbursements, we incurred approximately \$0.2 million of expense during the nine months ended September 30, 2024, as we used alternative methods for claims processing. CHC established a Temporary Funding Assistance Program to help bridge the gap in short-term cash flow needs for its customers affected by the disruption of its services due to the cyberattack. During the nine months ended September 30, 2024, we received approximately \$1.1 million from CHC through this program. See Note 4 Accrued Expenses for further discussion. As a result of the manual claims processing methods that we put in place following the CHC shutdown, our billing and cash reimbursement processes are nearly rectified as of September 30, 2024.

Going Concern

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America ("GAAP") applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business and do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. For the nine months ended September 30, 2024, the Company had a net loss of \$3.9 million and net cash used in operating activities of \$0.1 million. 29 Table of Contents As of September 30, 2024, the Company had an accumulated deficit of \$102.1 million and a working capital deficit of \$1.2 million. The Company's ability to continue as a going concern over the next twelve months from the date the condensed consolidated financial statements were issued is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has taken the following steps to capitalize the business:

— On April 14, 2023, the Company entered into a sales agreement with AGP, pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to \$5.8 million, to or through AGP, as sales agent (the "AGP 2023 Sales Agreement"). At the sale of our shares of common stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the registration statement (the "2023 Registration Statement") on Form S-3 (File No. 333-271277), filed by the Company with the SEC on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023. On April 8, 2024, we filed a prospectus supplement to our prospectus dated April 25, 2023 registering the offer and sale of up to \$1,061,478 of shares of our common stock (the "April 2024 Prospectus Supplement"). As of the date the condensed consolidated financial statements were issued, we have approximately \$3.7 million available for future sales pursuant to the 2023 Registration Statement, which includes approximately \$1.0A million of remaining availability pursuant to the April 2024 Prospectus Supplement. Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company's ability to continue as a going concern over the next twelve months from the date of issuance of this Quarterly Report on Form 10-Q. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern. Results of Operations for the Three Months Ended September 30, 2024 and 2023

Net Sales. Net sales were as follows:

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Service revenue, net less allowance for credit loss	\$ 4,528	\$ 3,687
Product revenue	\$ 61	\$ 84
Total	\$ 4,589	\$ 3,771

An increase of \$0.8 million as compared to the same period in 2023. During the three months ended September 30, 2024, patient diagnostic service revenue increased \$0.8 million as compared to the same period in 2023. This increase was due to a greater number of cases processed in the current year period. We processed 3,584 cases during the three months ended September 30, 2024 as compared to 2,105 cases during the same period in 2023, or a 70% increase in cases. The benefit of the increase in cases billed during the third quarter of 2024 as compared to the same period in 2023 was partially offset by a lower average price per case during the current year as a result of a different product mix. Product revenue decreased by \$0.1 million for the three months ended September 30, 2024 as compared to the same period in 2023. Cost of Sales. Cost of sales includes material and supply costs for the patient tests performed, costs related to HSRP products and other direct costs (primarily personnel costs, pathologist interpretation costs and rent) associated with the operations of our laboratory. Cost of sales increased by \$0.3 million for the three months ended September 30, 2024 as compared to the same period in 2023. 30 Table of Contents

Gross Profit. Gross profit and gross margins were as follows:

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Gross profit	\$ 2,277	\$ 1,885
Gross margin	44%	42%

Gross margin was 44% and 42% of total net sales for the three months ended September 30, 2024 and 2023, respectively. Gross profit was approximately \$2.3 million and \$1.9 million during the three months ended September 30, 2024 and 2023, respectively. The gross profit increased during the three months ended September 30, 2024, as compared to the prior year period, as a result of increases in case volume and revenue. We operate a fully staffed CLIA and College of American Pathologists ("CAP") certified clinical pathology and molecular laboratory. As such, it is necessary to maintain appropriate staffing levels to provide industry standard laboratory processing and reporting to ordering physicians. An increase in case volume will enable our laboratory to yield economies of scale and to leverage fixed expenses. Operating Expenses. Operating expenses primarily consist of personnel costs, professional fees, travel costs, facility costs, stock-based compensation costs and depreciation and amortization. Our operating expenses decreased by \$0.5 million to \$2.9 million for the three months ended September 30, 2024 as compared to the same period in 2023. The decrease was attributable to: (1) an increase of less than \$0.1 million in stock-based compensation expense, (2) an increase of less than \$0.1 million in general and administrative expenses due mainly to an increase of \$0.1 million legal and professional fees and franchise taxes, partially offset by a decrease of less than \$0.1 million in personnel costs (3) a decrease of \$0.4 million in sales and marketing expenses due mainly to a decrease in personnel costs of \$0.4 million as a result of a lower headcount, and (4) a decrease of \$0.1 million in research and development expenses mainly related to decreases in operating supply costs and personnel costs. Other (Expense) Income. We recorded net other expense of \$29 thousand and \$7 thousand for the three months ended September 30, 2024 and 2023, respectively, which was related to net interest expense. Results of Operations for the Nine Months Ended September 30, 2024 and 2023

Net Sales. Net sales were as follows:

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Service revenue, net less allowance for doubtful accounts	\$ 11,146	\$ 8,399
Product revenue	\$ 1,936	\$ 2,469
Total	\$ 13,082	\$ 10,868

An increase of \$2.2 million as compared to the same period in 2023. During the nine months ended September 30, 2024, patient diagnostic service revenue increased \$2.7 million as compared to the same period in 2023. This increase was due to a greater number of cases processed in the current year period. We processed 8,745 cases during the nine months ended September 30, 2024 as compared to 4,915 cases during the same period in 2023, or a 78% increase in cases. The benefit of the increase in cases billed during the third quarter of 2024 as compared to the same period in 2023 was partially offset by a lower average price per case during the current year as a result of a different product mix. Product revenue decreased by \$0.5 million for the nine months ended September 30, 2024 as compared to the same period in 2023. Cost of Sales. Cost of sales includes material and supply costs for the patient tests performed, costs related to HSRP products and other direct costs (primarily personnel costs, pathologist interpretation costs and rent) associated with 31 Table of Contents the operations of our laboratory. Cost of sales increased by \$1.3 million for the nine months ended September 30, 2024 as compared to the same period in 2023. Gross Profit. Gross profit and gross margins were as follows:

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Gross profit	\$ 4,913	\$ 4,005
Gross margin	38%	37%

Gross margin was 38% of total net sales, for the nine months ended September 30, 2024 and 37% for the nine months ended September 30, 2023. Gross profit was approximately \$4.9 million and \$4.0 million during the nine months ended September 30, 2024 and 2023, respectively. The increase in gross profit during the nine months ended September 30, 2024, as compared to the prior year period, was a result of increases in case volume and revenue. We operate a fully staffed CLIA and CAP certified clinical pathology and molecular laboratory. As such, it is necessary to maintain appropriate staffing levels to provide industry standard laboratory processing and reporting to ordering physicians. An increase in case volume will enable our laboratory to yield economies of scale and to leverage fixed expenses. Operating Expenses. Operating expenses primarily consist of personnel costs, professional fees, travel costs, facility costs, stock-based compensation costs and depreciation and

\$0.2 million for the nine months ended September 30, 2024, which included \$0.2 million of proceeds from debt and \$0.1 million of proceeds from the issuance of common stock. These were partially offset by \$0.4 million in payments on our long-term debt and finance lease obligations. Cash flows provided by financing activities totaled \$1.9 million for the nine months ended September 30, 2023, which included \$2.2 million of proceeds from the issuance of common stock partially offset by payments on our long-term debt and finance lease obligations of \$0.3 million. For further information regarding the Company's future funding requirements, see the Going Concern disclosure in Note 1 of the Notes to Unaudited Condensed Consolidated Financial Statements included with this Quarterly Report on Form 10-Q. Off-Balance Sheet Arrangements At each of September 30, 2024 and December 31, 2023, other than certain purchase commitments of approximately \$2.3 million and \$1.9 million, respectively, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. The purchase commitments are mostly for laboratory reagents used in our normal operating business. 33 Table of Contents Contractual Obligations and Commitments No significant changes to contractual obligations and commitments occurred during the nine months ended September 30, 2024, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024. Critical Accounting Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. Our critical accounting estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024. Recently Issued Accounting Pronouncements See the accompanying unaudited condensed consolidated financial statements and Note 2A - Summary of Significant Accounting Policies in the Notes to unaudited condensed consolidated financial statements for additional information regarding recently issued accounting pronouncements. Impact of Inflation Inflation generally affects us with increased cost of labor and operating supplies. We do not believe that price inflation had a material adverse effect on our financial condition or results of operations during the periods presented. Item 3. Quantitative and Qualitative Disclosures About Market Risk We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures As of the end of the period covered by this Quarterly Report on Form 10-Q, management performed, with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and no evaluation of controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2024. 34 Table of Contents Changes in Internal Control over Financial Reporting We have evaluated the changes in our internal control over financial reporting that occurred during the three months ended September 30, 2024 and concluded that there have not been any changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 35 Table of Contents PART II. OTHER INFORMATION Item 1. Legal Proceedings The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management's expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results. The Company is involved in legal proceedings related to matters, which are incidental to its business and is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. Item 1A. Risk Factors As disclosed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. The following information updates, and should be read in conjunction with, the factors discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other filings we make with the Securities and Exchange Commission, which could materially affect our business, financial condition or future results. The risks described in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. We have incurred losses since our inception and expect to incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability. We have incurred losses since our inception and expect to incur losses in the future. At September 30, 2024, we had a working capital deficit of \$1.2 million. For the nine months ended September 30, 2024, we had an operating cash flow deficit of \$0.4 million and a net loss of \$3.9 million. For the period ended September 30, 2024, we have experienced negative cash flow from development of our diagnostic technology, as well as from the costs associated with establishing a laboratory and building a sales force to market our products and services. We expect to incur substantial net losses through at least 2024 as we further develop and commercialize our diagnostic technology. We also expect that our selling, general and administrative expenses will continue to increase due to the additional costs associated with market development activities and expanding our staff to sell and support our products. Our ability to achieve or, if achieved, sustain profitability is based on numerous factors, many of which are beyond our control, including the market acceptance of our products, competitive product development and our market penetration and margins. We may never be able to generate sufficient revenue to achieve or, if achieved, sustain profitability. 36 Table of Contents We may need to raise substantial additional capital to commercialize our diagnostic technology, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts or force us to restrict or cease operations. As of September 30, 2024, we had cash of \$1.1 million and a working capital deficit of \$1.2 million. Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we may be required to raise additional capital to complete the development and commercialization of our current product candidates and to pay off our obligations. To date, to fund our operations and develop and commercialize our products, we have relied primarily on equity and debt financings. In future periods, when we seek additional capital, we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which we may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of our product candidates, restrict or cease our operations or obtain funds by entering into agreements on unattractive terms. The sale or issuance of our common stock to, or through, AGP, or otherwise, may cause significant dilution and the sale of the shares of common stock acquired by AGP or others, or the perception that such sales may occur, could cause the price of our common stock to fall. On April 14, 2023, we entered into a sales agreement with AGP, pursuant to which we may offer and sell our Common Stock, having aggregate sales proceeds of up to \$5.8 million, to or through AGP, from time to time, in an at-the-market offering (the "2023 ATM Offering"). We are limited in the number of shares we can sell in the 2023 ATM Offering due to the offering limitations currently applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company's public float as of the applicable date of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the AGP 2023 Sales Agreement. Sales to, or through, AGP by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. From April 14, 2023 through the date of issuance of this Quarterly Report on Form 10-Q, we received \$0.1 million in gross proceeds through the AGP 2023 Sales Agreement from the sale of 11,847 shares of Common Stock. The Company has an additional \$3.7 million available for future sales pursuant to the AGP 2023 Sales Agreement. On January 8, 2024, we filed a prospectus supplement to our prospectus dated April 25, 2023 registering the offer and sale of up to \$1,061,478 of shares of our common stock. We have approximately \$1.0 million of remaining availability pursuant to this prospectus supplement. We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders. As of September 30, 2024, approximately 444,444 shares of our common stock were reserved for issuance upon exercise or conversion of outstanding warrants. Additionally, 304,025 shares of our common stock were reserved for issuance upon exercise of outstanding stock options. The exercise or conversion of these securities will result in a significant increase in the number of outstanding shares and substantially dilute the ownership interests of our existing stockholders. The shares underlying the equity awards from our equity plans are registered on a Form S-8 registration statement. As a result, upon vesting these shares can be freely exercised and sold in the public market upon issuance, subject to volume limitations applicable to affiliates. The exercise of options and the subsequent sale of the underlying common stock could cause a decline in our stock price. Cybersecurity risks could compromise our information and expose us to liability, which may harm our ability to operate effectively and may cause our business and reputation to suffer. Cybersecurity refers to the combination of technologies, processes and procedures established to protect information technology systems and data from unauthorized access, misuse, attack, or damage. We rely on our information systems to 37 Table of Contents provide security for processing, transmission and storage of confidential information about our patients, customers and personnel, such as names, addresses and other individually identifiable information protected by the Health Insurance Portability and Accountability Act, (HIPAA), other privacy laws. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or incidents. We also rely on our employees and consultants to safeguard their security credentials and follow our policies and procedures regarding use and access of computers and other devices that may contain our sensitive information. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyberattacks and any such attacks could result in losses described above, as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to, misuse of, or disclosure of such information could have similarly adverse consequences for us. For example, our vendor, Change Healthcare, disclosed a security incident in February 2024 which resulted in temporary inaccessibility of certain of its information technology systems. While the Change Healthcare incident did not materially adversely affect our business, financial condition or operating results, it did result in temporary delays in our ability to complete our typical billing and reimbursement processes. If, in the future, we are unable to prevent or mitigate the impact of such security or data privacy breaches or other incidents, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. The regulatory environment surrounding information security and privacy is increasingly demanding, with the frequent imposition of new and changing requirements. A compliance with changes in privacy and information security laws and with rapidly evolving industry standards may result in our incurring significant expense due to increased investment in technology and the development of new operational processes. We have not experienced any known attacks on our information technology systems that compromised any confidential information. We maintain our information technology systems with safeguards designed to protect against cyberattacks including passive intrusion protection, firewalls and virus detection software. However, these safeguards do not ensure that a significant cyberattack could not occur. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems' improper functioning or damage or the improper access or disclosure of personally identifiable information such as in the event of cyberattacks. A security incidents, including physical or electronic break-ins, computer viruses, attacks by hackers and similar incidents can create system disruptions or shutdowns or the unauthorized disclosure of, access to, or misuse of confidential information. If personal information or protected health information is improperly accessed, tampered with, misused or disclosed as a result of a security breach, we may incur significant costs to notify and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of the privacy or security rules under HIPAA or other similar federal or state laws protecting confidential personal information. In addition, a security breach of or other incident affecting our information systems could damage our reputation, subject us to liability claims or regulatory penalties for compromised personal information and could have a material adverse effect on our business, financial condition and results of operations. 38 Table of Contents Our products that we sell as research use only products and/or that we offer as laboratory developed tests could become subject to government regulations requiring marketing authorization, and the marketing authorization and maintenance process for such products may be expensive, time-consuming and uncertain in both timing and outcome. A number of our products are currently, and in the future will be, labeled and sold as research use only (RUO) products. Even though our products are labeled and sold as RUO products, the United States Food and Drug Administration (FDA) could question whether our products are intended for research use only. For example, in August 2021, we were contacted by the FDA regarding HemeScreen, and we have subsequently revised the labeling for HemeScreen. Should the FDA disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with RUO products, our products could be subject to government regulation as diagnostic products. Diagnostic products are regulated as medical devices by the FDA and may require marketing authorization from the FDA through clearance following the premarket notification (510(k)) process, authorization following a request for de novo classification or approval following the submission of a premarket approval (PMA) application, in each case prior to marketing. Obtaining the requisite marketing authorizations can be expensive and may involve considerable delay. Moreover, if the FDA believed we inappropriately labeled our products as RUO products, it could allege that we had misbranded or adulterated our RUO products. If the FDA asserts that our RUO products are subject to marketing authorization, or that our RUO products are adulterated or misbranded, our business, financial condition or results of operations could be adversely affected. Additionally, our CLIA laboratory offers testing utilizing our laboratory developed tests (LDTs). Historically, the FDA has exercised enforcement discretion with respect to most LDTs and has not required laboratories that offer LDTs to comply with the FDA's requirements for medical devices, such as the FDA's requirements pertaining to

[illegible]

Disclosure - LEASES - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - LEASES - Future Minimum Lease Payments (Details) - Calc 2 link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) link:presentationLink link:calculationLink link:definitionLink 99941005 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) link:presentationLink link:calculationLink link:definitionLink 99941006 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - BUSINESS DESCRIPTION (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - LONG-TERM DEBT (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - LONG-TERM DEBT (Financed Insurance Loan) (Details) link:presentationLink link:calculationLink link:definitionLink 99940304 - Disclosure - LONG-TERM DEBT (Business Loan Agreement) (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940605 - Disclosure - LEASES - Operating and Financing Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - STOCKHOLDERS' EQUITY (At The Market Offering Agreement) (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - STOCKHOLDERS' EQUITY (Registered Direct Offering) (Details) link:presentationLink link:calculationLink link:definitionLink 99940705 - Disclosure - STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 99940706 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 99940707 - Disclosure - STOCKHOLDERS' EQUITY (Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - FAIR VALUE (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - EQUITY INCENTIVE PLAN (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) link:presentationLink link:calculationLink link:definitionLink 99941004 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) link:presentationLink link:calculationLink link:definitionLink 99941007 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - BUSINESS DESCRIPTION link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - EQUITY INCENTIVE PLAN link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - EQUITY INCENTIVE PLAN (Tables) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - LEASES - Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 prpo-20240930_def.xml EX-101.CAL EX-101.DEF 9 prpo-20240930_def.xml EX-101.DEF EX-101.LAB 10 prpo-20240930_lab.xml EX-101.LAB Document and Entity Information [Abstract] Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value Cash Accounts Receivable, Net, Current Accounts receivable (net of allowance for credit losses of \$2,755 and \$2,572, respectively) Inventory, Net Inventories Other Assets, Current Other current assets Assets, Current Total current assets Property, Plant and Equipment, Net PROPERTY AND EQUIPMENT, NET Assets, Noncurrent [Abstract] OTHER ASSETS: Finance Lease, Right-of-Use Asset Finance lease right-of-use assets, net Operating Lease, Right-of-Use Asset Operating lease right-of-use assets, net Intangible Assets, Net (Excluding Goodwill) Intangibles, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] CURRENT LIABILITIES: Long-term Debt, Current Maturities Current portion of long-term debt Current portion of long-term debt Finance Lease, Liability, Current Less, current portion Current maturities of finance lease liabilities Operating Lease, Liability, Current Less, current portion Current maturities of operating lease liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Deferred Revenue, Current Deferred revenue Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] LONG TERM LIABILITIES: Convertible notes, less current maturities and discounts Long-term debt, less current maturities and debt issuance costs Finance Lease, Liability, Noncurrent Finance lease liabilities, less current maturities Long term portion Operating Lease, Liability, Noncurrent Operating lease liabilities, less current maturities Long term portion Liabilities Total liabilities Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (Note 5) Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY: Preferred Stock, Value, Issued Preferred stock - \$0.01 par value, 15,000,000 shares authorized at September 30, 2024 and December 31, 2023, 47 shares issued and outstanding at September 30, 2024 and December 31, 2023, liquidation preference of \$39 at September 30, 2024 Common Stock, Value, Issued Common stock, \$0.01 par value, 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, 1,482,133 and 1,420,125 shar es issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance at end of period Balance at beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Accounts Receivable, Allowance for Credit Loss, Current Allowance for credit losses Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Preferred Stock, Liquidation Preference, Value Preferred stock, liquidation preference Common Stock, Par or Stated Value Per Share Common stock, par value (in \$ per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Common stock, shares issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Product and Service [Axis] Products and Services [Domain] Service revenue, net [Member] Service revenue, net [Member] Service revenue, net Product [Member] Product revenue Product Revenue From Contract With Customer Excluding Assessed Tax Revenues, net of Contractual Allowances and adjustments Revenue, net of contractual allowances and adjustments Allowance for doubtful accounts, revenue Allowance for doubtful accounts, revenue Adjustment for allowance for credit losses Allowance for credit losses Revenues Net sales Cost of Goods and Services Sold Total cost of sales Gross Profit Gross profit Operating Expenses [Abstract] OPERATING EXPENSES: Operating Expenses Operating expenses Operating Income (Loss) OPERATING LOSS Nonoperating Income (Expense) [Abstract] OTHER (EXPENSE) INCOME: Interest income and (expense), net Interest income and (expense), net Interest expense, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest LOSS BEFORE INCOME TAXES Net Income (Loss) Attributable to Parent Net loss NET LOSS Net loss Earnings Per Share, Basic LOSS PER COMMON SHARE, BASIC Earnings Per Share, Diluted LOSS PER COMMON SHARE, DILUTED Weighted Average Number of Shares Outstanding, Basic WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC Weighted Average Number of Shares Outstanding, Diluted WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, DILUTED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] Equity Components [Axis] Equity Component [Domain] Preferred Stock [Member] Preferred Stock Preferred stock [Member] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Accumulated Deficit [Member] Accumulated Deficit Total Precipio, Inc. [Member] Total Precipio, Inc. Noncontrolling Interest in Joint Venture [Member] Noncontrolling Interest in Joint Venture Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance at end of period (in shares) Balance at beginning of period (in shares) Issuance of common stock in connection restricted stock awards Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common stock in connection restricted stock awards (in shares) Stock Issued During Period, Value, Purchase of Assets Issuance of common stock in connection with purchase agreements, net of issuance costs Stock Issued During Period, Shares, Purchase of Assets Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock in connection with at the market offering, net of issuance costs Stock Issued During Period, Shares, New Issues Issuance of common stock in connection with at the market offering, net of issuance costs (in shares) Shares issued (in shares) Stock Issued During Period, Value, Issued for Services Issuance of common stock for consulting services Stock Issued During Period, Shares, Issued for Services Issuance of common stock for consulting services (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Shares of fractional common stock paid in conjunction with reverse stock split. Fractional Common Stock Shares Payment of fractional common shares in conjunction with reverse stock split (in shares) Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash flows used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Operating Lease, Right-of-Use Asset, Amortization Expense Amortization of operating lease right-of-use asset Finance Lease, Right-of-Use Asset, Amortization Amortization of finance lease right-of-use asset Finance lease ROU assets Amortization of Debt Issuance Costs and Discounts Amortization of deferred financing costs, debt discounts and debt premiums Share-based Compensation Stock-based compensation Professional Fees Value of stock issued in payment of services Provision for Doubtful Accounts Provision for credit losses Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the period in the carrying value of operating lease liability. Increase (Decrease) in Operating Lease Liabilities Operating lease liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Finance Lease, Principal Payments Principal payments on finance lease obligations Payment of Deposits on finance lease right-of-use assets. Payment of Deposits on finance lease right-of-use assets Deposits on finance lease right-of-use assets Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Issuance of common stock, net of issuance costs Proceeds from Issuance of Long-term Debt Proceeds from debt Repayments of Notes Payable Principal payments on long-term debt Net Cash Provided by (Used in) Financing Activities Net cash flows provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) NET CHANGE IN CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH AT END OF PERIOD CASH AT BEGINNING OF PERIOD Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL CASH FLOW INFORMATION Interest Paid, Net Cash paid during the period for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY Capital Expenditures Incurred but Not yet Paid Purchases of equipment financed through accounts payable Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating lease right-of-use assets obtained in exchange for operating lease obligations Prepaid insurance financed with loan Prepaid insurance financed with loan Prepaid insurance financed with loan Finance lease right-of-use assets obtained in exchange for finance lease obligations Finance lease right-of-use assets obtained in exchange for finance lease obligations BUSINESS DESCRIPTION [Abstract] Business Description and Basis of Presentation [Text Block] BUSINESS DESCRIPTION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES LONG-TERM DEBT [Abstract] Debt Disclosure [Text Block] LONG-TERM DEBT ACCRUED EXPENSES [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES COMMITMENTS AND CONTINGENCIES [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES LEASES [Abstract] The entire disclosure of information about leases. Lease Disclosure [Text Block] LEASES STOCKHOLDERS' EQUITY [Abstract] Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY FAIR VALUE [Abstract] Financial Instruments Disclosure [Text Block] FAIR VALUE EQUITY INCENTIVE PLAN [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] EQUITY INCENTIVE PLAN Net Sales Service Revenue and Accounts Receivable [Abstract] SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract] Net Sales Service Revenue and Accounts Receivable [Text Block] Net Sales Service Revenue and Accounts Receivable [Text Block] SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE SUBSEQUENT EVENTS [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted Earnings Per Share, Policy [Policy Text Block] Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding securities not included in the computation of diluted net loss per share Schedule of Debt [Table Text Block] Schedule of debt Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses The tabular disclosure of balance sheet information relating to lessee. Lessee, Balance Sheet Information [Table Text Block] Summary of balance sheet presentation of our operating and finance leases Lessee, Operating Lease, Liability, Maturity

[Table Text Block] Summary of estimated future minimum lease payments for operating leases Finance Lease, Liability, Maturity [Table Text Block] Summary of estimated future minimum lease payments for finance leases Represents the weighted average lease term and discount rate of leases. Lessee, Weighted Average Lease Term And Discount Rate [Table Text Block] Schedule of other information Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of stockholders' equity, including warrants and rights Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of stock option activity Disaggregation of Revenue [Table Text Block] Schedule of Net Revenues Schedule of Gross to Net Sales Adjustments [Table Text Block] Schedule of Gross to Net Sales Adjustments [Table Text Block] Schedule of Gross to Net Sales Adjustments Schedule of Reported Revenues Net of Collection Allowance [Table Text Block] Schedule of Reported Revenues Net of Collection Allowance [Table Text Block] Schedule of Reported Revenues Net of Collection Allowance Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Receivables Schedule of Allowance for Doubtful Accounts [Table Text Block] Schedule of Allowance for Doubtful Accounts [Table Text Block] Schedule of Allowance for Doubtful Accounts Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Customer Revenue and Accounts Receivable Concentrations Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Range [Axis] Range [Domain] Maximum [Member] Maximum Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to AGP 2023 sales agreement. AGP 2023 Sales Agreement [Member] AGP 2023 Sales Agreement Represents information pertaining to at the marker offering. At The Market Offering Agreement Legal Entity [Axis] Entity [Domain] Represents information pertaining to A.G.P./Alliance Global Partners. AGP [Member] AGP Business Acquisition [Line Items] Business Acquisition [Line Items] Accumulated Net Income (Loss) Accumulated Net Income (Loss) Net loss Working Capital (Deficiency) Working Capital (Deficiency) Working capital The amount of aggregate authorized offering price of common stock under the agreement. Sale of Common Stock, Aggregate Offering Price, Authorized Aggregate authorized offering price Amount available for future sale of shares pursuant to the sales agreement. Sales Agreement, Amount Available For Future Sales Amount available for future sale of shares pursuant to the sales agreement Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Summary of Significant Accounting Policies [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Stock options, unvested options, vesting period Vesting period of unvested awards (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Awards outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Securities not included in the computation of diluted net loss per share (in shares) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock options Warrants [Member] Warrants [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Department of Economic and Community Development [Member] Connecticut Department of Economic and Community Development (DECD) Department of Economic and Community Development (DECD) Loan [Member] Connecticut Department of Economic and Community Development (DECD) [Member] Financed Insurance Loan [Member] Financed Insurance Loan [Member] Business Loan Agreement [Member] Business Loan Agreement [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Amount of short-term and long-term debt and lease obligation on Department of Economic and Community Development . Debt and Lease Obligation on Department of Economic and Community Development Total long-term debt Debt Issuance Costs, Noncurrent, Net Debt issuance cost Debt and Capital Lease Obligations Total long-term debt Total debt Long-term Debt, Excluding Current Maturities Long-term debt, net of current maturities Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Term Loan [Member] Term loan Proceeds from Issuance of Other Long-term Debt Proceeds from long-term debt Debt Instrument, Term Debt instrument, term Debt Instrument, Maturity Date Debt instrument, maturity date Maturity date Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Amortization of Debt Issuance Costs Amortization of debt issuance cost Debt Instrument, Face Amount Debt instrument, face amount Loan Agreement [Member] Loan Agreement [Member] Loan Agreement Fee Type [Axis] Fee Type [Axis] Fee Type [Domain] Fee Type [Domain] Fee Type Default Fees [Member] Default Fees [Member] Default Fees Debt Instrument, Periodic Payment Long-term Debt, Gross Convertible notes Debt Instrument, Fee Amount Fee Debt Instrument, Unused Borrowing Capacity, Amount Additional borrowing capacity Other Accrued Liabilities, Current Accrued expenses Employee-related Liabilities, Current Accrued compensation An amount of interest accrued from temporary assistance program Accrued amount from temporary assistance program Amount received from Temporary Assistance Program Taxes Payable, Current Accrued franchise, property and sales and use taxes Accounts Payable, Other, Current CHC temporary funding assistance Interest Payable, Current Accrued interest Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Domain] CPA Global [Member] CPA Global Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingency, Damages Sought, Value Loss contingency, damages sought Loss Contingency Accrual Loss contingency accrual Other Commitment Other Commitment Lessee, Lease, Description [Table] Heme Screen Reagent Rental [Member] HemeScreen Reagent Rental [Member] Minimum [Member] Minimum Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating Lease, Payments Operating leases Number of options to renew under the operating leases. Operating Lease, Number Of Options To Renew Facility leases Lessee, Operating Lease, Renewal Term Renewal term Sales-type Lease, Net Investment in Lease Net investment in leased assets Assets and Liabilities, Lessee [Abstract] Balance sheet presentation of our operating and financing leases Amount of lessee's right to use underlying asset under operating and finance lease. Operating And Finance Lease, Right-of-Use Asset Total lease assets Present value of lessee's discounted obligation for lease payments from operating and finance lease. Operating And Finance Lease, Liability Present value of net minimum lease obligations Operating Lease Liabilities, Payments Due [Abstract] Operating leases, estimated future minimum lease payments Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2024 (remaining) Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2025 Lessee, Operating Lease, Liability, Payments, Due Year Two 2026 Lessee, Operating Lease, Liability, Payments, Due Total lease obligations Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Amount representing interest Operating Lease, Liability Present value of net minimum lease obligations Finance Lease Liabilities, Payments, Due [Abstract] Finance leases, estimated future minimum lease payments Finance Lease, Liability, Payments, Remainder of Fiscal Year 2024 (remaining) Finance Lease, Liability, Payments, Due Next Twelve Months 2025 Finance Lease, Liability, Payments, Due Year Two 2026 Finance Lease, Liability, Payments, Due Year Three 2027 Finance Lease, Liability, Payments, Due Year Four 2028 Finance Lease, Liability, Payments, Due Total lease obligations Finance Lease, Liability, Undiscounted Excess Amount Less: Amount representing interest Finance Lease, Liability Present value of net minimum lease obligations No definition available. Operating And Finance Lease Liabilities, Payments Due [Abstract] Operating and finance leases, estimated future minimum lease payments Amount of lessee's undiscounted obligation for lease payments for operating and finance lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year. Lessee, Operating And Finance Lease, Liability, Payments, Remainder of Fiscal Year 2024 (remaining) Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in next fiscal year following latest fiscal year. Lessee Operating and Finance Lease Liability Payments Due Next Twelve Months 2025 Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in second fiscal year following latest fiscal year. Lessee, Operating And Finance Lease, Liability, Payments, Due Year Two 2026 Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in third fiscal year following latest fiscal year. Lessee, Operating And Finance Lease, Liability, Payments, Due Year Three 2027 Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fourth fiscal year following latest fiscal year. Lessee, Operating And Finance Lease, Liability, Payments, Due Year Four 2028 Amount of lessee's undiscounted obligation for lease payments for operating and finance lease. Lessee, Operating And Finance Lease, Liability, Payments, Due Total lease obligations Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance lease. Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount Less: Amount representing interest Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current. Operating And Finance Lease, Liability, Current Less, current portion Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. Operating And Finance Lease, Liability, Noncurrent Long term portion Operating Lease, Weighted Average Remaining Lease Term1 Operating leases (in years) Finance Lease, Weighted Average Remaining Lease Term1 Finance leases (in years) Operating Lease, Weighted Average Discount Rate, Percent Operating leases discount rate Finance Lease, Weighted Average Discount Rate, Percent Finance leases discount rate Operating Lease, Cost Operating lease costs Short-term Lease, Cost Short-term lease costs Amount of finance lease cost including amortization expense and interest recognized by lessee for lease contract. Finance Lease, Cost Finance lease amortization and interest expenses Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] The maximum amount of aggregate sale proceeds of common stock under the agreement. Sale of Common Stock, Maximum Aggregate Sale Proceeds Aggregate sale proceeds of common stock The cash fee expressed as a percentage of aggregate gross proceeds from the sale of the shares of the company under the agreement. Cash Fee As A Percentage Of Gross Proceeds Of Sale Of Stock Percentage of cash fee Payments of Stock Issuance Costs Equity [Abstract] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Expected Term [Member] Term Measurement Input, Risk Free Interest Rate [Member] Risk free rate Measurement Input, Price Volatility [Member] Volatility rate Measurement Input, Share Price [Member] Share price Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to pre-funded warrants. Pre-Funded Warrants Represents information pertaining to RDO Common Warrants. RDO Common Warrants Represents information pertaining to registered direct offering. Registered Direct Offering [Member] Registered Direct Offering Common Stock, Capital Shares Reserved for Future Issuance Stock reserved for future issuance Share Price Share price (in dollars per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Underlying shares (in shares) Class of warrant, number of securities called by warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollars per share) Exercise price (in dollars per share) Period from issuance, after which the warrants become exercisable. Warrants, Period After Issuance In Which Warrants Can Be Exercised Period from issuance after which the warrants become exercisable Warrants and Rights Outstanding Warrants and rights outstanding Fair value of warrants issued Equity Securities, FV-N1, Measurement Input Fair value of warrant input The gross cash inflow from the additional capital contribution to the entity. Proceeds from Issuance of Common Stock, Gross Gross proceeds Threshold beneficial ownership percentage of warrants with its affiliates. Warrants, Threshold Beneficial Ownership Percentage With Its Affiliates Threshold beneficial ownership percentage of warrants with its affiliates Threshold beneficial ownership percentage of warrants at the election of the purchaser. Warrants, Threshold Beneficial Ownership Percentage At The Election Of The Purchaser Threshold beneficial ownership percentage of warrants at the election of the purchaser Threshold ownership percentage of warrants. Warrants, Threshold Beneficial Ownership Threshold ownership percentage of warrants The notice period to alter beneficial ownership percentage. Warrants, Notice Period To Alter Beneficial Ownership Percentage Notice period to alter beneficial ownership percentage The lock in period for the directors and executive officers to sell/transfer any securities held after the close of the offering under the purchase agreement. Purchase Agreement, Sale By Executives, Lock in Period Lock-in period Threshold resale registration period under purchase agreement. Purchase Agreement, Threshold Resale Registration Period Resale registration period The cash outflow on payments to financial advisor. Payments to Financial Advisor Cash fee paid Represents the sale lock in period by the company following the closing of the offering under the purchase agreement Purchase Agreement, Sale, Lock In Period Sale lock in period Represents the variable rate transaction lock in period under the purchase agreement. Purchase Agreement, Variable Rate Transaction Lock In Period Variable rate transaction lock in period Preferred Class B Conversion of Stock, Shares Converted Number of shares converted (in shares) Preferred Stock, Liquidation Preference Per Share Preferred stock, liquidation preference (in dollars per share) Preferred Stock, Dividend Rate, Percentage Preferred stock, dividend rate (percentage) Conversion of Stock, Per Share Conversion Price Conversion of Stock Per Share Conversion Price Conversion price (in dollars per share) Preferred Stock Convertible Shares Issuable Number of common shares issuable upon conversion of preferred stock Number of warrants or rights expired. Class of Warrant or Right, Expired Warrants expired Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Number of warrants issued during the period. Class of Warrant or Right, Warrants Issued Number of warrants issued Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Liability Class [Axis] Fair Value by Liability Class [Domain] Warrant Liabilities [Member] Warrant Liabilities [Member] Warrant Liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Term Expected term Warrants and Rights Outstanding, Measurement Input Warrants and Rights Outstanding, Measurement Input Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Revaluation recognized in earnings Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Equity Incentive Plan 2017 [Member]. Equity Incentive Plan 2017 [Member] Equity Incentive Plan 2017 Restricted Stock [Member] Restricted Stock Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for grant Percentage of annual increase in number of shares authorized for grant Percentage of annual increase in number of shares authorized for grant Percentage of annual increase in number of shares authorized for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Number of additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility rate The threshold exercise price of repriced stock options. Share-Based Compensation Arrangement by Share-Based Payment Award, Repriced Options, Threshold Exercise price Exercise price The retention period of the stock option repriced. Share-Based Compensation Arrangement by Share-Based Payment Award, Repriced Options, Retention Period Retention period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of period (in shares) Outstanding at beginning of period (in shares) Outstanding options Number of share options (or share units) repriced during the period. Share-based Compensation Arrangement by Share-based Payment Award, Options Repriced, Number Options repriced Share-Based Payment Arrangement, Plan Modification, Incremental Cost Incremental compensation cost Period over which an excess of the fair value of the modified award over the fair value of the award immediately before the modification will be recognized for award under share-based payment arrangement, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Share-Based Payment Arrangement, Plan Modification, Incremental Cost, Period Of Recognition Incremental expense period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock options, expected to vest, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Stock options, expected to vest, outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Stock options, expected to vest remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date Plan expiration date Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock granted Allocated Share-based Compensation Expense Stock-based compensation Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expense related to unvested stock awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unvested stock options, unrecognized compensation expense weighted average recognition period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award,

Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at end of period (in dollars per share) Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at end of period (in dollars per share) Concentration Risk [Table] Concentration Risk [Line Items] Number of Reportable Segments Number of segments Disaggregation of Revenue [Table] Payer Type Revenue Source [Axis]. Payer Type Revenue Source [Axis] Payer Type Revenue Source [Domain]. Payer Type Revenue Source [Domain] Medicaid [Member] Medicaid [Member] Medicaid Medicare [Member] Medicare [Member] Medicare Self-Pay [Member] Self-pay Payer Type Third Party Payer [Member]. Third-Party Payers [Member] Third party payers Contract diagnostic services [Member] Contract Diagnostic Services [Member] Contract diagnostics and other Services Revenue, Net [Member] Services Revenue, Net [Member] Service revenue, net Diagnostic Testing [Member] Diagnostic Testing [Member] Diagnostic Testing Disaggregation of Revenue [Line Items] Revenue from Contract with Customer, Including Assessed Tax Gross Revenues Contractual allowance and adjustments Contractual allowance and adjustments Contractual Allowances and adjustments Contract diagnostic services and other [Member] Contract Diagnostic Services and Other [Member] Contract diagnostic services, product and other Accounts Receivable, Gross Accounts receivable, gross Allowance for Doubtful Accounts Receivable Less allowance for credit losses Allowance for Credit Losses, Ending balance Allowance for Credit Losses, Beginning balance Accounts Receivable, Net Accounts receivable, net Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Total charges Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Sales Revenue, Net [Member] Net sales Accounts Receivable [Member] Accounts receivable Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Customer [Axis] Customer [Domain] Customer A [Member] Customer A [Member] Customer A Customer B [Member] Customer B [Member] Customer B Customer C [Member] Customer C [Member] Customer C Customer D [Member] Customer D [Member] Customer D Concentration Risk, Percentage Concentration risk, percentage EX-101.PRE 11 prpo-20240930_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 DOCUMENT AND ENTITY INFORMATION - shares 9 Months Ended Sep. 30, 2024 Nov. 03, 2024 Document and Entity Information [Abstract] Á Á Document Type 10-Q Á Document Quarterly Report true Á Document Period End Date Sep. 30, 2024 Á Document Transition Report false Á Entity File Number 001-36439 Á Entity Registrant Name PRECIPIO,Á INC. Á Entity Incorporation, State or Country Code DE Á Entity Tax Identification Number 91-1789357 Á Entity Address, Address Line One 4 Science Park Á Entity Address, City or Town New Haven Á Entity Address, State or Province CT Á Entity Address, Postal Zip Code 06511 Á City Area Code 203 Á Local Phone Number 787-7888 Á Title of 12(b) Security Common Stock, \$0.01 par value per share Á Trading Symbol PRPO Á Security Exchange Name NASDAQ Á Entity Current Reporting Status Yes Á Entity Interactive Data Current Yes Á Entity Filer Category Non-accelerated Filer Á Entity Small Business true Á Entity Emerging Growth Company false Á Entity Shell Company false Á Entity Common Stock, Shares Outstanding Á 1,482,333 Entity Central Index Key 0001043961 Á Current Fiscal Year End Date -12-31 Á Document Fiscal Year Focus 2024 Á Document Fiscal Period Focus Q3 Á Amendment Flag false Á X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Cover page. + References No definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a> + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD (\$ in Thousands Sep. 30, 2024 Dec. 31, 2023 CURRENT ASSETS: Á Á Cash \$ 1,053 \$ 1,502 Accounts receivable (net of allowance for credit losses of \$2,755 and \$2,572, respectively) 1,021 1,301 Inventories 590 384 Other current assets 591 495 Total current assets 3,255 3,682 PROPERTY AND EQUIPMENT, NET 753 739 OTHER ASSETS: Á Á Finance lease right-of-use assets, net 342 174 Operating lease right-of-use assets, net 447 612 Intangibles, net 12,106 12,818 Other assets 48 76 Total assets 16,951 18,101 CURRENT LIABILITIES: Á Á Current portion of long-term debt 444 235 Current maturities of finance lease liabilities 103 132 Current maturities of operating lease liabilities 205 218 Accounts payable 701 622 Accrued expenses 2,743 1,824 Deferred revenue 282 110 Total current liabilities 4,478 3,141 LONG TERM LIABILITIES: Á Á Long-term debt, less current maturities and debt issuance costs 84 106 Finance lease liabilities, less current maturities 190 18 Operating lease liabilities, less current maturities 254 407 Total liabilities 5,006 3,672 COMMITMENTS AND CONTINGENCIES (Note 5) STOCKHOLDERS' EQUITY: Á Á Preferred stock - \$0.01 par value, 15,000,000 shares authorized at September 30, 2024 and December 31, 2023, 47 shares issued and outstanding at September 30, 2024 and December 31, 2023, liquidation preference of \$39 at September 30, 2024 Common stock, \$0.01 par value, 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, 1,482,133 and 1,420,125 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 15 14 Additional paid-in capital 114,005 112,565 Accumulated deficit (102,075) (98,150) Total stockholders' equity 11,945 14,429 Total liabilities and stockholders' equity \$ 16,951 \$ 18,101 X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210-52\(19\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210-52(19)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210-52\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210-52(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210-6-04\(18\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210-6-04(18))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210-52\(30\)\(a\)\(1\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210-52(30)(a)(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount of asset recognized for present right to economic benefit. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 ->

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -

Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(6)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoriesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(22)) - SubTopic 10 - Topic 210 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(20)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(24)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(19)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(25)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(26)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(23)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8>: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(21)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 810 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (c) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 810 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 25 - Subparagraph (b) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 810 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (bb) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.4-08(g)(1)(iii)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 323 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (c) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 825 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 28 - Subparagraph (f) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15>: <http://www.xbrl.org/2003/role/exampleRef> - Topic 946 - SubTopic 830 - Name Accounting Standards Codification - Section 55 - Paragraph 12 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 946 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.6-04(14)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479170/946-210-50-14Reference 17>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(i)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18>: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(ii)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)(A)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iv)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(5)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22>: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1

Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4:

Paragraph 13 - Subparagraph (h) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details)
Name: us-gaap PreferredStockLiquidationPreferenceValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details) Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details) Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details) Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details) Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD \$ in Thousands 3 Months Ended 9 Months Ended Sep 30, 2021 Sep 30, 2023 Sep 30, 2023 Sep 30, 2024 Sep. 30, 2023 Revenue, net of contractual allowances and adjustments \$ 5,280 \$ 4,569 \$ 13,265 \$ 11,043 Adjustment for allowance for credit losses (71) (51) (183) (175) Net sales 5,209 4,518 13,082 10,868 Total cost of sales 2,932 2,633 8,169 6,863 Gross profit 2,277 1,885 4,913 4,005 OPERATING EXPENSES: Á Á Á Operating expenses 2,874 3,333 8,793 10,771 OPERATING LOSS (597) (1,448) (3,880) (OTHER EXPENSE) INCOME: Á Á Á Interest expense, net (29) (7) (45) (12) LOSS BEFORE INCOME TAXES (626) (1,455) (3,925) (6,778) NET LOSS \$ (626) \$ (1,455) \$ (3,925) \$ (6,778) LOSS PER COMMON SHARE, BASIC \$ (0.42) \$ (1.04) \$ (2.69) \$ (5.39) LOSS PER COMMON SHARE, DILUTED \$ (0.42) \$ (1.04) \$ (2.69) \$ (5.39) WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC 1,480,217 1,394,596 1,456,653 1,258,633 Service revenue, net Á Á Á Revenue, net of contractual allowances and adjustments \$ 4,599 \$ 3,738 \$ 11,329 \$ 8,574 Adjustment for allowance for credit losses (71) (51) (183) (175) Net sales 4,528 3,687 11,146 8,399 Total cost of sales 2,579 2,401 7,105 6,050 Product revenue Á Á Á Revenue, net of contractual allowances and adjustments 681 831 1,936 2,469 Net sales 681 831 1,936 2,469 Total cost of sales \$ 353 \$ 232 \$ 1,064 \$ 813 X - DefinitionAllowance for doubtful accounts, revenue + ReferencesNo definition available. + Details Name: prpo AllowanceForDoubtfulAccountsRevenue Namespace Prefix: prpo Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionInterest income and (expense), net + ReferencesNo definition available. + Details Name: prpo InterestIncomeAndExpenseNet Namespace Prefix: prpo Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2:

-Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap Revenues Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrl:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrl:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt ProductOrServiceAxis=prpo ServiceRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=us-gaap ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R5.htm IDEA: XBRL DOCUMENT v3.2.4 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD (\$) in Thousands Preferred Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Precipio, Inc. Noncontrolling Interest in Joint Venture Total Balance at beginning of period at Dec. 31, 2022 \$ 11 \$ 108,588 \$ (92,297) \$ 16,302 \$ 65 \$ 16,367 Balance at beginning of period (in shares) at Dec. 31, 2022 47,141,013 \$ A A A Increase (Decrease) in Stockholders' Equity \$ A A A Net loss \$ A (6,778) (6,778) (6,778) Issuance of common stock in connection restricted stock awards \$ A 16 \$ A 16 \$ A 16 Issuance of common stock in connection restricted stock awards (in shares) \$ 2,492 \$ A A A Issuance of common stock in connection with purchase agreements, net of issuance costs \$ 3,175 \$ 1,760 \$ 1,760 Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares) \$ 206,250 \$ A A A Issuance of common

Publication - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(A)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31>: <http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32>: <http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35): <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37): [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A -Details Name: us-gaap ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <a href=): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7):

[action](#) S99 - Paragraph 1- SubParagraph (SX 2101-04) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45:
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-41Reference 49:](#)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY \(Parenthetical\)](#) Sep. 21, 2023 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract] A Reverse stock split 0.05 X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_Data Type: xbrli:pureItemBalance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD \(\\$\) \\$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: A Net loss \\$\(3,925\) \\$\(6,778\) Adjustments to reconcile net loss to net cash flows used in operating activities: A Depreciation and amortization 900 931 Amortization of operating lease right-of-use asset 165 153 Amortization of finance lease right-of-use asset 66 63 Amortization of deferred financing costs, debt discounts and debt premiums 2 2 Stock-based compensation 1,054 1,168 Value of stock issued in payment of services 309 A Provision for credit losses 183 175 Changes in operating assets and liabilities: A Accounts receivable 97 \(622\) Inventories \(206\) 72 Other assets 249 306 Accounts payable 55 468 Operating lease liabilities \(166\) \(150\) Deferred revenue 172 \(90\) Accrued expenses 919 629 Net cash used in operating activities \(126\) \(3,673\) CASH FLOWS FROM INVESTING ACTIVITIES: A Purchase of property and equipment \(179\) \(77\) Net cash used in investing activities \(179\) \(77\) CASH FLOWS FROM FINANCING ACTIVITIES: A Principal payments on finance lease obligations \(62\) \(62\) Deposits on finance lease right-of-use assets \(28\) A Issuance of common stock, net of issuance costs 78 2,245 Proceeds from debt 250 A Principal payments on long-term debt \(382\) \(316\) Net cash flows provided by financing activities \(144\) 1,867 NET CHANGE IN CASH \(449\) \(1,883\) CASH AT BEGINNING OF PERIOD 1,502 3,445 CASH AT END OF PERIOD 1,053 1,562 SUPPLEMENTAL CASH FLOW INFORMATION A Cash paid during the period for interest 54 29 SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY A Purchases of equipment financed through accounts payable 24 3 Operating lease right-of-use assets obtained in exchange for operating lease obligations 0 58 prepaid insurance financed with loan 317 372 Finance lease right-of-use assets obtained in exchange for finance lease obligations \\$ 205 \\$ 0 X - DefinitionThe increase \(decrease\) during the period in the carrying value of operating lease liability. + ReferencesNo definition available. + Details Name: prpo_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: prpo_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionPayment of deposits on finance lease right-of-use assets. + ReferencesNo definition available. + Details Name: prpo_PaymentOfDepositsOnFinanceLeaseRightOfUseAssets Namespace Prefix: prpo_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionPrepaid insurance financed with loan + ReferencesNo definition available. + Details Name: prpo_PrepaidsInsuranceFinancedWithLoan Namespace Prefix: prpo_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount \(premium\) and debt issuance costs. + ReferencesReference 1: \[http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2:\]\(#\) \[http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3:\]\(#\) \[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \\(b\\)\\(2\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4:\]\(#\) \[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5:\]\(#\) \[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOffinancingCostsandDiscounts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: \\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2:\\]\\(#\\) \\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3:\\]\\(#\\) \\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CashFlowFromInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other amounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: \\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2:\\\]\\\(#\\\) \\\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3:\\\]\\\(#\\\) \\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - DefinitionAmount of increase \\\\(decrease\\\\) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: \\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2:\\\\]\\\\(#\\\\) \\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: \\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\(b\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2:\\\\\]\\\\\(#\\\\\) \\\\\[http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3:\\\\\]\\\\\(#\\\\\) \\\\\[http://www.xbrl.org\\\\\]\\\\\(#\\\\\)\\\\]\\\\(#\\\\)\\\]\\\(#\\\)\\]\\(#\\)\]\(#\)](#)

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-3>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1> + Details Name: us-gaap ProfessionalFees Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 11: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-3>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477314/942-235-S99-1>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 31: <http://www.xbrl.org/2003/role/exampleRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4J>Reference 32: <http://www.xbrl.org/2003/role/exampleRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4K>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 34: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-2>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A> + Details Name: us-gaap ProfitLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479319/326-20-50-13>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap RepaymentsOfNotesPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT Y3.24.3 BUSINESS DESCRIPTION 9 Months Ended Sep. 30, 2024 BUSINESS DESCRIPTION [Abstract] Å BUSINESS DESCRIPTION 1. BUSINESS DESCRIPTIONBusiness Description.Precipio, Inc., and its subsidiaries, (collectively, “ăcweăă, “ăcousăă, “ăcourăă, the “ăcCompanyăă or “ăcPrecipioăă) is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. “ăcOur products and services aim to deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. We develop innovative technologies in our laboratory where we design, test, validate, and use these products clinically. We believe these technologies improve diagnostic outcomes across various diseases within the hematologic field. We then commercialize these technologies as proprietary products that serve the global laboratory community in furtherance of our mission to eliminate or greatly reduce the prevalence of misdiagnosis. To deliver our strategy, we have structured our organization to develop diagnostic products, including our laboratory and research and development (“ăcR&Dăă) facilities located in New Haven, Connecticut and Omaha, Nebraska, respectively, which house teams that collaborate on the development of new products and services. We operate clinical laboratory improvement amendment (“ăcCLIAăă) laboratories in both New Haven, Connecticut and Omaha, Nebraska where we provide essential blood cancer diagnostics to office-based oncologists in many states nationwide. To deliver on our strategy of mitigating misdiagnoses we rely heavily on our CLIA laboratory to support R&D beta-testing of the products we develop, in a clinical environment. “ăcThe development of laboratory products involves a qualified facility; highly skilled laboratory staff; and access to viable patient specimens to conduct development and testing. Our CLIA laboratory in New Haven, which is operated by our pathology services division, encapsulates these components, and also generates revenue for us which covers costs associated with operating this laboratory. This structure of utilizing our clinical lab to obtain samples and utilize the equipment and staffing to develop, test and validate our products, significantly reduces the development costs and timeline for our products. This also enables us to accelerate the time to market of new product development and launch. “ăcFurthermore, as a clinical laboratory, we are always the first user of every product we develop, which allows us to optimize important laboratory functions such as

workflow, inventory management, regulatory and billing issues. As a vendor, this places us as a reputable user of our own products, and we believe gains us significant credibility with existing and prospective customers. Furthermore, because we use our products as part of our day-to-day operations, we are able to deliver a high level of hands-on, experienced support to customers, improving their experience with our products. Our Products Division commercial team generates direct sales and works with our key distributors. Global healthcare distributors, such as ThermoFisher, McKesson, and Cardinal Health, have partnered with us to form the backbone of our go-to-market strategy and enable us to access laboratories around the country that can benefit from using our diagnostic products. Our operating structure promotes the harnessing of our proprietary technology and genetic diagnostic expertise to bring to market our robust pipeline of innovative solutions designed to address the root causes of misdiagnoses. Going Concern. The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business and do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. For the nine months ended September 30, 2024, the Company had a net loss of \$3.9 million and net cash used in operating activities of \$0.1 million. As of September 30, 2024, the Company had an accumulated deficit of \$102.1 million and a working capital deficit of \$1.2 million. The Company's ability to continue as a going concern over the next twelve months from the date of issuance of these condensed consolidated financial statements in this Quarterly Report on Form 10-Q is dependent upon a combination of achieving its business plan, including generating additional revenue and avoiding potential business disruption due to the macroeconomic environment and geopolitical instability, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has taken the following steps to capitalize the business:—On April 14, 2023, the Company entered into a sales agreement with AGP, pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to \$5.8 million, to or through AGP, as sales agent (the AGP 2023 Sales Agreement). The sale of our shares of common stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the registration statement (the 2023 Registration Statement) on Form S-3 (SEC No. 333-271277), filed by the Company with the U.S. Securities and Exchange Commission (SEC) on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023. On April 8, 2024, we filed a prospectus supplement to our prospectus dated April 25, 2023 registering the offer and sale of up to \$1,061,478A of shares of our common stock (the April 2024 Prospectus Supplement). As of the date the condensed consolidated financial statements were issued, the Company has approximately \$3.7 million available for future sales pursuant to the 2023 Registration Statement, which includes approximately \$1.0A million of remaining availability pursuant to the April 2024 Prospectus Supplement. See Note 7 Stockholders' Equity, AGP 2023 Sales Agreement, for further discussion. Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the date these condensed consolidated financial statements were issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance of this Quarterly Report Form 10-Q. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1:

[illegible]

Direct Offering

On June 8, 2023, the Company, entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the "Registered Direct Offering"), an aggregate of: (i) 206,250 shares (the "Shares") of its common stock, \$0.01 par value (the "Common Stock"), at a price of \$9.00 per share, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 15,972 shares of Common Stock, at a price of \$8.98 per Pre-Funded Warrant. The Company reviewed the provisions of the Pre-Funded Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The Pre-Funded Warrants are immediately exercisable, have an exercise price of \$0.02 per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. All of the Pre-Funded Warrants were exercised during the year ended December 31, 2023 and no Pre-Funded Warrants were outstanding as of September 30, 2024. In a concurrent private placement (the "Private Placement") and together with the Registered Direct Offering, the "Offering"), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, for no additional consideration, warrants (the "RDO Common Warrants") and, together with the Shares and the Pre-Funded Warrants, the "Securities") to purchase up to 444,444 shares of Common Stock. The Company reviewed the provisions of the RDO Common Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of \$12.60 per share, and will expire December 12, 2028. The fair value of the RDO Common Warrants of approximately \$3.5 million at the date of issuance was estimated using the Black-Scholes model which used the following inputs: term of 5 years; risk free rate of 3.89%; volatility of 143%; and share price of \$9.00 per share based on the trading price of the Company's common stock. The Company allocated \$1.3 million of the issuance proceeds to the RDO Common Warrants based on the relative fair value of the RDO Common Warrants, Common Stock and Pre-Funded Warrants issued in the Offering. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. The Registered Direct Offering resulted in gross proceeds to the Company of approximately \$2.0 million. The net proceeds to the Company from the Registered Direct Offering are approximately \$1.8 million, excluding any proceeds that may be received upon the cash exercise of the RDO Common Warrants, after deducting the financial advisor's fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Registered Direct Offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments and others. The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions. Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements (the "Lock-Up Agreements"), agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, during the 90-day period following the closing of the Registered Direct Offering. The Purchase Agreement also requires the Company to use commercially reasonable efforts to file a registration statement with the SEC to register the resale by the Purchasers of the shares of Common Stock issuable upon exercise of the RDO Common Warrants within thirty (30) days of the date of the Purchase Agreement. The Company filed this registration statement on Form S-1 (File No. 333-273172), which was declared effective by the SEC on July 19, 2023. On June 7, 2023, the Company also entered into a financial advisory agreement (the "Financial Advisor Agreement") with A.G.P./Alliance Global Partners (the "Financial Advisor"). Pursuant to the terms of the Financial Advisor Agreement, the Financial Advisor agreed to use its reasonable best efforts to arrange for the sale of the Securities. The Company paid the Financial Advisor a cash fee of \$140,000 generated from the sale of the Shares and Pre-Funded Warrants. The Financial Advisor Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Financial Advisor, including for liabilities under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties, and termination provisions. Pursuant to the Purchase Agreement, the Company has agreed that, subject to certain exceptions, (i) it will not issue any shares of common stock or securities exercisable or convertible into shares of common stock or to file any registration statement or amendment or supplement thereto for a period of ninety (90) days following the closing of the Offering and that (ii) it will not enter into a variable rate transaction for a period of one hundred eighty (180) days following the closing of the Offering. The Registered Direct Offering was made pursuant to the 2023 Registration Statement, as supplemented by a prospectus supplement dated June 9, 2023. As a result of sales already made through the ACP 2023 Sales Agreement and the Registered Direct Offering, the Company has \$3.7 million of remaining availability under the 2023 Registration Statement. Preferred Stock. The Company's Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. Series B Preferred Stock. The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the "Series B Preferred Stock") with the State of Delaware, which designates 6,900 shares of our preferred stock as Series B Preferred Stock. The Series B Preferred Stock has a stated value of \$1 thousand per share and a par value of \$0.01 per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering consisting of the Company's Series B Preferred Stock and warrants. The conversion price of the Series B Preferred Stock contains a down round feature. The Company will recognize the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation. There were no conversions of Series B Preferred Stock during the three and nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and December 31, 2023, the Company had 6,900 shares of Series B Preferred Stock designated and issued and 47 shares of Series B Preferred Stock outstanding. Based on the stated value of \$1 thousand per share and a conversion price of \$8.00 per share, the outstanding shares of Series B Preferred Stock at September 30, 2024 were convertible into 5,875 shares of common stock. Common Stock Warrants. The following represents a summary of the warrants outstanding as of September 30, 2024: 444,444 RDO Common Warrants to purchase up to 444,444 shares of Common Stock. The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of \$12.60 per share, and will expire December 12, 2028. X - References No definition available. + Details Name: us-gaap StockholdersEquityNoteAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.4-08\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.4-08(e)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE 9 Months Ended Sep. 30, 2024 FAIR VALUE [Abstract] FAIR VALUE 8. FAIR VALUE FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements. FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows: Level 1 "Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 "Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and Level 3 "Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability. Common Stock Warrant Liabilities. Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated statements of operations. Bridge Note Warrant Liabilities. During 2018 and 2019, the Company issued warrants in connection with the issuance of convertible notes. All of these warrants issuances were classified as warrant liabilities (the "Bridge Note Warrant Liabilities"). The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black-Scholes model. During the nine months ended September 30, 2024, the last remaining warrants related to Bridge Note Warrant Liabilities expired and thus at September 30, 2024 there were no warrant liabilities to be valued. As of December 31, 2023, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 0.4 years; volatility rate of 71% to 77%; and risk free rate of 5.33% to 5.40%. During the three and nine months ended September 30, 2024, the changes in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were zero. During the three and nine months ended September 30, 2023, the changes in the fair value of the warrant liabilities were less than \$1 thousand, respectively. X - References No definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details Name: us-gaap FinancialInstrumentsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 EQUITY INCENTIVE PLAN 9 Months Ended Sep. 30, 2024 EQUITY INCENTIVE PLAN [Abstract] EQUITY INCENTIVE PLAN 9. EQUITY INCENTIVE PLAN The Company currently issues stock awards under its 2017 Stock Option and Incentive Plan, as amended (the "2017 Plan") which will expire on June 5, 2027. The shares authorized for issuance under the 2017 Plan were 320,699 at September 30, 2024, of which 14,705 were available for future grant. The shares authorized under the 2017 Plan are subject to annual increases on January 1 by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares determined by the Company's Board of Directors or Compensation Committee. During the nine months ended September 30, 2024, the shares authorized for issuance increased by 71,006 shares. Stock Options. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the condensed consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. During the nine months ended September 30, 2024, the Company granted stock options to purchase up to 75,862 shares of common stock at a weighted average exercise price of \$4.99 per share. These awards have vesting periods of up to four years and had a weighted average grant date fair value of \$4.54. The fair value calculation of options granted during the nine months ended September 30, 2024 used the following assumptions: risk free interest rate of 3.94% to 4.26%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 133% to 139% based on historical volatility of the Company's common stock over a time that is consistent with the expected life of the option. On August 30, 2024, the Company's board of directors (the "Board") approved a one-time stock option repricing (the "Option Repricing"), effective August 31, 2024 (the "Effective Date"). The repricing was undertaken in accordance with, and as permitted by the 2017 Plan. The Option Repricing applies to all Relevant Options (as defined below) granted pursuant to the 2017 Plan that were held by employees, including executive officers and non-employee directors of the Board, to the extent such options had an exercise price in excess of \$6.56, the closing price per share of the Company's Common Stock as reported on The Nasdaq Stock Market on August 30, 2024. A Relevant Option means all outstanding eligible stock options granted to eligible employees, service providers and non-employee directors of the board of the Company before and including December 31, 2022. As of the Effective Date, all such options were repriced such that the exercise price per share was reduced to \$6.56, provided that the original exercise price will apply to stock option exercises during a one year retention period. Under the terms of the Option Repricing, if prior to the first

The following table summarizes stock option activity under our plans during the nine months ended September 30, 2024:

	September 30, 2024	September 30, 2023
Average exercise price outstanding at January 1, 2024	\$232.74	\$46.56
Granted	75,862	4,999
Forfeited	(5,173)	-
Outstanding at September 30, 2024	303,433	187,554
Exercisable at September 30, 2024	187,554	7,524

As of September 30, 2024, there were 274,463 options that were vested or expected to vest with aggregate intrinsic value of \$0.1 million and a remaining weighted average contractual life of 6.8 years. Restricted Stock Awards. Restricted stock awards are subject to vesting restrictions. If a grantee's service with the Company is terminated prior to vesting of the restricted stock, all unvested shares shall be forfeited and returned to the Company. Upon vesting, the restricted stock award shall no longer be deemed restricted. As of September 30, 2024, there were 2,492 and zero restricted stock awards that were vested and unvested, respectively. There were no restricted stock awards granted during the three and nine months ended September 30, 2024. At September 30, 2024, there were 2,492 restricted stock awards granted during the three and nine months ended September 30, 2023, respectively. Stock Compensation. For the three and nine months ended September 30, 2024, we recorded non-cash stock-based compensation expense for all stock awards of \$0.4 million and \$1.1 million, respectively, within operating expense in the accompanying statements of operations. For the three and nine months ended September 30, 2023, we recorded non-cash stock-based compensation expense for all stock awards of \$0.4 million and \$1.2 million, respectively, within operating expense in the accompanying statements of operations. As of September 30, 2024, the unrecognized compensation expense related to unvested stock awards and the Option Repricing was \$1.9 million, which is expected to be recognized over a weighted-average period of 1.7 years.

X - Definition The entire disclosure for share-based payment arrangement. + References Reference 1:

Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS 9 Months Ended Sep. 30, 2024
SUBSEQUENT EVENTS [Abstract] A SEQUENCE OF EVENTS The Company has evaluated events and transactions subsequent to September 30, 2024 through the date of this Quarterly Report on Form 10-Q, and there are no other events to report other than what has been disclosed in the condensed consolidated financial statements.
ReferencesNo definition available. + Details Name: us-gaap SubsequentEventsAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855-Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2+Details Name: us-gaap SubsequentEventsTextBlockNamespacePrefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Terminated false True Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229-Section 408-Subsection A-Paragraph 1+Details Name: ecd NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229-Section 408-Subsection A-Paragraph 1+Details Name: ecd NonRule10b51ArrTrmndtFlag Namespace Prefix: ecd Data Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229-Section 408-Subsection A-Paragraph 1+Details Name: ecd Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229-Section 408-Subsection A-Paragraph 1+Details Name: ecd Rule10b51ArrTrmndtFlag Namespace Prefix: ecd Data Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K-Number 229-Section 408-Subsection A-Paragraph 2-Subparagraph (d) IDA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 9 Months Ended Sep. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Basis of Presentation Basis of Presentation. The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to a 1-for-20 reverse stock split which was effected on September 21, 2023, unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements. As of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated financial statements are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 contained in our Annual Report on Form 10-K, filed with the SEC on March 29, 2024. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2024. Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted Recently Adopted Accounting Pronouncements In June 2022, the Financial Accounting Standards Board (the "FASB") issued ASU 2022-03, Fair Value Measurement (Topic 820) ("ASU 2022-03"). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06A "Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)": Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related earnings per share ("EPS") guidance for both Subtopics. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements. Recently Adopted Accounting Pronouncements Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09A "Income Taxes (Topic 740)" improvements to Income Tax Disclosures ("ASU 2023-09A") which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740-A Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company's financial position, results of operations or cash flow. Loss Per Share Loss Per Share Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company's common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:

	September 30, 2024	December 31, 2023
Diluted net loss per share:	\$ 5,875.5	\$ 5,875.5
Total	753,752	705,976

X - ReferencesNo definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap BasisOfAccountingPolicyPolicyTextBlockNamespacePrefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260-SubTopic 10-Section 50-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2+Details Name: us-gaap EarningsPerSharePolicyTextBlockNamespacePrefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyPolicyTextBlockNamespacePrefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) 9 Months Ended Sep. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Schedule of outstanding securities not included in the computation of diluted net loss per share The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:

	September 30, 2024	December 31, 2023
Stock options	303,433	234,213
Warrants	444,444	465,888
Preferred stock	5,875	5,875
Total	753,752	705,976

X - ReferencesNo definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1+Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlockNamespacePrefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT (Tables) 9 Months Ended Sep. 30, 2024
LONG-TERM DEBT [Abstract] A schedule of debt Long-term debt consists of the following:

	September 30, 2024	December 31, 2023
Accrued interest	\$ 152,436	\$ 287,384
Operating lease right-of-use assets, net	\$ 447,843	\$ 612,736
Lease liabilities	\$ 254,468	\$ 407,716
Current maturities of long-term debt	\$ 584,727	\$ 929,926
Compensation expense	\$ 929,926	\$ 754,754
Fringe benefits	\$ 152,436	\$ 287,384
Temporary funding assistance	\$ 1,057,846	\$ 1,057,846
Interest expense	\$ 199,468	\$ 274,345
Other	\$ 1,824	-
Total	\$ 2,544,444	\$ 3,444,444

+Details Name: us-gaap PayablesAndAccrualsAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. +

[illegible]

gaap SubsidiarySaleOfStockAxis=prpo AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei LegalEntityAxis=prpo AllianceGlobalPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) 9 Months Ended Sep. 21, 2023 Sep. 30, 2024 shares Sep. 30, 2023 shares Summary of Significant Accounting Policies [Line Items] Á Á Reverse stock split 0.05 Á Á Securities not included in the computation of diluted net loss per share (in shares) Á 753,752 705,976 X - Definition:Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition:Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition:Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap Data Type: xbrli:pureItem Type Balance Type: na Period Type: duration XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Securities not included in the computation of diluted net loss per share (in shares) 753,752 705,976 Employee Stock Option Á Á Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Securities not included in the computation of diluted net loss per share (in shares) 303,433 234,213 Warrants [Member] Á Á Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Securities not included in the computation of diluted net loss per share (in shares) 444,444 465,888 Preferred stock [Member] Á Á Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Securities not included in the computation of diluted net loss per share (in shares) 5,875 5,875 X - Definition:Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition:Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT (Schedule of Debt) (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Á Á Total long-term debt \$ 528 \$ 341 Current portion of long-term debt (444) (235) Long-term debt, net of current maturities 84 106 Connecticut Department of Economic and Community Development (DECD) [Member] Á Á Debt Instrument [Line Items] Á Á Total long-term debt 123 146 Debt issuance cost (10) (12) Financed Insurance Loan [Member] Á Á Debt Instrument [Line Items] Á Á Total long-term debt 261 207 Current portion of long-term debt (300) \$ (200) Business Loan Agreement [Member] Á Á Debt Instrument [Line Items] Á Á Total long-term debt \$ 154 Á X - Definition:Amount of short-term and long-term debt and lease obligation on Department of Economic and Community Development . + ReferencesNo definition available. + Details Name: prpo DebtAndLeaseObligationOnDepartmentOfEconomicAndCommunityDevelopment Namespace Prefix: prpo Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition:Amount of short-term and long-term debt and lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap DebtAndCapitalLeaseObligations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition:Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition:Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition:Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LongTermDebtCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition:Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LongTermDebtNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap DebtInstrumentAxis=prpo DepartmentOfEconomicAndCommunityDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=prpo FinancedInsuranceLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=prpo BusinessLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT (Narrative) (Details) - USD (\$) \$ 3 Months Ended 9 Months Ended Jan. 08, 2018 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jul. 31, 2024 Dec. 31, 2023 Jul. 31, 2023 Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Current portion of long-term debt Á \$ 444,000 Á \$ 444,000 Á Á \$ 235,000 Á Financed Insurance Loan [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Current portion of long-term debt Á 300,000 Á \$ 300,000 Á Á \$ 200,000 Á Interest rate (as a percent) Á Á Á Á Á 9.99% Á 9.99% Debt instrument, face amount Á Á Á Á Á \$ 300,000 Á \$ 400,000 Term loan | Department of Economic and Community Development (DECD) Loan [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Proceeds from long-term debt \$ 300,000 Á Á Á Á Á Debt instrument, term 10 years Á Á Á Á Á Debt instrument, maturity date Dec. 31, 2027 Á Á May 31, 2028 Á Á Á Á Á Interest rate (as a percent) 3.25% Á Á Á Á Á Term loan | Department of Economic and Community Development (DECD) Loan [Member] | Maximum [Member] Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Amortization of debt issuance cost Á \$ 1,000 \$ 1,000 \$ 2,000 \$ 2,000 Á Á X - Definition:Amount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap AmortizationOfFinancingCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition:Face (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards

[Codification - Section 50 - Paragraph 1B - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69B - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69C - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 55 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap DebtInstrumentFaceAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.5-02\(22\)\(a\)\(1\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 55 - Paragraph 8 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.4-08\(f\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph \(SX 210.12-04\(a\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69B - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69C - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69E - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69F - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(e\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(f\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 15: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1E - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1E - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1E - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(b\)\(1\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(b\)\(2\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 26: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 45 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 820 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(bbb\)\(2\)\(i\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 820 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(bbb\)\(2\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.5-02\(22\)\(a\)\(2\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap DebtInstrumentMaturityDate Namespace Prefix: us-gaap Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMmDnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name:](#)

Period Topic: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD (\$) \$ in Millions Feb. 06, 2017 Sep. 30, 2024 Dec. 31, 2023 Loss Contingencies [Line Items] Á Á Á Other Commitment Á Á 2.3 Á CPA Global Á Á Á Loss Contingencies [Line Items] Á Á Á Loss contingency, damages sought \$ 0.2 Á Á CPA Global | Maximum [Member] Á Á Á Loss Contingencies [Line Items] Á Á Á Loss contingency accrual Á \$ 0.1 \$ 0.1 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap LossContingenciesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe value (monetary amount) of the award the plaintiff seeks in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap LossContingencyDamagesSoughtValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionMinimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + ReferencesNo definition available. + Details Name: us-gaap OtherCommitment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: srt LitigationCaseAxis=prpo_CPAGlobalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Narrative (Details) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Sep. 30, 2024 USD (\$) item Sep. 30, 2023 USD (\$) Dec. 31, 2023 USD (\$) Lessee, Lease, Description [Line Items] Á Á Á Operating leases Á \$ 200 \$ 200 Á Operating lease right-of-use assets obtained in exchange for operating lease obligations Á \$ 58 Á Finance lease right-of-use assets obtained in exchange for finance lease obligations Á \$ 205 Á Á Operating lease right-of-use assets, net \$ 447 Á 447 Á \$ 612 Finance lease ROU assets Á \$ 66 63 Á Minimum [Member] Á Á Á Á Lessee, Lease, Description [Line Items] Á Á Á Á Facility leases | item Á 1 Á Á Renewal term 1 year Á 1 year Á Á Maximum [Member] Á Á Á Á Lessee, Lease, Description [Line Items] Á Á Á Á Renewal term 5 years Á 5 years Á Á HemeScreen Reagent Rental [Member] Á Á Á Á Lessee, Lease, Description [Line Items] Á Á Á Á Finance lease ROU assets \$ 0 \$ 0 \$ 0 \$ 0 Net investment in leased assets \$ 100 Á \$ 100 X - DefinitionNumber of options to renew under the operating leases. + ReferencesNo definition available. + Details Name: prpo OperatingLeaseNumberOfOptionsToRenew Namespace Prefix: prpo_Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYmMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeasePayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount, before allowance for credit loss, of net investment in sales-type lease. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-6 + Details Name: us-gaap SalesTypeLeaseNetInvestmentInLease Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=prpo_HemeScreenReagentRentalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Operating and Financing leases (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Balance sheet presentation of our operating and financing leases Á Á Á Operating lease right-of-use assets, net \$ 447 Á 447 Á \$ 612 Finance lease right-of-use assets, net 342 174 Total lease assets 789 786 Current maturities of operating lease liabilities 205 218 Current maturities of finance lease liabilities 103 132 Operating lease liabilities, less current maturities 254 407 Finance lease liabilities, less current maturities 190 18 Present value of net minimum lease obligations 752 775 HemeScreen Reagent Rental [Member] Á Á Balance sheet presentation of our operating and financing leases Á Á Finance lease right-of-use assets, net \$ 0 \$ 0 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease. + ReferencesNo definition available. + Details Name: prpo OperatingAndFinanceLeaseLiability Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating and finance lease. + ReferencesNo definition available. + Details Name: prpo OperatingAndFinanceLeaseRightOfUseAsset Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsAndLiabilitiesLesseeAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=prpo_HemeScreenReagentRentalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Future Minimum Lease Payments (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Operating leases, estimated future minimum lease payments Á Á 2024 (remaining) \$ 60 Á 2025 224 Á 2026 214 Á Total lease obligations 498 Á Less: Amount representing interest (39) Á Present value of net minimum lease obligations 459 Á Less, current portion (205) \$ (218) Long term portion 254 407 Finance leases, estimated future minimum lease payments Á Á 2024 (remaining) 37 Á 2025 134 Á 2026 95 Á 2027 69 Á 2028 29 Á Total lease obligations 364 Á Less: Amount representing interest (71) Á Present value of net minimum lease obligations 293 Á Less, current portion (103) (132) Long term portion 190 18 2024 (remaining) 97 Á 2025 358 Á 2026 309 Á 2027 69 Á 2028 29 Á Total lease obligations 862 Á Less: Amount representing interest (110) Á Present value of net minimum lease obligations 752 \$ 775 Less, current portion (308) Á Long term portion \$ 444 Á X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease. + ReferencesNo definition available. + Details Name: prpo LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in next fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: prpo LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fourth fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: prpo LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in third fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: prpo LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in second fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: prpo LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: prpo_LesseeOperatingAndFinanceLeaseLiabilityPaymentsRemainderOFFiscalYear Namespace Prefix: prpo_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X -

DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance lease. + ReferencesNo definition available. + Details Name: prpo_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: prpo_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease. + ReferencesNo definition available. + Details Name: prpo_OperatingAndFinanceLeaseLiability Namespace Prefix: prpo_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current. + ReferencesNo definition available. + Details Name: prpo_OperatingAndFinanceLeaseLiabilityCurrent Namespace Prefix: prpo_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. + ReferencesNo definition available. + Details Name: prpo_OperatingAndFinanceLeaseLiabilityNoncurrent Namespace Prefix: prpo_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY (Common Stock) (Details) - USD ($) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2018 Dec. 31, 2018 Class of Stock [Line Items] Á Á Á Á Common stock, shares authorized (in shares) 150,000,000 150,000,000 150,000,000 250,000,000 150,000,000 Issuance of common stock for consulting services $ 58 $ 309 Á Á Á Common Stock Á Á Á Á Class of Stock [Line Items] Á Á Á Á Issuance of common stock for consulting services (in shares) 12,593 50,186 Á Á Á Issuance of common stock for consulting services $ 100 $ 300 Á Á Á X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1>Reference 4:

[illegible]

DefinitionThe lock in period for the directors and executive officers to sell/transfer any securities held after the close of the offering under the purchase agreement. + ReferencesNo definition available. + Details Name: prpo_PurchaseAgreementSaleByExecutivesLockInPeriod Namespace Prefix: prpo_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionRepresents the sale lock in period by the company following the closing of the offering under the purchase agreement + ReferencesNo definition available. + Details Name: prpo_PurchaseAgreementSaleLockInPeriod Namespace Prefix: prpo_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThreshold resale registration period under purchase agreement. + ReferencesNo definition available. + Details Name: prpo_PurchaseAgreementThresholdResaleRegistrationPeriod Namespace Prefix: prpo_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionRepresents the variable rate transaction lock in period under the purchase agreement. + ReferencesNo definition available. + Details Name: prpo_PurchaseAgreementVariableRateTransactionLockInPeriod Namespace Prefix: prpo_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmount available for future sale of shares pursuant to the sales agreement. + ReferencesNo definition available. + Details Name: prpo_SalesAgreementAmountAvailableForFutureSales Namespace Prefix: prpo_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe notice period to alter beneficial ownership percentage. + ReferencesNo definition available. + Details Name: prpo_WarrantsNoticePeriodToAlterBeneficialOwnershipPercentage Namespace Prefix: prpo_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionPeriod from issuance, after which the warrants become exercisable. + ReferencesNo definition available. + Details Name: prpo_WarrantsPeriodAfterIssuanceInWhichWarrantsCanBeExercised Namespace Prefix: prpo_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThreshold ownership percentage of warrants. + ReferencesNo definition available. + Details Name: prpo_WarrantsThresholdBeneficialOwnershipPercentage Namespace Prefix: prpo_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThreshold beneficial ownership percentage of warrants at the election of the purchaser. + ReferencesNo definition available. + Details Name: prpo_WarrantsThresholdBeneficialOwnershipPercentageAtElectionOfPurchaser Namespace Prefix: prpo_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThreshold beneficial ownership percentage of warrants with its affiliates. + ReferencesNo definition available. + Details Name: prpo_WarrantsThresholdBeneficialOwnershipPercentageWithItsAffiliates Namespace Prefix: prpo_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockLiquidationPreference Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) - \$ / shares 1 Months Ended 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Class of Stock [Line Items] Á Á Á Á Warrants expired 5,593 0 15,091 13,012 Á RDO Common Warrants Á Á Á Á Class of Stock [Line Items] Á Á Á Á Underlying shares (in shares) Á 444,444 444,444 Á 444,444 Exercise price (in dollars per share) Á \$ 12.60 \$ 12.60 X - DefinitionNumber of warrants or rights expired. + ReferencesNo definition available. + Details Name: prpo_ClassOfWarrantOrRightExpired Namespace Prefix: prpo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=prpo_RdoCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY (Warrants) (Details) - RDO Common Warrants - \$ / shares 1 Months Ended Jun. 30, 2023 Sep. 30, 2024 Class of Warrant or Right [Line Items] Á Á Number of warrants issued 444,444 Á Class of warrant, number of securities called by warrants 444,444 444,444 Period from issuance after which the warrants become exercisable 6 months Á Exercise price (in dollars per share) Á \$ 12.60 \$ 12.60 X - DefinitionNumber of warrants issued during the period. + ReferencesNo definition available. + Details Name: prpo_ClassOfWarrantOrRightWarrantsIssued Namespace Prefix: prpo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod from issuance, after which the warrants become exercisable. + ReferencesNo definition available. + Details Name: prpo_WarrantsPeriodAfterIssuanceInWhichWarrantsCanBeExercised Namespace Prefix: prpo_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=prpo_RdoCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE (Narratives) (Details) - Warrant Liabilities 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Dec. 31, 2023 Y Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and rights outstanding \$ 0 Á \$ 0 Á Á Revaluation recognized in earnings \$ 0 Á \$ 0 Á Minimum | Volatility rate Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and Rights Outstanding, Measurement Input Á Á Á Á 0.71 Minimum | Risk free rate Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and Rights Outstanding, Measurement Input Á Á Á Á 0.533 Minimum | Term Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and Rights Outstanding, Measurement Input | Y Á Á Á 0.3 Maximum Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Revaluation recognized in earnings Á \$ 1,000 Á \$ 1,000 Á Maximum | Volatility rate Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and Rights Outstanding, Measurement Input Á Á Á Á 0.77 Maximum | Risk free rate Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and Rights Outstanding, Measurement Input Á Á Á Á 0.0540 Maximum | Term Á Á Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Á Á Warrants and Rights Outstanding, Measurement Input | Y Á Á Á 0.4 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2:

[http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain \(loss\) recognized in income from liability measured at fair value on recurring basis using unobservable input \(level 3\), + ReferencesReference 1](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3), + ReferencesReference 1): [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2): [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities \(usually equity\) from the issuer at a specified price, + ReferencesReference 1](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price, + ReferencesReference 1): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, + ReferencesReference 1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, + ReferencesReference 1): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 14.F\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-599-1Reference 2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=prpo_WarrantLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3 EQUITY INCENTIVE PLAN (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions 3 Months Ended Aug. 30, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Á Stock-based compensation Á $ 0.4 $ 0.4 $ 1.1 $ 1.2 Á Employee Stock Option Á Á Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Á Granted (in shares) Á Á Á 75,862 Á Á Granted (in dollars per share) Á Á Á $ 4.99 Á Á Weighted average grant date fair value (in dollars per share) Á Á Á $ 4.54 Á Á Risk free interest rate, minimum Á Á Á 3.94% Á Á Risk free interest rate, maximum Á Á Á 4.26% Á Á Term Á Á Á 6 years Á Á Exercise price $ 6.56 Á Á Á Á Retention period (in years) 1 year Á Á Á Á Outstanding options 304,000 303,433 Á 303,433 Á 232,744 Options repriced 177,000 Á Á Á Á Incremental compensation cost $ 0.5 Á Á Á Á Incremental expense period (in years) 1 year 4 months 24 days Á Á Á Á Stock options, expected to vest, outstanding (in shares) Á 274,463 Á 274,463 Á Á Stock options, expected to vest, outstanding, aggregate intrinsic value Á $ 0.1 Á $ 0.1 Á Á Stock options, expected to vest remaining contractual term Á Á 6 years 9 months 18 days Á Á Unrecognized compensation expense related to unvested stock awards Á $ 1.9 Á $ 1.9 Á Á Unvested stock options, unrecognized compensation expense weighted average recognition period (in years) Á Á Á 1 year 8 months 12 days Á Á Restricted Stock Á Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Stock options, expected to vest, outstanding (in shares) Á 2,492 Á 2,492 Á Á Restricted stock granted Á 0,2492 Á 0,2492 Á Awards outstanding (in shares) Á 0 Á 0 Á Á Minimum [Employee Stock Option Á Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Volatility rate Á Á Á 133.00% Á Á Maximum [Employee Stock Option Á Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Stock options, unvested options, vesting period Á Á Á 4 years Á Á Volatility rate Á Á Á 139.00% Á Á Equity Incentive Plan 2017 Á Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Number of shares authorized Á 320,699 Á 320,699 Á Á Shares available for grant Á 14,705 Á 14,705 Á Á Percentage of annual increase in number of shares authorized for grant Á Á Á 5.00% Á Á Number of additional shares authorized Á Á 71,006 Á Á Equity Incentive Plan 2017 [Employee Stock Option Á Á Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Á Plan expiration date Á Á Jun. 05, 2027 Á Á X - DefinitionPercentage of annual increase in number of shares authorized for grant + ReferencesNo definition available. + Details Name: prpo_PercentageOfAnnualIncreaseInNumberOfSharesAuthorizedForGrant Namespace Prefix: prpo_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) repriced during the period. + ReferencesNo definition available. + Details Name: prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricedNumber Namespace Prefix: prpo_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe retention period of the stock option repriced. + ReferencesNo definition available. + Details Name: prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepricedOptionsRetentionPeriod Namespace Prefix: prpo_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe threshold exercise price of repriced stock options. + ReferencesNo definition available. + Details Name: prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepricedOptionsThresholdExercisePrice Namespace Prefix: prpo_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which an excess of the fair value of the modified award over the fair value of the award immediately before the modification will be recognized for award under share-based payment arrangement, in 'PnYmNDtnHmNs' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: prpo_ShareBasedPaymentArrangementPlanModificationIncrementalCostPeriodOfRecognition Namespace Prefix: prpo_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYmNDtnHmNs' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYmNDtnHmNs' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock \(or unit\) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(vi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(vi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(vii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(vii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(viii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(viii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ix\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ix) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(x\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(x) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xiii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xiii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xiv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xiv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xvi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xvi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xvii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xvii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xviii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xviii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xix\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xix) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xx\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xx) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxiii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxiii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxiv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxiv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxvi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxvi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxvii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxvii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxviii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 29](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxviii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 29): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxix\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 30](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxix) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 30): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxx\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 31](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxx) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 31): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxxi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 32](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxxi) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 32): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxxii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 33](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxxii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 33): [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(xxxiii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(xxxiii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 34)

Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAn excess of the fair value of the modified award over the fair value of the award immediately before the modification. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmMnDTnHmMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYmMnDTnHmMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2017Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3 EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) - Stock options 9 Months Ended Sep 30, 2024 \$ / shares shares Number of Options A Outstanding at beginning of period (in shares) | shares 232,744 Granted (in shares) | shares 75,862 Forfeited (in shares) | shares (5,173) Outstanding at end of period (in shares) | shares 303,433 Exercisable at end of period (in shares) | shares 187,554 Weighted-Average Exercise Price A Outstanding at beginning of period (in dollars per share) | \$ / shares \$ 46.56 Granted (in dollars per share) | \$ / shares 4.99 Forfeited (in dollars per share) | \$ / shares 18.26 Outstanding at end of period (in dollars per share) | \$ / shares 7.19 Exercisable at end of period (in dollars per share) | \$ / shares \$ 7.52 X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3 SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Narrative) (Details) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) segment Sep. 30, 2023 segment Sep. 30, 2023 USD (\$) segment Sep. 30, 2023 segment Dec. 31, 2023 USD (\$) SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract] A A A A Number of segments | segment 1 1 1 1 A Deferred revenue | \$ 282 A \$ 282 A \$ 110 X - DefinitionNet Sales Service Revenue and Accounts Receivable [Abstract] + ReferencesNo definition available. + Details Name: prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract Namespace Prefix: prpo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to

report separate financial information on that content in the entity's financial statements. 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 47-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 47-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 54-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 54-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-18> + Details Name: us-gaap NumberOfReportableSegments Namespace Prefix: us-gaap Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3 SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments \$ 5,280 \$ 4,569 \$ 13,265 \$ 11,043 Service revenue, net Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 4,599 3,738 11,329 8,574 Medicaid | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 8 10 33 22 Medicare | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 8 10 33 22 Medicare | Service revenue, net Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 1,819 1,691 4,435 3,736 Medicare | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 1,819 1,691 4,435 3,736 Self-pay | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 1 39 33 155 Third party payers | Service revenue, net Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 2,743 1,998 6,796 4,661 Third party payers | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 2,743 1,998 6,796 4,661 Contract diagnostics and other | Service revenue, net Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 28 Á 32 Á Contract diagnostics and other | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments 28 Á 32 Á Service revenue, net | Diagnostic Testing Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Revenue, net of contractual allowances and adjustments \$ 4,599 \$ 3,738 \$ 11,329 \$ 8,574 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-51](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-51)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 4: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 5: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 6: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 7: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 8: [http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 91-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91) + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 11.L\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 11.L)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/21474798](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5)

page 22 - Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13): [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt ProductOrServiceAxis=prpo ServiceRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: prpo PayerTypeRevenueSourceAxis=prpo MedicaidMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: prpo PayerTypeRevenueSourceAxis=prpo MedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: prpo PayerTypeRevenueSourceAxis=us-gaap SelfPayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: prpo PayerTypeRevenueSourceAxis=prpo PayerTypeThirdPartyPayerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=us-gaap ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3 SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) - USD ($) in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Sep 30, 2023 Sep 30, 2024 Sep 30, 2023 Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments $ 5,280 $ 4,569 $ 13,265 $ 11,043 Allowance for credit losses (71) (51) (183) (175) Net sales 5,209 4,518 13,082 10,868 Medicaid A A A Disaggregation of Revenue [Line Items] A A A Allowance for credit losses A A (12) A Medicare A A A Disaggregation of Revenue [Line Items] A A A Allowance for credit losses A A (66) A Self-pay A A A Disaggregation of Revenue [Line Items] A A A Allowance for credit losses A A (3) A Third party payers A A A Disaggregation of Revenue [Line Items] A A A Allowance for credit losses A A (102) A Service revenue, net A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 4,599 3,738 11,329 8,574 Allowance for credit losses (71) (51) (183) (175) Net sales 4,528 3,687 11,146 8,399 Service revenue, net | Medicaid A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 8 10 33 22 Allowance for credit losses (3) (4) (12) (10) Net sales 5 6 21 12 Service revenue, net | Medicare A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 1,819 1,691 4,435 3,736 Allowance for credit losses (27) (20) (66) (43) Net sales 1,792 1,671 4,369 3,693 Service revenue, net | Self-pay A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 1 39 33 155 Allowance for credit losses A (3) (3) (15) Net sales 1 36 30 140 Service revenue, net | Third party payers A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 2,743 1,998 6,796 4,661 Allowance for credit losses (41) (24) (102) (107) Net sales 2,702 1,974 6,694 4,554 Service revenue, net | Contract diagnostics and other A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 28 32 A Net sales 28 32 A Product A A A Disaggregation of Revenue [Line Items] A A A Revenue, net of contractual allowances and adjustments 681 831 1,936 2,469 Net sales 681 831 1,936 2,469 X - DefinitionAllowance for doubtful accounts, revenue + ReferencesNo definition available. + Details Name: prpo AllowanceForDoubtfulAccountsRevenue Namespace Prefix: prpo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3): [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4): [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5): [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6): [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7): [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4):

[illegible]

7M7H.RJ)=QC+M'ES'E.-^JRH0+&L^JUVUJGT77I7YZKV XD^L,N17 JW-MM24^XN->?7 XA<O?^Y1WZ<E\$J9KE2 MG9Y/K'K\$;\$U6Y0N1@. [MDE6ZK\$A [WOH1]SZG[C]^LJ]>>.;RGN?>XIS@&F5,URN+., 9TKHNL15G#>#2#+C.AN^YSJ9[E] MOUXNDHVB BM?659PLAWQC+N-M4L9K#V\$QGTG+&^XO.E.J\$90Q0U?U7Q39>L!+!^P^R?>9X.+O?R.3^YZD3W^M)C6LJOGW\$KZ2/E.11BL &L1Y8S9#>#>#4SJ=BLT1#F5FV5N\$J0J6&P2 &G34I3R0!N+O^N=[TO, "ZEBQ?Q\$?>X158 IQD=C+XLJ0J1M0H4+>],636". MNV?6? 20L0,.)>P^PO0EN07W75]^T2G^1>|D2|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|UJ>R MD@Z-&2&(S[C1N;HDP=Y->W-UO7\$W!^M&=7U>RHOV/Z4H 18506H2B MB4(NK 8Y^>4;UE175P]>IL.O)2J@&- &70&4)1&BTA10TTJ]B@>J@>ATAZ M2ZB+>0L-Z41 9060FD1BB^<L^K%OZ1^>MV9V;YEUL&J11 M67TYKW^X&LOM6 M,S3U^P^>J|K.O>V?>T3V7J@|VK<..WKXU^J [KW@>ZU;Z2\$STTS]+4#113|U|2 J MOCW^>VHQ>1E|H|E|G;P.JOJ5C>0 T>V&QF1Y9N1C>2>=|O|>+A5N#BAEM CMQZ^>K^J|OJ2^6T^Z2D>4KDQ&7B@M@>^**U^T41)-480?5^CET^7BC-M (L)I^*V^T (H+4+11\$4V1B J=J7W+6WW+&+Y3F4X9VZLSJEAMT:Q9^QO U M1A6 =1.802QJ102E>8JCI?>\$.A\$8. \$4J M@>4510XP\$]>@5 MON9QJ53.3@>3J.R#0.-ZD1 9060FD1BB^<M^&.. %>6MDUE>1?>38KVL&^>P7T3 MWEILH(ZOHS^>8YQ,KJ L/>J-P|GOC^>RM^Y+U|W4:SJ|Y|>J^J-ZZ HQM(1^>.XVF-7+D^> &G&F\$>M96W4Y118RP[VW<L2V;RJ|4|>X4>YIPL^>M\$>C31/7MF474-N2&RJ>OJ.X-R55Y. @6QJUA163V1B13F=C M^_J3CZQJ^>1 MWA9JYV7.^>4&R(A+5072@N@M1^>BU T44R-1^QEZ; [>7]> J M68#1070\$G G./O>U>J^>1&18506H2B89J]3&EG I3+1 [4MX72 M^C-AJ]^>V\$TB43;R17V,6NV.SV+1.8.1^5YVOF@>U^>JH@XG13>D2M M9NC(HK-88M.A1?1]H-WAWFEP^<M^>J35^>5/U>Y1(T1PQJSHNSGOR^>YHAB MMANKU.S.16W.F3E<[QKOOI^QWYQO ALU.527 M@MA-(B%\$U49&K-\$.NF;7MHJS M0ND,UUA462YKJFO^LHUU!0P9=0H;0D%>+2%\$>1@>.QEPQJSUO.K[BT]SQJ.LM^F.G.Z&P533N];.8%J8K<=NCUJ|B.A.U?P^M/(>+>S5M1|>+>?>CPI0 MBVNAMI^>BU^TIS& CG\$HOK9E\$<C^>Y^>VO>CG>?CGET?>7R)Y?>FV IW M+3YE99EMZHSJ^>[MS2]QV&UJ+M =N|NJ|@PD LC#AK&L+J^>I.B^>#^>4E M1MASSR3S^>OHA=RK\$>^CEXS\$>L2IUD6? \$6DD6?5\$>@7DYFB8K9>U>.6.J\$S^>M^>W3AQ0HQ6>3V24D;C^>P^>G^>QD^>QJ YRVAS43ID&9\$ ALI&?>@>(VATLZV25]H1 M04W\$<^>A21^>1A?>62<K^>8V&F^>Y^>M|E1P^>1EH&Y:O&CX. P231G>2=NZEK@>J?>N?>N&KJF D^>VTF6S;S. MP18=N^>N^>ZAYJ|UW+EPBNW1.556|O|T;06F1U6^>C&^>(Y-M^>?>H^>C^>=HW5P1^>M^>?>[J04SFDDF;1?>62^>MNPVB8VZM1K^>O&1XFU->+>?>X^>OTFL B<^>T^>7%>A. MQBA=>F>5>E.QO.EQ:YGHOGHZ W83Q9QJ0Y-OY3<430510>E.O.;S^>T4^>S^>M12?>7178%>20%>RA.<^>1^>YGM Y^>TZ;LJ WQCP\$5 GNH^>Q918;?>J^KY=>=@ MK.O?>[DHNJZJWGLY^>G94^>J?>838S^>[>00M61^>1^>Y>UT^>Y^>W8UTP2]IC[K1^>2%>..@>J^>F75J02^>M^>MP|F62R0&74D74P :B|>|>X;|W;W^KZ MQ1Q 9475^>SUWX8=>LB|H;S9^>B> [9+ MTS<^>8L3^>GK3ZLN^>P^>NRWA3B0F=TOO7^>W^>PWJW>V>V>=HY:81^>ACA&B&QZIN; MUMB^>FCAR^>91X(OB5G7P&P1K2K^>^>4|X1F4|>1C142464A/S^>Y^>K|>X2&[>J MJTJ;QWN^>A>?>^>^>J^KO1^>OB&E. B1QL;E!H\$5@>QJMPQE0A^>O^>H5P1^>P^>GT1 M39C^>UWLE8^>1^>M6T^>7^>L^>(25;^>X^>1^>O^>7&R^>K1^>O+X^>H1^>^>P^>S&E8^>8+4^>D2^>M1^>L^>FH9&..@>J^>K2&O(337J^>C(WC5WVJ2B3 &16&[EB8 MQ>RZ4W T0F^>9O^>V^>L!1^>VBJO^>U>.>9RVMW^>?P^>M^>W^>V^>ES^>O^>QA^>EK.GV7+F M|E1F7TA-WKSLLI>HU4KJ^>?^>7.8^>6^>L+K&P^>SC^>_>M^>Q4M1P4!!>2V^>?>1!>1^>LCU>=<^>9^>CD&W BA? G.PXJDIJ>+>@2D|MI@UBJY)O|>R^>V UCMJ|&8;XQ5Q11^>RZ&8Q^>%.>X^>3^>H+>A+>E=IR1FO^>U^>M^>Q54C@VQJ5/M^>G^>TC\$OS^>+>?>7^>M^>\$. S(!U^>O^>W^>1Y^>1^>S^>#&K^>QWXO>+>[M63 M4B/317K/P^>R^>XP8? KT@69A^>^>S2J J07J^>7B^>0^>QZ1^>S^>S^>G^>HSG. 5^>TH+>MA^>LCR@>KV^>B^>7^>R^>7^>L^>C^>N^>Q^>83F200>+>J^>R25^>H^>F^>A^>A^>7+>#>1GIED6Q4A6D.3 M^>H^>U^>WJ|B- &8Y|YJ32D2PQ>+>JSG+I^>ZCHUD^>HJN1=OQ>P3YK<0^>0^>9>?>TYE M^>ACN(J)<^>P^>HKKJGW@>U^>6T1 M^>P^>S^>6L^>6L+>B.S.G^>X^>Q^>NAT^>9Y3E^>J^>E^>I

0%#HJZ\$YU0HXT!>ZJ^>OF\$DXD7Y941&U-M\$.#JF=E\$(>,@B9<1/|RH;N!M.../40 M.(9@%)JL0SPW/DK!X!>:P-J[KB|HJZRJ5L3RP) WX@ (U,9%DTNK)WR7@Q&RKPF-ME @>5>!*MZD#!-1.)JD!D?>ZH&U(A326G14)4C%G.#H44132-A*FA66N M*5H&4&K,FTH \$!<=>18U-RBQ|H|&|07*+4+0!\$TWX4L!D#*# MUJ@>RH M!<E, [K81R|P]>:Z37\$U!>5!D8.2-VH:7#1<+<X4E 9!>=B|T9 M!YH6041790,N95(H)>= T53\$Y2(K)>#&KJKO(R&V\$JBED>RN|,M-BQ|<BCL%>|OTTF,ST|>UPDKED(C,F,H&H2N<&&*>V,J@F55RZ| MJX@153VH|G7H<1E6&C,2K)UK5F1.ZRW (Q5O!<Q\$OSCR!<1A8(TO=5-/7 MJ6B7,5&E1P58%MAXR\$M6YYP1&X<12K8%<@<8B|P9-E-6\$44RQF,IE5 ME>=>JH4+XZP7!79C<C#MU'DX&L7M!>LF1BB@>5.B2HYHCW,|IC<B,D5&GLC<=>MSM-19EOI25IAP1+3Z<@>7J,P4%>E25P7!BM06604.C9D@>B#>M#P!6H<EX&L V,@>)DX#Q04,9|Y|BU%> &VPB5<@TMJ45C5C<K#O6N-MD|H|LAH B&L<=>|XK6MU6Q4Q!<1C9&45%>).9R|KJ1(1B=F2|T|>QH8S,L MJHKX6M!<5!T1<BK482VVBV CN=>C|T|T#>P#W&C YG1F5=F+1>Y>U>J>B M!MOCQF\$>4>3!>30R<@>3=HJ0U>V5>W2FYMV19.G@>1VJ3CU=>A#(A9&3!>..M28Y9J9@FO&OBP(RB\$>QID9Q,K9K!534 MIXB-M|A|EAC5A5Q,@>613+1&B|CYG|97Q|>26C-/9@O!>N!>A!>3\$!>M!>#SWUD|>#N<CEX13<4+7W>=#\$KX<ZU502&50\$WJ>#>^>9C+88,&|Z|FQ.NX> M0<=>[Q,8ZFTG3-LA-WH2,E>9-J|>HJ0YA?>0&X|7|QHYH**N27J|H09.OX<MC#|>LC9>+>G%,>4ZM0<UE48.0-#>2Z>9B\$F)DQ|>[O-J|>1A<E5-G+>M42 M1>,>|FJ@>UE7|QOHDW5|J5+4RM|H|H|MA0XO9VM3W3!WQ<V!K.545.G78F-MZ MN<M|>U68=&UX9Y<V-APYB@>@>1I9F*2F<6N<+>|CQ MAQVO|8X|M!>=|JQ@>F.P-36J9WQ|T6\$|1G<7+1UC<626\$|1TUNK|M\$>JP>+!5H<M>?>OX15H&|> ZQ,>28G XQ|>?A.2H8MDL7R|(KH,V M|KU|H|<+>1.O,P<C#B1D>M|J|T16+!>ENJ9F|>J|>H+1 MBLK7+3ZT|B&=>^AN3F&XT|>4QZJ.G 8*>DWAVV>J|>L1+>1+N<+>=>1W>?>2.68 M=BFU!>..6#>|/80|T|BVC7B5,Y4D,18\$0ZNNW? 6P<S1<=>K|>5,FDDH6D@>X M7+1+>HE=J|>5,3#>6T|>L|W0!>5N42ECX34RKDZ U(6<2+1W<M|T|S|>X<=>ZP<FKW3U|<=>ZNA<FV<QUNZ+3|341|UW6G757J 7 MQ?>H?> >I>Z>G|>Y|OYHBMQ<R&N<O2CWA?>4WJ9|>HJ|>23V KB8>VE|>Q59>JZ MU+1,2BGUJ>7-L>XZ7VBOQ<=>16VFS3B|J0F6MELG 48@>4/4&T5<Q8V&A MQHLY7A21H2>YJ/C/5%5S|> ^Y7 46L#H10 (> 9EF<P<4SP1 M#<=>9>>9>PO<VJR-W H9657F9Q|OLFR3|CYD05\$>EF173,1WUVUC<=>1196 M3KGPBR#H!<=>GCTA05A9|>U, NJM|>O<G&DP99\$>T2A=H,O9<|G|CZPZ&3 L M%VR<@>[O|Q453R=>A|>#Q<,>B2H\$>U\$>CYY>@>QLZ,/G+>(\$CA (3ZQ 8,<X1B\$<=>\$>XVF|ZNY<^>6|1,<N8|>O?>5ZBA*E6V*2V@0=>):\$>V<V-BD<9|<Re>8<=>C0@>A|>#B M70>J6+>YCE@>W|6FU Y.VM<C<=>Q|>PWRQ M,YU<3<,>C20Z|<=>=>PWOQF<|>[>#9RFFL,15L\$<=>|>Q?>SMU|F7>9>9P M?>XQ?>FOFXDBFFQ K1<C.MRRO@>P/LZQ<=>H\$>H\$8\$A|>O&C&W*=>=>=>W! M#WP>+>8W556Q?>J|KU#>2>,>8U>U+D|6|(<CSK|H?Y<WA=)H!>+>|>XDS>=>2B<A M#>+>74L|D&10XJ V,93+E<=>@>F&D|U&H|>51-X31|JGX&5L|E|>H0B#M\$>S|8?>J, MN2<M&W4H<=>(>O P52#V=>X|Y|>#S<=>Q?>6HQ|>AZFFZG&G<B|Z RI-Z!<=>=>MO3<+>OYZ|J9|>H|>R775NN3\$>T1\$>U<QW6 5CH,AFZ>51Q<4\$>+P3R X0<H\$ M.0W\$<=>RB3?>=>=>J07Z&|>|>UJ361+14#>K,M99\$>AHR=>U>VU JV0+>1O=>|>=>99M|, MO J>G<?>5&R T|>2MTM9|O|>NIN,H8< S N1>+>OTFE,B E2D<Q|>QTVQH M!>H55|ZNN<=>GOLE\$5|D9374SH<N5|>K7Q1<=>5\$>V&V71<=>4\$>L#1+10 (> " M9EG<1+10 (>|>@>9<=>+>PO<VJR-W H9657F17M12P6%>AN12<=>2OP 21+16L<VUCAGAW-VV1A MKD<B2<=>=>SGCOW<EWN<D<JX51, BUSHBQ<94X4YH7R<9%>DQ2?>RA(9%>K6R\$>M1<A M4VUJ72|D|>JZJTF M|ODV,W<=>CXY+MLD+>)>.*T66W|>51C<V|>2<=>QK3L+1+9X1 C,<=>=>8!>1 MK\$?>HWWZ<0+>K1#>,>3&G6<=>O\$>=>8Y|Y|>O<S&XGZ<O+>1\$>9>=>78V-1AXD&3R V#N3<H\$+>1<=>|>M|O|>9X?>Z<XW\$>90<HVB5D&Y<9 M&WGSY0B,M A<5RMI+>R|J\$U QX<C0Q0D352KB|>G8Y|>#K10F1T<4>9|M 7T2U ZB+>#L1FT4CA<=>IRPOH1<=>V|>B(XA0X2,CGN/K<5ND7Z<7VBBZ>^>Q513 MQ<=>1>1,*&=>=>D2G/A4+1K5(WK3|>P&\$>R=>H|>HW0N<3<=>KRTH<DAN|>7VAS3 M=YKA|HKMA45\$>|>Q<60-MH2F@>QA(W,1J2ZV(S<=>@>T9|>|>PNB9\$>H&|>#>1#> M99*692*682>=>H%BC,H33%>GL9T(WTX,Y%>J6,E(96B9V,9Z&QD|>DGY9 21 ME\$>=>640E&N!>AHD51\$Z\$>=>Q7<=>Z#8,>O|H?>0%>M6|>^>|>|>M:Z82)>#R81 R<@>7' MH-LRHBZX<+>B4H\$5|Y|Y|>)>|>A0<PC CX17<+>D7H<76-8EN%>Z<3|C.RP<Q|>M91A<P4H.EA|>DP,/@>K1/LHGXW&PFE5|>U@>U|>H<6<|>X<N,D47|P1<=>1+>M7H|>E<Y>D3TH<=>K+>+>=>2M3|<=>E|>P<|>K|>K<Z48@>JZWJNHQ7PM2-19H&VOIU MWL<V+|>0<=>(\$>9>+>PO<VJR-M H9657F9Q|>H8< (MVFWM2 XJ|>HRSU<V=RGTW+70,H&1<=>L7\$0,9C|>X1<=>|> FBD0 F53A|F|>M6F=>VU9&lt

[illegible]

[illegible]

false false R3.htm 995200105 – Statement – CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet
http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false
R4.htm 995200200 – Statement – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet
http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm
995200300 – Statement – CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet
http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5
false false R6.htm 995200305 – Statement – CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet
http://www.precipiodx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)
Statements 6 false false R7.htm 995200400 – Statement – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet
http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm
995210101 – Disclosure – BUSINESS DESCRIPTION Sheet http://www.precipiodx.com/role/DisclosureBusinessDescription BUSINESS DESCRIPTION Notes 8 false false R9.htm 995210201 –
Disclosure – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES Notes 9 false false R10.htm 995210301 – Disclosure – LONG-TERM DEBT Sheet http://www.precipiodx.com/role/DisclosureLongTermDebt LONG-TERM DEBT Notes 10
false false R11.htm 995210401 – Disclosure – ACCRUED EXPENSES Sheet http://www.precipiodx.com/role/DisclosureAccruedExpenses ACCRUED EXPENSES Notes 11 false false R12.htm
995210501 – Disclosure – COMMITMENTS AND CONTINGENCIES Sheet http://www.precipiodx.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES
Notes 12 false false R13.htm 995210601 – Disclosure – LEASES Sheet http://www.precipiodx.com/role/DisclosureLeases LEASES Notes 13 false false R14.htm 995210701 – Disclosure –
STOCKHOLDERS' EQUITY Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 995210801 – Disclosure – FAIR VALUE
Sheet http://www.precipiodx.com/role/DisclosureFairValue FAIR VALUE Notes 15 false false R16.htm 995210901 – Disclosure – EQUITY INCENTIVE PLAN Sheet
http://www.precipiodx.com/role/DisclosureEquityIncentivePlan EQUITY INCENTIVE PLAN Notes 16 false false R17.htm 995211001 – Disclosure – SALES SERVICE REVENUE, NET AND
ACCOUNTS RECEIVABLE Sheet http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivable SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE
Notes 17 false false R18.htm 995211101 – Disclosure – SUBSEQUENT EVENTS Sheet http://www.precipiodx.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 18 false false
R19.htm 995445 – Disclosure – Insider Trading Arrangements Sheet http://xbri.sec.gov/eed/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm
99920202 – Disclosure – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 99930203 – Disclosure – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet
http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables
http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 99930303 – Disclosure – LONG-TERM DEBT (Tables) Sheet
http://www.precipiodx.com/role/DisclosureLongTermDebtTables LONG-TERM DEBT (Tables) Tables http://www.precipiodx.com/role/DisclosureLongTermDebt 22 false false R23.htm 99930403 –
Disclosure – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. (Tables) Sheet http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. (Tables) Tables 23 false false R24.htm 99930603 – Disclosure – LEASES (Tables) Sheet
http://www.precipiodx.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.precipiodx.com/role/DisclosureLeases 24 false false R25.htm 99930703 – Disclosure –
STOCKHOLDERS' EQUITY (Tables) Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables
http://www.precipiodx.com/role/DisclosureStockholdersEquity 25 false false R26.htm 99930903 – Disclosure – EQUITY INCENTIVE PLAN (Tables) Sheet
http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables EQUITY INCENTIVE PLAN (Tables) Tables http://www.precipiodx.com/role/DisclosureEquityIncentivePlan 26 false false
R27.htm 99931003 – Disclosure – SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables) Sheet
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables) Tables
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivable 27 false false R28.htm 99940101 – Disclosure – BUSINESS DESCRIPTION (Narrative) (Details) Sheet
http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails BUSINESS DESCRIPTION (Narrative) (Details) Details
http://www.precipiodx.com/role/DisclosureBusinessDescription 28 false false R29.htm 99940201 – Disclosure – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)
Sheet http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Details
http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 99940202 – Disclosure – SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Outstanding Securities) (Details) Sheet http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details) Details http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 30 false false
R31.htm 99940301 – Disclosure – LONG-TERM DEBT (Schedule of Debt) (Details) Sheet http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails LONG-TERM DEBT
(Schedule of Debt) (Details) Details http://www.precipiodx.com/role/DisclosureLongTermDebtTables 31 false false R32.htm 99940302 – Disclosure – LONG-TERM DEBT (Narrative) (Details)
Sheet http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails LONG-TERM DEBT (Narrative) (Details) Details
http://www.precipiodx.com/role/DisclosureLongTermDebtTables 32 false false R33.htm 99940303 – Disclosure – LONG-TERM DEBT (Financed Insurance Loan) (Details) Sheet
http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails LONG-TERM DEBT (Financed Insurance Loan) (Details) Details
http://www.precipiodx.com/role/DisclosureLongTermDebtTables 33 false false R34.htm 99940304 – Disclosure – LONG-TERM DEBT (Business Loan Agreement) (Details) Sheet
http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails LONG-TERM DEBT (Business Loan Agreement) (Details) Details
http://www.precipiodx.com/role/DisclosureLongTermDebtTables 34 false false R35.htm 99940401 – Disclosure – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES. (Accrued Expenses)
(Details) Sheet http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES.
(Accrued Expenses) (Details) Details http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 35 false false R36.htm 99940501 – Disclosure –
COMMITMENTS AND CONTINGENCIES (Narrative) (Details) Sheet http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND
CONTINGENCIES (Narrative) (Details) Details http://www.precipiodx.com/role/DisclosureCommitmentsAndContingencies 36 false false R37.htm 99940601 – Disclosure – LEASES – Narrative
(Details) Sheet http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails LEASES – Narrative (Details) Details 37 false false R38.htm 99940602 – Disclosure – LEASES – Operating and
Financing Leases (Details) Sheet http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails LEASES – Operating and Financing Leases (Details) Details 38 false false
R39.htm 99940603 – Disclosure – LEASES – Future Minimum Lease Payments (Details) Sheet http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails LEASES –
Future Minimum Lease Payments (Details) Details 39 false false R40.htm 99940604 – Disclosure – LEASES – Other Information (Details) Sheet
http://www.precipiodx.com/role/DisclosureLeasesOtherInformationDetails LEASES – Other Information (Details) Details 40 false false R41.htm 99940605 – Disclosure – LEASES – Operating and
Financing Lease Cost (Details) Sheet http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails LEASES – Operating and Financing Lease Cost (Details) Details
41 false false R42.htm 99940701 – Disclosure – STOCKHOLDERS' EQUITY (Common Stock) (Details) Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails
STOCKHOLDERS' EQUITY (Common Stock) (Details) Details http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 42 false false R43.htm 99940702 – Disclosure –
STOCKHOLDERS' EQUITY (At The Market Offering Agreement) (Details) Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails
STOCKHOLDERS' EQUITY (At The Market Offering Agreement) (Details) Details http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 43 false false R44.htm 99940703 –
Disclosure – STOCKHOLDERS' EQUITY (Registered Direct Offering) (Details) Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails
STOCKHOLDERS' EQUITY (Registered Direct Offering) (Details) Details http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 44 false false R45.htm 99940704 – Disclosure –
STOCKHOLDERS' EQUITY (Preferred Stock) (Details) Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails STOCKHOLDERS' EQUITY (Preferred Stock)
(Details) Details http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 45 false false R46.htm 99940705 – Disclosure – STOCKHOLDERS' EQUITY (Series B Preferred Stock)
(Details) Sheet http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) Details
http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 46 false false R47.htm 99940706 – Disclosure – STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) Sheet
http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) Details
http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 47 false false R48.htm 99940707 – Disclosure – STOCKHOLDERS' EQUITY (Warrants) (Details) Sheet
http://www.precipiodx.com/role/DisclosureStockholdersEquityWarrantsDetails STOCKHOLDERS' EQUITY (Warrants) (Details) Details
http://www.precipiodx.com/role/DisclosureStockholdersEquityTables 48 false false R49.htm 99940801 – Disclosure – FAIR VALUE (Narratives) (Details) Sheet
http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails FAIR VALUE (Narratives) (Details) Details http://www.precipiodx.com/role/DisclosureFairValue 49 false false R50.htm
99940901 – Disclosure – EQUITY INCENTIVE PLAN (Narrative) (Details) Sheet http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails EQUITY INCENTIVE PLAN
(Narrative) (Details) Details http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables 50 false false R51.htm 99940902 – Disclosure – EQUITY INCENTIVE PLAN (Summary of Stock
Option Activity) (Details) Sheet http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails EQUITY INCENTIVE PLAN (Summary of Stock Option
Activity) (Details) Details http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables 51 false false R52.htm 99941001 – Disclosure – SALES SERVICE REVENUE, NET AND
ACCOUNTS RECEIVABLE (Narrative) (Details) Sheet http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableNarrativeDetails SALES SERVICE REVENUE,
NET AND ACCOUNTS RECEIVABLE (Narrative) (Details) Details http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 52 false false R53.htm
99941002 – Disclosure – SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) Sheet
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE
(Schedule of Net Revenues) (Details) Details http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 53 false false R54.htm 99941003 – Disclosure –
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) Sheet
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails SALES SERVICE REVENUE, NET AND ACCOUNTS
RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) Details http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 54 false false
R55.htm 99941004 – Disclosure – SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) Sheet
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails SALES SERVICE REVENUE, NET AND
ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) Details http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 55
false false R56.htm 99941005 – Disclosure – SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) Sheet
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE
(Schedule of Receivables) (Details) Details http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 56 false false R57.htm 99941006 – Disclosure –
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) Sheet
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails SALES SERVICE REVENUE, NET AND
ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) Details http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 57
false false R58.htm 99941007 – Disclosure – SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations)
(Details) Sheet http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails SALES
SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details) Details
http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables 58 false false All Reports Book All Reports prpo 20240930.xsd prpo 20240930_eal.xml prpo-
20240930_def.xml prpo 20240930_lab.xml prpo 20240930_pre.xml prpo 20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbri.sec.gov/dei/2024 http://xbri.sec.gov/eed/2024 true true JSON
78 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "prpo 20240930x10q.htm": { "nsprefix": "prpo", "nsuri": "http://www.precipiodx.com/20240930", "dts": { "schema":
{ "local": { "prpo 20240930.xsd" }, "remote": { "http://www.xbrl.org/2003/xbri-instance 2003-12-31.xsd", "http://www.xbrl.org/2003/xbri-linkbase 2003-12-31.xsd", "http://www.xbrl.org/2003/xl-
2003-12-31.xsd", "http://www.xbrl.org/2003/xlink 2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt 2005.xsd", "http://www.xbrl.org/2006/ref 2006-02-27.xsd",
"http://www.xbrl.org/rrr/arerule/esma-arerule 2018-11-21.xsd", "http://www.xbrl.org/rrr/role/negated 2019-12-16.xsd", "http://www.xbrl.org/rrr/role/reference 2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbri.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbri.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbri.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbri.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbri.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
"https://xbri.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbri.sec.gov/country/2024/country-2024.xsd", "https://xbri.sec.gov/dei/2024/dei-2024.xsd", "https://xbri.sec.gov/eed/2024/eed-
2024.xsd", "https://xbri.sec.gov/eed/2024/eed-sub-2024.xsd", "https://xbri.sec.gov/sftp/2024/sftp-2024.xsd" }, "calculationLink": { "local": { "prpo 20240930_eal.xml" }, "definitionLink": {
"local": { "prpo 20240930_def.xml" }, "labelLink": { "local": { "prpo 20240930_lab.xml" }, "presentationLink": { "local": { "prpo 20240930_pre.xml" }, "inline": { "local": { "prpo-
20240930x10q.htm" } } }, "keyStandard": 236, "keyCustom": 54, "axisStandard": 18, "axisCustom": 2, "memberStandard": 21, "memberCustom": 28, "hidden": { "total": 17, "http://fasb.org/us-
gaap/2024": 12, "http://xbri.sec.gov/dei/2024": 5 }, "contextCount": 240, "entityCount": 1, "segmentCount": 52, "elementCount": 547, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-
gaap/2024": 744, "http://xbri.sec.gov/dei/2024": 29, "http://xbri.sec.gov/eed/2024": 4 }, "report": { "R1": { "role": "http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation",
"longName": "995200900 Document DOCUMENT AND ENTITY INFORMATION", "shortName": "DOCUMENT AND ENTITY INFORMATION", "isDefault": "true", "groupType": "document",
"subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration 1-1-2024-To 9-30-2024-glkrZUKtkWgHdC48SaFg", "name": "dei:DocumentType", "unitRef":
null, "xisNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo 20240930x10q.htm", "first": "true", "unique": true
}, "uniqueAnchor": { "contextRef": "Duration 1-1-2024-To 9-30-2024-glkrZUKtkWgHdC48SaFg", "name": "dei:DocumentType", "unitRef": null, "xisNil": "false", "lang": "en-US", "decimals":
null, "ancestors": { "p": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo 20240930x10q.htm", "first": "true", "unique": true } }, "R2": { "role":
"http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 Statement – CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName":


```

CONSENSUED-CONSOLIDATED-BALANCE-SHEETS,"isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As-Of 9 30 2024 U6dH-wWtEu68Yea63owsKA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As-Of 9 30 2024 U6dH-wWtEu68Yea63owsKA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995200105-Statement-CONDENSED-CONSOLIDATED-BALANCE-SHEETS (Parenthetical)", "shortName": "CONDENSED-CONSOLIDATED-BALANCE-SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As-Of 9 30 2024 U6dH-wWtEu68Yea63owsKA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As-Of 9 30 2024 U6dH-wWtEu68Yea63owsKA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995200200-Statement-CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "shortName": "CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 KJezCFGnSEaj28KXDvXu1w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 KJezCFGnSEaj28KXDvXu1w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995200300-Statement-CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "shortName": "CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As-Of 12 31 2022 us-gaap:StatementEquityComponentsAxis-us-gaap:CommonStockMember-Cvnd-WnthkOhYp0RrLxRuG", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As-Of 12 31 2022 us-gaap:StatementEquityComponentsAxis-us-gaap:CommonStockMember-Cvnd-WnthkOhYp0RrLxRuG", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995200305-Statement-CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "shortName": "CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 KJezCFGnSEaj28KXDvXu1w", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 KJezCFGnSEaj28KXDvXu1w", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995200305-Statement-CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "shortName": "CONDENSED-CONSOLIDATED-STATEMENTS-OF-OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 KJezCFGnSEaj28KXDvXu1w", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 KJezCFGnSEaj28KXDvXu1w", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995210101-Disclosure-BUSINESS-DESCRIPTION", "shortName": "BUSINESS-DESCRIPTION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995210201-Disclosure-SUMMARY-OF-SIGNIFICANT-ACCOUNTING-POLICIES", "shortName": "SUMMARY-OF-SIGNIFICANT-ACCOUNTING-POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995210301-Disclosure-LONG-TERM-DEBT", "shortName": "LONG-TERM-DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true }, "longName": "995210401-Disclosure-ACCURED-EXPENSES", "shortName": "ACCURED-EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 grkZUKtkWgHd-C48SaFg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm",
```

```

{"id": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:DebtDisclosureTextBlock", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:DebtDisclosureTextBlock", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R23": {"role": "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930403-Disclosure-ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R24": {"role": "http://www.precipiodx.com/role/DisclosureLeasesTables", "longName": "99930603-Disclosure-LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "prpo-LesseeBalanceSheetInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "prpo-LesseeBalanceSheetInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R25": {"role": "http://www.precipiodx.com/role/DisclosureStockholdersEquityTables", "longName": "99930703-Disclosure-STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R26": {"role": "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables", "longName": "99930903-Disclosure-EQUITY INCENTIVE PLAN (Tables)", "shortName": "EQUITY INCENTIVE PLAN (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R27": {"role": "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables", "longName": "99931003-Disclosure-SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)", "shortName": "SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{"ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R28": {"role": "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "longName": "99940101-Disclosure-BUSINESS DESCRIPTION (Narrative) (Details)", "shortName": "BUSINESS DESCRIPTION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": {"contextRef": "As-Of-9_30_2024-Ud6H-wWTeU68YEa63owsKA", "name": "prpo:AccumulatedNetIncomeLoss", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": [{"p": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true}, {"uniqueAnchor": {"contextRef": "As-Of-9_30_2024-Ud6H-wWTeU68YEa63owsKA", "name": "prpo:AccumulatedNetIncomeLoss", "unitRef": "Unit-Standard_USD-azLHODWL5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": [{"p": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true, "unique": true} ]}, {"R29": {"role": "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "99940201-Disclosure-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit-Standard-shares-Mm-DRpTS0GuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": [{"p": "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true}, {"uniqueAnchor": null}, {"R30": {"role": "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails", "longName": "99940202-Disclosure-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-grkKZUKtkWgHd-C48SaFg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit-Standard-shares-Mm-DRpTS0GuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": [{"p": "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": true}, {"uniqueAnchor": {"contextRef": "Duration_1_1_2024_To_9_30_2024-us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-us-gaap:EmployeeStockOptionMember-MZOrjRopka7bm-TPfk2KA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit-Standard-shares-Mm-DRpTS0GuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": [{"p": "td", "tr", "table": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "ix:continuation": "div", "div": "div", "body": "html", "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "unique": true} ]}, {"R31": {"role": "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "longName": "99940301-Disclosure-LONG TERM DEBT (Schedule of Debt) (Details)", "shortName": "LONG TERM DEBT (Schedule of Debt) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": {"contextRef": "As-Of-9_30_2024-Ud6H-wWTeU68YEa63owsKA", "name": "us
```



```

"ancestors": [ "p", "td", "tr", "table", "us-gaap:FinancialLeaseLiabilityPaymentsRiderOffFiscalYear", "unitRef", "Unit-Standard_USD_azLHODWLS5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "-3", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" } }, "R40": { "role": "http://www.precipiodx.com/role/DisclosureLeasesOtherInformationDetails", "longName": "99940604-Disclosure-LEASES-Other-Information (Details)", "shortName": "LEASES-Other-Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": "null", "ancestors": [ "p", "td", "tr", "table", "prpo:LesseeWeightedAverageLeaseTermAndDiscountRateTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "uniqueAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": "null", "ancestors": [ "p", "td", "tr", "table", "prpo:LesseeWeightedAverageLeaseTermAndDiscountRateTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R41": { "role": "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails", "longName": "99940605-Disclosure-LEASES-Operating-and-Financing-Lease-Cost (Details)", "shortName": "LEASES-Operating-and-Financing-Lease-Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration-7-1-2024-To-9-30-2024-KJezGfGnSEaj28KXDvXu1w", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit-Standard_USD_azLHODWLS5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": [ "p", "td", "tr", "table", "us-gaap:OperatingLeaseCost", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "uniqueAnchor": { "contextRef": "Duration-7-1-2024-To-9-30-2024-KJezGfGnSEaj28KXDvXu1w", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit-Standard_USD_azLHODWLS5UihNU4KmWhV4w", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": [ "p", "td", "tr", "table", "us-gaap:OperatingLeaseCost", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R42": { "role": "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails", "longName": "99940701-Disclosure-STOCKHOLDERS'EQUITY (Common Stock) (Details)", "shortName": "STOCKHOLDERS'EQUITY (Common Stock) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true" }, "uniqueAnchor": { "contextRef": "As-Of-12-20-2018-767271n0WU1qQu9pGIgwG", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CommonStockSharesAuthorized", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R43": { "role": "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "longName": "99940702-Disclosure-STOCKHOLDERS'EQUITY (At The Market Offering Agreement) (Details)", "shortName": "STOCKHOLDERS'EQUITY (At The Market Offering Agreement) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit-Divide_USD_shares_V1NyOrjeB0e8oin2u2JYg", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true" }, "uniqueAnchor": { "contextRef": "As-Of-4-2-2021-dei-LegalEntityAxis-prpo-AllianceGlobalPartnersMember-us-gaap-SubsidiarySaleOfStockAxis-prpo-AtMarketOfferingMember-ZHRFI9wB3kwpoldvjTsw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit-Divide_USD_shares_V1NyOrjeB0e8oin2u2JYg", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CommonStockParOrStatedValuePerShare", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R44": { "role": "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "longName": "99940703-Disclosure-STOCKHOLDERS'EQUITY (Registered Direct Offering) (Details)", "shortName": "STOCKHOLDERS'EQUITY (Registered Direct Offering) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit-Divide_USD_shares_V1NyOrjeB0e8oin2u2JYg", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true" }, "uniqueAnchor": { "contextRef": "As-Of-6-8-2023-us-gaap-SubsidiarySaleOfStockAxis-prpo-RegisteredDirectOfferingMember-N7ZfOUwixugC5u40jibXA", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R45": { "role": "http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails", "longName": "99940704-Disclosure-STOCKHOLDERS'EQUITY (Preferred Stock) (Details)", "shortName": "STOCKHOLDERS'EQUITY (Preferred Stock) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true" }, "uniqueAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R46": { "role": "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails", "longName": "99940705-Disclosure-STOCKHOLDERS'EQUITY (Series B Preferred Stock) (Details)", "shortName": "STOCKHOLDERS'EQUITY (Series B Preferred Stock) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As-Of-9-30-2024-Ud6H-wWTeU68YEa63owsKA", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "uniqueAnchor": { "contextRef": "Duration-7-1-2024-To-9-30-2024-us-gaap-StatementClassOfStockAxis-us-gaap-PreferredClassBMember-TGVUdhmtCKOeMWwlp0_ZFw", "name": "us-gaap:ConversionOfStockSharesConverted1", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "R47": { "role": "http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails", "longName": "99940706-Disclosure-STOCKHOLDERS'EQUITY (Schedule of Warrants) (Details)", "shortName": "STOCKHOLDERS'EQUITY (Schedule of Warrants) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration-9-1-2023-To-9-30-2023-z6-6LS0na0avoHTBfd8KBA", "name": "prpo:ClassOfWarrantOrRightExpired", "unitRef": "Unit-Standard_shares_Mm-DRpTSOGuqEA7EN5Pmw", "xsiNil": "false", "lang": "null", "decimals": "-1", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "prpo-20240930x10q.htm", "first": "true", "unique": "true" }, "uniqueAnchor": { "contextRef": "Duration-9-1-2023-To-9-30-2023-z6-6LS0na0avoHTBfd8KBA", "name": "prpo:ClassOfWarrantOrRightExpired", "unitRef": "Unit-Standard_shares_Mm-DRp
```

"p","td","tr","table","prpo:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","first":true,"unique":true}},"R55":{"role":
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails","longName":"99941004-Disclosure-SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)","shortName":"SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"55","firstAnchor":{"contextRef":"Duration 7 1 2024 To 9 30 2024 KJzGFCGNSEaj28KXDvXu1w","name":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","unitRef":"Unit-Standard-USD-azLHODWL5UihNU4KmWhV4w","xsiNil":"false","lang":null,"decimals":"3","ancestors":{"p","td","tr","table","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","first":true},"uniqueAnchor":{"contextRef":
"Duration 7 1 2024 To 9 30 2024 prpo-PayerTypeRevenueSourceAxis prpo-MedicaidMember-srt-ProductOrServiceAxis prpo-ServiceRevenueNetMember-sAz8-iPmy0izp3218Of-kw","name":"prpo:AllowanceForDoubtfulAccountsRevenue","unitRef":"Unit-Standard-USD-azLHODWL5UihNU4KmWhV4w","xsiNil":"false","lang":null,"decimals":"3","ancestors":{"p","td","tr","table","prpo:ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","unique":true}},"R56":{"role":
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails","longName":"99941005-Disclosure-SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)","shortName":"SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"56","firstAnchor":{"contextRef":"As-Of 9 30 2024 U6dH-wTtUe68YEa63owsKA","name":"us-gaap:AccountsReceivableGross","unitRef":"Unit-Standard-USD-azLHODWL5UihNU4KmWhV4w","xsiNil":"false","lang":null,"decimals":"3","ancestors":{"p","td","tr","table","prpo:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","first":true},"uniqueAnchor":{"contextRef":"Unit-Standard-USD-azLHODWL5UihNU4KmWhV4w","xsiNil":"false","lang":null,"decimals":"3","ancestors":{"p","td","tr","table","prpo:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","first":true},"uniqueAnchor":{"contextRef":"Duration 1 1 2024 To 9 30 2024 glrKZUKtkWgHd-C48SaFg","name":"us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease","unitRef":"Unit-Standard-USD-azLHODWL5UihNU4KmWhV4w","xsiNil":"false","lang":null,"decimals":"3","ancestors":{"p","td","tr","table":
"prpo:ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","unique":true}},"R58":{"role":
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails","longName":"99941007-Disclosure-SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details)","shortName":"SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"58","firstAnchor":{"contextRef":
"Duration 7 1 2023 To 9 30 2023 srt-MajorCustomersAxis prpo-CustomerMember-us-gaap-ConcentrationRiskByBenchmarkAxis-us-gaap-SalesRevenueNetMember-us-gaap-ConcentrationRiskByTypeAxis-us-gaap-CustomerConcentrationRiskMember-UFamRJQsxUi-ZXy68eXYeQ","name":"us-gaap:ConcentrationRiskPercentage1","unitRef":"Unit-Standard-pure-yB3W-IYDcKRX7-ljpbh5A","xsiNil":"false","lang":null,"decimals":"2","ancestors":{"p","td","tr","table","us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"Duration 7 1 2023 To 9 30 2023 srt-MajorCustomersAxis prpo-CustomerMember-us-gaap-ConcentrationRiskByBenchmarkAxis-us-gaap-SalesRevenueNetMember-us-gaap-ConcentrationRiskByTypeAxis-us-gaap-CustomerConcentrationRiskMember-UFamRJQsxUi-ZXy68eXYeQ","name":"us-gaap:ConcentrationRiskPercentage1","unitRef":"Unit-Standard-pure-yB3W-IYDcKRX7-ljpbh5A","xsiNil":"false","lang":null,"decimals":"2","ancestors":{"p","td","tr","table","us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock","ix:continuation","div","div","div","body","html"]],"reportCount":1,"baseRef":"prpo-20240930x10q.htm","first":true,"unique":true}},"tag":{"us-gaap:AccountingPoliciesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountingPoliciesAbstract","lang":{"en-us":{"role":{"label":"SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]"}"},"auth-ref":[]},"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","presentation":{"http://www.precipiodx.com/role/DisclosureAccruedExpenses","lang":{"en-us":{"role":{"label":"Accounts Payable and Accrued Liabilities Disclosure [Text Block]","verboselabel":"ACCRUED EXPENSES","documentation":"The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."}}},"auth-ref":{"r41","r43","r48","r727"}"},"us-gaap:AccountsPayableCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsPayableCurrent","crdr":"credit","presentation":{"http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets","lang":{"en-us":{"role":{"label":"Accounts Payable, Current","terseLabel":"Accounts payable","documentation":"Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."},"auth-ref":{"r41","r553"}"},"us-gaap:AccountsPayableOtherCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsPayableOtherCurrent","crdr":"credit","presentation":{"http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails","lang":{"en-us":{"role":{"label":"Accounts Payable, Other, Current","terseLabel":"CHC temporary funding assistance","documentation":"Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."}}},"auth-ref":{"r41"},"us-gaap:AccountsReceivableGross":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsReceivableGross","crdr":"debit","presentation":{"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails","lang":{"en-us":{"role":{"label":"Accounts Receivable, Gross","terseLabel":"Accounts receivable, gross","documentation":"Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."}}},"auth-ref":{"r114","r175","r176","r748"}"},"us-gaap:AccountsReceivableMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsReceivableMember","presentation":{"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails","lang":{"en-us":{"role":{"label":"Accounts Receivable [Member]","terseLabel":"Accounts receivable","documentation":"Due from customers or clients for goods or services that have been delivered or sold."}}},"auth-ref":{"r509}}},"us-gaap:AccountsReceivableNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsReceivableNet","crdr":"debit","presentation":{"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails","lang":{"en-us":{"role":{"label":"Accounts Receivable, Net","totalLabel":"Accounts receivable, net","documentation":"Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."}}},"auth-ref":{"r456","r508","r564","r747","r748"}"},"us-gaap:AccountsReceivableNetCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsReceivableNetCurrent","crdr":"debit","presentation":{"http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets","lang":{"en-us":{"role":{"label":"Accounts Receivable, Net, Current","terseLabel":"Accounts receivable (net of allowance for credit losses of \$2,755 and \$2,572, respectively)","documentation":"Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."}}},"auth-ref":{"r678}}},"prpo:AccruedAmountFromTemporaryAssistanceProgram":{"xbrltype":"monetaryItemType","nsuri":"http://www.precipiodx.com/20240930","localname":"AccruedAmountFromTemporaryAssistanceProgram","crdr":"credit","presentation":{"http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails","lang":{"en-us":{"role":{"documentation":"An amount of interest accrued from temporary assistance program","label":"Accrued amount from temporary assistance program","terseLabel":"Amount received from Temporary Assistance Program"}}},"auth-ref":[]},"us-gaap:AccruedLiabilitiesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccruedLiabilitiesCurrent","crdr":"credit","presentation":{"http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails","http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets","lang":{"en-us":{"role":{"label":"Accrued Liabilities, Current","terseLabel":"Accrued expenses","totalLabel":"Accrued expenses","documentation":"Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."},"auth-ref":{"r43}}},"prpo:AccumulatedNetIncomeLoss":{"xbrltype":"monetaryItemType","nsuri":"http://www.precipiodx.com/20240930","localname":"AccumulatedNetIncomeLoss","crdr":"credit","presentation":{"http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails","lang":{"en-us":{"role":{"documentation":"Accumulated Net Income (Loss)","label":"Accumulated Net Income (Loss)","negatedLabel":"Net loss"}}},"auth-ref":[]},"ecd:Additional402vDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Additional402vDisclosureTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Additional 402(v) Disclosure [Text Block]","terseLabel":"Additional 402(v) Disclosure"}"},"auth-ref":{"r608}}},"us-gaap:AdditionalPaidInCapital":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdditionalPaidInCapital","crdr":"credit","presentation":{"http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets","lang":{"en-us":{"role":{"label":"Additional Paid in Capital","terseLabel":"Additional paid in capital","documentation":"Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to: additional paid-in capital (APIC) for common and preferred stock."}}},"auth-ref":{"r54","r553","r779"}"},"us-gaap:AdditionalPaidInCapitalMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdditionalPaidInCapitalMember","presentation":{"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity","lang":{"en-us":{"role":{"label":"Additional Paid in Capital [Member]","terseLabel":"Additional Paid in Capital","documentation":"Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."}}},"auth-ref":{"r426","r667","r668","r669","r670","r728","r782}}},"ecd:AdjToCompAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToCompAmt","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Adjustment to Compensation Amount","terseLabel":"Adjustment to Compensation, Amount"}}},"auth-ref":{"r621}}},"ecd:AdjToCompAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToCompAxis","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Adjustment to Compensation [Axis]","terseLabel":"Adjustment to Compensation"}}},"auth-ref":{"r621}}},"ecd:AdjToNonPeeoNeeoCompFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToNonPeeoNeeoCompFnTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]","terseLabel":"Adjustment to Non-PEO-NEO Compensation Footnote"}}},"auth-ref":{"r621}}},"ecd:AdjToPeeoCompFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToPeeoCompFnTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Adjustment To PEO Compensation, Footnote [Text Block]","terseLabel":"Adjustment To PEO Compensation, Footnote"}}},"auth-ref":{"r621}}},"us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue","crdr":"credit","presentation":{"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity","lang":{"en-us":{"role":{"label":"Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition","verboselabel":"Stock-based compensation","documentation":"Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."}}},"auth-ref":{"r29","r30","r273"}"},"us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract","presentation":{"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows","lang":{"en-us":{"role":{"label":"Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]","terseLabel":"Adjustments to reconcile net loss to net cash flows used in operating activities."}}},"auth-ref":[]},"ecd:AggtChngPnsnValInSummryCompstnTblForApblYrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AggtChngPnsnValInSummryCompstnTblForApblYrMember","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]","terseLabel":"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"}}},"auth-ref":{"r654}}},"ecd:AggtErrCompAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AggtErrCompAmt","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure","lang":{"en-us":{"role":{"label":"Aggregate Erroneous Compensation Amount","terseLabel":"Aggregate Erroneous Compensation Amount"}}},"auth-ref":{"r580","r590","r600","r632}}},"ecd:AggtErrCompNotYetDeterminedTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AggtErrCompNotYetDeterminedTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure","lang":{"en-us":{"role":{"label":"Aggregate Erroneous Compensation Not Yet Determined [Text Block]","terseLabel":"Aggregate Erroneous Compensation Not Yet Determined"}}},"auth-ref":{"r583","r593","r603","r635}}},"ecd:AggtPnsnAdjsSvcCstMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AggtPnsnAdjsSvcCstMember","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure","lang":{"en-us":{"role":{"label":"Aggregate Pension Adjustments Service Cost [Member]","terseLabel":"Aggregate Pension Adjustments Service Cost"}}},"auth-ref":{"r655}}},"prpo:Agp2023SalesAgreementMember":{"xbrltype":"domainItemType","nsuri":"http://www.precipiodx.com/20240930","localname":"Agp2023SalesAgreementMember","presentation":{"http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails","http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails","lang":{"en-us":{"role":{"documentation":"Represents information pertaining to AGP 2023 sales agreement","label":"AGP 2023 Sales Agreement [Member]","terseLabel":"AGP 2023 Sales Agreement"}}},"auth-ref":[]},"ecd:AllAdjToCompMember":{"xbrltype":

"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": { "r621" } }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": { "r628" } }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": { "r584", "r594", "r604", "r628", "r636", "r640", "r648" } }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": { "r646" } }, "prpo_AllianceGlobalPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "localname": "AllianceGlobalPartnersMember", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Alliance Global Partners", "terseLabel": "AGP [Member]", "terseLabel": "AGP" } } }, "auth_ref": { "us_gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r302", "r308" } }, "us_gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails": { "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": { "r112", "r177", "r181" } }, "us_gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails": { "lang": { "en-us": { "role": { "label": "Allowance for Doubtful Accounts Receivable, Period Increase (Decrease)", "negatedTotalLabel": "Total charges", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r681" } }, "prpo_AllowanceForDoubtfulAccountsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "AllowanceForDoubtfulAccountsRevenue", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails": { "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts, revenue", "negatedLabel": "Adjustment for allowance for credit losses", "negatedTerseLabel": "Allowance for credit losses" } } }, "auth_ref": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { "us_gaap_AmortizationOffinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffinancingCosts", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance cost", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": { "r66", "r238", "r663", "r735" } }, "us_gaap_AmortizationOffinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffinancingCostsAndDiscounts", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "verboseLabel": "Amortization of deferred financing costs, debt discounts and debt premiums", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": { "r238", "r531", "r532", "r663", "r735" } }, "us_gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Securities not included in the computation of diluted net loss per share (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r158" } }, "us_gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r14" } }, "us_gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us_gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r14" } }, "us_gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r84", "r94", "r104", "r134", "r161", "r165", "r170", "r171", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r321", "r325", "r350", "r390", "r461", "r522", "r523", "r553", "r571", "r695", "r696", "r739" } }, "us_gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": { "us_gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails": { "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Balance sheet presentation of our operating and financing leases" } } }, "auth_ref": { "us_gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r100", "r115", "r134", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r321", "r325", "r350", "r553", "r695", "r696", "r739" } }, "us_gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS." } } }, "auth_ref": { "us_gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "OTHER ASSETS." } } }, "auth_ref": { "prpo_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "AtMarketOfferingMember", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails": { "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the marker offering." } } }, "auth_ref": { "localname": "AwardExercPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": { "r643" } }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": { "r644" } }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": { "r639" } }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": { "r639" } }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": { "r639" } }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": { "r639" } }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": { "r639" } }, "ecd_AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": { "r639" } }, "us_gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": { "r642" } }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r641" } }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": { "r640" } }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": { "r640" } }, "us_gaap_BasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)" } } }, "auth_ref": { "us_gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r317" } }, "us_gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescription": { "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "BUSINESS DESCRIPTION", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to

holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS,) } } }, "auth_ref": { "r40", "r72", "r73" } }, "prpo_BusinessLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "BusinessLoanAgreementMember", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": { "documentation": "Business Loan Agreement [Member]", "label": "Business Loan Agreement [Member]" } } }, "auth_ref": { } }, "prpo_CPAGlobalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "CPAGlobalMember", "presentation": { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "CPA Global [Member]", "label": "CPA Global" } } }, "auth_ref": { } }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "order": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of equipment financed through accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": { "r11", "r12", "r13" } }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "order": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r10", "r102", "r516" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "order": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH AT END OF PERIOD", "periodStartLabel": "CASH AT BEGINNING OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r10", "r69", "r129" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "order": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "NET CHANGE IN CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r69" } }, "prpo_CashFeeAsPercentageOfGrossProceedsOfSaleOfStock": { "xbrltype": "percentItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "CashFeeAsPercentageOfGrossProceedsOfSaleOfStock", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "lang": { "en-us": { "role": { "documentation": "The cash fee expressed as a percentage of aggregate gross proceeds from the sale of the shares of the company under the agreement." }, "label": "Cash Fee As A Percentage Of Gross Proceeds Of Sale Of Stock", "terseLabel": "Percentage of cash fee" } } }, "auth_ref": { } }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY" } } }, "auth_ref": { } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": { "r619" } }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": { "r616" } }, "ecd_ChngInFrValOfOutstgAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutstgAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Year over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": { "r614" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { } }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails", "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r96", "r108", "r109", "r110", "r134", "r152", "r153", "r155", "r157", "r163", "r164", "r178", "r207", "r209", "r210", "r211", "r214", "r215", "r245", "r246", "r250", "r253", "r260", "r350", "r410", "r420", "r421", "r422", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r448", "r470", "r487", "r501", "r502", "r503", "r504", "r505", "r658", "r664", "r671" } }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r108", "r109", "r110", "r163", "r245", "r246", "r248", "r250", "r253", "r258", "r260", "r410", "r420", "r421", "r422", "r533", "r658", "r664" } }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": { "r27" } }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)", "verboseLabel": "Exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r261" } }, "prpo_ClassOfWarrantOrRightExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ClassOfWarrantOrRightExpired", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Expired", "terseLabel": "Warrants expired" } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityWarrantsDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Underlying shares (in shares)", "verboseLabel": "Class of warrant, number of securities called by warrants", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r261" } }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityWarrantsDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": { "r27" } }, "prpo_ClassOfWarrantOrRightWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ClassOfWarrantOrRightWarrantsIssued", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityWarrantsDetails", "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during the period." }, "label": "Class of Warrant or Right, Warrants Issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": { } }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": { "r620" } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": { "r620" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "order": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 5)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r49", "r87", "r301", "r447" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES [Abstract]" } } }, "auth_ref": { } }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingencies", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r75", "r197", "r198", "r510", "r684", "r689" } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Stock reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r52" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails", "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r561", "r562", "r563", "r565", "r566", "r567", "r667", "r668", "r670", "r728", "r778", "r782" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in \$ per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r52" } }, "us-

gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails": "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth-ref": { "r52", "r448" } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth-ref": { "r52" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth-ref": { "r6", "r52", "r448", "r467", "r782", "r783" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, \$0.01 par value, 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, 1,482,133 and 1,420,125 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth-ref": { "r52", "r393", "r553" } }, "ecd-CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth-ref": { "r625" } }, "ecd-CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth-ref": { "r624" } }, "ecd-CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth-ref": { "r626" } }, "ecd-CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth-ref": { "r623" } }, "us-gaap-ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth-ref": { "r17", "r18", "r36", "r37", "r174", "r509" } }, "us-gaap-ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth-ref": { "r17", "r18", "r36", "r37", "r174", "r509" } }, "us-gaap-ConcentrationRiskByTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth-ref": { "r17", "r18", "r36", "r37", "r174", "r509", "r661" } }, "us-gaap-ConcentrationRiskLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r509" } }, "us-gaap-ConcentrationRiskPercentage1": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth-ref": { "r17", "r18", "r36", "r37", "r174" } }, "us-gaap-ConcentrationRiskTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth-ref": { "r16", "r17", "r18", "r19", "r36", "r83", "r509" } }, "us-gaap-ConcentrationRiskTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth-ref": { "r17", "r18", "r36", "r37", "r174", "r509" } }, "prpo-ContractDiagnosticServicesAndOtherMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ContractDiagnosticServicesAndOtherMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails" }, "lang": { "en-us": { "role": { "label": "Contract diagnostic services and other [Member]", "documentation": "Contract diagnostic services and other [Member]", "terseLabel": "Contract diagnostic services, product and other" } } }, "auth-ref": { "prpo-ContractDiagnosticServicesMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ContractDiagnosticServicesMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" }, "lang": { "en-us": { "role": { "documentation": "Contract diagnostic services [Member]", "label": "Contract Diagnostic Services [Member]", "verboseLabel": "Contract diagnostics and other" } } }, "auth-ref": { "us-gaap-ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableNarrativeDetails", "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth-ref": { "r264", "r265", "r268" } }, "prpo-ContractualAllowanceAndAdjustments": { "xbrltype": "monetaryItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ContractualAllowanceAndAdjustments", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" }, "lang": { "en-us": { "role": { "documentation": "Contractual allowance and adjustments", "label": "Contractual allowance and adjustments", "negatedLabel": "Contractual Allowances and adjustments" } } }, "auth-ref": { "prpo-ConversionOfStockPerShareConversionPrice": { "xbrltype": "perShareItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ConversionOfStockPerShareConversionPrice", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" }, "lang": { "en-us": { "role": { "documentation": "Conversion of Stock, Per Share Conversion Price", "label": "Conversion of Stock Per Share Conversion Price", "terseLabel": "Conversion price (in dollars per share)" } } }, "auth-ref": { "us-gaap-ConversionOfStockSharesConverted1": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" }, "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "verboseLabel": "Number of shares converted (in shares)", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth-ref": { "r11", "r12", "r13" } }, "us-gaap-ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Convertible notes, less current maturities and discounts", "terseLabel": "Long-term debt, less current maturities and debt issuance costs", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth-ref": { "r7" } }, "us-gaap-CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Total cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth-ref": { "r62", "r63", "r385" } }, "dei-CoverAbstract": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth-ref": { "dei-CurrentFiscalYearEndDate": { "xbrltype": "dateTime", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format-MM-DD" } } }, "auth-ref": { "prpo-CustomerBMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "CustomerBMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "auth-ref": { "prpo-CustomerCMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "CustomerCMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]", "terseLabel": "Customer C" } } }, "auth-ref": { "us-gaap-CustomerConcentrationRiskMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth-ref": { "r74", "r174" } }, "prpo-CustomerDMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "CustomerDMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "documentation": "Customer D [Member]", "label": "Customer D [Member]", "terseLabel": "Customer D" } } }, "auth-ref": { "prpo-CustomerMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "CustomerMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "auth-ref": { "us-gaap-DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" }, "lang": { "en-us": { "role": { "label": "Debt and Capital Lease Obligations", "totalLabel": "Total long-term debt", "verboseLabel": "Total debt", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth-ref": { "r85", "r86" } }, "prpo-DebtAndLeaseObligationOnDepartmentOfEconomicAndCommunityDevelopment": { "xbrltype": "monetaryItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "DebtAndLeaseObligationOnDepartmentOfEconomicAndCommunityDevelopment", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" }, "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation on Department of Economic and Community Development", "label": "Debt and Lease Obligation on Department of Economic and Community Development", "terseLabel": "Total long-term debt" } } }, "auth-ref": { "us-gaap-DebtDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "LONG-TERM DEBT [Abstract]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not

compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } },
"auth-ref": { "r76", "r131", "r192", "r193", "r194", "r195", "r196", "r205", "r206", "r216", "r222", "r223", "r224", "r225", "r226", "r227", "r232", "r239", "r240", "r242", "r357" } }, "us-
gaap-DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": {
"http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth-ref": { "r7", "r42", "r43",
"r85", "r86", "r135", "r217", "r218", "r219", "r220", "r221", "r223", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r258", "r529", "r530", "r531", "r532", "r551",
"r665", "r685", "r686", "r687", "r734", "r736" } } }, "us-gaap-DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount",
"documentation": "DebtInstrumentCarryingAmount", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "lang": { "en-us": { "role": {
"label": "Long-term Debt, Gross", "terseLabel": "Convertible notes", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but
is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth-ref": { "r7", "r86", "r243" } } }, "us-
gaap-DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face
amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth-ref": { "r217", "r357", "r358", "r529", "r530", "r551" } } }, "us-
gaap-DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument, Fee Amount", "terseLabel": "Fee", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth-ref": { "r46" } } }, "us-gaap-DebtInstrumentInterestRateStatedPercentage": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest
rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth-ref": { "r45", "r218" } } }, "us-gaap-DebtInstrumentLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r135", "r217", "r218", "r219", "r220", "r221", "r223", "r228",
"r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r258", "r529", "r530", "r531", "r532", "r551", "r665", "r734", "r736" } } }, "us-gaap-DebtInstrumentMaturityDate": {
"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date", "documentation": "Date when the debt instrument is
scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth-ref": { "r106", "r528", "r730", "r731" } } }, "us-gaap-DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument, Name [Domain]", "documentation": "The name for
the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth-ref": { "r7", "r135", "r217",
"r218", "r219", "r220", "r221", "r223", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r258", "r529", "r530", "r531", "r532", "r551", "r665", "r685", "r686", "r687",
"r734", "r736" } } }, "us-gaap-DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment",
"documentation": "DebtInstrumentPeriodicPayment", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth-ref": { "r77", "r39" } } }, "us-gaap-DebtInstrumentTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtFinancialInsuranceLoanDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": { "label": "Schedule of Long Term Debt Instruments [Table]", "terseLabel":
"Schedule of Long Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth-ref": { "r7", "r23", "r26", "r38",
"r79", "r80", "r135", "r217", "r218", "r219", "r220", "r221", "r223", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r241", "r528", "r529", "r530", "r531", "r532",
"r551", "r665", "r734", "r736" } } }, "us-gaap-DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": {
"http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnTnHnMnS
format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r7", "r23", "r26", "r38",
"r79", "r80", "r135", "r217", "r218", "r219", "r220", "r221", "r223", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r241", "r528", "r529", "r530", "r531", "r532",
"r551", "r665", "r734", "r736" } } }, "us-gaap-DebtInstrumentUnusedBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
"documentation": "DebtInstrumentUnusedBorrowingCapacityAmount", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails", "lang": { "en-us": { "role": {
"label": "Debt Instrument, Unused Borrowing Capacity, Amount",
"documentation": "Additional borrowing capacity", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the
balance sheet date." } } }, "auth-ref": { "r46", "r205" } } }, "prpo-DefaultFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname":
"DefaultFeesMember", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails", "lang": { "en-us": { "role": { "documentation": "Default
Fees [Member]", "label": "Default Fees [Member]", "terseLabel": "Default Fees" } } }, "auth-ref": { "r77", "r39" } } }, "us-gaap-DeferredFinanceCost

"http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.preciiodx.com/role/StatementConsolidatedStatementsOfOperations"}, "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "LOSS PER COMMON SHARE, BASIC", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r122", "r141", "r142", "r143", "r144", "r145", "r146", "r150", "r152", "r155", "r156", "r157", "r160", "r315", "r319", "r335", "r336", "r387", "r401", "r518" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.preciiodx.com/role/StatementConsolidatedStatementsOfOperations"}, "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "LOSS PER COMMON SHARE, DILUTED", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r122", "r141", "r142", "r143", "r144", "r145", "r146", "r152", "r155", "r156", "r157", "r160", "r315", "r319", "r335", "r336", "r387", "r401", "r518" } }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://www.preciiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"}, "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": { "r14", "r15", "r159" } }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "errdr": "credit", "presentation": { "http://www.preciiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails"}, "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r43" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition", "presentation": { "http://www.preciiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails"}, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost-Not yet Recognized, Period for Recognition", "terseLabel": "Invested stock options, unrecognized compensation expense weighted average recognition period (in years)", "documentation": "The weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r306" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "errdr": "debit", "presentation": { "http://www.preciiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails"}, "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation expense related to unvested stock awards", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": { "r726" } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.preciiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails"}, "http://www.preciiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails"}, "http://www.preciiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10 digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r573" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.preciiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails"}, "http://www.preciiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails"}, "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { } }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r573" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r573" } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r657" } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r573" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r573" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r573" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.preciiodx.com/role/DocumentDocumentAndEntityInformation"}, "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r573" } }, "eed_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": { "r612" } }, "eed_EqtyAwrdsAdjExclgValRprtInSummaryCompstnTblMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummaryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": { "r653" } }, "eed_EqtyAwrdsAdjgsMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjgsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": { "r653" } }, "eed_EqtyAwrdsInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": { "r653" } }, "us-gaap_EquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "documentation": "Equity Incentive Plan 2017 [Member]", "terseLabel": "Equity Incentive Plan 2017" } } }, "auth_ref": { } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.preciiodx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"}, "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r6", "r97", "r118", "r119", "r120", "r136", "r137", "r138", "r140", "r145", "r147", "r149", "r162", "r170", "r190", "r191", "r263", "r310", "r311", "r312", "r313", "r314", "r316", "r318", "r319", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r361", "r379", "r400", "r411", "r412", "r413", "r426", "r487" } }, "prpo_EquityIncentivePlan2017Member": { "xbrltype": "domainItem", "nsuri": "http://www.preciiodx.com/20240930", "localname": "EquityIncentivePlan2017Member", "presentation": { "http://www.preciiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails"}, "lang": { "en-us": { "role": { "label": "Equity Incentive Plan 2017 [Member]", "documentation": "Equity Incentive Plan 2017 [Member]", "terseLabel": "Equity Incentive Plan 2017" } } }, "auth_ref": { } }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "xbrltype": "decimalItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiMeasurementInput", "presentation": { "http://www.preciiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails"}, "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Measurement Input", "verboseLabel": "Fair value of warrant input", "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": { "r339", "r340", "r341" } }, "eed_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": { "r622" } }, "eed_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}, "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": { "r580", "r590", "r600", "r632" } }, "eed_ErrCompRecoveryTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}, "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": { "r577", "r587", "r597", "r629" } }, "eed_ExecutiveCategoryAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } } }, "auth_ref": { "r628" } }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": { "http://www.preciiodx.com/role/DisclosureFairValueNarrativesDetails"}, "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis

```
"Line Items]", "Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, {"authRef": { "r337", "r338", "r348", "r546" }, "us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": { "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } }, {"authRef": { "r337", "r338", "r348", "r546" } }, {"us-gaap-FairValueByLiabilityClassAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } }, {"authRef": { "r342", "r343", "r345", "r346", "r347", "r349" } }, {"us-gaap-FairValueDisclosuresAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us"}, {"role": { "label": "FAIR VALUE [Abstract]" } }, {"authRef": { "us-gaap-FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputsReconciliationByLiabilityClassDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputsReconciliationByLiabilityClassDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } }, {"authRef": { "r342", "r343", "r344", "r345", "r346", "r347", "r349" } }, {"us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Revaluation recognized in earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } }, {"authRef": { "r343", "r349" } }, {"prpo-FeeTypeAxis": { "xbrlType": "stringItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "FeeTypeAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails"}}, {"lang": { "en-us"}, {"role": { "documentation": "Fee Type [Axis]", "label": "Fee Type [Axis]" } }, {"authRef": { "prpo-FeeTypeDomain": { "xbrlType": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "FeeTypeDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtBusinessLoanAgreementDetails"}}, {"lang": { "en-us"}, {"role": { "documentation": "Fee Type [Domain]", "label": "Fee Type [Domain]", "terseLabel": "Fee Type" } }, {"authRef": { "prpo-FinanceLeaseCost": { "xbrlType": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "FinanceLeaseCost", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails"}}, {"lang": { "en-us"}, {"role": { "documentation": "Amount of finance lease cost including amortization expense and interest recognized by lessee for lease contract.", "label": "Finance Lease, Cost", "terseLabel": "Finance lease amortization and interest expenses" } }, {"authRef": { "us-gaap-FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease Liabilities, Payments, Due [Abstract]", "terseLabel": "Finance leases, estimated future minimum lease payments" } }, {"authRef": { "us-gaap-FinanceLeaseLiability": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability", "totalLabel": "Present value of net minimum lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } }, {"authRef": { "r363", "r375" } }, {"us-gaap-FinanceLeaseLiabilityCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Current", "negatedLabel": "Less, current portion", "terseLabel": "Current maturities of finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } }, {"authRef": { "r363" } }, {"us-gaap-FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesTables"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of estimated future minimum lease payments for finance leases", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } }, {"authRef": { "r738" } }, {"us-gaap-FinanceLeaseLiabilityNoncurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Current", "negatedLabel": "Less, current portion", "terseLabel": "Current maturities of finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } }, {"authRef": { "r363" } }, {"us-gaap-FinanceLeaseLiabilityPaymentsDue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total lease obligations", "documentation": "Amount of lessee's undiscounted obligation for lease payments from finance lease." } }, {"authRef": { "r375" } }, {"us-gaap-FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }, {"authRef": { "r375" } }, {"us-gaap-FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }, {"authRef": { "r375" } }, {"us-gaap-FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }, {"authRef": { "r375" } }, {"us-gaap-FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }, {"authRef": { "r375" } }, {"us-gaap-FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2024 (remaining)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } }, {"authRef": { "r738" } }, {"us-gaap-FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Amount representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments from finance lease." } }, {"authRef": { "r375" } }, {"us-gaap-FinanceLeasePrincipalPayments": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments on finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease." } }, {"authRef": { "r365", "r371" } }, {"us-gaap-FinanceLeaseRightOfUseAsset": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Right-of-Use Asset", "verboseLabel": "Finance lease right-of-use assets, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } }, {"authRef": { "r362" } }, {"us-gaap-FinanceLeaseRightOfUseAssetAmortization": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails"}}, {"lang": { "en-us"}, {"role": { "label": "Finance Lease, Right of Use Asset, Amortization", "terseLabel": "Amortization of finance lease right of use asset", "verboseLabel": "Finance
```

```

http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "lang": { "en-us": { "role": { "documentation": "Shares of fractional common stock paid in conjunction with reverse stock split", "label": "Fractional Common Stock Shares", "negatedLabel": "Payment of fractional common shares in conjunction with reverse stock split (in shares)" } } }, "auth-ref": {} }, "us-gaap-GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity" } } }, "auth-ref": { "r60", "r64", "r93", "r134", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r250", "r520", "r522", "r672", "r674", "r675", "r676", "r677", "r695" } }, "prpo-HemeScreenReagentRentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "HemeScreenReagentRentalMember", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails", "lang": { "en-us": { "role": { "documentation": "Heme Screen Reagent Rental [Member]", "label": "HemeScreen Reagent Rental [Member]" } } }, "auth-ref": {} }, "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Income (Loss) From Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest" } } }, "auth-ref": { "r61", "r89", "r93", "r388", "r397", "r520", "r522", "r672", "r674", "r675", "r676", "r677" } }, "us-gaap-IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]" } } }, "auth-ref": {} }, "us-gaap-IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business" } } }, "auth-ref": { "r21" } }, "us-gaap-IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services" } } }, "auth-ref": { "r2" } }, "us-gaap-IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid" } } }, "auth-ref": { "r2" } }, "us-gaap-IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable" } } }, "auth-ref": { "r514" } }, "us-gaap-IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities" } } }, "auth-ref": { "r2" } }, "us-gaap-IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth-ref": {} }, "prpo-IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of operating lease liability", "label": "Increase (Decrease) In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "auth-ref": {} }, "us-gaap-IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other" } } }, "auth-ref": { "r2" } }, "us-gaap-IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period" } } }, "auth-ref": {} }, "ecd-IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual" } } }, "auth-ref": { "r584", "r594", "r604", "r628", "r636", "r640", "r648" } }, "ecd-InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements" } } }, "auth-ref": { "r646" } }, "ecd-InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures" } } }, "auth-ref": { "r576", "r652" } }, "ecd-InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth-ref": { "r576", "r652" } }, "ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth-ref": { "r576", "r652" } }, "us-gaap-IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangibles, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges" } } }, "auth-ref": { "r186", "r682", "r683" } }, "prpo-InterestIncomeAndExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "InterestIncomeAndExpenseNet", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "documentation": "Interest income and (expense), net", "label": "Interest income and (expense), net", "verboselabel": "Interest expense, net" } } }, "auth-ref": {} }, "us-gaap-InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Interest Paid, Net", "terseLabel": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount" } } }, "auth-ref": { "r124", "r127", "r128" } }, "us-gaap-InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails", "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)" } } }, "auth-ref": { "r43" } }, "us-gaap-InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Inventory, Net",
```

```

payments in excess of discounted obligation for lease payments for operating and finance lease." }, {"label": "Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Amount representing interest" } ], "auth_ref": [ ] }, "us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesTables", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of estimated future minimum lease payments for operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": { "r739" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease obligations", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r375" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r375" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r375" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2024 (remaining)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r739" } }, "us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Amount representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r375" } }, "us-gaap-LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in PnYmNdTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r737" } }, "prpo-LesseeWeightedAverageLeaseTermAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "LesseeWeightedAverageLeaseTermAndDiscountRateTableTextBlock", "presentation": [ { "http://www.precipiodx.com/role/DisclosureLeasesTables", "lang": { "en-us": { "role": { "documentation": "Represents the weighted average lease term and discount rate of leases.", "label": "Lessee, Weighted Average Lease Term And Discount Rate [Table Text Block]", "terseLabel": "Schedule of other information" } } }, "auth_ref": [ ] }, "us-gaap-Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r7", "r42", "r43", "r44", "r47", "r48", "r49", "r50", "r134", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r322", "r323", "r326", "r350", "r446", "r519", "r574", "r695", "r739", "r740" } }, "us-gaap-LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r58", "r88", "r395", "r553", "r666", "r679", "r732" } }, "us-gaap-LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [ ] }, "us-gaap-LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r44", "r101", "r134", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r322", "r325", "r326", "r350", "r553", "r695", "r739", "r740" } }, "us-gaap-LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "auth_ref": [ ] }, "us-gaap-LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG TERM LIABILITIES" } } }, "auth_ref": [ ] }, "sr-LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": { "r7", "r20", "r685", "r686", "r687" } }, "us-gaap-LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r190", "r200", "r201", "r204", "r309", "r527", "r691", "r692" } }, "us-gaap-LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": { "r190", "r200", "r201", "r204", "r309", "r527", "r691", "r692" } }, "us-gaap-LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": { "r199", "r659" } }, "us-gaap-LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss contingency, damages sought", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": { "r690", "r691", "r692" } }, "srt-MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails", "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": { "r174", "r536", "r555", "r558", "r699", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r7
```

"lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth-ref": { "r339", "r340", "r341", "r547" } }, "prpo-MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "MedicaidMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" }, "lang": { "en-us": { "role": { "documentation": "Medicaid [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } } }, "auth-ref": { } }, "prpo-MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "MedicareMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" }, "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } } }, "auth-ref": { } }, "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails", "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum" } } } }, "auth-ref": { "r200", "r201", "r202", "r203", "r270", "r309", "r341", "r304", "r409", "r410", "r416", "r438", "r439", "r492", "r494", "r497", "r498", "r499", "r511", "r512", "r525", "r533", "r541", "r547", "r548", "r549", "r556", "r607", "r741", "r742", "r743", "r744", "r745", "r746" } }, "ecd-MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } } }, "auth-ref": { "r639" } }, "ecd-MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } } }, "auth-ref": { "r647" } }, "srt-NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } } }, "auth-ref": { "r174", "r536", "r555", "r558", "r699", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777" } }, "ecd-NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } } }, "auth-ref": { "r621" } }, "us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "erdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash flows provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, "auth-ref": { "r126" } }, "us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES." } } } }, "auth-ref": { } }, "us-gaap-NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "erdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } }, "auth-ref": { "r126" } }, "us-gaap-NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES." } } } }, "auth-ref": { } }, "us-gaap-NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } }, "auth-ref": { "r69", "r70", "r71" } }, "us-gaap-NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES." } } } }, "auth-ref": { } }, "us-gaap-NetIncome(Loss)": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncome(Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." }, "auth-ref": { "r65", "r71", "r90", "r99", "r116", "r117", "r120", "r134", "r139", "r141", "r142", "r143", "r144", "r145", "r148", "r149", "r154", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r315", "r319", "r336", "r350", "r399", "r469", "r495", "r486", "r560", "r695" } }, "prpo-NetSalesServiceRevenueAndAccountsReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "NetSalesServiceRevenueAndAccountsReceivableAbstract", "lang": { "en-us": { "role": { "documentation": "Net Sales Service Revenue and Accounts Receivable [Abstract]", "label": "SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]" } } } }, "auth-ref": { } }, "prpo-NetSalesServiceRevenueAndAccountsReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "NetSalesServiceRevenueAndAccountsReceivableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivable" }, "lang": { "en-us": { "role": { "documentation": "Net Sales Service Revenue and Accounts Receivable [Text Block]", "label": "Net Sales Service Revenue and Accounts Receivable [Text Block]", "verboseLabel": "SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE" } } } }, "auth-ref": { } }, "us-gaap-NonAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } } }, "auth-ref": { } }, "ecd-NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non GAAP Measure Description [Text Block]", "terseLabel": "Non GAAP Measure Description" } } } }, "auth-ref": { "r620" } }, "ecd-NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } } }, "auth-ref": { "r584", "r594", "r604", "r628", "r636" } }, "ecd-NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } } }, "auth-ref": { "r611" } }, "ecd-NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } } }, "auth-ref": { "r610" } }, "ecd-NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } } }, "auth-ref": { "r628" } }, "ecd-NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } } }, "auth-ref": { "r647" } }, "ecd-NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } } }, "auth-ref": { "r647" } }, "us-gaap-NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" }, "lang": { "en-us": { "role": { "label": "Noncontrolling Interest in Joint Venture [Member]", "terseLabel": "Noncontrolling Interest in Joint Venture", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } } }, "auth-ref": { "r33", "r263", "r667", "r668", "r669", "r670", "r782" } }, "us-gaap-NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER (EXPENSE) INCOME." } } } }, "auth-ref": { } }, "us-gaap-NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableNarrativeDetails", "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } } }, "auth-ref": { "r521", "r524", "r673" } }, "prpo-OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating And Finance Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating and finance leases, estimated future minimum lease payments" } } } }, "auth-ref": { } }, "prpo-OperatingAndFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "OperatingAndFinanceLeaseLiability", "erdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease.", "label": "Operating And Finance Lease, Liability", "totalLabel": "Present value of net minimum lease obligations" } } } }, "auth-ref": { } }, "prpo-OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "erdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current.", "label": "Operating And Finance Lease, Liability, Current", "negatedLabel": "Less, current portion" } } } }, "auth-ref": { } }, "prpo-OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "erdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.", "label": "Operating And Finance Lease, Liability, Noncurrent", "terseLabel": "Long term portion" } } } }, "auth-ref": { } }, "prpo-OperatingAndFinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "OperatingAndFinanceLeaseRightOfUseAsset", "erdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeasesDetails", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating and finance lease.", "label": "Operating And Finance Lease, Right of Use Asset", "totalLabel": "Total lease assets" } } } }, "auth-ref": { } }, "us-gaap-OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "erdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Operating Expenses", "verboseLabel": "Operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } } }, "auth-ref": { } }, "us-gaap-OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES." } } } }, "auth-ref": { } }, "us-gaap-OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "erdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "OPERATING LOSS", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } }, "auth-ref": { "r93", "r520", "r672", "r674", "r675", "r676", "r677" } }, "us-gaap-OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "erdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease

costs","documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right of use asset, calculated by amortization of remaining right of use asset and accretion of lease liability." } } }, "auth_ref": { "r369", "r552" } }, "us_gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terselabel": "Operating leases, estimated future minimum lease payments" } } }, "auth_ref": { } }, "us_gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Present value of net minimum lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r363" } }, "us_gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less, current portion", "verboseLabel": "Current maturities of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r363" } }, "us_gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terselabel": "Operating lease liabilities, less current maturities", "verboseLabel": "Long term portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r363" } }, "prpo_OperatingLeaseNumberOfOptionsToRenew": { "xbrltype": "integerItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "OperatingLeaseNumberOfOptionsToRenew", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Number of options to renew under the operating leases", "label": "Operating Lease, Number Of Options To Renew", "terselabel": "Facility Leases" } } }, "auth_ref": { } }, "us_gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terselabel": "Operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r366", "r371" } }, "us_gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Right of Use Asset", "terselabel": "Operating lease right of use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r362" } }, "us_gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Operating Lease, Right of Use Asset, Amortization Expense", "terselabel": "Amortization of operating lease right of use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right of use asset from operating lease." } } }, "auth_ref": { "r663" } }, "us_gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOtherInformationDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terselabel": "Operating leases discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r374", "r552" } }, "us_gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOtherInformationDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term1", "terselabel": "Operating leases (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r373", "r552" } }, "us_gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "BUSINESS DESCRIPTION [Abstract]", "auth_ref": { } }, "us_gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails", "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terselabel": "Accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r43" } }, "us_gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terselabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": { "r114", "r553" } }, "us_gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terselabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r103" } }, "us_gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Other Commitment", "terselabel": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": { } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terselabel": "Other Performance Measure, Amount", "auth_ref": { "r620" } }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggregateErroneousCompensationAmount", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terselabel": "Outstanding Aggregate Erroneous Compensation Amount", "auth_ref": { "r582", "r592", "r602", "r634" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terselabel": "Outstanding Recovery Compensation Amount", "auth_ref": { "r585", "r595", "r605", "r637" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terselabel": "Name", "auth_ref": { "r585", "r595", "r605", "r637" } }, "us_gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "lang": { "en-us": { "role": { "label": "Total Precipio, Inc. [Member]", "terselabel": "Total Precipio, Inc.", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": { } }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terselabel": "Pay vs Performance Disclosure", "auth_ref": { "r609" } }, "us_gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES [Abstract]", "auth_ref": { } }, "prpo_PayerTypeRevenueSourceAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PayerTypeRevenueSourceAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "lang": { "en-us": { "role": { "label": "Payer Type Revenue Source [Axis]", "auth_ref": { } }, "prpo_PayerTypeRevenueSourceDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PayerTypeRevenueSourceDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "lang": { "en-us": { "role": { "label": "Payer Type Revenue Source [Domain]", "auth_ref": { } }, "prpo_PayerTypeThirdPartyPayerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PayerTypeThirdPartyPayerMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "lang": { "en-us": { "role": { "label": "Payer Type Revenue Source [Member]", "verboseLabel": "Third party payers", "auth_ref": { } }, "prpo_PaymentOfDepositsOnFinanceLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PaymentOfDepositsOnFinanceLeaseRightOfUseAssets", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "documentation": "Payment of Deposits on finance lease right of use assets", "label": "Payment of Deposits on finance lease right of use assets", "negatedLabel": "Deposits on finance lease right of use assets" } } }, "auth_ref": { } }, "us_gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": { "r9", "r93", "us_gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self constructed assets." } } }, "auth_ref": { "r67" } }, "prpo_PaymentsToFinancialAdvisor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PaymentsToFinancialAdvisor", "crdr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "documentation": "The cash outflow on payments to financial advisor", "label": "Payments to Financial Advisor", "terselabel": "Cash fee paid", "auth_ref": { } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terselabel": "Peer Group Issuers, Footnote", "auth_ref": { "r619" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terselabel": "Peer Group Total Shareholder Return Amount", "auth_ref": { "r619" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEO Actually Paid CompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terselabel": "PEO Actually Paid Compensation Amount", "auth_ref": { "r611" } }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO [Member]", "terselabel": "PEO", "auth_ref": { "r628" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO Name", "terselabel": "PEO Name", "auth_ref": { "r621" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terselabel": "PEO Total Compensation Amount", "auth_ref": { "r610" } }, "prpo_PercentageOfAnnualIncreaseInNumberOfSharesAuthorizedForGrant": { "xbrltype": "percentItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PercentageOfAnnualIncreaseInNumberOfSharesAuthorizedForGrant", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Percentage of annual increase in number of shares authorized for grant", "label": "Percentage of annual increase in number of shares authorized for grant", "terselabel": "Percentage of annual increase in number of shares authorized for grant", "auth_ref": { } }, "us_gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716",


```

r717, "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725" } }, "us-gaap-PlanNameDomainName": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { [ "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share based payment arrangement." } } }, "auth_ref": { "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725" } }, "ecd-PnsnAdjsPrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrSvcCstMember", "presentation": { [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terselabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": { "r612" } }, "ecd-PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terselabel": "Pension Adjustments Service Cost" } } }, "auth_ref": { "r656" } }, "ecd-PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terselabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": { "r611" } }, "prpo-PrFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PrFundedWarrantsMember", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Class B Member", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Class B", "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": { } }, "us-gaap-PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Convertible Shares Issuable", "terselabel": "Number of common shares issuable upon conversion of preferred stock", "documentation": "Number of common shares issuable upon conversion of preferred stock" } } }, "auth_ref": { "r247" } }, "us-gaap-PreferredStockDividendRatePercentage": { "xbrltype": "percentItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Percentage", "terselabel": "Preferred stock, dividend rate (percentage)", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": { "r246", "r493", "r495", "r496", "r500" } }, "us-gaap-PreferredStockLiquidationPreference": { "xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference Per Share", "terselabel": "Preferred stock, liquidation preference (in dollars per share)", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": { "r23", "r24", "r51", "r664", "r698" } }, "us-gaap-PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": { [ "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference, Value", "terselabel": "Preferred stock, liquidation preference", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": { "r132", "r250", "r262" } }, "us-gaap-PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": { [ "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terselabel": "Preferred Stock", "verboseLabel": "Preferred stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": { "r561", "r562", "r565", "r566", "r567", "r568", "r778", "r782" } }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terselabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r51", "r245" } }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terselabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r51", "r448" } }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terselabel": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": { "r51", "r245" } }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terselabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r51", "r448", "r467", "r782", "r783" } }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": { [ "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terselabel": "Preferred stock - $0.01 par value, 15,000,000 shares authorized at September 30, 2024 and December 31, 2023, 47 shares issued and outstanding at September 30, 2024 and December 31, 2023, liquidation preference of $39 at September 30, 2024", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r51", "r392", "r553" } }, "prpo-PrepaidInsuranceFinancedWithLoan": { "xbrltype": "monetaryItemtype", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PrepaidInsuranceFinancedWithLoan", "crdr": "debit", "presentation": { [ "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Prepaid insurance financed with loan", "label": "Prepaid insurance financed with loan", "terselabel": "Prepaid insurance financed with loan" } } }, "auth_ref": { } }, "us-gaap-ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terselabel": "Proceeds from issuance of common stock", "verboseLabel": "Issuance of common stock, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r1" } }, "prpo-ProceedsFromIssuanceOfCommonStockGross": { "xbrltype": "monetaryItemtype", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockGross", "crdr": "debit", "presentation": { [ "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross cash inflow from the additional capital contribution to the entity", "label": "Proceeds from Issuance of Common Stock, Gross", "terselabel": "Gross proceeds" } } }, "auth_ref": { } }, "us-gaap-ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": { [ "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-term Debt", "terselabel": "Proceeds from debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": { "r8", "r419" } }, "us-gaap-ProceedsFromIssuanceOfOtherLongTermDebt": { "xbrltype": "monetaryItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "crdr": "debit", "presentation": { [ "http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Other Long-term Debt", "terselabel": "Proceeds from long-term debt", "documentation": "Amount of cash inflow from issuance of long-term debt classified as other." } } }, "auth_ref": { "r8" } }, "us-gaap-ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": { [ "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" ], "lang": { "en-us": { "
```

"durationItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "PurchaseAgreementSaleLockInPeriod", "presentation": {
"http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "documentation": "Represents the sale lock in period by the company following the closing of the offering under the purchase agreement", "label": "Purchase Agreement, Sale, Lock In Period", "terseLabel": "Sale lock in period" } } }, "auth_ref": { } },
"prpo_PurchaseAgreementThresholdResaleRegistrationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname":
"PurchaseAgreementThresholdResaleRegistrationPeriod", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": {
"role": { "documentation": "Threshold resale registration period under purchase agreement", "label": "Purchase Agreement, Threshold Resale Registration Period", "terseLabel": "Resale
registration period" } } }, "auth_ref": { } }, "prpo_PurchaseAgreementVariableRateTransactionLockInPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.precipiodx.com/20240930",
"localname": "PurchaseAgreementVariableRateTransactionLockInPeriod", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails",
"lang": { "en-us": { "role": { "documentation": "Represents the variable rate transaction lock in period under the purchase agreement", "label": "Purchase Agreement, Variable Rate Transaction
Lock In Period", "terseLabel": "Variable rate transaction lock in period" } } }, "auth_ref": { } }, "ced_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024",
"localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs
Performance Disclosure" } } }, "auth_ref": { "r609" } }, "ced_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "PvpTableTextBlock",
"presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure",
Table" } } }, "auth_ref": { "r609" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {
"http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails",
"http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails",
"http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails",
"http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Range [Axis]", "auth_ref": { "r200", "r201",
"r202", "r203", "r260", "r270", "r208", "r209", "r300", "r309", "r341", "r382", "r383", "r384", "r409", "r410", "r416", "r438", "r439", "r492", "r494", "r497", "r498", "r499", "r511", "r512", "r525",
"r533", "r541", "r547", "r548", "r549", "r550", "r556", "r563", "r688", "r697", "r730", "r742", "r743", "r744", "r745", "r746" } } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails",
"http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "http://www.precipiodx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails",
"http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails",
"http://www.precipiodx.com/role/DisclosureLongTermDebtNarrativeDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails",
"http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Range [Domain]", "auth_ref": { "r200",
"r201", "r202", "r203", "r260", "r270", "r208", "r209", "r300", "r309", "r341", "r382", "r383", "r384", "r409", "r410", "r416", "r438", "r439", "r492", "r494", "r497", "r498", "r499", "r511", "r512",
"r525", "r533", "r541", "r547", "r548", "r549", "r550", "r556", "r563", "r688", "r697", "r730", "r742", "r743", "r744", "r745", "r746" } } }, "prpo_RdoCommonWarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "RdoCommonWarrantsMember", "presentation": {
"http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails",
"http://www.precipiodx.com/role/DisclosureStockholdersEquityWarrantsDetails", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to RDO Common
Warrants", "label": "RDO Common Warrants" } } }, "auth_ref": { } }, "ced_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024",
"localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery
of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": { "r577", "r587", "r597", "r629" } }, "prpo_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.precipiodx.com/20240930", "localname": "RegisteredDirectOfferingMember", "presentation": {
"http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to
registered direct offering", "label": "Registered Direct Offering [Member]", "terseLabel": "Registered Direct Offering" } } }, "auth_ref": { } }, "us-gaap_RepaymentsOfNotesPayable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "ordr": "credit", "presentation": {
"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable", "negatedTerseLabel":
"Principal payments on long-term debt", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": { "r68" } },
"ced_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "RestatementDateAxis", "presentation": {
"http://xbrl.sec.gov/ced/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } },
"auth_ref": { "r578", "r588", "r598", "r630" } }, "ced_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname":
"RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ced/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel":
"Restatement Determination Date" } } }, "auth_ref": { "r579", "r589", "r599", "r631" } }, "ced_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ced/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/ErrCompDisclosure", "lang": { "en-us": { "role": {
"label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": { "r586", "r596", "r606", "r638" } }, "us-
gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": {
"http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock",
"documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }
}, "auth_ref": { "r14" } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsAccumulatedDeficit", "ordr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails",
"http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated
deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)" } } }, "auth_ref": { "r55", "r81", "r394", "r414", "r415", "r423", "r449", "r553" } }, "us-
gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": {
"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "terseLabel":
"Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)" } } }, "auth_ref": { "r97", "r136", "r137", "r138", "r140", "r145", "r147", "r149", "r179", "r180", "r191",
"r310", "r311", "r312", "r313", "r314", "r316", "r318", "r319", "r319", "r327", "r329", "r330", "r332", "r334", "r359", "r361", "r411", "r413", "r426", "r782" } }, "us-
gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerExcludingAssessedTax", "ordr": "credit", "presentation": {
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails",
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails",
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails",
"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer Excluding Assessed
Tax", "totalLabel": "Revenues, net of Contractual Allowances and adjustments", "verboseLabel": "Revenue, net of contractual allowances and adjustments", "documentation": "Amount, excluding
tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by
governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": {
"r91", "r92", "r161", "r166", "r167", "r169", "r171", "r172", "r173", "r174", "r266", "r267", "r385" } }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "ordr": "credit", "presentation": {
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails", "lang": { "en-us": { "role": { "label": "Revenue
from Contract with Customer, Including Assessed Tax", "terseLabel": "Gross Revenues", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of
performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent
with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r91", "r92", "r161", "r166", "r167", "r169", "r171", "r172",
"r173", "r174", "r266", "r267", "r385" } }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "ordr": "credit",
"presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails",
"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Revenues", "totalLabel": "Net sales", "documentation":
"Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and
interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r91", "r92", "r121", "r134", "r161",
"r166", "r167", "r169", "r171", "r172", "r173", "r174", "r178", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r350", "r388", "r522", "r695" } }, "us-
gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "ordr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails",
"http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Finance lease right-of-use assets obtained in exchange for
finance lease obligations", "terseLabel": "Finance lease right of use assets obtained in exchange for finance lease obligations", "documentation": "Amount of increase in right-of-use asset
obtained in exchange for finance lease liability." } } }, "auth_ref": { "r372", "r552" } }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "ordr": "debit", "presentation": {
"http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": {
"label": "Right of Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right of use assets obtained in exchange for operating lease obligations",
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r372", "r552" } }, "ced_Rule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements",
"lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r647" } },
"ced_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": {
"http://xbrl.sec.gov/ced/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement
Terminated" } } }, "auth_ref": { "r647" } }, "prpo_SaleOfCommonStockAggregateOfferingPriceAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930",
"localname": "SaleOfCommonStockAggregateOfferingPriceAuthorized", "ordr": "credit", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails",
"http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "lang": { "en-us": { "role": { "documentation": "The amount of aggregate authorized
offering price of common stock under the agreement", "label": "Sale of Common Stock Aggregate Offering Price Authorized", "terseLabel": "Aggregate authorized offering price" } } },
"auth_ref": { } }, "prpo_SaleOfCommonStockMaximumAggregateSaleProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname":
"SaleOfCommonStockMaximumAggregateSaleProceeds", "ordr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails",
"lang": { "en-us": { "role": { "documentation": "The maximum amount of aggregate sale proceeds of common stock under the agreement", "label": "Sale of Common Stock, Maximum Aggregate
Sale Proceeds", "terseLabel": "Aggregate sales proceeds of common stock" } } }, "auth_ref": { } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails",
"http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails",
"http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the
entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": { } }, "prpo_SalesAgreementAmountAvailableForFutureSales": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "SalesAgreementAmountAvailableForFutureSales", "ordr": "credit", "presentation": {
"http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails",
"http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "lang": { "en-us": { "role": { "documentation": "Amount available for future sale of shares
pursuant to the sales agreement", "label": "Sales Agreement, Amount Available For Future Sales", "terseLabel": "Amount available for future sale of shares pursuant to the sales agreement" } } }
}, "auth_ref": { } }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": {
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfCustomerRevenueAndAccountsReceivableConcentrationsDetails", "lang": { "en-us": {
"role": { "label": "Sales Revenue, Net [Member]", "verboseLabel": "Net sales", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it
serves as benchmark in concentration of risk calculation." } } }, "auth_ref": { "r174", "r660" } }, "us-gaap_SalesTypeLeaseNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SalesTypeLeaseNetInvestmentInLease", "ordr": "debit", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesNarrativeDetails",
"lang": { "en-us": { "role": { "label": "Sales-type Lease, Net Investment in Lease", "terseLabel": "Net investment in leased assets", "documentation": "Amount, before allowance for credit loss, of
net investment in sales-type lease." } } }, "auth_ref": { "r95", "r185", "r378", "r680" } }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": {
"http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables", "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing
Receivable [Table Text Block]", "verboseLabel": "Schedule of Receivables", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the

gross-carrying value, allowance, and net-carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth-ref": { "r53": "r59" } }, "us-gaap-ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth-ref": { } }, "prpo-ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables", "lang": { "en-us": { "role": { "documentation": "Schedule of Allowance for Doubtful Accounts [Table Text Block]", "label": "Schedule of Allowance for Doubtful Accounts [Table Text Block]", "terseLabel": "Schedule of Allowance for Doubtful Accounts" } } }, "auth-ref": { } }, "us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails", "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth-ref": { "r14" } }, "us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of outstanding securities not included in the computation of diluted net loss per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth-ref": { "r14" } }, "us-gaap-ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth-ref": { "r31", "r32", "r317" } }, "us-gaap-ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureLongTermDebtTables", "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of debt", "documentation": "Tabular disclosure of information pertaining to short-term and long debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth-ref": { } }, "us-gaap-ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Schedule of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite lived intangible asset. Excludes indefinite lived intangible asset." } } }, "auth-ref": { "r186", "r187", "r188", "r189", "r190", "r386", "r513", "r526" } }, "prpo-ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables", "lang": { "en-us": { "role": { "documentation": "Schedule of Gross to Net Sales Adjustments [Table Text Block]", "label": "Schedule of Gross to Net Sales Adjustments [Table Text Block]", "terseLabel": "Schedule of Gross to Net Sales Adjustments" } } }, "auth-ref": { } }, "prpo-ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables", "lang": { "en-us": { "role": { "documentation": "Schedule of Reported Revenues Net of Collection Allowance [Table Text Block]", "label": "Schedule of Reported Revenues Net of Collection Allowance [Table Text Block]", "terseLabel": "Schedule of Reported Revenues Net of Collection Allowance" } } }, "auth-ref": { } }, "us-gaap-ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth-ref": { "r272", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" } }, "us-gaap-ScheduleOfStockByClassTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails", "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth-ref": { "r21", "r22", "r23", "r24", "r25", "r26", "r77", "r79", "r80", "r81", "r108", "r109", "r110", "r163", "r245", "r246", "r248", "r250", "r253", "r258", "r260", "r419", "r420", "r421", "r422", "r533", "r658", "r664" } }, "us-gaap-ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityTables", "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of stockholders' equity, including warrants and rights", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth-ref": { "r27" } }, "us-gaap-SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableTables", "lang": { "en-us": { "role": { "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Customer Revenue and Accounts Receivable Concentrations", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth-ref": { "r16", "r17", "r18", "r19", "r36", "r63" } }, "doi-Security12bTitle": { "xbrltype": "securityTitleItem", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "Security12bTitle", "presentation": { "http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth-ref": { "r572" } }, "doi-SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItem", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth-ref": { "r574" } }, "us-gaap-SelfPayMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfPayMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfReceivablesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails", "lang": { "en-us": { "role": { "label": "Self Pay [Member]", "terseLabel": "Self-pay", "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed." } } }, "auth-ref": { "r699" } }, "prpo-ServiceRevenueNetMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ServiceRevenueNetMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "documentation": "Service revenue, net [Member]", "label": "Service revenue, net [Member]", "terseLabel": "Service revenue, net" } } }, "auth-ref": { } }, "prpo-ServicesRevenueNetMember": { "xbrltype": "domainItem", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ServicesRevenueNetMember", "presentation": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfNetRevenuesDetails", "lang": { "en-us": { "role": { "documentation": "Services Revenue, Net [Member]", "label": "Services Revenue, Net [Member]", "terseLabel": "Service revenue, net" } } }, "auth-ref": { } }, "us-gaap-ShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth-ref": { "r2" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock options, unvested options, vesting period", "verboseLabel": "Vesting period of unvested awards (in years)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth-ref": { "r542" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan; stock or unit appreciation rights plan; performance target plan)." } } }, "auth-ref": { "r290" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "verboseLabel": "Awards outstanding (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth-ref": { "r287", "r288" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date", "terseLabel": "Plan expiration date", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth-ref": { "r701" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth-ref": { "r298" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth-ref": { } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is

used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r272", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r543" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": { "r28" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r281" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r281" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r285" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Cross", "terseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r283" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": { "r293" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)", "terseLabel": "Outstanding options", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r279", "r280" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r279", "r280" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "prpo-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricedNumber", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) repriced during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Repriced, Number", "terseLabel": "Options repriced" } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "erdr": "debit", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Stock options, expected to vest, outstanding, aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r295" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Stock options, expected to vest, outstanding (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r295" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "erdr": "debit", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental compensation cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": { "r305" } } }, "prpo-ShareBasedCompensationArrangementByShareBasedPaymentAwardRepricedOptionsRetentionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRepricedOptionsRetentionPeriod", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "documentation": "The retention period of the stock option repriced.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Repriced Options, Retention Period", "terseLabel": "Retention period (in years)" } } }, "auth_ref": [] }, "prpo-ShareBasedCompensationArrangementByShareBasedPaymentAwardRepricedOptionsThresholdExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRepricedOptionsThresholdExercisePrice", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "documentation": "The threshold exercise price of repriced stock options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Repriced Options, Threshold Exercise price", "terseLabel": "Exercise price" } } }, "auth_ref": [] }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails"], "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301" } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails": "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r285" } } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r283" } } }, "prpo-ShareBasedPaymentArrangementPlanModificationIncrementalCostPeriodOfRecognition": { "xbrltype": "durationItemType", "nsuri": "http://www.precipiodx.com/20240930", "localname": "ShareBasedPaymentArrangementPlanModificationIncrementalCostPeriodOfRecognition", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": "lang": { "en-us": { "role": { "documentation": "Period over which an excess of the fair value of the modified award over the fair value of the award immediately before the modification will be recognized for award under share-based payment arrangement, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost, Period Of Recognition", "terseLabel": "Incremental expense period (in years)" } } }, "auth_ref": [] }, "us-gaap-SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [] }, "http://www.precipiodx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails": "http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref":

[] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options, expected to vest remaining contractual term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r297" } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options, expected to vest remaining contractual term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth-ref": { "r295" } }, "us-gaap-SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth-ref": [] }, "us-gaap-ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "presentation": { "http://www.precipiodx.com/role/DisclosureLeasesOperatingAndFinancingLeaseCostDetails": { "lang": { "en-us": { "role": { "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth-ref": { "r370", "r552" } }, "us-gaap-SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth-ref": { "r72", "r130" } }, "us-gaap-StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails": { "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth-ref": { "r96", "r108", "r109", "r110", "r134", "r152", "r153", "r155", "r157", "r163", "r164", "r178", "r207", "r209", "r210", "r211", "r214", "r215", "r245", "r246", "r250", "r253", "r260", "r350", "r419", "r420", "r421", "r422", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r448", "r470", "r487", "r501", "r502", "r503", "r504", "r505", "r658", "r664", "r671" } } }, "us-gaap-StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth-ref": { "r6", "r52", "r56", "r57", "r97", "r118", "r119", "r120", "r136", "r137", "r138", "r140", "r145", "r147", "r149", "r162", "r179", "r180", "r191", "r263", "r310", "r311", "r312", "r313", "r314", "r316", "r318", "r319", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r361", "r379", "r400", "r411", "r412", "r413", "r426", "r487" } }, "us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails": { "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r136", "r137", "r138", "r162", "r361", "r385", "r418", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r468", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r487", "r564" } } }, "us-gaap-StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]", "documentation": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]" } } }, "auth-ref": [] }, "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]" } } }, "auth-ref": [] }, "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]" } } }, "auth-ref": [] }, "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.precipiodx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails", "http://www.precipiodx.com/role/DisclosureSalesServiceRevenueNetAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth-ref": { "r136", "r137", "r138", "r162", "r175", "r361", "r385", "r418", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r448", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r468", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r487", "r564" } } }, "us-gaap-StkPreOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/ro/err/comp/disclosure", "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth-ref": { "r581", "r591", "r601", "r633" } }, "us-gaap-StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/ro/award/timing/disclosure", "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth-ref": [] }, "us-gaap-StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Issuance of common stock for consulting services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth-ref": [] }, "us-gaap-StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)", "verboseLabel": "Shares issued (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth-ref": { "r6", "r51", "r52", "r81" } }, "us-gaap-StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of common stock in connection with purchase agreements, net of issuance costs (in shares)", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth-ref": [] }, "us-gaap-StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Issuance of common stock in connection restricted stock awards (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth-ref": { "r6", "r51", "r52", "r81" } }, "us-gaap-StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "verboseLabel": "Issuance of common stock for consulting services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth-ref": [] }, "us-gaap-StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in connection with at the market offering, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth-ref": { "r6", "r51", "r52", "r81", "r426", "r497", "r502", "r570" } }, "us-gaap-StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Issuance of common stock in connection with purchase agreements, net of issuance costs", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth-ref": [] }, "us-gaap-StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Issuance of common stock in connection restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth-ref": { "r6", "r81" } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "Stockholders' Equity Including Portion Attributable to Noncontrolling Interest", "presentation": { "http://fasb.org/us-gaap/2024", "localname": "Stockholders' Equity Including Portion Attributable to Noncontrolling Interest", "presentation": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth-ref": { "r33", "r34", "r35", "r97", "r98", "r110", "r136", "r137", "r138", "r140", "r145", "r147", "r179", "r180", "r191", "r263", "r310", "r311", "r312", "r313", "r314", "r316", "r318", "r319", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r351", "r352", "r356", "r360", "r379", "r412", "r413", "r424", "r450", "r467", "r488", "r489", "r506", "r570", "r666", "r679", "r732", "r782" } } }, "us-gaap-StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY [Abstract]", "documentation": "Stockholders' Equity Note Disclosure Text Block", "presentation": { "http://www.precipiodx.com/role/DisclosureStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth-ref": { "r78", "r133", "r244", "r246", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r263", "r333", "r490", "r491", "r507" } }, "us-gaap-StockholdersEquityNoteStockSplitConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio", "presentation": { "http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails": { "http://www.precipiodx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentetical": { "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth-ref": { "r82" } }, "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS [Abstract]", "documentation": "Subsequent Events Text Block", "presentation": { "http://www.precipiodx.com/role/DisclosureSubsequentEvents": { "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth-ref": { "r380", "r381" } }, "us-gaap-SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails", "http://www.precipiodx.com/role/DisclosureStockholdersEquityAtMarketOfferingAgreementDetails",

```
http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails"}], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock" } } }, "auth_ref": [ ] }, "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.preciidx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION" } } }, "auth_ref": [ ] }, "ecd-TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List Table Text Block", "terseLabel": "Tabular List Table" } } }, "auth_ref": { "r627" } }, "us-gaap-TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.preciidx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "terseLabel": "Accrued franchise, property and sales and use taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r42", "r43" } }, "prpo-TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "TermLoanMember", "presentation": [ "http://www.preciidx.com/role/DisclosureLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loan [Member]", "label": "Term loan" } } }, "auth_ref": [ ] }, "ecd-TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": { "r619" } }, "ecd-TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": { "r626" } }, "ecd-TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": { "r646" } }, "ecd-TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": { "r640" } }, "dei-TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.preciidx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [ ] }, "ecd-TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": { "r649" } }, "ecd-TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": { "r650" } }, "ecd-TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": { "r650" } }, "ecd-TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r648" } }, "ecd-TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": { "r648" } }, "ecd-TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": { "r651" } }, "ecd-TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": { "r649" } }, "ecd-UndrlygSecurityMktPriceChngPct": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": { "r645" } }, "ecd-VstngDtrFValOfEqtyAwrdsGrntdAndVstInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtrFValOfEqtyAwrdsGrntdAndVstInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": { "r615" } }, "prpo-WarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "WarrantLiabilitiesMember", "presentation": [ "http://www.preciidx.com/role/DisclosureFairValueNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrant Liabilities [Member]", "label": "Warrant Liabilities [Member]", "terseLabel": "Warrant Liabilities" } } }, "auth_ref": [ ] }, "us-gaap-WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.preciidx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]", "terseLabel": "Warrants [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": { "r561", "r562", "r565", "r566", "r567", "r568" } }, "us-gaap-WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.preciidx.com/role/DisclosureFairValueNarrativesDetails" ], "http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants and rights outstanding", "verboseLabel": "Fair value of warrants issued", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price" } } }, "auth_ref": { "r729", "r730", "r731" } }, "us-gaap-WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.preciidx.com/role/DisclosureFairValueNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": { "r729", "r730", "r731" } }, "prpo-WarrantsNoticePeriodToAlterBeneficialOwnershipPercentage": { "xbrltype": "durationItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "WarrantsNoticePeriodToAlterBeneficialOwnershipPercentage", "presentation": [ "http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "The notice period to alter beneficial ownership percentage." }, "label": "Warrants, Notice Period To Alter Beneficial Ownership Percentage", "terseLabel": "Notice period to alter beneficial ownership percentage" } } }, "auth_ref": [ ] }, "prpo-WarrantsPeriodAfterIssuanceInWhichWarrantsCanBeExercised": { "xbrltype": "durationItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "WarrantsPeriodAfterIssuanceInWhichWarrantsCanBeExercised", "presentation": [ "http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Period from issuance, after which the warrants become exercisable." }, "label": "Warrants, Period After Issuance In Which Warrants Can Be Exercised", "terseLabel": "Period from issuance after which the warrants become exercisable" } } }, "auth_ref": [ ] }, "prpo-WarrantsThresholdBeneficialOwnership": { "xbrltype": "percentItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "WarrantsThresholdBeneficialOwnership", "presentation": [ "http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold ownership percentage of warrants." }, "label": "Warrants, Threshold Beneficial Ownership", "terseLabel": "Threshold ownership percentage of warrants" } } }, "auth_ref": [ ] }, "prpo-WarrantsThresholdBeneficialOwnershipPercentageAtElectionOfPurchaser": { "xbrltype": "percentItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "WarrantsThresholdBeneficialOwnershipPercentageAtElectionOfPurchaser", "presentation": [ "http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold beneficial ownership percentage of warrants at the election of the purchaser." }, "label": "Warrants, Threshold Beneficial Ownership Percentage At The Election Of The Purchaser", "terseLabel": "Threshold beneficial ownership percentage of warrants at the election of the purchaser" } } }, "auth_ref": [ ] }, "prpo-WarrantsThresholdBeneficialOwnershipPercentageWithItsAffiliates": { "xbrltype": "percentItemType", "nsuri": "http://www.preciidx.com/20240930", "localname": "WarrantsThresholdBeneficialOwnershipPercentageWithItsAffiliates", "presentation": [ "http://www.preciidx.com/role/DisclosureStockholdersEquityRegisteredDirectOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold beneficial ownership percentage of warrants with its affiliates." }, "label": "Warrants, Threshold Beneficial Ownership Percentage With Its Affiliates", "terseLabel": "Threshold beneficial ownership percentage of warrants with its affiliates" } } }, "auth_ref": [ ] }, "us-gaap-Weighted
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

C2-AJLO@/J>N31>9U<#88. B*8'fIthPIK14U.ZQAC MOK<C14Y#<W<JH'fYH>#5Y3P3+<#0BQJOXV<K'2+&L2+&RE...B'<S/K.M<HR.N.2+>8TD#>G9EAICZ<SAS5MS/<U6G3?<2+YMH.7G+>0>AU<O>OGHS<G.MOS<6#+&8R+&8L>O2'P2V0>WL'JH'fYH>#YSAU)MO4D<-Y<Y'fR.XFHZ<#PGSGUC<XX-GJ<V=V15ADH<@5LNNKQOQC<@WZ L8V1M.VM<0>2U'MPC<+&1N-MK<Q.O'fTV<#<PDL3?<H24DR'7BPBXKJH80771->G<T'HL'P'5\$SG><Z-J.M%<7&A.F%PIE.BIE.BNIP8P'<#<OIX>>PI=I@<4:#(BU P+Z85fIT<S&SZf+GD261#MVSfI'f5\$.P+>WVYV.GYXG&UOPOV'fH(MXJ)2+>7A)N5GK+&OMP0A<=7&2+&T.M%<6B90V14NM3<6A.CIR7D%<#5JX1B MfJ<fH'fOUI>U>.V<T'fO'2E'8&GACU<K&ZNDQGWX<2W.MK<JZKZUfI77>0A.MJ05MIAV<V#<#>M=IYVY<71%3LWM'RE<#<5'6u3+<M-Z<0>G<X51#Z<8C.M94<ANC3D&T)4>?<Q<1>QV#4Gf8L'5.2&8&fLDTWOZXLZ<+&56UfQZR<916.M.E6<#XUHK'192ZN'>#>DEI<S<6%4L7N.M2<P+>6VNG2<N5J0T8fSHNN+&J'>2 GA1+>#>TS.OOKEPf&A87fUfL24T.M'fQSO88(RfEJC@B5BfJG.OP<S+&F5.95\$ZBSfF<MH'fAB.88fYW)F&XYLYLM.MH7f(El1J9<06E*W=MRHfO<K5.KI-ML_L'Z<fLW1 <+15f0>M'L%5O7K5<#>NXfIB1LZT'f\$E<@<RMS

[illegible]

>[J5<0NWYV]1L1C5.Y9 RHZ1ARKJE68S.M^4(1-N)(J)OP.NVPP.L42D.Z.GZDO.T6H2J0IW<66V%QBJW#1<E!<OGU.MHV#5
YUX\$0?>,AMN4.Y9<77-22+8AF1<J>DST6'G'P'N1!>KKG;@D^A+9/M-M-NYMUC)HO33TDPN'P6,S,NJ!T\$4M0!71Q7F,#@>?>A;UH!-8R-j9'VFJ5#5
M'YH<WJ>+5'5'Kf3'L+DHH5%<CE>2'<P<=>X1=58V)G'.<*>1+KMSJ.MHE=>M+SEU=>S/6<1\$Q<.>UATX.M.E&K%<
(E4VY<UQKQ9GDI>S.O&M'IN'.G.KQ.YEE>C7V9'<4P42H1D)EJTW'>MOIN>?>F9B3V9NN8R/71&1'PWEHH&J4P1J1>1XXMFU-U-K?>.>NW.VO'<M^K0T'FWJ67O2FPUG?>
7W2'32G1<+>M'YJ18'1D2'5694KCH'7'>1'6D6X!<@>G.MI^<8RJHE054HP49D'>F9V910Q221J'FVD7PQ57&SXL'>GH90<H-H'0&Q%<Q'>Q0H7&G;MLHJLB92KW4?>
[=W<X5K'3#>=B9A60S'P-8Q:3!<@>K-AN'NH019HX00&SX<4J.MBHHHHJ00Q'VE'>QJIM<@>QVOTB'RC;[Q=>1<1WS1;1#>+>1N;74'S&K=>A1#61.M<+>JTX0;JL6B+D8;J0I=>6T9JCA;
X!A6<0JBZ'9%P%L+>+O5<@>GQBTX.MJ>9H8XJ!T.<@>(1X^<#2;2&H2O5'=>F;0*?>.<@>SXH@Q2QMGM).0P3\$>I62.X.M:04L&G'LP'P'1P'NIQJ;
E>@XJ9H5N\$VVK)MAGR,<@>1TV<1T+FWY'6=>RUCR.MP'<@>YH54&G0:WJ'F2CP'>G-25Z7M'1JPB>-039Z1\$>\$.FW00LCV7B>M+>3J'>0JGE6*129.1PT>S:DIF
MX,7'7&(1K1DSW)>H^2'1(SBLG)>5U-D'G.S4HFH0<6HUM1H<0C6GW0H.MK'HE&S5L'0'9JEGEU0'7T3N5\$>(<L)8V'>5&S'HX>=>414/9301QNIQD;M+>8>NG&QJ
[J]6H.7&T&S'U-H8-E+75Y'>89X4M'<S>B&S;L'Y%>S.2.X+MUHLE2@Q3HJ'F>E:(1A74E+XWJ;CZ=>1<2T0IWDY'FGT\$>12F<@>J7B>M5D-1VPB147G.G10;L%0
1U<<R.H+X<N@>M1;HHGE2.TEMJ3V8Y;X5PWV.M8J9;2#>.<KJ.%>1<2XOOE7=>\$X<12A[AO<=<6&Z0J6<1Z1'>Q&20/&8.M&10RA7U<17IQ<DG^B+1W@>?
77<@>4NBW'.8@>O.EG1\$>.<H&Q.M'NDZ&BORY@K1'HZ60'MSF'D&C'1Y)TRR<@>137R@M-QE\$4#<1<@>1<253N\$>'>MMU9(LWG5BS);<@>NXPR[1H<1=>YU7M
M1'HW(METS&K65G4Z;H1<=<6&TAB.M5WFI10'1B)15R'W3R16C(MH.ME'7;1;19%>?08=M'YU1;1Y1WEH5E
MHFE[62EYK<CU>)<@>JHJ'U=>=<M'61PL5M/AW'7F9.5537.14\$>J1;9&Q[0Q;+A1D13'X1V0IR.2<1BTBPTK>GVK'1SV3ZWHE5;3>9?>66G?U7M'KB3KJK.M
(MB8J<1YJ3+ZN50IBW;B8'>AVS7PJU<1>OP41'1<1Z<15PKXH.SBQ.M0<1>RZ<XQ)50Z.NXJ1UU<1>UUM<@>F74J8YGDZWM&N90YMN57IE3Q0J2TK.M1)9'>F6^M(L'Q47
CF%45B1G+N>XX<B<@>RX\$>+UN2TBZH'4G/Q&K<6F.MP\$>0H9+1<530/2%>202RQ5%>DYMAAB&R'MV20/AB5E(64C.XEK&G\$K<2C<OK3L<61'>50J1P'2T.N05AB+Y)15Z)8S3
MN4141T'C'THDN09/SXYKN<@>Y1YF>C'XZUW'K.SD7'.ZLU2M1/BX'UNAMMC9'.M@1>=>Z.A514K0)X&T6J;Y)X=>.&6K5W(1+1+0&(<@>S563A.J%>+>K#6'>21
M1QE0&4EFJ>N#1.8Q'N'7HXSUV&VJ.XP=>@>CY.7M.GEWN&1G'WHHQPS>S<=<M9W-LW11WP-Y'P>3JH<=<6Q.EE<@>S=>7;4ZJ&E;EHOU'7%97TSF<@>EVU7BLE
M'J'SSGNBQ19VIG<1JWRK39FXVHY8'2'>0<=>7V&DZUCJUNQ/9H'NZC<@>1Q'X.MGTF<@>C03'JDP.(D)U'>.>2<=>1E'64DJY
M5F'556(K<1<1JGL+R&Z'Y<=>E.T082)<@>M'Y89J01'<@>Y3M'QONQ'OWQ4F<1N'TM3U<SHEF+>1VDP>*<CJ5JAR6-78)JP>5D7521+0001.N7JOP.74/7&SXY'>J'V.MJ<@>U9'1P'7&1E+7
1\$.(U1=<1&0.R\$4WK<1&C'94.236749A5DJO6W=>M77C<1JTX1+Z8&S5Y'>V8>B'Q09'14<6+6+1'>1M'>R'D4B>9AC<8LJH<S014'M'51'4LJF7A<1Z'X'G<5P'16A5'>7R&=>\$VSOQ'H'
J7D)S)DIGEW'J'U<@>FM<@>MKPDE.5.B+W+162ZY.V6HA)7R(XVJ.EJ'F'2'>1&K<9)Z>5'>5T\$>A6VNAKAD%>8.2RUNN.WT'>=>6J\$>S12Z'U<77SB'1F>F.ME1'<1
HJ.A:>?Q'HRB1'<E+>J5PH'HQ=>N=>SOM;WK)1<1J.12Z)8@>Q>B2'TF'>MMF'>+AV7056.MP+>.>.>.>F'Z'15R'<@>1<1J>HJ)UJ.FD.>+948N0U<@>FC5E)F
M&K59G'>YFWS'2T.TF.NJ'>=>B9J'PJ'U4JQZJ'GHQJ'DWF6&ARF8'>Q.N.HW@>9L'>V6<1V<1\$>PA'IT#0'>R8067
M5'>H'043J'1HGB'SBM'YTF'UR9'1'<@>F0V'1'<@>A0S'Y'ISO'<1'F'6'>AE2=>1&6&4MRX<42>6EYDIO9R'WASPLI7'<6'>TJ'<PN'>P) (BPBL8J[1X12)QJ5)WIM0MHRJ
M9'>H.HI.AN2'<QJ'>W64UL2'UJ'YK.S5N9&8GRFE)PLB'V1837VU9F0K5R1'>MWMKR1<=>EG.QXMA80'4'5K1XC'>P-R2A/STDE.9PIN<@>R.Z1.M'>=>Y5'M'<0ZDQFZ0R4'J4ENJ;
L.MU&=>5V146C3'QJ'>S.ZSC'4L3'>V.M'Y'V1H<@>1'>J3DQ'JUV'J'K19R)F(TO<@>D+>1.NR<6V151+H.E7J'4XM47'>TMW\$>@>MQJ3_5G=>P'>+A1H<X<S(YKZJQJQJ7HJ4<@>J&R'<1
T2ELX_MNCG5S>E;HA'M'>JHU40V=>4R1U'>OS4Y8JR;+<E2.M'<@>3'>J'>?>RR;ZE2'>PW'52.4G<1JH60A'4GXB'ZC6D'E'2'>J'7MM.N2/K91-M17PD.<1'4E'1'K2&G'>
PLA>=>0E8AZ'>ON<@>N'>A.NZHPASE'<Y'>S'>NG'>1'>X2<1'>=<C'U4M48D<6G6N1'>M'>F&G62<P&S'F'9'>(WPKN0)UE/CC/PW)CAXI'E'0'HYD2UWAS'1H<1'>C'2J) MEKA'1'<1
H2W8'>NJP->N0&B9C<@>(WEH180'<4.5F2'>OHJ6<@>B&BKEP.<JF<=>1'>+>9&SDEH=>?>N+51'>0CQ3'>3VPIN<@>Z&N1'>N'>+>V4SVF'<@>CPOMAR.4P<=>=>Z'U'>O'>USN&8&Q'>U'>B'>+>P
M0YV5&4'>HEP9J'<@>FW'>N3A'<K'>P1'<1JSSBBD'3.HK<@>V=>506<=>6FP\$>0'>N\$>M->1U.5Y1WFB1A-5TJ'>A&

MJJ1C45WAT9T^E3M1;~_5W06GV2K2MP@-JFKB9K5D8LQRQ0871)>+IGC+1RS6FVWHNMCRHBQJ)IET@YK74~;8,914LIKW^CJ3(2~93=
MJJN-B6W-V9T9PQXNGJ;#587W@XAF55=XV1FK8JRNMDW&=BN+IMP=61JL;#6R-M1-U7^ZD-Z^P+HL3W1-N5;+E=-WY7L9T;C~N6)JMFLE=-D54>9Q;SZ~/MKE/(~^*2J0X?
SGO(O5B>WW<1%;%KXSGF92XD>30;N9-YLK7Y+HV0E7F-M3U1A~^Z-N-A2^;T~?Q5KD>URAE-J^TAKIKMH^LC72VQBC^KU2Y+T1QZ@Q)
M1J9D@;).S2J0O5W5#9A83.72<~J>J3(0)09J1~06<@S1M;+6>K1CP2MP-M;4&S577C.8K3V(HO>PV-YT^VJH8>NP4Y7~^EFH1LHUA+M>?2?
(R16V.Q4&S<~3Y\$~.IR0Y;H#0L^C;6/898GV7;_CK)K7Q)M^ENYFX^M>2~YT:SHJE>=P9QU^CH6<457+1%3=9&9%+WD<~H10XK1XSN^T;WB6;1M&6.97W#0FHHJE,FE)(%1?
9YVY0^ZKZ>T^*V80C-GHSMCS5C)<~2K1^/M(7&+1UH&BRZ(HX56P-9XQ,M;6&J19F7J1E-EICA<+%S^K0A@5DM,C;-7M^X1+~
PIYK(1^;5%Q5;V70@QX15+J3N8H3K^MHDQ6&5##^ZMYLJKBO~1M;)>~YB2X&J1WEQJ2I276F6L2T%N;WHK;K1+Y+Q1PN>);&^2S6C=-MIE-D?ECJ;?
FM6&+1+V;DMIEU41~;FBC~;KI=FFYUQKNN^WV1CJRKY2K;M~570V0CNH2;S(=@+H3ZB8HK7VJ0PBC^Y^G2JH@UP9XLEQ0?66HNF1V4V8R-MHJ^HUQO1?
9JOES10J;Bj;+GF+S^99F4FUE8N8N(V1<~(H:7515J~FJX-MEZR09&C2;13FGFLHODC@M;OSTIO7);UUTLW;J~.8095.8%017R27Z~+E=QE6G6C4J>W56W^%6GR
M6VJ06N;5FJ;3H59J5-M5(KH&A0FZ(H^H^VSM;U2BE^&O3;Q4U7JL@<@JY-E-CJ9JP~1;@YBT+M235~8~5U2P^K&GB-N(MLZC.GK9U8LR(>E%\$JFC&M<=<70Z?%
IDKAJ10^S-MQ3+7-5&JLU0;@H-7&5JL>~;0&6%2%&@>?C^NDH-6ETR7Y&8Y9F1C5J9P~R-MUF>5UT.GR-777M;5-YG+MXU4H9J3J-SELJ-UCB.MCD2=~/GA\$;NXMVHJ4_
M38B;SU6RGX7YWO~;IDVIM5.W8R)JL^H8~^*5J+1A/80X)A.M~(E@Z)A2V-ZX3Y-6=G-Z^J)JF.CKP&JH^QWL729NYAI+MY2H#%?
44V4G1=)J9^>~5%04G<3JOK7Z>5UG5L5L5&M5&S~MS#68SG@.94%RRNNH4Y4ZCF6(AI9M~.Q7~YBS=-IH@ON^P^CUZ=C6JL6-MOIAF7V.Y>V>
(KVN/MR~7/X8MLE0SH^EPMXJ^%M5UJ@PU=1^9Y.M;~+ZLFIJGVBYR.ZNI2^UT1KM&@B=3A>C-XV#(RCUUD8_GJZJF>PIK7-M@K5V5D2H(Q7>?TIV7I?
ECAG37OMR)FQ;PV4LU<LFF>20X>~3)BW<6K9HJ41E~RCHP~*M&C80K7Q?AE1C1K~>=33F6TQ<61JL1/SC1#>4T5?7+J^KJYR3Z&Q(CH(4BQ1M^V1JHU~^NZI
W65^HW(HJ8&K&BEE8>V>F8N0X)<@C~.B3~^LZJ49J1^M^VHJ~LFW3MQ8^7H;J019TJ~J4J13D7T;JZVW(BPXH.MH.M~1FFS88.X~^HDD66V^VD2BC.H8EU<4H7
~Z2J3?260CZJ8J2_0M0^A-M^N>EX3EV>S^>HU7GQ_#;SM_7N;TV4(8E\$+0\$VQ\$BXB8M357+1HD+4^2KI>~M&RJ-DPJCR/D1>YYSU+Q~B^RK+KFU^#SIP-M-
D1J>C>C35>5>D7J\$G>N+XUJLBIQ7%L1^TJ1J#60N^8Y122B@<+X+S5-M-LKT41QKJ1+5;U21A0+1~O1~LS8C1+1~VQJZJ;EJH;WIZ(3K\$PEA-M\$EAKP<=>8JFF+1+0+>=!N=
15HSHG<~M&YFZ+EV5^7~J~;ISW;DPR6=(HBL+VWY)IDB6G5V0<~0&JZLHVXU~1)M2~>XRYV~GM0J13J>S<~F-H(9GWEPX>~;GGTJZG\$54M&C<XK~\$RL%~+M&83:4>+!M
JEMPU6DQX8JW7;8V<V3~.GNJYU6&G8T^LFF_4#<ZG=E~M303VILF-M80456~P~1#>3>G;AQNQI2+P=S2&OZQ>0~#S5M0F4H7B2M30@RTQME.5JMK
RU;Z&10UOQSTW&L&S0&CZ&~%LZY^Y~LW-DH3J)U-W~F8Q9.15~1TTL~#56GJ4J^6SLG4A+1+9W^S&AL0XGAA-MBNP69NJ1H2;SY^1
(W1VD@<=FA1C(FP%2QA^D=^#EYIMR>Z?DYJ>2_#0K.M2)IG9TP^XQV^TR7:9J80=8JM8WQXJ(OR2^~W^JFPDU6=PIH=1Z14Q?);
MBSQ^HGCBBP1OYV=6=S4+N.XQF53126QJIBQ4V1^2V3+1+L+TPQ^MQ1-MQTF[EX13XN+IM30J&Q8\$;YU;@A~EJ^3GJ-Z9IGC-X1U+1+OJSY/90X-MGK6K:0+TfH6:~
(3.N9G;ELK3J0FV05F;158M3;7^12W15LX)8H~MBK+G&Y;Y~W^ARV<~(A3N^9SG>P~+R4B#4J<~19TRN&G&C37=4R/G366%WQ\$J~7\$;J<8;14TNZD+~9R~KGJ;Y~N~KS^?>
~J57+1JQ-C=7EE;HY0OQ^F-MO84Q19%<~(7-B(AUJ);~1B0JG7E-FJ@J29QMQRZFQ3.OZ%1+QJ1<~@BP@<~MG2)BBI&RNEB2-KNDP5E~W;8&0154\$OX<~(4~1S6G-
L8CJ8Q@<~VLE)D-MP-HH(B)JL3F;JS=6^<ZJDFH+D~1~J~M&R-LYB-VJ@JQFVW~TR-MKD(K94_QO+HGL>T^44V~9P=K^PIB>Y;C&K7P0&K<7~Y1&54.9-9
M&CY<14X74&P4C)XROV87RZ~M^S;ON51-LM-FXN2PAT2G&D^DVFNW>~JEG-M^FDPJ+Y+C@>~OKF+X1C^)(CD572;Q\$YOHU28RN~+0+HMDNMJPEKR^~_HI^@~Y
MCJ<~L7W45TC@1;~Y?7^14Q^QH@U~H-KL;Y7GE.YCRQLZ@DXRF~1^JGL9-MW~44~K~<H09CJ&A~_BD(C~3LABD>~IZON^G9);4550JQKKA;XGJ7JZ-MD13IP~HLRZMQJWL+HY
M3HB84G<~;0+16^<~TWBVR0>~;1092~9Q>@~H>?7~6.RRSF3UG~<~M7J7M~>~G;K147J^C~LN<~O~J~W~1%>O~J~O+98E=8#~+~\$C^YN<~O~J^?CM-7A-MYXU<N1<~<M5LR:
M&BXC@<~49PJN^90X<~0~39KNK;E4W17RA1TQ^94~7(BK472GJ5~57-19Y-MJG<3RPM?2%BNUFJ7H@&M&I5>5//@OM^Y>7>PGN1XBGU9^25YWE;Y%#<
M~9ZBLRANU&X&E13J9K<~X~;7D9Y-MQ=BEJP~#6B-4-N7&KVOJ>ZQW9Y7LME#<14HY>26~32V5NAG>39GKC-M@7;7ZB.RGG&L^SR2;Y~M&M&H(9CY-8)SM
C0N=OCGNSR?B~6=5ISR^G3<~<M^SMBL1~7/M[XE6GM~C&B^9OB>~<@Q^H=5.S29HEJ^Q>J^EGW4J0-M@>(Q.5TR>Y;56N6M1L39J2VJHJ8DDRDTU1V7(JL1P/DEP/QA~9?/C^VJ79J
M^F26G<~)L5&<0MR^P95Q1@<~<4P^<~<ONBHI0NC1*~C&N46B7G472UUY9=WT+M+>+>@JL;ZIW^7AFS>~;@F2;3~J(CE<B&P;1H2H~K7;7VNW(WJNJRJVW
MYEZ7G>N6G76HW;9;50=V6J&1^L(P~1U~Z^<~K@60S2J2UN2U+&EY4QJ7F^M1Q;3(1%GSJ\$~<~%JH4C+9^UJXEA6<6~H3-E^~W(8PU4ZJ)<~JH(C~M>SAGK1^?~1
^XH6=>91NLM<4ULJ)4T3C2TPM(C>D6&J^<~S^JNFI\$~_NE-S^BN~KX^PVO.6^4X(C~<OQH~RM1^%KJQ>4UMTFP6G3N;J^E~WHDI(CYAZ_R1^M^T^E^2~16@+~J+9M5SEITY;~
M^9J9DEMBXV6;~Z&ZUJ^LW~ZVCG;F&ONK-M3^49Y^&5&SRK~<~AKJFX50I(8B~E~C&K249?7^HVA+1TK1JL287_HPNQJY1~102~16~Y^6+M~
JFG&ALN2Z~SNAU3=G2Q0Q0)MU1\$13)3YE&K-EW9H-HMPNQJLTMDSJ(L(RBJP>@EGV466GDC&C%U=2~L\$FW^XN~TO1~W<~<~%ZC^
M^DG<~O~\$SKID9H9J(LJVSJ0

[illegible]

[illegible]

T\$Q~UQ)&U\$D;+W:QOCAR7|Q~M'SFJPAK#2GMPFO/8H%)-EXH*YJLP9FB8LHS^UM1-M>P?-HGJ4;K@:E%7/Q5MN^~E_Q_&OR^G_JXB^OQ&A1LWY+4=-VIC7?BH9PYI
M)V~1-8-FG@~\$U\$B>US+;A-X\$^O#19;A9|0%UBZ61W3JWA:21R*3?JIE)*M-D^32Z9Z,2C|(DBVM=^#V|P|6|G@)MGUH6*%&-GUN-M+&&CM3XWY+|T|HH#LDA?@+43<
>B|?TR0B53%)++S+U09|QH7;~>K|MCXDF2^~\$*#W)N^NR#;-N|2|B-7|B|6|(\$L8MA;~\$M-\$1D)-@-Q9H#=-;XL87F:.(TOFM@~_VY7WK;ZOIH2M9WB|N9
|DEN4J|B|~<AA2Z~UQ4B1|D|PHQ|R+&E7WN7YG4CP\$@<B4BNX9R|;C'Y|&#%F7RE+2H1_LX-|J|_MP@<
O^LZ~7^C6BM0:69SLV28GP4740^\$KOR@BC\$9^VG>J19>44IVYF~E_M3FZVWHDKURLA/X3#9PSH|&%+HY0=N+;7^~PU^~.002|T5S|I#B5H|
M2G6|E|9T^<|&#&#^VU&V?;FAX4~L^<|D9T?)@<SN0K?T^OM8Y1=7;#J3A;M4JQMQ+U9UX9Y4I9D|UWVP&0;|BC^>NXB(D^?P8+OAO6123CWM7E^X&80&^RGW?A-S9?F3QWVAI;
(Z2800;|?2MRUN13 MJG~<@0^~0*E(LX)0XE;AA{#=-NAFE6_-&.B9X^Z2+TD+@<PR>|8U?F=1?>M<-S|R;AUD-8^S;55&29Z<|AZZ#D3CWM<H_-&#J+EN5^8PDH7(|053T
MB1+~&1;RMH|{MG:5^~01ZUNFQJ^3Y;15^72Q2W4|}H8900L|E|F\$K57WMB^DB^D_PYJ3Q;|?4QZLEZ|{VJCM3T239&F^W;#HUEU^>W&S=PD-3P-M^5^76PB3|W3H~;
(.6#Y)Y%Q|A|{I\$^430-?>_>P+V&S^AURQ|H|N-MBT+&%K&B;C2-2+^69HUMQ;CZB~JL;TJTN72D~2WXXR3M^M^F92|&-G&S|WWH|W;F8B^HG7>UR+IA3@D7;
M|H|3_-Z#Q/S>3^C^=-(KBU7|K|VFO~L|JCOI?@Z^N%?%4=|B@)MRL%K-&+94L-M!\$?<33#D(=-B!^6MY#-.1+M^=^#2|LX6\$Y9|Q%;Y4MN(1^S?XOMJ|)((-M3;T%(=6^JH#C|
(4=TK3;M|S|^C+~&~>K|P3;M-M-VP-DAHX:5~>|SQ6|1\$#J;Z_K0;M0HL~&3;E.VQ?J3X?7^LB5U1Z|S|WW^<K-MY|P^TDB2^1\$+|>40+1^B|15(V+<@+T3XMH|T_-)=GDH^K~&~&#%|J|
WJ&F^M|J|36^E+1^7G|W@|JW~@KWKBB^T)?(X~&|F|B;C^095^A763ME0P&UN^K3F49R4|JQF|H|3P05^>D&M^GK^H|H|C04G>|H<-!>|K>R;3^4H|QF+>J|N56WOW~
J|>=32392-M^5%Q06&K67V|H|>=WWBH&B^I^PN2|T2CY4|CQ~<^<A^K3+WO5VY2@>S<M<F7Z^KV0@IBG<-G+KD70K^O5H-N8@<4^Y^88|JW4Z5P>S?>|+<+>7|C&5B
M^JXB~RETGZ|A~98&|Q|T^14|N13L|>XEF7C|NR_9>Q<E^76Y1~5^>|5M^K3-NAMI=>P9Y5U0Q^>15^7LEF|>Q-U3N54LC2(1^>H^>4^>F|J|U~
MU1D)C=\$FZ8S+FE=O_Y#J<|J2_6L|I?>31XL\$="M9M^~.M\$+M_-4M<&|@78XUA@?+=EA^>-&RV^>99<1^CG^>27<2;=AU^1UE0|H|P&+>+|G2Y13F^D2D)8N;CQCH<
I?;DE1W^XZ|&+~&M0YS32~10^M?>C^&V1K52F4Z>G6E^YH78C3+>@2X(CZ?>Y;Y-MNABM+WGS5HX0TA M@2^157^|Y2J^HFI4#-MW|B|4VZP6GDH0>@<1^TEPQ5MOEYR^A|H?>
31?9-MU59HBBBU~<+&4EM\$>F78?H1P^&S8+<C^E3N|H7XDV3|G57W>F5X80&N1^M^#0Y;WQ5?0X^<6_43F^%V|Y?1^K6D^>4Y;IYJ9>+>M^>1415H-KJ\$8|
Q_Q-BN^1&1>2P2VU96.7C-INN)D5O-X.E296.C-XZ)5=-R4NUCF-M^K3+M_-RTU+&@<KSDY7C03(1^>41^>|HANO)7&C6W5?>@77L|6VIE1E(45104
MVJ9K40QDL8B^M^5<1+GQPI^823_LW0^64M^YTJ5R|KQ<Q^Q23Z-IZ_Y-M6S0=4@&S?>H;X1-D^T+VHCO+5^>IB(T^Z-Y|X|>8261>|5WE7|HQEAD4|<8RA
MNTP^<F^%6^<N\$-N^Y7GVK>@/PBS^T5-Z&PP;RLW|E>;3^TK9;5F^#0&K2^M04O2YI@<HDB756&^&E|D^9#M8S>2(9NU^N^ZZ;C8T=5|PRX;^HJ-A5|)M|&^<
EK|<F;8F^3P^3&3?)>35%W^52-CY^41<0@<HNNY|QH@<M>|/S\$<N^G_E\$<#2R47;E>=>O^H^>E^>#6|B|J^M|>D|J^K-A^>|S MEK@<L2MV7?>5=1<+H^YAB-DE
B2|VY^E=6W1P^X\$&OFD~&Y2RPZ@R-M4LY2|ZM&>=RRAS4|H^H^M^CAG5|7D|<45%N9B@<Y\$YZR2|VKH15E|L;M0D0B~M^|EDGX0=>JFP67?7T6^>11+>|TTO M<
<AS^<8|H|P<C(L:17OY~>O_Q2|G<81?>2 BSXK42^2PH&89IN^V|@<Q^M-AKX62Q6|@<F|OY0YC%&E~>14S^WRLX^M-(R9+>G^X^/84
<2P5|T~<W7T;R|B)8+941|H|M>4V(F&I~JULP|9#>MA<8^H^<~>RYFGC-M^8D^>N^7Q9V+U^Y3X^|H^>Q|JMH6GV453>|>6THG^>7|O|PIE~>J|84.P)GUY<NDU+0V4CL^&1R1(
PD0<MQ@2N-H|RPFEQ0D|V|E|5^5&M5L1^4A&+3&K1COFDMKC=R7|f-j|B|1\$>^3O,0%<XURX|H|<|>V^N^FN;^IP9B>C3^C^&Z^MGP|<?
NWR~3F^>H|H9B>>~>D<P^M^Y^COXBP|f|_8GW^RUSX?P_-+>=>C9B^M^<=>CX9R-Z^8N^7V^T^&V3V^Z^MMG3|S|>QY8+&BLW&f>P_->P>0+<S|YV4B-
J|V+&MQSZR2HD^>U?2>15~>H^A-M^A^M+FO^QK^XK;^#TP\$%3|B|B|WAZ+EXW>HEE\$|LTY|>ON|_MFL6PFR|WHU|FHC|O|>FQ2=VBV;3^>575W|D9K-
M^MY9X-M^<R|J46~>TV6&3^S;J9SL^P^>WBB~O@<4^ZB^V+>6H8?|UW~C^1 MBGBB4%N^>E^A6Y2AU^|SA-Z|>6J10(|JQW4=^M^>F|F|T@<VGS^0\$X-
M<3-QX_VPIZ(5KM<Z&6Z&6S^|KG=H<2JBG6&4M;M^>M^JHMT7^Y|U\$<K^S2-M^>1^>|&F|C|>H^>1^>|A|A|22^H^>Z^3KEZVY^Q=74B^*|&~>LS;P|JX^M^P27-M^>B|J^>+>5)-
~8N+~>=47|VCM_KZ4-J3VN^Z6_CPU|I\$~51(1^\$|B?Z)0|<G-MD^2_O9;S8B=7,72DMH^>|S3J^>G:1V^V>~>K=7|J.P.5|J8|)6UG6V%
M^>R^<+>6G|V^MCGZ@<Z^H0&EK1+43~>1HH+V>?>#RC24ZU^P_ZQ0TRIO^J4ZF^ME^>|<J>BV|K1=U21-|>C|B CEX^|H^>4^21-33&@|J9N>+X#7-
>22;M^7ZK8W^>@<Y=R|<SOX063E?>|H|H|A|<E@<N^<QKR2E|X780L^<A52PAT1^6^>6 MCAQ?T^>1^>+&CM^<E6WV4M|>|>J3Q<+>H\$S-P.A.57P7M_-R|O|>?@&##
M^>M^H^/9+<1^Q?F3&~<K^M^P2E05X^>=JOM\$9S^>@RF@~<Q^NEX~>HJQ\$5X2^>ZP+>N654PP+WTY@<P-U+6+>@TG|Q95N^>J|L|A|EY2331+>
M&H|V74|<|>DV3H|<45>4@<F9205Z2T7H;8D^M^>#8C;VY^>M^>M9\$>VWTFU5D^M^>A&S^G^>5^>=>?Q>K^>+>EL1R2;6M^>M^>X|J6;U+U|90H9S72_0+^>C>Z|>F=D;J|U>?1
KYQPL^QPW^>V+>J2|>S\$>QFLH|N@<M^N^>=O7(=-9PN^>7^>?>7H8H|>|QHGE~>J^>?>VAPXN^|W2A^>L^>U^>J^>WK0096^>MHY^?C@<^>ZXT4+>I|U?P&6KYW^>PW_NN^<=J^|T+>=?/
I|QCB9|67W16<0VW;6XZ MP(5BP&_IPM^>F35N|<UT5^Y8W7?>0O|H|E44|G|C|>J|>R=^>6|B|MY|XUQ^M^>AK&~>#>=>Y4EG)0^>6^>_JL@IGBQ^>M^>9;ZIK~01Z^>G0^>6^>3JXM-H-63&
<3L2>~>M1A4YAO<0>7>27;SW3D0-7J^>V^>G~>H<~>|>=>|>=>2)P|H^>@<W1WV9UGZ|QZ^>V^>+&|H|H|MQ|>=QX^>0(T^>SMD+>JUV^>5V8;9^>70RG^>H|U|K|337%>9J|O|
MFUK00YGLH|3BP|05_12P^>P|H^>M|F&A>GK^>J|T2Q|>44~>J|O^>T^>C+<=<OAPJ^>P^>H^>Y^>J^>K&4^>Q4^>M^>3|<C66^>F\$|N^K|Z|>V5M|H4|QRP<C^>Z15Z(V&~>K741N9 M&
7RYN^M\$>@<3VY>G|JY^>X^>8^>I^>F^>Z&N&B^>C^>|>S2VA2^>D-K^>X^>V18B>2^>2|5|F^>M&X^>|<OOH(C|Z^>U^>P|B>35 CIMMH41|8@<4T|6I^>?P4UVH^>O|U7K^>~>U^>M^>H^>71T^>#9R-
%\$|Q71L<~>J0Y7U4Y@<0^>E^>N^>T^>J|B(Z<P^>9|@<X^>M^>S^>P^>1^>#Z&M^>^>S^>L>~>#^>_MAECS9|<S^>N^>0^>XHX^>|EHHL-3%W0=6J_->P|8^>6NXA>R&~>C^>F\$&D(N>BYZ
M^>H82<@<JXDP688QY+>J>2HT^>1^>136I3^>Q^>P^>M^>N^>#|ZIG0D|<4@<B^>M^>H^>R^>H^>FVQ<@<S^>M^>^>P^>F^>D^>F^>X^>S^>G^>7H^>G^>K^>H^>5^>|H^>N^>W<M^>6JW^>14M^>S^>^>8@<#^>N<~>RL+T^>L8Y7
3UX^>2G3|>0300<Z|HVA7^>7Q^>5W8Q MSX|>QU^>1P^>LB5^>H^>4=I&8|1FC(1^>51^>3INB^>RAA^>O2WJ20GP092&K48H?>CA-M^>H8=1^>T^>G^>
O|>#^>M^>F^>1+>3^>3CM^>0^>4^>4^>V^>T^>1WUNO|H@<N^>1^>IDHW^>U@<M^>T^>S^>=7.P0X&3^>QYB|J^>W4(L8Q^>0^>+>V^>K^>+>J^>+>Y^>9@<N^>#=-U1-MJT^KCD0^>O22G^>#^>U^>|DE^>J2|<H^>Y^>VSG~>~&
15@<4^>2^>+>1R^>9K|<X^>A^>1^>34^>M^>UOPZGB|P^>Y&B^>N^>YSGUO|1|QYLM@<1^>#Y&B7&^>DU-8>Q^>4^>MU|N^>V^>H^>W7U>~>JBA^>A^>B^>8M^>M^>X^>26-
<J|P15@<HCH|<#^>@<GN^>C^>N^>%JZ&6QC(P~>M1^>F^>I^>13D^>Y~>02>9|4<~>M^>V^>T^>@<1^>?<~>Z^>C^>2^>Y^>P79V^>P1^>LM^>S^>X9H^>+>Z|>S^>QHR^>?>P^>3^>Y^>H^>f^>J^>AP^>AK^>M0~>+>|Y^>Y~>H1^>A|<#^>|N^>
4;8T+>#^>K325|0-LM~>^>SV6@<MK1&X5AT1R-8GLP^>|Y^>I^>Y>L^>S^>P^>@<RWXZ-MUEH^>DPP.P@<~>P^>S^>+>3^>C&K&K^>0^>9^>0^>IX^>U^>8^>+>+>@<ZM^>JVD^>C^>Y^>P^>L^>Z^>=Z MEH^>+>M^>R^>C^>f^>J>@<M^>|
<4^>J&M&4254Y^>W20N^>104+>@<X^>J^>K^>+>BL^>H^>C^>KPFN80^<~>6^>H^>~>DH_-M5N^>S2^>F^>4^>M^>^>H|L2+>W^>4ZHK&C&X73\$P-R8XDGM^>J^>X^>P7K&E2|>O^>V^>X^>F2|>@<M^>|
4M\$N4A0BH@<9B\$R83YAC|<J^>K^>Y+76M^>2^>M^>O4M^>P^>#E=^>@<H\$|NK6^>PD7^>F^>W^>O^>U^>+>M^>+>M3K&AR^>O^>A^>L^>~>V^>U^>J^>P^>T^>MAG=^>90^>Q^>AHS^>Q
^>|EA6|TGRY@<004V5C^>H^>MV6^>5&Z^>J^>Y^>C^>K^>D|Y|~>C^>M^>X9F^>W^>T^>K^>|<#^>+>TOL^>P^>7M^>O^>ZC^>B^>Z^>Y+>V^>2^>H^>A@<^>C^>O^>D^>@<A|JRO^>U^>XEXOR^>H^>W^>L^>T68Q^>M@<N^>V^>RBP^>
=I^>V|>~>J^>M^>D^>L07^>^>H|H6^>#^>CB^>|>X2B&~>V^>R^>+>V^>M^>V^>W^>V^>4^>~>74^>T^>A^>V^>H^>M^>W^>O^>S^>9HB^>S^>I^>RPN^>W4A0BA^>|<#^>K^>~>W^>~>9^>+>@<Q^>H^>WE^>~>SM^>~>|>~>AM7^>N^>T^>M^>ASG|<S^>DYH^>H^>C^>J^>J^>~>^>
(T^>9@<T^>U^>LH^>|QD^>L^>PV^>@<+>VQD^>C^>R\$^>R|>R>~>M7^>?>@<B^>D^>Z^>M^>T^>P<~>#^>1^>Y@<|>P^>~>+>D^>K^>R^>F^>D^>S^>+>V^>T^>~>J^>M^>@<GZ^>+>DD=^>S^>M^>+>C^>U^>~>7^>P^>N^>|>E^>2^>OW1^>~>C^>
TOGB@<Z^>C^>LOW^>S^>@<1TZ@<~>Y^>A4IG^>O^>S|>M^>~>@<0LAI-D^>YBV|FV^>1~>(Q3|>B&L^>ZV|L3~>H5^>4^>|H|D2<~>M^>J^>M+>S^>O^>J^>O^>7^>M^>C&R\$^>X^>@74F
5^>J^>X~>2P1^>Q|S^>P^>1^>B|7UN8H^>V^>Q80^>2^>M^>D^>M^>^>Q|ZL@<~>K^>W^>P^>P^>O^>S|>Q4E^>W&Z^>9D^>A&~>9^>S^>|ARJ|70=2J^>M^>N^>@<A|JRI^>1^>3^>7H<~>+>M^>+>S^>BU^>T^>2D&K^>H
J^>M^>B^>T2^>C^>G^>A53^>T^>F^>|>KPAUBQBB^>N0-B-1&S^>P^>@>|>J>U^>6NLG^>M^>Y^>P^>F^>EPG^>J5>=M299P.56+4H|35H|>W|P14?>@<W^>G^>X|<~>Y^>M^>1=1^>ZL3CJUX8|
M^>U2WJZEX^>IYCA4R^>2OU^>U^>P^>V^>K10^>|<6^>@>=>002|>=>Q>A0+>NW^>~>@<0|<G^>#^>J^>H^>M0X77(6^>S^>7+>+>W^>8!^>M^>93P8.OQ:60J&~>G^>12AT8K^>C^>W3AU^>M^>+>5QYV4~>S^>V^>H^>~>Z|4^>f^>
f^>S^>X3N>W&G8&4H^>19BEP^>Q~>I&X&3&6B^>G|J|>H|9GWA^>U^>H11U^>M^>~>U^>G^>B^>T^>P^>GM^>^>=24@<^>#F1PO_YFIB00MAP45^>W^>O^>=W^>95(F^>1D^>4^>8C^>@<Q^>M^><O^>+>W30-
>Z^>S^>Q&B>~>D^>Y^>~>Z^>W9>=H|Q^>G^>106^>G^>J|3^>S;025E^>T7|O_N^>M^>M^>2D^>B^>R^>B^>C^>K^>3^>Y^>1^>|KTVZ^>+>3^>P^>2^>~>#A(VI^>45^>8DEGPDH|L^>G2Q^>Q^>N^>
M^>1>+>+>V7D^>H^>Y9E^>+>+>KBC0^>P^>F|E|L^>H^>Z|H|L^>L|L|J^>X^>Y^>J^>H^>J^>H^>T^>+>A3^>@<2^>J^>H^>FGD|J^>M^>S^>H^>M^>M^>6X4L&6~>0^>S^>H^>7^>@>~>#>=>D^>A^>U^>D^>0|5^>1^>Y|T^>L^>?>7^>X5^>S^>P^>+>#^>U^>VA1^>?#
MW^>Y+>1^>FO^>Y^>+>Y&~>H^>C^>G9|H^>J58~>J^>D|S~>B^>U|B^>?~>X^>Y0&B^>=S^>Q|T9^>Y^>U^>33E^>A^>G^>S^>U|X2D@<6^>7^>M^>2^>)^>X^>H^>E^>N^>B^>J^>R^>X^>S^>Q^>56G^>M^>4^>C^>TBS^>P^>X^>|R4^>L^>6^>6^>K^>C^>@<0#1>J9 M^>
W^>CB^>W^>C^>B^>G^>N^>J^>4F8^>~>4^>M^>L^>3^>P^>D19S^>+>X^>W^>B^>C^>X^>Q^>U^>K^>7|P^>E^>W^>M^>^>+>+>W^>6X^>1^>1^>T2;G^>N^>P^>C^>I^>W^>|5G^>E^>M^>B9M^>S^>K^>J^>C^>S^>B^>W^>B^>O^>3^>S^>A^>2W^>G|A^>~>V|Q^>S^>|
<@>D^>@>V^>H|OX^>A^>L^>@<5H7+<C3?>S9L=|<C^>M^>^>U^>@<Z^>E^>F^>EV^>F^>J09>|<C^>O^>W|RK^>~>A^>G^>|P^>R^>@<^>=W0S^>O^>~>C3^>S^>7=G|Q^>1^>V^>R^>M^>N^>S^>A^>O^>N^>8^>R^>M^>D^>N^>D^>W2E5~>#59CKH|H3?>
^>H^>B^>#9R^>Y|0U6^>L^>2^>H0^>46W^>M95UAQ^>|X^>D106V^>W22\$>FHV~>+>|G|R^>O^>7^>1^>E^>7^>D^>U^>@<S^>V^>S^>F^>=H^>S^>F4S^>M^>^>M^>5^>J^>7^>B^>D^>M^>S^>I^>V^>U^>P^>D^>V^>=G^>f^>
>3/4&4L^>4^>G^>W^>M^>+>U^>^>Z^>X^>@<X^>Y^>Y|>MH^>1^>H50^>#^>B^>P^>7^>9K7^>C^>Y^>N^>R^>Y44P^>B^>K^>A^>J^>W^>L^>^>X^>O^>S^>~>L^>M^>P^>D6IX^>#1=^>M^>8^>9^>I^>E^>P^>I^>T^>4^>C^>I^>X^>V^>X~>J|@<T^>+>V^>T^>N^>S^>9A~>Q^>Y2^>A^>O^>
U^>X1P^>X^>~>0^>M^>Y^>R^>B^>28^>B^>C^>Y^>I^>F^>@<4S^>M^>Q^>X^>W^>5<~>H^>M44|O^>98%~>^>J^>Z^>=U\$60^>70P1^>2Y4^>=A^>O^>|Q\$C^>G^>K^>~>H^>D^>=C^>GBX
D^>O^>X1^>=^>@4&21D^>P^>G^>R^>S^>C^>|G^>H^>X^>V^>#^>44&XV|~>H^>7^>U^>B^>J^>Y^>X^>L^>N^>J^>N^>ACA1^>Z^>W^>Y^>Z02IG^>K^>Q^>D^>N^>F^>~>F^>7D^>M0^>IASD>~>1Y&~>=H32^>M^>2^>5^>V9|2URV.QP46|X^>
|K^>N^>1G2^>U^>H^>L^>S^>W^>D^>Y~>50^>M^>^>G^>M^>B^>H^>+>I^>P=^<~>C^>9^>J^>7^>J^>B^>~>|>@<E^>H^>=39;R^>K^>J^>S^>1X^>R^>Y^>N^>=P^>2^>M^>F^>7^>C^>K09L(T@<~>92^>T^>?>^>F^>2H^>9^>J^>Z^>P^>7Q^>G^>#^>S^>A^>T^>F6^>0ED&
|M^>GZ^>N^&

[illegible]

[illegible]

```
Z1-0;@;-7B1+30XAF-M-00N9J+-Z-B4I;IRK=-L-WKK#Q3HNFNQI[=];A;T;A53,U#+153;S150-MHTU(RKEE,T;1%#@VHR)U@BK=:A4Q+Q30J@P;.##+WBD;9H;F;P;G;+@MFR2C;QHW#SWGC[X^~\]NW,XTC<1.D$%X[A-](#H);[C];I;Z+1+@X-LY-M[SHST]T+W(OG-W2THGXUULL[28P&T;Z6R]RC@FP#908)+SG1N'89K1';JD M=+7D'9)HV0DA_20.KXSTH$R8R513K&MS2#7XEFF4E~LX9TG[U?6BIUXV;2Z-M;+K3.A.W@Z@9FUH3&+_03/6G76G;%&9L(IE(C33-6&RBUIRUPSN;M5)Q.IA9
```

M@JW&M/4EN-EAP\$TFNEDG8%.-<5GM)K%#&6&T9H*#B42f|@UQ.KR3;F9+K6V+Mj3+M63P?+51%M).JWE\,P2*FU9J2GK5:XB0Y"2T2SP3j]8W[Rj6VB,YGF-MF_-T<0U? %0;4Jf=6E^<8P>GKG+ME+MD5B#P+SJJ+?J7AHL^CWELE=|,H62G ML,TS5H+V&#B02,16,8J_AZ@&-UESHJ,DM3N^!TN@UU2LTD0>,\$0WKQ0-42 MDY44DPMN\$Z%=>QC,E,1AX02=>X3ZG;@>@ (B15=89?JY5)"|,|CJPSYUHTP-FCM32;_Y,@A1-6,%X>ACDZ-DQ\$@D*X4R01HRDZ M@GIXP91E,VUM*G%\$0V6GHWW9G(|@HROBMM4-S'91ME78Q@_T+17,?PQ.MA-X@044NWU:8-RH-LSA2N,%%Z862\$&+4JE#Tf*QTD,~Jk+XQF-1H-MPF5Tj,6;#-L- VLBMMJKVD%T9W\|T%\$QFOMU0W,I_-VY?#DT;7AB=W&A|J=A5-MX=??2KJ47>NUA;VPPA13B4W6VS0LWG^4-*#_EP==PPNB85|fW)E65H8^4-MKX7#;3F5&Jr|,}*K? KK->@UQ668FfQj=9GHM5M4&+&U\$|f4TfM956GE#1MB%); M2X=B5\$+?H55QNIv;^5?>K2P2@?7Zi0LZG;B-KZTf?Z5A+FD@88?2F62\$3%\$A(M M>0>_UE-;fTKK#Pkr|_ZA;4%3X;2U?>_J&?j^6VZ5Z-RU*;SK18R=K+XQN-M09NKLZVQ1Q2f(1;_SB-HQ@NC+X|XJ^*#74=H7X44;PY@876 INUA?F-Q-A^1JCP?6JfTj-M8T NKfZ2ZLj%#6E2\$Q>QXQ-H|_WVRVt-IAJ3-B=S6Q+L&F;f;MSLJf+Z-Z-M0;|CY5\$1X0K;GLX8HQJ|<D01E66;|\$DLV;_f(MSV)Cj;NW08D%=>C%>+2P3?T9N-M=M= f|>FDfDZ|XNQX%<09@1MPP37fJfTK8B;VfOEBHQU1L5+D;CXDGYSYf;f;|_Hf|@f2=6G1X|MMj|_L;Zf2%>+46A\$Q@GMCGBASZ4R/VU;EC/97K;?%Q8R|>-RHAFGACD*K+ MP;_J\$SEFQQ"MI".Q?j\$|N9=6^YEN^AEU#B^9?@POJ\$@P_X?X<@(|F7IX3+DX|)JER>?PQX?+D-M8S%#RX63Q-Y4C|_L\$;+<CR8+=QGS|Q9_-J9-BTU|,?_fZ-(^_-#SKZDH@= M3SN;ZVSF<L1+>-3&QUTVU8N?Y2DZ(S;L);fT|NAPKQ;C#D?7H<CTF7j_H-M+G-C-(N%)-_VT>NU@?@G(AD<-M;|<4^>=74;470_-S|<^Y;X/B>=9f66G70 M#-H4BjKl(16+>=Y<N?+OP8,YCYVl09)B;_0?30JHPF@S#D?Yj|9*%KJZ@Q;f;C-MN;84N)K<_f-W61&H4Z@Z_VC;ZMP4;2JNQJ+M#A=1XTC437?>S;J3J60& M\$ZRPVU;34UIE66^9V8f3J3U-ME^&W-N(P;S)j|_j4L3GTSFR61^f;Y2LVZ?Y-JM?A;9-U?j|Q@E7V;U06U5M;6^FLE0A4Q0YBH7@fFR)RX/P-E8HS@24;1%|f6?> &H&32#ZE=ZIGC@Q@_ILC#_ML6L6W+M4M%\$?Y17-;CjH4&L7UA4F09j|;X9+X3E01?HL1ZYO4A5M;f+&+MCS?S(f=-SGO4N;1&&-&EJ@fAT7QX;6>2?3>_ /AXIO%Q5>F33*E;PU_-M#^04AIXT_-&16NG,Y747,XWZIF#0@=6N0-6ZK;4*^1&D19B&DA5|D<3IR/_M?I@_JP7D<6#;|9^FYH|V_-?jT>_-"518.(#=#V3;|fj^6H@)E5@ @MH1T;jN;N6OUKTYXOM?9EHQ|f#H#VQKBJ920R5""=>Z^G6>O^_JZM?V-M35f3B+2^82_DZB65HYEU@;=WYU2|;U\$A;H50A^QY%Y4WMBVL&CU40_U5 MMMMkH(VWVZU)Yf^<1_-&9Q14W77H#+M5UUVF&=K30VfJBA-MD>?C;_CJHWHRD2<3^8CZ?Z9;f;PDTJfW4H3fJQ%U?>|<LS-&HF\$JY4-MOX-MNFC;-JD>QMCMBX6Z; &H@C@<^91?9D7D-fJOKSP&-Z^_<L_U_QJZ1fT2C|M#&S?8|-(8K@<fJTCCT;0\731+J2fJ|>5;^5^NMR1B74B^VK7ZV;0WW^*9> &M&PV9J#&65KIUfE23^2K2PE@I@=URH73H4f|<0SD>K>|Y2I_MY_-?j?OS^G4?U4Q-PN?F^LD.TQ_A-5^?S^C1f0LMGZK%98C(K-RP^M- !0PPf|PSQ|+O>F^@=W^ORZ<8EN)F(UY+?U8C2^X=GNT;/JS_8Z9Z3+L7W8-M#X?+L7W80+EV2;L>_RY&_/9>ZW^168FK#-655DJPT7XEELS\|UY^Y^LS28(M< <N6H;6PYE+5fX6Z2WTV-M9G4f#-VP+NG;R)09YXUf;CwK+>?j?WfFE-MNMR^fA-6G60fJTQPERW%;71-UAVf|;1939-MND^fP60;7j_N<@<J7>3>_? X1N;1-E7;E7f;?5fZPV9_-#>+f>Qj9VRH7fR;M4/209j+|f;UJfT;G-4Z;7K-2D;M^Y;fI0Z?2JfGLWDRF-Mf;=D-M%NJSX(M<D?2j@_fIDTBH(2-3VKV5,YJATG0%QZD;G:0ZQA@<C^A>A^T&K(Z-9>_>_0_-5L_M-?>f6Hj&Z^_f&0^Z^+<+0_5.N#W6XS;+UJE=|0A19A4fJN5R2V2Y>fFFM@|@<834J/GACB>=,Y^<3>3^1X2|/SS#PUISQ@<C^&8SR_%@/LCV%|f;_FHF-MPLV\$369+59Gj;D9B^4A=HLK4A@P|_<QWQ@S^>#0^>3>|<^>@>U4_A;# MF3j;#G;3LD25R^VM^V;LVN4N^W-VQT6A@NINE2MKRT&AZ&7LOP-M>#*O)/_ZXYG7L^<ATZAJ-AW|DYN.74+-N+3L6-M3Z-8T8AFV|U;MR)AV-4-MX^O5BT6V6(K)W^<U? W+2IUP#6XW&|_5#>+??5-MN3?QR6E+5;3Kf|U;UX%<A7+6j#ER?APN#F|_A;2(0SA0PVP^=>5Tf_M_-U2>A.M%#|@SMA=??CX^7Z>_L^N%ZX30D;?#9j_-W-USA=57--RH6j MVI^\$M|U|_C^B?X&HEH&P64NR|;GG^<WV+>GT+UB1;JG%5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@_fT?> V;N;9W-WA;M%50Q;_<_H;Hj|&=B-Z)^E;5HT_-SBAQG;D6X5J|N9W-|HWSM\$2Z3f|@<P-DP M7X3YJ^>W+HG+>GK312&E)3RTIDF8^B3^Y;TB8C4NA,K^<VH-6@ MZ&4(A.\$2L=JQ;H9%I:P6\$1^M69U@f>|\$/>_H^Z<455ESD@<?Jj^*T<J_O_M0680H=|QF<=&|0@_M;7!^*Tf;f+>@DTGE/;P6=4CX|>%)<=|88K?UYN-MR0@_6f;OS|+R4.4Y2G4 Y4>Gf>Y0f|<65HHF4%AJZfWj|P;P.39L0;_ME>=|>|30D-VH|>|>f7;?3RQM@ODV8^B\$;LYM=C5\$<4#&K6T.P;Lj^100X_M(BX&49R5Z5B3^fH&@<DfT-D+>|>5_M.2>_>_fV-VR(fJKj) KNfTR=|f+|<M@RPfZJ6525RHFNZ;L3B469-MK\$>+J;XRV1JG?5?B2|H&M-M9SF@U2F+QC|UP\$W+16JZ+>D0+5^X8VYVY^%SHBLNj3H\$&CD>7MX^FO M)?J?>_>G@C@Q@_@AB^V+>@R@CS@<|_YB^<4^X%_M@N=8AGB88BPC|M@2%&84^>?JZ^_PZ7B0|;|D5A4M^4@<K@<X^<A;L50T0_M^5YHNNK8R(WH5^334OPCY)Z^;@F>A8-(0% @X1GG@<@B^F;UB0WT4+QQ#M2f6V4?D_259K^Y135GPC9Q?39NGB|&fJ_60;X5T^_S^<^PAX&M-MWCZ1^<PTf_K^>S5(XCPDY+XNK08K^<EZFfH<->|H1TBHN? fTJZ&CFV?>=1;M2(IS2);2@JP?Q@<(7-BS?K#2^0R^;MN70+<_SW|_L%XY^;%=MAV-B)XHJJ^<(6LJH-86\$PZ<=<(3f4XRB\$;H0IT#99T6H\$|f|/\$+M=2%M|> MP3;REI2Z&#&K;J28R|f@<Q\$<X^&K^<04-7S;N2@G\$|;EC|H-104Z-H(NO-MZf_-H^<U\$R|@<U?7;M=3jZCfV|=Y?7^14C_%6R&K&T5DA^X0#&#7f|8_X43f M^_PL1M=Y24.83+>|A-4O\$Y3K1Z-K^>+9P?@MGP|AH&A#LGK\$;S^>F-JG_M-|TRD8Q3W%|f;_!^1^1R>G00-IEBj9G M5f3;+4C%D|BL@<fE|8E8^TJZ>4-3QHA(X_PXRY)8K00I|f_8E_-D|HC5%OS_MfW|f^f_670Q@-0-08;26KV&|B|>?FQP=M^_STQ^8#_60S;^1-MY^>3>^PG6-M_6BM\$M<#+>@

[illegible]

*-\$F 9B\$, @_2 522R,B&!A+XHFB=0LJHW*5HR U0\84G) *37 MB2=
@^(-3I=M!RITT+#+%J\$5.#T6E+AUU@* 5|>%BPGJ MG!SLE<\$X
0X'06>!C@OG:P0'#0JG|Q"GZB\$.E.&P^"OPI3 X FH7OHZ:L896 M !"#,X87E>A*]3?
U""G\$RYG+0%O.,[M3++35U\$|>/,T503US#7&]O3E"\$PC M,7/5FGV>%-OTQ9\$YF;
{\$.G;ZZI7CNC/7|\$9US0\ (E)X8D+!>!(D0?J=-.R&
M#IB))FDJ8\$.TMC88N)FV)K_Z,5\$*J'4D5R RM") 9-%"0 F|\ (J1%;D.VQ">
MI+,,%/B2WXTKL!3-"[' 8I\A;K.5-,M0,KD4)F0PL9'#QHNT M;Y15 ^ ^S'1
XP1Q#QD>>B@=@LJ'H[4UNL?UNJNU ;W=[_3+8T584 %'J4. =QXHJV7/'XTI
O)W4Z2U.^AU)@5_) M-DL 2LU0V5'\$ FYE5^X,>RP'7]*P2
G08'I%_30^%B@M'@#Q@>1"5LDMTZ M#)XQQD"DB!F/X_9TFU#I0
^5IKZ"#J\$1K58.3:+ANYZ'XF+!HMX1E_-Z<)>8. M_S 1J\$X|?,L^>"HH
/B'>I72&77E2U^)&VG_@FD7#4*YH3G)%B7I/H-\$LANP /0#)J=2G(DL1@&'(A,(-JVL MC--
(K+!*VKY|=NP(3%>,%ZQP\$?. ^N8HDV4=P8IVQXX.0]ZPR9ZK01YA.B1EV5>3C.2Y IJ/?
7EX:# MHF^8^M8J!YC&GJ^ZP\FY#*Q\$ 5>XAB.A>9-%+\$"C@L#D6:-LC8"%%N [H
M<@!GP,7T9\$9DA> "UD072P;30Z1[! M6!:*0H M #+T+@L\$!M^A|@F&0T4@\$J%
T_,^#>HR%81E@/J4K78.1XOU"&Z_ ^:H_%O^XF\$ 0\0S (5=>W2'\$#;)
%W|)"@6[V?;J#X6?% M'+LX&IE#LP1W] (SO(!_32F56]2HB!VQJF%Q"H-
MO!>2V^8HB2^X4EJI*\$E&0DG7;K[1@+J! X9@A _JIV\$WEGE1_B+8[B*U4/Z(2 MT S?
TC8'PZ*VARE:05PV&)'_6PNQ(R-DRC&_Z8"I&RH-(B808?>M1\$"6[DR&/_L 6(-:44>
(0%^JR? M@)=E0BXX=&F,#&"J)#NCP'2*?@I(%J /+2
M6;D/2%4UOYS62MU6D\$*P,Y]*%E34KJ3G'Y\$|/X8L ; ^#V-4SEW<%3QG^T&)
MV8Y2({0:&;T=Q]0VD&R'W)XK3^,% "BVF'N> ZFK@!1J/&!:PB,0^<[NXEFEB
MKACPE1EB6&KN>-G((* G.,%Q)1-|&>|?UFT&D5J>;4| *_Z!_ |GD*A6B*%^8
MJG:3)+3A(E;P#4-84;A#4@| |^0#+ D!\$*5V-4EBM4\$429!;9";0GTF!ORNDY
MH^ ^GS9VHZCXJ MB7FDJ+0) !JRDDVPDPP1.:2B,@ZX0IFC!_;0--!DXOQN10
MV7C#40@MM*/_7DIX)1H]+43PO^6C/?6.]#D2#[XD3TS %| WL)U-B6.(B"Q
MPKJ4YF/6IS@0]4JR+G@8_4+.5^8H'BVUEA:/HB#+/VM4D E*7WL8>% M)FS1
^)E706GZI *@77IG-#%*JU*Y1RAT]J:36@VPFY\$0|1=
M0X!5%]+0EFR:Q*6T4"V"&8D(X:&!AA@JPF080+X72/-!Z68L;O!|L!MC| (Q9
M| -7M!A@&H3E*) ^PIZ.[@>J'G-(-LV\$JL5H!C@WML] %1D\$P9/F02,)9'+=7BYLXF!
<3#T\$#SC-;C<;,Z"EPJW(VYK#10%0FT M4_"F68T|L>/8Z?-B3]+2JKM/J +..3?
+^*PPA#\$W<"/M,6CF;6I"ZF6JL M,!4]-B=8SB3 [U<%?>K>D;#)+-1+"5>/3JRN/H/?H"]JH
JGDEL6@E0*J#@7 M% @2_D15#7A]TJF30&X.[K"@T|4:KP?HS #! :F!AQ
&O\$M&A/)R#&6/P-P6B! MGRBNR=J%| %OB, 4K1:
("W5HS1Z@LE&2DFD=9:">K+DG686[7)7,SQG(4E+'T M 0F
Q(TDC8/XPL5ZON'Z0,2!LK_(-SWEJN"4MM1+N"HW'&8K10%9-+9M+OFC
M2J5;Y&KS98%-ZZTNPB5-9LLMW@@+-FP=CRIF 9% C,(IKE;SZN5*N@>Z YWWB
M2YF;NBO@)(T:E*Q\$M@D\UF,C ;QE,|2^4BH>(+0BD@'1QJ,%#2.D,I.\$WGQ
M6E;M=N%>KI!%RT#*M/0+K+8C'D00%B:8DTA&3(B<[*V"+AO|=X73E9
UV;HJ):K"2K(MYB()F-0M.@0ZW#^PKQ#&!|!5C(-1M:P@%EC,P%E%68A)CI%6\$+-L79D
!\$BOBN)A) MYLP. MA&0VRH6@>IMV(H#U?H4#
<%^#>EWMXMTD2(EY'#9>TCO3^O6D(FEL8@4_-GFJ M2 H#)*LJU:R*4BJUQDE6]494N,V
7J?8[T|:@B:Q1ST:DML 6+3)>?JY6:9BM1 MM0Y0[4R,T(YJ1H-
=.MM%"H&YB=DFT/UZ"XP"F[3,1JTOQGJX3, M7;0U.9P4+=F\$4|_+!#!WS?
6|R4D',% 'I%CH<*RUN?6#AMK9OU2A+G: ^ROTF#0C2EYB/S0JBR264F
MAY\$8)#4AHO032^LG&J^K=G WW[5?WC0'J;&=-'R8/E+!H9U
MQM.3N/[W/[NMJNYOTQ/IL9US2B1!|D;-VN@(_H@D7N&M6&*F37J8NL\$S*T
M,!*L\A2#0+!;17&:[IN/)7#6@C V>=@/F]OZ:[|^W*>."'[#<5TF],42 M^QT]=(AM,?,8P,
)Y1F_J>JS?=Z+N2SPC-3KI9*=NO'CMN.C!EXUZ MO;Y3:U=K[?;+DFQ7D-&
(U"=*^Q[Q)=,T@GIJQ\$8]/-G%?]+Z|.W5N[RRUDQ> M226FEDM>(W>'4ZM";
[T1CGHVDQ^65.6\$SC7TZ6JR%MV\F"63;.F.#J,0 M:88S.^I'5M%9>\$@"\$FD1V,?29?
\$#4RN/U=+E5:UU&AW^&|,=B<4R[T]&M5F M&
(*_BK"TC^F*3I+EIHS139IT'VILI(7+4|&H>KF=&EA)O[O6Y"M%PA2O+&&\$
MI+2(>|P^T4%O'%_Z7%),QDBW\$F4D",JQ]_C*B4\$,_!POG-
#69G\$L#83D)P|,"B):)UB;QK#_SW#_V!A7QK(M+V37W%C=RU.R|>)|V-
2L>A/UD\$D30S0VEOWJV8YN7CTF0(WUTBX, & MC",_Z]73E8PG/NN(SYC5))"<-
+YN>!2HEP>?YL=(70;P81: M8/(> X+)/%\$#@BM+CW,M|+

{90%3+2T\B+= "R&;2TR[5"C.40+X48RR=>J@6_MY!(O[7])JZ\EW@Y4%XN?WYU+
<*5FX,!IT[P&"M_01&(3"3A[@C2"S?Q80_:E: M^>F>|*EW"\$ R9J\I;7!B4U#552N48
=L9+RD+G0[27^:8.P)_ ^V,=L0Q!R M4L;Q5%&# 'X?81_S[K[W54-5R*;<2H"P#_6_K/N?
6%W+A&1YO)S+ E=G8HH:\$32R%9%LKA: ^&F8\$4^'1BK5;:*1GPL" M>?
CF.9>X/43QR[;8C[<@BNQ6IV5@ZNUMEB5\$=LK;HJN<)SP\$*>T;J_!(3I?&-MJF#+!7BT(
GG!?!&-T-69D;D#;!;W&8FZ@G+UG\$'AYQ7LB^N]_[Q3:Y1AXZ^MT_I2?.M[&0>":@'@'J-
1:N)Y(ZOUL7*&[DT0_H8(9/V4CQ7"6T'Y]5*KTUXI MY;=RA_*"|E=&^5Q3NA64WVE4"
[I?;=U+MV<;R;#):O-W>;:GYYPD%T>2J_M0L@SAJQ:3><3;B1&<2-(H;J#W55-
KS5U0NI5F>U.NP9LD>".1>*""^MV3CUNNRX^LKMN('L4#FS!DVSG0C=VED;;716
M2AF;+E=J]'^3,W!M'[,DB%[IPK9F;C>J]J>9ALU2K M[!;IG<<*<&^<@C:6^JGXSM>2%JVN-BU:!,F?;^|LS!YM?.=K",WM%NFE1TLO
M;2'J5)O/+/^D1GD_RB#C[.*F<<*_9,YVS=WAV5.@U6>,)X.5U4SIB#J9;S@J
M3(YAS@Z1;Z;G[N"A CCZ/1 F\WVVB.A(&'?MTMA@? M-Z =MWBK5974@:GZT4UT-
&FR,SS"5!X6:1H#N(-JGHQ_MK0J/K#!#D9RTF)ZQIPZ9P6;/Y?*QA>AW5@O-3L-
^;A]1RA;;Z56JE::L^ ^: ML[N206?
XM2N_I#N\$G^A1/DE)G6(KSR.8N8M.@|3CF_0U.X%M?>H_C@O#4N
M6!#!%T]'=^BL0K_?#X%>>Q-8I.M?X:D,>C>"&'*(.:1GZYS.P-K.'8H
M)W3L,9]325GBD7=-J92QG@ZAJ29WB1SOMT=N>:61)8;Z7# #L=G_8'2|%\UI
MQS'MAKK\$(B4Y^P\$E1.#(\$Y'I1 X\!Rj,J#,-F7\$C@5W)\7%R%#VJ|T)>'G^*IHO+^%T_0L"T'
&;XK]#U/N/P3R(B,^)Y|N(@|(MH) M(S[M&'1MQ.=;T#ND\$.<3M6#5+_&4 M]R:
(G):2OZN=-|%HAK@NUA1GXP*<J" M*D-@J83;EZL!"G_E9,AYI1|22/<*Q7BB,P
Q4C"^=X5MISMW>JBM&KVXZ7XD2/7**E M7:X5|))#O!0G>N03+|4D'SBI5VN-PJ|Y
|0A3F63|PTR|T"+SG\$2|W<*.SD M'*.E.&DEGW@I3H|(U8&79T(81(H,A628?-
P!G@;3V;)1#@6%A: + MNI-RMH|;STU?J>F38W=_Q<+>|F%Z:'R#QL*3F\$B|O.LRG-
M&U7AH6" MH^>RS7|5"\$X(P3>F9";QWYKK!BU\R.!>F&1AA;PY*!(N!D' @D!E,<|C
MT_\$B^|C'B" JZ;5(CQ=V)(XGWPXZ5CXU>&V@ZH!UYMAG8VI?4K"%|D@\$R M]F!B!??
(!F/_QX/)Z%C.:87PLJ|F7\$_"J)70&2/H'D)ES@F^;,*U#6'Y MGCJR! U#"0\$N]1,
MY!G0#0B|W?7.8:*15VH-+*C*!Z,8^GB/Q7QHOJR^E19W14:C2\$J_J@*,=;
M#":YWY+QHK;D;3]/06X@/8SU0R|1\$(&6!V:BW0!@+ \$ALN<+>+L3+;TA2#A
MY+MFT\$|7^X'I64,'GHS,:R2)^6.Y\$F@M7?H4R1DOZB^GGH4G&AG8D38EN6D&
M%V**3+*[3%|TYU/3|YX9"<:#Q8;"M"W0:5&)/OJB,6>!F2W!*T 964-)|< M
M_GB\$\$\$ZV25T7G#!HH>:TR?SCH602^40PM5U@|HJQ9_NLG?Y] M1_\$UURPK&>"6-&BG-
*(#!=#0|Q\$F! C6""K0),RF,Q>(^)SX@)C]+I:&KS M'QQ/VJ69\$NDE
'@B@_*2XQ@0[HxV9^Y1 O[7)MM|!+_O!2R+&|XJ608WG\$2[N8DY='M!1B+*]X M*
<18'O%2F&/YQ_O(L6).7@|Q4JC|7**E6FX7XZ7R-%YJ>;!R2JLW[V""/B4(M)-
UXUIF3|9_D.F[B#5GO"@E4*B%!+ESE-%=&ATRNV E!G+> M! :F7U,W0=LZBV
MG7H>JENVAWKVAJ8W\$\$_*65E+LVNA5G(G&&XW8&S>.)"'CQ'2]MDI-[9*7SQT M7,SS)
(FEI' @R;#/\$|2V""HI\|J|+^&\$RN)D9-9P*WAR8>-'HT5V;@PV>/M+IA@LLE-
G8C@TK&\$;JTM8>-)B7O-3.QN,#WX\$5L|<&! U(J=P[2HPRI;3-3 U3SL|P|DU,T5
&|C8&@;35\$051F05CD|. <%Z0_@I)?S/H73WE M=TKUW=V"| O"?W8ROU9J-
QXZR&-&J|D9RA^?K='M;KJTZEYHPXID=0/:E0 MJL?
MV,K4H-4PA+Y9!;I9|:7#ABS>,49S77AK>ZCIF:N_65>RX%%VPM%VPV
M_+@V6Z[16KD74S!!OIA@\$|9LWG7&DC%IM MI82QZ:S.@WV
MFP*=&|_X&GBG4NJT.@70%+Q3*)][G!=5?>C|)D6:Z1E+WUKEF>6A'O4HE)MF
M".L8LIUP|)J35X|G.H8Z;F^=:&_ 'X?ZSIRS(L_NV2W7^842E_?@F#S X\, M(2H>=BC?-
!R;9RIGCT:IUM-A|:69,?BU<#,"PCS%9,:D>DP)+:=U[2Z=)TXWA%"'#&M"C9M
MF7P>!!T"(N@M^&(K#@)P3,4LW<90/3N].\$S3F;WV,SB!@F=S@: M@L[_P0\$/C_E&>:C
/\$,#S,!Z9HG|^>N84 MOIHP7|I;9YY%\$S73:F4M%+ M#LBX\$|_P;*GLJGF?"4=1K(KRZQ"
&"<&.;3F\$;#ORJ(O,20L*8HI3 M(X%7_03PPTC8)7F;-EK_|M;|13_\$%=1|KA*E)HRS-
|O.@EX#+T|:56.*5\$PV-F7E)VE0HRP7B0TT^E,!. MK)E4G:QV+-3"?H!:0^GK1
\$8J>KTXO|G,I,J@1?.Q_>#5|KPTK8E9VG5R-@8 M@*"ED5EF'|H|RG2OS\$FHK+S=-
_K^*K'=ZJ23*N5Z|Q=#^SP\$?G7QAM%=\$C.1/WY5JY:),>!/N;\$&F%G--
>%J2C774|S|AK#0/3_M^|_3H_VY09Z\$G0^H_'T7@YYZ:<-3OFTJ#
[P*1U7\$";FA_F'A06EQ\$J@W0\$P MIJN5H\$TO9G\$R VK^\$:Q:ZP7>8?P?
2#I|N44\$J:PF=JN"2|'T<+7KXV%E.A< M;\$2A0//3HS8 WMD#N|JS*.>TYQ_OP2ZO
2_[P4BNWB^9PSS&Y7|;4X)_JIM|H|SVAJ5J5NS|_M%>*C\$|/F1*..CGR1=U!|P;/Y9?
4IT4>'YU34YFRN_"|=)##*ST9(F"
M!)XH":SN9(DUVPPK(8&'Y\$ "W"NVKXOR;TH!/&^U;%9)^2L?(Y-O:RUD3KUY@

MOS)EGK,JSN);)^['FAG1R6?C^_IG1G3FC^/;^,Y7W_*/3;@KG3Z==V8J>="='M<'I>G%:I-
%?%?;
F;;+1J% ^19\$ \$9]A?.NV#_)&57[LA9'Y7G0QFJ/#N<7&HSB1Z:+Q_)QKWKE;/AS+FAJ/\$ ^CO)!
WWM=QQX4YK7X#X.' ">-F"GQ"#1QK^H[X=J?(UQZ;OQ2,@I'S3Z MA<;R<&<_7#?
Z,"@O<,0)3169 MT\$TCWQ56[)K9N0#=#T AC:U@R8-]. "&2# X#,8(+!&)F.%\%-&)&P(UP\$?
1S! MX\(*W1#O@Q\O'1OA: ,9![1 SS8#6_N2FBV\$3_+^QCXL&,'L&R30\=_CX21T M+;?
T0EB9-S/?1P'H"H@&T,&S)3*##O!M\$T>XMB\$LW_-'CJ!I""& @^\$*O^/" M:6I/W[D&
<(GKL?!"FB>S60; [-:1 T<|X0'@=)"NV?G#2*^K01CI-!H 0^CP M[(?9P31-[X@3WP-
JZ0L4%E% @7J8W]\$V+A*Z.XQ\ZV*G1Y,CD.+A8JJ4&@*P M+4"QX60:Q>;F"!']@RZ4C2-
ES^[WNR\$HYHF&!A/W?*G;5./+94FH)S*=1 M%#B]F,@X:E%ICT" M/@9^HLI[#52QT-
+3]EB() ^90:C|2#T=BS9WG-74J+2I5?4#T|. &#OP8F=<:
MJFJXC*2^+|: +M@VY|T9B#QH: ^%?@8""YK!*D"&,H?CW#85+(?
MN1=MRM1RPDA9AH99.N)N4G&M& M@<\$R=("&41QJ=
(J+H1%E(DSH>97D,A,%7PS=OYWOL6.C>B(CR!PC9(UC\$8)-M8,D##?) !:CSKOS@
MG7DJM4_5)KG@NDC| RX|C/SL^B*X|.JA=M\$3?E.; M:R^A#!(TBH;.7#9T-
HKY&GG\$2ZU<"*T|XJ7<*N;0Y1(OC6)^4Q[Q4BUW"L6? M1|04@BRG>%G>@EO@93-
XV2U7"[SD9_+)34[|DRF=78W|O;/Z|-G=JH_LP7)| M@0,O?2O<2X%;P
^87K@CO[*LNGQ)I^&|VTNJJ7*[LTTEYXOZ5%?:>K3<';@; M2!935&|-
Y%2O;1,Y|0M+IZ9J2DVK:VPHJ&D1:"KEZE9U0>T-36|@LI"ZGS;/ M60G9GCQ)R0Q#@0?
N|%D_G%,)AYSU+56: =9D,*S4KM4P^Z^7]E'S.H+")(O?& M_ "+WI|_P3'=#6QL#?
6CI5ISI47GK?SU@VV\$|O/7Y;(2RN-P49[A5UA:W?S||D%FPT&/2(72*MMZ]B@7JHV
MJ@4;K,!=>>PYL("VXK>."JD^IPUT*T)W7|+%ST4@;K6!N(TW1&|L4K?QG: _!
MJZN6:K7ZK%|71#36%,S;. UM+MJW|:VO7HLV5V|)%JRS*!BXE> MF9-0C=S930-
MKQ(B1C@8U4JYWOS%T/Z-)|@!)C8?:B#+-!?*Q|+|A>KB#067 M\$C.1/WY5 |&,%
)_RHTUJN5VHJ9WTUC&(C^?W_ZS^G1WMP"1/PW-M")1@9+J9OE9YZ:<_3GF\$1=_8XW|_
,"%74R?9I<1*H-T|,*KE:|+V9Q,@-J M_A'\$HO4"[S#^SZC1DR^GD#"%"S52V);@<1PM?
OUJTS%2^W*4K>P93TWC90JL\$ M&..*NK4%;-;&MOI6IA\$?|Y|(.S3Z@3|R;-
'#02MA;'H63R3!ANKDGNE&?GH& M)R/@+|5JJ5.K&>'0#BR |X^L?P1K,Z@Z1.P8)
\$@Z% A1K1V'J2 @QYHO\$I8 M-A1|W0"!A3-
SJG":ACKE=CIRX=)T7*)M;,\$3OQU\$<"#G@81P'N/E(MS>/HOOE(S>?&?"
W<'01"X*R\$-8QCF:&9Q232|4QW\$CH\$Y3TL+WJ-O=FJ%JU3
MJU9_,V9/NUK26|_2KN|:'JE>9!@U.U2\$6=3?YZT0HD:S_NY TOU7*S.'|
MCWBI%)VJ^41,>;=H5,TE7FJ%@LDC7BJ%ALDG8@I!EE.%|(LEW@I!%E.6KOO M|?QO
BZW|W_6/G,7.*[5+7]2\$+MG WGGOCV:] =UR:ZLZ?F^('ZW>;/@UX)? M5|BO|^ ^I9I-
W>_CU'H,=;F7ZKW|,2%ZZ|*OESE8=-GZ/X0P%16PU13QL|L(-
MJCO/)6@SRN:#B'@D0XQ'(62&UYLXBT%V^*U65><>00FV=S@|E3,@KJ3XM;*I
M)OYU5.C56BLM#-|MVBI4'#!G8% @1Z6^ (J== ^052J|W:KHB"^ OB?QH|#?52
ML_&0SL G%1=::DDZWJ4(UVQ)Y@L<3|%LS W\$F?/-U4,Y5:'5MN|*|>@SPSW M-
^2,MW+/-^5C3J6X!@ZMH,!?!U(V;O)N> M+/-8&?E-[W,= [D;18!U)6IWT|3Q6-
G)3>|S+5.D.IW5)^H++BBXX\$GY9(UZ-M(P>3U*8&(4TO7TZ+NL63),K'RP F&&0E5!>)\$?
R-7 |VOIY"4/7V6+|.YT\$RY=TH|9F'ZZ MC(" 6ZY\$((RQ"PKI.N9"5.EZ=4-9)U
MAMOLO=F-)A|8FQ,U*6WI |;HBR: 8"0!3/[G#>)X(8'A#78^&%R0.|&8;Z
MOK=#Y&':2*R1#S3Y@RZ4Z J-/ =OIFRM#|;|-|, M-#EJL5:M-
6N| |>EW4T2U! =*@E:Y^>9B/YROHJY<2LO+J+ M>*C?53PT|KL+?
V!I=R>O'H>3*7.^9TF*,OPXC4T#=#!T0?'L1"+05L.P\$5(Z^CU
M*FF5|#9*_E|PKFH6QQW@79^%=VT9O)BA-S|^MN<# M8-(P2YW0-GV.CP\$! ?O
C8501.G@G_D46TYEGQC9970"8C?J)_D7I%1,02Q8W-M7>,D@@M3EN.5\$PW1<@J-
3S\$@4@2 QV,Q!H,) <0=;'1G5RLXG' &[B8&J1_W^ MSI^F2Y1R,A1-7=T@0+-VQ&./62B
MI)\$*B-C,20V)&7NXGE6,5=WWRZJX*P'\$A"9*A.8Z#A F;@4+F\$;\$FA-#;2X
M)'DSD+L9X*1B,_0|,)@F8/A=X!* ^OAMAB7/8DRG|HI^'SZO^+^?T"!X |;#
MACC|)TB+|W|/G;\$@;V4MN8YQFR/ K&78\$G 3_ D;%8>%|3/P*4XX>HZ_G
MK,D2TB&9"V|<|, @/(|@ERE77|/GP*3^8(!@&=\$OB&L3HSN#|8|U |L4AB.\$P M+#+_E"?
+U8H)|,4%^,;\$6\$^104%Y|,O(1@V@XT@PTG;B3^TDHZ4LT@3V7>.9)0PJ82#&Q(=IQ+L?
I7*VZWFX MA%D#Y5UB_O;A&=-E-3L!DI7?7*1_ ^XZ;6D% @8PC80!K1.+B6031"5T@A-/C_
MJR:H#*.VRXM?I3=X%^K"=<)6P7.C>;,"^P!PCO9! ?FCJ=M'<2-J6Q&@U!* MS8%0-
UF1#-"8 S9Z;-%J\$@.+ M@ALJN*6Q+C|\$8-32|.WD((@NBX+T@|HJXY J8/%;; ^D3
@TH(W,B7%I@AD% M- #|;SMXQH3<90))M-6^>*|00.>BZ,U9K_#|AI1,)_%HA,R!;J2F
MB'4(P>LMP+*47TCH232-7P:"ZGY+0P)'HPIY\$'Z9|D(%/(<1EY&TNK(VQ!Q

M'0)^+ \$I+ '7HEU: ?&S)*5J2K+-(7Z\$PR+ZNT R(LI'V0ZTETDWJ783P>NXY, MWMD^ ^?4J
5KUR;M;LBMEIV%;-M|/_\$?@<=<0@\$6?^\$9_V
MXYF/.P=_G3E7_M*3J'I_ \$8'W2BBP;^CH)2=I*
MC62I>\$!1SX\C%,!XLM*Q\$U[DABR!A%!YFD8(KJ\$K_DWK2W%'UKDM@#XX)GT<MNU*
56N]G9HR/S0=E.B?+C-C=;?.-KXY(A7(&3A/+)*)NM,'(!%<):HY9T20-MO(<-
!XI8@H@;96BM4JF:[7H+**Q=:YPW:07VN5DQQ7FO76W7FV:GV;0;,[36 M(#?- =T-
8TD<,>JN(L/-6J);I-#9/9(VRH19(0\$N7N&H)FTD>+5I:P:7IQHFI
MGM+X(RSS@4':4%&J0&G:UX074#I(1*;NI<%P2?:5G4EW3N MR'I(F\$G)AGE
M1<#U2\$"%G9OZ(@^L>P"HF(HS[H>,'RG7]+P_7R-TI'BPS0:0\DN^\$=&&94 MK]>
<"\$O'QCC!AL[*8#P@*TO#H5HW=ZK-%^(E_XF/59NV?NGN?&Z\ P>D=:/? MK/PO-
NUOLVRT[P6&)]R(HE*W(A_@IGDPZ<*SW@R=Y47"%U=#E3(8UJKTP
M[H&CF8@;D=VK0\43&*X\$E-,RT>\HP5-HP0'!2A&7N%U(%O)CX+*D2A.C]&#G
M:4M),4)I,MA#0K 4,S?1)CI[W.(\$UX*:L_ HFT!O]BPGY!,!-UJE.:/ \$0VVRZ\$G,4K9371!
M)9%+N^)FJLCP(. (#WO5#*%?'H1X>O?5^<)3),Z("#Y M\$!GF-!,'DPXTQ50"<I*AM,W2*
+>C25CN=,3D\ (1\$H\$2P4S#LR5E%K"#!9 M8(""\$P LHQQH-I!*(O)N],#
=5W\$#ULBX9#9TP99A_<4@3B@HV7C3]5+('\$ M70*L\$H=J\BY(4LRZTE0NZ7 Q
H!YL=\$Y&+PQ9Q/""[8X"Y*P+ FIP">=#FH4 MZ:
B'52D@^YO.>^E">]#Y#8,L^PI_0#VIR:RCI4/MC'KF3U#T@I2]@I,*RL.
M58S543NQJ)WHD6'E3;+0G9,ABH\I8B]30W?E!C' @JY4(Z#" (JUOTI?)84,
M*OZ1Q%U0OR^K,IAYH'2W+6^N3C!O+1N+5W:/AXB>D,YL%CJST)G;HS-EG&VW
MMUNI]JKBW&IAG*V]VSO?;>U6SUMVO5'OVY9H]&9CNA^ [QZ>'AT>G;P^.#S^\
M/CI^WST]/IPWFFVJM7FIF)LN"C6.H>'98,69VBKTP*+&(VK_@WNK/N1ZV*Q
MT>2\WF["KCE&0\ND.E8;WA%@_@@C+-\H6>X; M7CP2(=#PS600ADX&<1N6A#
<%S9F3\$J^X\DHZA M7APE@6?5LQ3Y)1D."#FJ-OX;F'+ "0\>P1/T?V
EW<_TD_K.P&,%7KR#\$7_UM\5EQY3+4\|YI>/K6,BN@9-1JUH(
M'=JJR11H,'P1K#0I^# "R_)S95[28;BP_=FW5[88ACNMQ]'(K'5;&+Z4%+)T:
M""KP3:+"SDC)6/RP7FZ%,5D9?!!@7&)\E4*I%)R"-]7OQ7*929JVG2&C<2 MF"L/\$?
E:#+\B55&8S&KL.A3-HW=-HU^"36:'LPL+ENEP@4W\$*02,A^:' MX*GU,HX
^AMUXY@*#IO=\$[TU(&65V0+T;)B,-+)B8@C%FF(3-995:(!%5G%1L|EH.?
M9%ABL%RU!;"PP4R"4,9_@=|#:Y9I-/Q-[HNE&E?]|@LJP9((ILPIFDFS.O6[7 M1*?
5/&]T1/6\T:A9Y[U:K7)>ZYA5N]WLU7J5YDS.O=K%\$HC7\ \$E8]WFM5: MV M*NLUI.
<0Q:ULZVZ9JC4,N=;J8T'F,AG\$S%A4,E^H S;%EG_ T63+>B@<\$2N,^S):9?@1S7SJ1
M)4.'?DFAY!&10_@ (ZSON"2@K@27+=^A4%1),!;D,R'0#/Q+B[2#M+*4="=4
M,#'8(K0"IZ<2WCQY%LFC04;H&:6+?!'G,:%WCK0+@9L-K!URNF:Y##AFX%*X_
M3JTQK!8P!YX/>+2,2%A#SW?J P23C)2;MEC|@,56H8^3:%0P1H0XQLL)AV1-
MZ6VEN,5>[+AL9X&CXC*A6X*-2ZH;Q34DMCNI+FG4\$JU/(Q\|-
;3@*P7@X&60,)/K4/56(#@0V5440X,
MH],>.9X31@'#/ND^(1;E[I=8R+WP(!;_Z9"_%26SX>SA)>.0FU\@N02:=32
M\$B,0S.38\$AZE'4V*1@,Y%ZM),4%5,(DHX<(:_I/*P.8(%C3XD_Z8).(HK0HJ
M9: +*_J1_Z(F)+[6?S#26M*HM!(3<)S<^J4(D?Q*&("0ZWF"5B@),@^%I@@\ZC#-
-4I&>V19#HH M\N=*@P:5!WCR5%*-SJ#V#;#8H\"Q:%2(Q:-DJ:B_0\NPOJ-
Q,#EFQ%MH6K M4V;JK2WGFUNCJUF'(O_#]-
LIF*N<((KPI@U9JM%7"U!G_9XIHVJ!9U#BD,&\$
MPR%IP2^3ZD+R'+LB\$K+P.6M;Z+2;:850,V,465EHC|E):S76^)LTI88CQOHT MK5.?
^IY+G,^1-#|\%B^4F;&H?*9<@P*08QM =+.#':58>#7R3L]JH;E4RC(NK
MUV600Y;REYBW X'W@DU[, 54"60H],3;3^]+/_>H'_4P#=>@CY.PLZEF.E"
(0R/WC,,^;@ [MXMA3^UI(ME82*A'XQF.(I*UG;OP06Q\4S62T*[Y TQ&YO,,6!/?
\$U&/M+^&B6VG|E,3B/ MX+.Y*UV TA%+@#K7_:M%3]
MCRAJYY@WB^9#W\$+=^:JFDULR3E@\$P,+0L(XZ&/G74R8B]G#P@-61>@JF;9\$25
M/'BI,^!G5;)4*FYT-KID\$)FB=\$'%U% @65Y88X 0?;.9ZN"=!,^D1X2PE13 M(D*90*+PVA
D&:9HY["UGJC R7VZ^#&S(-UI6IGSMD3XX#-Z+ZH.>I7HN8"U
M1JRB<"Z+8^F\$*ILN1,-2A,%?0/ZUX[*@&N&2L:>Y%8IXA\RC_ \$OEFG*.IVA M<-
<*!N" _AO@JF0JD1>8J+C0S#Q0E!,DZ0XFY1(3H(WIT9;4X\840X_[B*R'G M98+)>:ER-
5D^%*F8\ D":N,OTXMQ"DI'\EXW V2CD_EC"(E0\)<"9I4:D?
M>"\$TEA*A"5K\$0D1J1.JI4JK6FJT\NYBZ0X9]"SHSFKY8H^ M3#<0({#82!\QG-
C,SD+&">=O;I6D?P_%OKQYXU8&6Y+ DB-C%DBQ*QH_*A,;MRA6"BVH(,4)?
7AZ[IA=J@7)QC09W2
1(1L5BG&62V\<3X/X5*\$5J6\ V*A&HU& "_RR%JRRJPT,C\ (PR!JY"7YIQ)#A2-MY&%"/

D&I!5&B@BFU6"]TBA5:LW5+"#[27[:'ZO8PE L62L7'6K*CISAE(I,
MC".A'R*0M6HR"Y"6#&6=\$C)\$#]2A9N][T2#M0[Z9;#MWHL3>;7B+6^)^87'+"
MRN2:C).=COQ!QOF2HD= 67HP2(EAKJ;Z2[#QQJ]?87WU-4## BNR-.]/@V\$
M&:+3W34ZDL+%~+@L[Y'ST=:V8 4OU-NRW9"0/SDE>/A!G9Z+JQ]20^+8XBC5-
6.! "L8'T"=3JC*! ("+IG"Q2&A;)VJ MT8A)(P#.P'3MA[9XLD.Z?P4=R(3G2H4,%
@%HAQK""J/N4Y1? X4^EOPN\$4 M[/#E5"I+8!>#X/W2G*I-'U%:B1)3/3#I(*A63,"@Z#R,
^33@8X00\$Q\$@& M7,W(9&F"|^=2HVRJ, @)T!ACR,6,(E,Z)K8Y,@=8C#Y:(J3 H
BOR1R)0'5E!Z'N>P 9\$V1_HF2.*6JEVD I27QX* @!W M()B,./YBWY'.2?
I5*5K5T#%AO*4&,HRJR5DR'_T@J1W"M\LYH.I2%^<1J*!&
M;P_=KLJO*B.E0#3X]*T)M0:-2-FP>4,[!UL5TR.?6/EX8R47YT.O\$D /@)[M-
E;FJMS;1";9@@@!5!773>!,&E\$Q\$TZE7!UDR5R6:HX(T\ (Q?74"%N%/A% S
MQCVT*DUY2EQHJL4@!O,5X>8\$Z>HP*<8(YN>X^IM1*R>G3BN\=\$H5V7">TE@R
MP@^:7Q&!KTKCJ(TF*6"?) "I+#[AA5QJH6%:I:XP); 0[@@HK01SY.N"1/E.
M*!5E"AC=@P'!0C=P_"#Y0!():!%V,MC[A"U-3U.LTE0<@)UA-M_90L8S2C=MD-MPX[" 4F,
<:(EXB#>?J4&@DFZJY>EA)NF)69Z%-K72=\$WJU)_5-R.4,%F KTY+=T=Y)
MS\$1/ZJ2H5+G4402UI\$>274^;'4_544_K3_N*RX[0QNRN^J3!YB1;H[SD1&

Z!H%/ U/'W\$14D-T*!>N7",|= \$!JLP&C)+B\$\$.?J1):.\$!^_?|?L|LK\ 04(B07@ 5<\$9%/Y"KL"L3
MB"@C>*G)104DI|!%"5#\$HO[\$ *P8.!9';&6+76J3"._2>(B),/3Q![3;9")
M(&2;F(6@\$TZ1M!AQH%J;;2R9)9H:9^),0K44SAJRj%,\U-S6[0QLFI%3##
MS5EF,N*)YN88|?&"#)V://6Y' 9"JUC=%L.E3,GFI:2'5.RFE*W=Z4UINH I-MTD\$J+,?5E%--
&2=(R08*(1P2*E(MXZ3&'D\R5CNWD(SJ<)%LOVC0_05\$+ M;5YNRE2R=\$[
<(Y01)Y:&DNVU63@N<\$ V>CBI#[=#6_G 23*(0VGAU23-Z<&
M462,@,7J2(-1+&:XZ\$J97F> .Q^'.J;I.Q) M8EGU%X9R\$YY!J:
@K4J@,*"?),.C1U.9A&E#66P-2FT9N,2E)#Y2MCD-,%
MKY0U2JF;T9==WM0'I@+2JF9FVAF9\3XX*K0RJ/"18X:8RQ%A\$X*A52XQ;).
MIOVM3(4Q^^QX.AUV+0 Y@NH#U3?7 8RV\$. (A);B*:7/-!%>:1?F/Z
M'4I86F342\$+*1\$:P2GD81S8(IE"13B8#DB&:DN[:DI\BO=LE\$NDP);4,;4A
M(O@*CY^:G@>O:%B>CL9#ZB/P=BFMR[, -> FV1M\H(I-'DG.JH5..O=%"IW(X0JJ-H(?
2N(M9&W \$X1X*Z!V M%3<-P6#+H?02^TA:JEW?2P>,)0=!2./#U*)-(M?
ED92@#4U=Q65R,%TJ!B- MIB;,1T4Z1 MSBS2F44Z8./WQAU4PJIEQ0 M'_P1:%.
(2C):HI?%|=012&W)Q #Z*(7V^F0_/>R4|
MK554XD+./IJ.8FHG?,U3GC\$!_:#>&!TM[+R6)?8|Q7(Y#MX8| M-G7F|T02MJSOG-
G*5#8'H-*!S&/. *F2Q4I%HI2QU3/OL 0M#_Q6C,0)V/O" M2TQ03B@EI8%T"M E64
TQQ)A0H\$^'^KZ=-DXX>/'Q/7" (+&E5L66#7 ,+BXO! M<^>X 0@9>.(FD351PABH
,7PBPIRDWD:)M.0 S&=W*!5R8WRL;[_U ^!1S-M(L.>3R#EF)7TR-+YM 1Q(DEM-
)TZ[13"QGL 5@_P:+. _:MJ8 M6J63NNB=^GO(;TYHAZ;SABF7Z7=.3[==J+:4WIS[@LQ:
FVAI=ME6.>?LYJP MW9P9L?E159E:?
>K&_/NPJYL49&:\$9\$]0J4T\$OM\$/Y;TN,3U>_+U_&KXL&V|=
M+.1"R:."XA"KV)64UH\+CP9-C#CO'6):Q9\$#'/4IZ".LL\#7RDQ>F#V#-%E,
M,J>2321Z0F6P)VDJ!-.1M#[JZ0X2!U/2+*T>6_KDF(T5XMXEU)B4ZBH!G"C5
MDOP@./8A5]7@[_AHVHEQPC&LXT1BZX,CQWAF6JJ03R>B:;%E ,>ER5FWL>_(
M@JR*)0\0+,R3\$0HIB4HJ"<%\$V M^IQK-
=U4VC8\$(M#51;;9(8<"G\$A\$_@EDBNY&)^34ZH\C\$, %BP0Z-\$>6P%"Q&>BJ#|
M=W*V=VB#(6 M\$7'S995.STW'Q>A2,BL\$TXGH)54R"K3[*!YYO]3/SF*AI/RV
M(U)VI<%->#\ZB"!F/-N=R34G40L\$J|(&K|2>16D7I:Z0NJU^:3>NC^IXT&L
M>IEP5J^_\$.5!>9G>5H.+JH;>9>E;#D9K(W/XD@_+)\$9Q>,(^DMJJ[C:>,) M+
(J)1.5TR+,P"EXJ>.ENO%2?STOMA_&2UCF?=G0N(^>"6 MB09E8&SJQ?@#+
MF.*L#Z;85(QJ49T9GW (B)K!-E?EXCIE 5J!_]"B\$+HN# JI+W]99YHOU*0 M?CY)OSE?
3G?63?4CWZ;8V(X\N^_J-BRP.)J*#C6':&_+ O,SMR2CDZQQ'H() M=&A)&AI(ZF5H5
+4):X_!F)!PC*--S\$X2X2'6G6 W?TU0\N.\$UC[OLV%\$E MK+(9\$9%#>=((QD+
(K'9'+,26AAC:0A5I.?!M0)N.T&*Y7?^,!*W*9:OP9 M)OSEJ#7UD\S)J!H4G:!*JJ\$J]0^Q#CG
_L#,& CMW#@1)3/7M'@2&KLJ2*X! M'<,L\LQK"KXHXR,=
(I'9RICE,PE#L^/JIKB'(#&9'NTXQ5;XW2G+YND6C.P6 M!2-%P4A1,+)* /7'DD>S-
QIB{(X%)\$L_84[K|S2WTI6'9)"ND//4L%HQQGS; M\$'-
MW+0QG9N0:0>6?)D8_+R\$+5=+TCMD:22F_TN4^V=!N>>'((X="QO8R|+)
MEE7GV#FG|*O9C>EK!X7RWG>%%6,!YD<35D<5^=-[2AM]=WI.YL-P7,,C790
M9I0<#1L[,M&75I/D\ZA/+>U)Y0ZR\$RT8X6@B;H;0K03;[%9\$(>IM4!J'"PU M;R!H\$OS

4?/JEM@?F'WHEL Q3VPU M;2EMPX>;![%C\S0GS)QSTXW6#B1/
M%^:\$(BY5ZM+L,B12NI2S9IMA*KCU@.2KU-USC^?L)RI=G<^9V"J+"A-4%9-NM"-22
SK5//1T@*),XRC#@)NFM)Q|"0JDQ*EM6A3MLI5T
",1T\GI=1DP4>1S#P2J))"@J2"8KH6(E/E(W7?)S0B,Z#'0MN M0',QX,EB%2\$"LI:*O1U,
U)53C(\$F40NJ9DJH,Y*\$6BE)NK4) TVO1BTOL>3 MK\9.N2D3S!;?
ZS9=1="C-.LOC R%4\$WX38] %PB5I\$ ^27-./KW3.D:S0VU*2 MXZ
U/ @H74K,L2U.Y1KTQ6IU#3:(UE*3! 4GTLU@&O+&"G 7S*>G7H;0XDA47-#GGLK#^*
IU&WA*2FCH+38"9E2-J+.%30#&?A-0? MC@4I009-D95BIZC-9BP019X<-
)0,X72\OF2|@ "I3IV?%F%3=(KB!D4<13@UB MT,V:*X&=D-
CA12W2/\$EGT1%JB2VBJ9OEQU?(4WKF'=R!)ZE)Z=.E9/8K/ M#X5^&'AD7FNS(S@VE8
KH5(JL03Y\$B&:E&%,MW!0@&G+&;L^=E;A24]>F\$P9
M2N"7ML#%7L:Z0K,*TWX['H*2S'M/^5).1UG ?+DXKGV[YY-D#(AY1RI,'6V4 M=)
F\ D(Z*HQ)EK!3P\OPM3W3HY.I9!/K/-&*PW3-B 54RC!DU>/3VCRW#'J2 M*)?
&^/>E,T05@616RBI*LHRIH5QUGNI%F2?P22-ZXS,ZZA/C3_R6&FUW\OE/ M-
=A.GVZB#=4 N\$=Q+IL"CGRG+%(GK8||+FEE5T=.5PW,ROW*CE_ M.1TTQV4Q_)8KJ2/8:;
(YM=+O3>THEYR%^?2YQ,A24Y[T]>6,'\$ '!D)+2WB^ MFIZC'\$:EFQ)'FM)D^M'SW)|-
()3L@2?0&_+P>:/*P:W:W%/GI<J MLXZF\7CZ9XUPF.8-3<[?^-.
XW.3HAU<@+5HK[\$XZW#E^!,GB;U""R+/9ZI=,6 MG=W6>;J=
I9TWZOW6>:=5\$>>J=J.ZV^G9-6\$VY/GL_ 3BJG;FI1/6Z3 ,OW] M,JA/A+7ZT]QU/VA)/
6QN,?:F5#7Z\K@-(B-=HG*0S)|%)1SWB(P4=Y(DEN M AS|<7+/M\7?1,4.-;Q
MYXUJK|^IBMZYJ-KM\T9'U,|-5KM^WF_4JHW>;JUO=F9)I2Y?=3;VO1/A.7Z0
M00^|76FV=ZN;)YAZV9#+# U|+JL1#4K-= %OM2KG8G>W: M5M5N"=J[;9F)&H#WW-
"-7\$^>[_9IYWNQ4.Y5FQZJV&F(&(!TC-!0/TSDR*|7" MPX8S|)#)KR,YA(+.
I639H^8:V_MJ_|3UVH&')%IQK#&5_B*E @#K[X.%C%%!@
M(=%ZS|OGU7,T@_ _J'UQLB<:O4|5ZZCY|1-2U^_ _9I:|H1U||#U|\$Z?!R(NF M|H
G/G^80'EW_/KL>QCVCPZO/AY6_AW|)(@/#;P;8G=)/ /I)NG(^# M8S'TJKPU,*;7?
34:#U=A5%OF3O5%_Z569*&9X0?7|#QB704=[!W,V%W"; MCWS_[:Z8'.J]&%Y5WKS N-
X<5E-)Q|!L"9?/9&\$K#;C MG3A?
O:X50'M]=O73'UQU8<|;C"E1"J_ =J5+DF>;8X41^*I@,\$)4C61!@@COB M|=SR@=
{4Z9"\$:E0Z+ZR72!9IWZJ|QLO.N9-BIA|1W|+1K;+# J,(3*
M7+@W|^9CZ\MS7&32WZWR^<'U\$!SK*)S2X0VK;5I-Z|S:|/3/&ZV:;5Y1M7/>
MK.Q:NZW=2F6W-JLQ6NI=Y^ |P8.;5|NMLJ'69&RFK_9QZNZK|7(|?Y7W+|R7
M.:NZ5|1PYZKTRNJKTFF]*G..-;+?,O)U|K^_JN[UM|C2CZ5ZQ(K=K5XO@!
M3DC2E0BP64LL09"J_18-JB18!4S!-.R_K^|_| @0\$Q:(QYXO&ZTQJLQPYMXY
MX^MS:|M@?<+(E-AW*:%\$)!R|!|DQ1R)\$4CUEG\$.@|YKQAG)TP*\$>X>-TW
MG|J0KV|_4Y5J|0E/B|J\$M>&.E^&'S\$^AK_-@K2JA?PC'*)++1YVBX|,|
M|9K/XN.RU^V0T">'1('Y=4|W#K>AJI98T9ZCIT.W_MJ6B-UC55
ME[C,,RX1OV9E@9U*."YSY-17F"Z24RSHUW^7?G"=>3MZVO49VVJ?
S6=^!U%5[IFJNKHV!R@)5_YE?*F&.'|+KK|Z#>:|JQ/WYGMK*|#'80(=CO;:!
MG[NI5LV<:7L5MKB9XNB(?^4^<'43Y>+):)OD@|H53,KLM,7DDW0/,AFN)%Y7X%)9-L
MT|_0-(-L*)*7%1|Y|P)%F1Z:>\$Z<<0'9=%0^(!AC!^GG:U1B+=./3#^Y
M2C_F,2;|B3HO&L9-0|4_B8|5\$J#SY%G*\$(XDU35+9JE|'NH+//.VM||QH'#
M=%XTC(=9RI!9*O_H_(-L)1J7DEE*&Y,90T3>&(.@VM&QW1T5H?
&8\$W28:._SUU(XW_6<(RIV%#<%R(5Q\$B)=XW=MJ?Q4=K<7'9T8(
M;H%T@%>2""P7P45\$>(D7P9W&K>AH+3X^,R)P!RR?2Q!|Y?*WB. N|?*WUV^+
MCM;BXS,C^/;F>!\$&VUVW('B3F4*&I59I7P1!;Y2TDNM_Q%*[8;@JX9E#
M>*.ZVP2Y(*6'GK?52Q#_OV.Z3*"F0D"PX@X9!._@5AY%KQV:C'40CW8A56
M(A&)N!1BI,X'R5IH.8X/ZM32J%;Q>53\$I_JWH=3S)UO'=1 MI4^HC*U?
CMQ:M<);,;#6U%BLDMCT\2\$%GT9?T10-[HL4ZCJ*Z'M""?03K>S=
M|N|#B*@ZJ>IA9DKI8CP)(Q23-B9&QEP&&\$SE9LMY.!|4@2)50ZQ?1B7\$63K M/C-Q?
'+N81|+GQY|'3.G(U%("U!=P%|)G!VS35YA=O/.8&DZSA8&0+E7*.
M'S9TCI@%U1P3QU8'4Q-;,-((NP9BLQOUB^/FFM#:G7J%5PZ>1?T@&2#A8JHG
M7AW\$<12H83^|X3P^..37#,"QD62|WY:?'&-AWW<;# MG_WVX/%"O|3,"_ID22KM|
|1#:DK,EIN/ MZB3=GJ*E@PME|U|3'K-EY&AB! M-/H2C-&A*-M-
Z|JS)+8(6TM=5X\$G#/\$ (C9^H CJF:8N=0&S-EI#7R/5B6V55 M-'WD-|;-)
'&P;|1,5=-/SP8.M00/!Q8_-G%FG.W20:JEUD|YE+=Z_7;3;MG-MWW|6|&
|S71Q4Z%|FARZ9ZJE_BR-WJ&JJ^H4H71(?ZUPO7ZU3JLBKV>+6OCE
M'W>W/Z[VQ!++)-S3%58XRL(?>Z|"U|PGW+E96U2\$=SD?G"MV|)%56HVNW>[8

M0@%,!KB? 25QKL@?(FUPR&FAJ8?'GD1C|='XP7"[|380:#!I]QOX_#R|-.Z
MF(WRVR.EFYMS+^-R-|Y^9?LT|A=?B=GRBD@IT NNB3Q)_ \$G|2<93P\$8S_?&
MP|.W|E_*7>.N+13 9(K(.YCH)@%%[L#CUCB<,BHU\$ QK,FC)9D//&'.HJ
M#X"V|YB67YG Y05).FB%HS8)QR)j%Y&,|5BZ0>I"7/(@9YQ:33 M^76IPW^YVZN=
(AKG8: ^R|,PHFXR_ U|+ P04 " # @&99)5S1H| (M #8+0 & '!R<&|M,C R-#
Y,S|X97@Q,&0Q+FAF; >U::5/N!; ^*[K9
MEX:9Q,X+L+D.988"N|M,H4R;WIV=._M!MN586UER99F0_?7W',EVG %>J&%
MW7:F(9%EZ9SG/.?1D>R|)?_7|QS*E,F(Q^75V^IK\$*BHS)@V)-*,&6A?L/1CC?H|_?
W8*S#ZB8E S(<^CO^:##:AF_! M8!SLC,GY*>F^GQUNV=Y';PYGOY|?NVG/W|H|Z?7)
(.GW?_VU|Z/M'LR-W8=L; M#,E,4UEPPY6DPO>/SSJDDQJ3!
|Z_6"R|Q=A3>N|/WOJIR<2V+Y0JF|>;N+,_ MARWPR6B|OY"|>_Y|5_7-U3QD,\$O!
M7G8RJN=<|HW*@\$-U.XTX?+&WTN^PL>FS08#@_8_3';:QUS.^X(E)MCQ)I-5
MD^;SM&E3SK5 ,T\$-OV X=F042#"J@U"9=+HYP75WYO5JB9*FGJ",BV7P8L8S-M5I
SMB|O54;EBYYK@;|%TSQY;6J|" X7@Z'|/<,N39|*/H?|T=:|S^H7_7
M)G&W#>&2_;E@UKM0B1CZ'E^F/.0&N3+<|T. +7|\$(R.@+-.;^69,CQB1"7D
M38Z0DKN1\$1MX#&_T)\$[%G/4?,BUS0 M9<"EX)+U0Z&B#|YA+F-PUL;|7>|>YV'GV-?
@X<=*)!*9U1FR)W1'O#|L|^\$>@J7E0&9F"!TP'M=.;/PN,_R|+P9+D6Z>'D_W#D M-
T:H9B0'X2M@,3&*(<)E 7,E2E<2DU, '(Z|4U3\$&Y8B#ST;I G^LYP'I8L|? MOYN,1H-
I#4)YP|36_1A%2E.\$KA|H73PW<#^NW(5*1Z4X*W&;U75ESR|O<=^:.YQND906A.:Y5A>
B6:Q65DF<>E12!GFA0I0L4NF8YX M 4VZ8FK\$M*0#|X":IJHTA2&2EQ|8&)DL;
(\$Z19;""!>:E@980 |GD429VC9 MC58-?YH6)%)9!C:X09X(OE|K-
0X*2X2B%*.T;:005NY0>7R"@?F M4&(9EVR895V^12SX-J+@
*K\$&'DI8Y@;N(5WCP;#G|9%\$B|)#)H+C4)^0L0BEH5@RGC8@QE&
(WNJR|%\$6YS"D:L^SFT9 MBK;#M>|WO9W=%AY=X)T P0!|Q-*!|J50(#(&X.W-|H|+:@1
MAX2'NHU#O7PC\$ZK,WX"G1UB2.'0(M3IP4,Z|Q60|L:|O/Y64;_A.CB#6|U#5
M+KBE68(48\$@SIX_M?(<401BCA&B)'I81HZH+J9:T9Z^"1
M+KN,&;R10&:H|3;;C9*&1=GJ0M|T90@C<81JS,HXA8(Y!>7)4,H0|@PAW|'
MRU4\$W"C8'7K&W&5H|95=4/ 2_H|:2?"(AH*MI3.AL!XP##7.;3==O'M=&:!
M^HE!J4=I!=P#G1ON#J8'8"7LOW%%6?/HQEEZK>4+Q|R !=)67E\$*L156>YV;
M=8|&G|Z\$/T-BE-*E8%PMAR0IP0RH@X'4V.)T^IFQXMS6|\$0J4|U;R7-7CESE
M"!:_=FV+60&FV)3\$>EC6:P|OJHIV&"J9)|VOOT*=O'MSG|7<^J^M, (.KE<|6
MB@=NPW"UV&3TDF=E!@)A|*@N5T7|D?6N8HM*K;'YO??.(X9>\$D\$719N1|=Y M|
(P;6N634R)9VDH+PH'359L!&Z@(<3 C!U:RI(VRB<>GB)QGT\$% 2PAYT"101 M.G6J@*,+ "
|L6X%A 8MQQ@-UNJQ\$SI|MU,JRLV,1CTZ*)1 U62(S5@:|HN| |MX6#0@R Z-
UMKAQ/72ESH'-)VCHO@|>O&IPQ8j%+\$=15FD7&KP 8^ Q"KH5.4 MX9^@)36|-GW&
<(&|&\$GHLU#6FZ)5+>|,6)XHX>P\$=7(31SJNBE@YO5E@# 0 M(\$MJ|Q-XW @
1KK+5R!@EXPQJ|!.IELK 7:NZ@44YV)K50.L:AD*.&/Z4E,: MI==W1T|!2LX>2DJJM05
A"&?WMIQCT.YWX'416HS\$)AC-|2VDK2^PW:FP(<% M5OYH?,\$+I'"(M9O="O435Y=-
|A;M,||KJQ"|F30DZ_/0QOVR&@&E@A0-W^ M6&)E OCUJN,V5'&A3@219|3:@P|?
F%SJ\$R:J?"AREG"?D9BF49(9)OD@38 MIMMPV.#*Y1B6|8>N":ZX|;|+9H35|0 *&ZJ?
4|I4,LZB|H|F0>'P|IVO+*(H?BGHGK M=JCA#"B-J (6*F-45@VZ,_
FXQ_:#R4J@^H'%*VG/*WQL2Y,0%F#E,<0|>9W M?Z%I'H3
U@_J|0|YZY,C9XR;N.Y*0|"4TK UOQ_ ^Y/H31(2+D(|Y(*;9>VC M4Z_!>-KFCW0
5GV: ^*ZPC|WQ|C?40S3JVS0>9/0-JH>#W3<:|>C!Q.:QO;ZK
MGQ6E0/J+G(+8CCIWHM>_O>'N%W;O/PQ*0:-+49U#|58.? O.UP|.9|OWW\$)W
MI?;|&|8RO-'9&|H|>):Q_!N&|H^2AO<,W0/4J8_@T:ME0.YK9E7855NWJLP: MYI?
\$'DZ0^GSCB_KASL&^UN<_AL3/0'_^>W9P>OS'MX@|H8C,3F:OKX3\$MRQ%V_4.UG1V"
(??Q^EV+80L-X+53 MJ|6FYM7BG,Y9W^U|:6*8#NB%XG\$5TO|_4\$L# M!!0 (-,"
9EE+%;|W/0D #PR 8 <')P;RTR,#(T,#DS,'AE>#,Q
M9#N:.'1M|5MM;|LX\$0XK/'_VF@"VY9/D.*|OM+JS7,4YI+'":_CC|>
MDUA&9<9R0R+%(2.3|3N|(/H6=?GA|1&X_DH//X|M#*WWUZ7+|K|NA&_V|_OK
MT25IM(+@'_W+(+@:7|F*HW:G2|.*YIH;+G,J@F!XTR"-U)@B#(+Y?-Z>|JM2
M38/Q79":3|P%0DK-VK&)&^=G6_) _&8W/SS)F*(E2JC0S|QJ?QQ|:IR!AN!L
M_"RH_CO9B8P7YV,K((^YW"#!E-4;,@^M.8|&-G8|
MG9|'!8UCGD|;@B4F/&UWWZZ*%)^FRS+I3 L5\$|3P&<.^'Q_Y% :N#0!R1265 MR-
RT\$HQL0C?C'G&-+EA4)2N0IEQS2=<<+, (4Q|'+
>!O_YTVNOT!V3(L*/H71L'3#T,G:J'/7<")%#)7#AQ0,-Z3?;7?/ M@LGY&24YS4#V;RQ"|J?
_=Q9"@SOSG5S|C#)5Z=_MMX|+0SJKWR^97)/A/X>7G|>COP^A&"2&=|;

<9S3+&W&R9<&H M248"UITKFG,F>)-\$3!F>+
(A)J0FM2H\#Y:2.4\$,G@I&)5#%3[QJ=!00BA\$?B-M\ED7-*J>?7^N12N20M!"L[#Z,'@.ZUL
#2,S&XDU0_#1ZM\2="%"\$R;\|@<7U M1[|ZO7I MMF%AC>LJK=>O+2W?I*U[Q(Y
*951,;@'02^"B"(IG3&BV(RS.1"52;DFOY54 M 9C\$@MRQ0BH#]\$4^0 O@M]901";D5K&
(%UQ"..91FQR8E('HE&L#Q&0.5RL? MVAK@' 1VTEYV)V\|-CK[50LO.?:ID8D6Y!
[T%XP2**:+@25"[Q8PL"YA.P+ M.J\|)S1?D#(WJF2@*:16-C6#B*0D@R?%J2)C:!
(\$9D!.QGIY+8\$/@T&Q=OF20<'FT,C@A5 MS\$8[1"_'6(*H)\$SCO""=HCB*94!<2%
[X",=":E+:(>4IJ1P85\H&;\$8BC4Y M@"B/&<#&A?+P;;H^921"V"+NU* 1+=/6]WC
W9HFW;/8_?D'CGN@W(' ^R? M(*744.A0@;KL/%"R-E " Z&=ZTF?EH22 SO15LFIYDL9(#
(8(J6@H>VU-#74XTCSDDJ2#F,E)+ M[+G-61EFB79]TC:EM+0G-0-U#-
LFEQ0G/E24&1KL,FJL,HVH87+7>LI-WR- M,!0\$0H7V\$, "O!/K2T#K9;[3N3%%UT.-.:
[O"%I ^XS\$2.-4RMZ%,-2 9]W:8 M=5(55X!
'/JCGDQ+7UL5%P[++8L;!SNUT1K>T.;)CQX>XI2%0!;;=/H*(*@ MLPK87>*4Y9 ="T OU+
"%P44@1VP0R@L'KP IG[%Z(O#:+1O&!W.J"@M[V 8 MLR3!
<_P9!*!>;L7J"7+_ %TB/=R!1]_CXW@Q1">V+7; \$Y@DI>?A>6ITMI
MAKO;Y,NG*V12[9OMXL2<&T"? 7;^"JR7!JQXWX!UY<)V_ KQ,-/ON6S-(P#[M"M;#[%-
&4:DPQ&O)WE:~F=0&&N(, ^A)@{O}{^|\$?_,DWS=(9*F C#9D0

>P.+A;%XN=3IT&J54+W-BI#&+:Q9;9K>>|
R|((+?;^&/8S?DF]_HG%
Q3VCD8JOI.Z)A/P6:V,.NMDN#@ "30)4:J1C^~
_A MZTG/CTB?>W?28+[J]E,T8[2;0
MO@VL7C-|>%>
| ^8@|YGV\$J6@,#35;\$M43&/4[1V@
4(/(:+J454.^JLL, @M| M8DWQB<&CKV-
>2>Q%XFGOSF(N(.M,%-!\$\$Z*;65X#?-
AWU!Y(39>Z\7PFQ8QA
M_I;3J7_5KCP5LJP0HN_ MO>V)|<%JKR[:R-
CMVA_RH(V==PU[OZY1X70G|#DM,:0|DO"F
M1JY?K^S@_;>-ZY6N; UGMJ\$+W2.
Z<|.7)5V?M2>|GX2^&Z^61-
0UP5#!%|25XZOG%N(PG, Z?=^:@PI?
MO\$BZK*<34*|T;%!Q^W/<?*?4V]
[8N]04Z(*KBQMR=7\$S&EZ/:O=%_ =]EZ&]-
M3??H"U/C)J%NT/_J>S04=_-
]C0>VI^%/<'|O=:>R=J'R:US?._[37&^'^@%=
M?|;7^G?4Q0VX+|
(;N2EG"1D^L*A\$*|@GO^,ZN'7'WD 36Y7 M?

~~S|#V:QX@Y7~~
~~M_KS7=J|^<@7Y"A@V)#SIU[_F=:HW2]8?~~
~~^M->/!+ZE\RV/SZ0@\$)3LN!~~
~~MB"9@9TAGDE<9Z&F_?~~
~~7*RY#57UK&YIOM:A/V>Q?E_5!+P04"#~~
~~@&99MV8Z0[6P)"U-P&'!R<&\M,C R-#~~
~~Y,S!X97@S,60R+FAT;>U;;5/C M.!+^*[I,~~
~~[0Y4Q7D%AG48JAA>9JF:85@N4UOWZ4JQY!~~
~~MP!)V82YP4!422RVI6^Y'3[,Q(Z3;:>VUNKW~~
~~2.8AZ7;;N^U>MI|<#O\)./|S=(9=?R=;WX?~~
~~&VE3|Y=CS|U^6I&_ ;R^ZD\$;3;O_>/V^V3~~
~~MX8FKV&EUNF2H:*ZYX3*GHMT^O6B01FI,~~
~~>VWI!JWAU?MU&1BIRVD MU*P5F|AQ>(~~
~~E|)_1^/~~
~~@8X:2**5*,_ .Q|7UX%NR#A.%&L,.#=#O7M9\$~~
~~MQ'Q"M)D)JK&1437F>6!D\$?8[A1E~~
~~RS94K|CFS3L=CH_#0H:QSP?!X(E~~
~~M)MQO=3|LBA0?I_,RZ4P+%1/4|~~
~~G#ON|>>1|&K@TG?[,=V"T,ZB|]#YAR?~~
~~7@W/S|Z/CX;GWR|(MS-R M>75^<7Q^>?~~
~~2%G)U? ',%/^/7M#"1.KZRYSVB6-~~
~~V+OE@7G3?*5&I-"UY_IF#5)~~
~~MQ)3AR8R8E)K0JG0W4/;J"#5T)!@9214S];'1~~
~~00G@DSJ|U0:/JVO?G6@21 M%~~
~~((6FH75C| %S6!| -(S,K"?~~
~~6#,%+JW|@Z\$R6)DSX#8OKBX#3LO)@H^~~
~~3|EM MFN!<1U1XA|. ^!RH-~~
~~IBDW+,#Y8F\$NIXH67IT^SKJ?~~
~~5Z]/MP4+:UQ7;:E^:6GY M6|JZ2^P(E%~~

~~(9%8.ZT_LB|"B2T@DCBDTXFP)1F91K\EM)%
M#%H
OP6_\$9F02\4B7G#9).=YU");X)\$@.N;:
#&9[<7*A[:V\1ZT[4U[V;ZW M]
-)]K[=IOO>):AL:D6Q&KD%[P6)4YH/B-
E;E3) M0%,(K6QH!AY)2097BE-!\$AI!D2(R
W8RTL G=\$LA9Q+2F:H8B&;UF!)UXWJ>&
MLAB4@2\$%:HU CH\$#\$%<2#(81H@9-
X'83N E12G2)_Q;MITPQWPD:D'\$-C(_3 M[2)
(Q70!1(FC8[|%J"9C,!/N-\$S*:.%:?
AC<|;2*>^B|&3XPD/ >/1>=?>&@3 MP
3B4*UJ]3Q/L#^,X.!W),H8^@04U-RQ"0CBR
X%.#'B#W\$)6= <8-ZW]G4T#SW IA/GY7?
^7@?;@|\$\$V+MTR23A<6@|)U0QZ^O@NQF
M,(UWA>L4Q5\$L
-]I"ZL+KF.M(2%U".R0T)85S^D+)B,50K,D6^
#3.D4]O M(\$'/QXP< 5=WV+9MVMV-
W96[Y)@%Y0YLV#]!0JEAT&\$"=5E[
MH&1IH 0&0CN70SXX,64VF
SO!]Q;#R.KB3%A1\$N]?A,,SD8,4.)'+!5T
+2#6S](9B#%&|!G::G6:SD0(F@BY:"QW;?
4)^3#5 &=,[##RIBBO\$ ((Y
M=3N]&)G>-2RN'A9<%C<.^\$NBM?
30Q@HWWJ"B5 7@5MM(.HK Zzp"-E\$WR
MQ-P|@#X#[/P-62|-6?&F(>O\$N>UM)|
<-39]YV9H[\$/8(WL/X4T91J=#%: ^'>
MK3XSJ0TTQ*=FT).&Z29_N%W_U=U|WR
!G (;K1\7(8Q;7+++;<;F?"D^^,"'[-A-
^279%O_LW)>4/RINX%[;Z&O2#[&"VN M4-~~

~~Y<\$~~
~~KR6QUM"VY!Q#PB\$+Z5.7K%*.2.1BH]#S]M~~
~~7289=P8QNYE[I&\$|!9K M8PZZV2ZV)%~~
~~E!J)&+XQ?~~
~~ZV6\$/9'R4%UNV"4N7W\$O_VVU?,:R7/CMGJ..~~
~~M8~~
~~X'P.%F(VY;1IP!0GQP.=]RF3)ZC=&B2Z5LO&~~
~~T1M]5[M!T_1&!IJ-J>I>S#J\$T=H %~~
~~#SVBZ@%5#M*K+#!P+YL2:XL.".Q_(O%'8B|~~
~~MQNW% '\$',F2B@B29X-~~
~~[.|!OBP3ZD]D)HN<./Y1(H)P^@MIV/_L%UY*]~~
~~M0>TTE8[_Z!), 59/\$-2V[G?~~
~~XISE^Y4];_>)/6GV 3V]__:=|=YJ3R]:UUC0~~
~~MY!|2H76>CPU[Q*Y1 74M]#DUT:~~
~~<|E/"P(\$X9W(I!72-:&KE|PK*#1^!63EBZ~~
~~MLB6@V8;.=W<~~
~~IS|Y=%7:50#VJ)M||"HN9%":NT48\$YW7TY&~~
~~+>#WG-AM MX>S9IS_D7&Y;:NDT~~
~~3P@H|OGH|^G_A0N_6I76Q%1WYP%,..?0|~~
~~M"?_L/"5H:I'N;?S|6_ZJ'1I_U'+VXZ:^|TJG_H~~
~~O|XX-SKF!Z80PK8.4LX2<~~
~~MS:/>;WY/:>O2/=>#HD4EIH='BT=_7A:2"_Y~~
~~^W.3Z0U>C^UZ<^'#' MRQ|GD-F\$Y~~
~~(|*AO!!!|U";Z*M<:|.?~~
~~6DM==_)L9;_|V6IUENTSG21S2Z'BOP~~
~~MJ1A3\$*G"*O"H3<)R1078%;4[2^F(>Y7+E]E~~
~~[EI];ZR)2EPR*8)V!G2B>15~~
~~MXK_?;^WMS:,D5]:Q*;Y|'|V^X';X7U!+ P04~~
~~"# @&99D3A(&_@%#[M%P &'!R<&|M,C~~

~~R-# Y,S!X97@S,F0Q+FAT;>U8^V_-~~
~~A#^5VXNUB: M];(<-Y%= YGC8~~
~~92Q[65/7X::(FRB%*B1M&O_?~~
~~4[ZN'83KH&:]-V0PV_1![)~~
~~M.QZ_N^_8^|\$PAFE,TH"&|+/_]@9"\$2P3FBH~~
~~M)|G"!05P;+-C.JTSTS:;?~~
~~@_G&E2#1.J!XUAG5LMNM?&?~~
~~9[O>61LF;^'DSA^<~~
~~M%M)7MP/_]FP7'9R]]/-:-P|^=0>6=>5?~~
~~E1UMTW; ER3-F6(B)=RRAN,& M-~~
~~&*E,L^RUNNUN79-~~
~~(1>6/[5BE?"VQ87(J1FJL-'OZ1;|IB3L]Q*J"~~
~~0QD3E5~~
~~M;QIW_K5QCA***4[|/:O^+67G(MSV>R%;0:z~~
~~M^TAF8ZQ9J&+/_L>T?~~
~~NQD)0Y8N#\$XC9Y9V;SNO[]LD6|:Y-~~
~~E*9YDG*BV(KJN1]? M^1P7WEL~~
~~Y;):*A*I,B*2,+~~
~~[U70DLH3F,Z1JF(B'IJv;9@K|YE2QZU2VD<_~~
~~MQ8EP3LY2:L2T4,HQVVZW7-.K#-72]3HKEI~~
~~(4U1X.6+|Y;M=GN6~~
~~M%L1]R1[9FX!3(KVY4"W>)L>L_^9[%)THP!~~
~~^>"A]@Y MW,1HN *W93H]:]~~
~~[O\$4A)@K(S&FCU_W#TD2"E^<^O?H~~
~~8I;+6WW'-LTR!??_Y MF#F#X=0?~~
~~78|&E_[H=@RWUS"9CL:#T>3R!H:_#0=W_N~~
~~M'9.[Z>SNF+AXX9)1" M(-~~
~~*T/"]E8%4Q!1(\$ (L'PNL7(.^61.(.|"U,:2:DPE~~
~~*UT(F&&N-=R BF\$@:~~

~~ML(R))HS2P(1(R&*2#)45(5#4(X09S11-
YE2":S=!QV"4QC?'&'Y%4D8Y:|(@
M9C2"X88&2XTZN(TB%N"0!VLT(::2SK>
O8I%6|B6,E|2C E*[.]Y:=?+%T|' M|NJ-
;P+)@80BTQEA?|R!Y(7=T4MJ&V9\$SDE*
<^VP^D6+@.E>UJvw6KJ84:"^KF:
MKQQA!
()SDN74J_]TGR/>&A@>E4B*8[|GB'XL|#%^(
M)'["VH)2K-72 :+8#Q7N=W^2'2M](+ "*"_
62\$"-N^N8*6KH[:0>>DR2K-+6
M=0HUJHV0%#YQ3H^U.A0X2\$"?
I'#YJ"="O61">'<_I%1-C?YL&<3/A|1HR7%2
MC7G.4/M=')#TSR635+.O7,^?5X'"
<4_(*>#LSME)>+H#"^)68N+\$&88;9#4I
M\$K(*,GT8,)^'/_SSFH(6O+[G:@]<6@RZT(?
J:8Q[+|T]M":NE4AI+%?
T+=>.Q6VNT594+F2I1-U0UBU%RT%U8]|?
XDK&/BI5H(\$U@\$%MP7N
RF/DB!HA9SAXCPT>>%S>^6S>.
((N_]H6N6C*M YV09RP5D(+^SB]65-
MMW(+1C>78[BZ'(^&-Z-[:PHH?/?
8GL=T(OK*[MJG\|]=|=5-8X=V%4F5*=0K
MT.7V!XJMDXEDF*\R3%@/I.\$%L/Z18^MT5%
<;5QA|O=@ M+%8E7>B4;
&^C3+_ \$G(\B_ H6%%,A|A%>4_:R?
L;C6M"2BNZ'@)7U@XHXQM)Y
M3FF*Q\$>LF"9'6 ?<2C-
:|;Z.G:N:X>*D.%DCXA%2YFR/"ZG.:H>=/^N@
M)&%YK05#AL:0,>6*1!\$LLTICFBOS"3=|^_.~~

~~M@O<+*99IJ.F5D%Z=/8VX;"C4K-~~
~~UI+9]0+7*"^\$#KG70M+M]SLB"&G-)R7N#~~
~~M1&BG1U:"U270N6MV.KM\$5;;91:E3WFH7~~
~~@ P(!F6=PU~~
~~MMT<&5X,S)D,BYH=&WM6'MOVS80~~
~~M_RHW%VL3P'K:<1/9->~~
~~Z3FJ@2=Q\$0;&_!EJB+"*4J%%T'._3[ZB'(SOIF~~
~~MVPTU8%LBC|<[WOWNP<\$OAC%)8Y(&-~~
~~(1W_ME["\$6P3&BJ() "4*!Q=,16#+[*,~~
~~MI'!&I627::A>?/+OKV:]A M=@9[U_YXOZ~~
~~^OAC[O\TFY;:SZ[?OIV-~~
~~H&9;UL3.VK&/_N)SHFK8#OB1ISA03~~
~~M*>&6-3E002M6*O,L:~~
~~[5:F:N.*>3"\B^M6"6\ :W\$A+-F"A5\R3E~~
~~M1+%;JGD_OO,A;MS8~~
~~.FRFBH2J3(BDC"^]E[Y+*\$YG-~~
~~,57(J\$I*_:Y0C^YU2R MZ%6_H,~~
~~[9GQ09(4_.4FK\$M!#*,;N=?~~
~~KFG5RFJJ>M];EG.YHPSM?9B%H8T18*7~~
~~M+PY=N],?~~
~~6)H0SR5[Y&P"3HGTYD+%_=UC>DS_9]) +T3~~
~~MJEPX%SS\$RT4#+?[OCG8)4JK_.~~
~~('B%\$J:_F=~~
~~MCGF0*;;#00Y]39SRV]*3J;G(WS\$IXL3I)A<~~
~~M%NI^#[6>H,?~~
~~L^O+J>G3N@W\!SB%I8B%)3G=K.-~~
~~M3QT],,@TA4"D:>D096!5,042!" +!|+K&R?~~
~~ED3B"? U7-),2(6A%\$Z\$3##6 M&A] 1#"3-&~~
~~9\$VV8IH\$)D9~~

%DPR%%2%0E".\$*YHIFLRIA(!=!AV#D;H-
9T0A
MZ0I.R8*V81PS&L\$)2S'Z,\|+A(HI8@\$L>|/-
&&F\$HZ7P/.*A:M(50*?\$DP)BC1 M//-2KY
M0.
<9">KWBE^YP@@@\$YR3+J5<_J)|CWAH8'I5(
3M9BJ;R(W=&P MF0A**6NX*(G?L-:@) '-
='2"*|U!A<_J+|+C5#A\$07H&W0
)*W%_ %3%%#'R?U MT&*29)6T':<0HSKX2N
J9WJ7JFV"K03T10*7KYH1RB43P00-D%(-
M897RR!^ M/B1&2XY,-
>8Y0^DW<4#2/Y9,4EU|Y9I_7@4*I|/-
'|@&Y.P=|X?X&+ #182DR< MR&%RAU5-
B@59A1CGJ-/M TG#34;6IVMIO|
*1_IOXZ'W?|>#^Z/AP4=_8VFD
M7PN/Q"RF"-HLQ%'(GQ5P|B'CNE6CEN*^L
7BMV.M#<^K510Y,7|'8.ST.%%C"!J*H#!_-
>1=RHH;6 2YNE)\$[M"/K:YGP4E?
_4\$CN@_U05*AM5\$=+)[B
7G(7PPBX^WU9U*[?@;:3| |R8?X71T
M.KG7IL#03XLU+*8SV'XE*UJL)MAPQ|YU6I
>5WZEWTX>F|1WE1M0PC8H3_HK&-
LP>>4 MIEA B5NFBRQLI'=J,>TU*WVM.|
<|2%78(;-'R**E3%D>EVQVNA |O^E\$QB))
M6)YK^;#28UAYY8I\$\$2RS2F*:*_,)-X7--
L#M?*OKS|J=2/WK"J'R-Y;:2HL\$ M-PN)>
UUM26D5^>#QB%L3U1BNCMBVUN55WF(
#&7%)R8Y (M|)?
3(K6!U*W78,7N]3=XJQ^RB|BQ0QX0K|N%?;

~~4\$L! A0#% @ P(!F61J-MBH/K\$P DM0 !\$ (!
-!R<&|M,C R-# Y,S N>' -D M4\$L! A0#% @
P(!F69B%:\$+L\$ TO@ !4 (!&A0 M
-!R<&|M,C R-# Y,S! ?8V%L+GAM;%!+ 0(4
Q0 (, " 9EDX]T6-5CD M ;R P 5 " 3DE
!P&UL4\$L! A0#% @ P(!F68HT>Q?K40
M_ |% !4 (!&L@ ' !R<&|M,C R-# Y,S! ?
<')E+GAM;%!+ M 0(4 Q0 (, " 9EF:YN0I0VL"
#+[' 5 " 3@: 0!P M#\$P<2YH=&U02P\$"% ,4
" # @&99)5S1I/(#8 M+0 & @ &NA0,
<')P;RTR,#(T,#DS,'AE>#\$P9#\$N:'1M
M4\$L! A0#% @ P(!F64L5KW<]"0 /#(!@ (!
!XXX# M ' !R<&|M,C R-#
Y,S!X97@S,60Q+FAT;5!+ 0(4 Q0 (, "
9EG9CJ_ M M; D +4W 8 " 5:8 P!P&5X,S%D
M,BYH=&U02P\$"% ,4 " # @&99D3A(&_@%
#[%P & M@ 'XH0, <')P;RTR,#
(T,#DS,'AE>#,R9#\$N:'1M4\$L! A0#% @
P(!F M6=PUMT< XML 80 prpo-
20240930x10q_ htm.xml IDEA: XBRL
DOCUMENT 0001043961
srt:MinimumMember
prpo:WarrantLiabilitiesMember us-
gaap:MeasurementInputRiskFreeInterestRa
2023-12-31 0001043961
srt:MinimumMember
prpo:WarrantLiabilitiesMember us-
gaap:MeasurementInputPriceVolatilityMem
2023-12-31 0001043961~~

~~srt:MinimumMember~~
~~prpo:WarrantLiabilitiesMember us-~~
~~gaap:MeasurementInputExpectedTermMem~~
~~2023-12-31 0001043961~~
~~srt:MaximumMember~~
~~prpo:WarrantLiabilitiesMember us-~~
~~gaap:MeasurementInputRiskFreeInterestRa~~
~~2023-12-31 0001043961~~
~~srt:MaximumMember~~
~~prpo:WarrantLiabilitiesMember us-~~
~~gaap:MeasurementInputPriceVolatilityMem~~
~~2023-12-31 0001043961~~
~~srt:MaximumMember~~
~~prpo:WarrantLiabilitiesMember us-~~
~~gaap:MeasurementInputExpectedTermMem~~
~~2023-12-31 0001043961~~
~~prpo:WarrantLiabilitiesMember 2024-09-30~~
~~0001043961~~
~~prpo:Agp2023SalesAgreementMember~~
~~2023-01-01 2023-09-30 0001043961 us-~~
~~gaap:CommonStockMember 2024-07-01~~
~~2024-09-30 0001043961 us-~~
~~gaap:CommonStockMember 2024-07-01~~
~~2024-09-30 0001043961 us-~~
~~gaap:CommonStockMember 2024-01-01~~
~~2024-09-30 0001043961 us-~~
~~gaap:CommonStockMember 2024-01-01~~
~~2024-09-30 0001043961 2023-09-21 2023-~~
~~09-21 0001043961 us-~~

~~gaap:RetainedEarningsMember 2024-09-30
0001043961 us-gaap:ParentMember 2024-
09-30 0001043961 us-
gaap:AdditionalPaidInCapitalMember
2024-09-30 0001043961 us-
gaap:RetainedEarningsMember 2024-06-30
0001043961 us-gaap:ParentMember 2024-
06-30 0001043961 us-
gaap:AdditionalPaidInCapitalMember
2024-06-30 0001043961 2024-06-30
0001043961 us-
gaap:RetainedEarningsMember 2023-12-31
0001043961 us-gaap:ParentMember 2023-
12-31 0001043961 us-
gaap:AdditionalPaidInCapitalMember
2023-12-31 0001043961 us-
gaap:RetainedEarningsMember 2023-09-30
0001043961 us-gaap:ParentMember 2023-
09-30 0001043961 us-
gaap:NoncontrollingInterestMember 2023-
09-30 0001043961 us-
gaap:AdditionalPaidInCapitalMember
2023-09-30 0001043961 us-
gaap:RetainedEarningsMember 2023-06-30
0001043961 us-gaap:ParentMember 2023-
06-30 0001043961 us-
gaap:NoncontrollingInterestMember 2023-
06-30 0001043961 us-
gaap:AdditionalPaidInCapitalMember~~

~~2023-06-30 0001043961 2023-06-30~~
~~0001043961 us-~~
~~gaap:RetainedEarningsMember 2022-12-31~~
~~0001043961 us-gaap:ParentMember 2022-~~
~~12-31 0001043961 us-~~
~~gaap:NoncontrollingInterestMember 2022-~~
~~12-31 0001043961 us-~~
~~gaap:AdditionalPaidInCapitalMember~~
~~2022-12-31 0001043961 us-~~
~~gaap:PreferredStockMember 2024-09-30~~
~~0001043961 us-~~
~~gaap:CommonStockMember 2024-09-30~~
~~0001043961 us-~~
~~gaap:PreferredStockMember 2024-06-30~~
~~0001043961 us-~~
~~gaap:CommonStockMember 2024-06-30~~
~~0001043961 us-~~
~~gaap:PreferredStockMember 2023-12-31~~
~~0001043961 us-~~
~~gaap:CommonStockMember 2023-12-31~~
~~0001043961 us-~~
~~gaap:PreferredStockMember 2023-09-30~~
~~0001043961 us-~~
~~gaap:CommonStockMember 2023-09-30~~
~~0001043961 us-~~
~~gaap:PreferredStockMember 2023-06-30~~
~~0001043961 us-~~
~~gaap:CommonStockMember 2023-06-30~~
~~0001043961 us-~~

~~gaap:PreferredStockMember 2022-12-31
0001043961 us-~~
~~gaap:CommonStockMember 2022-12-31
0001043961 us-~~
~~gaap:EmployeeStockOptionMember 2024-
08-30 0001043961 us-~~
~~gaap:EmployeeStockOptionMember 2023-
12-31 0001043961~~
~~prpo:EquityIncentivePlan2017Member
2024-09-30 0001043961~~
~~srt:MinimumMember us-~~
~~gaap:EmployeeStockOptionMember 2024-
01-01 2024-09-30 0001043961 us-~~
~~gaap:EmployeeStockOptionMember
prpo:EquityIncentivePlan2017Member
2024-01-01 2024-09-30 0001043961 us-~~
~~gaap:RestrictedStockMember 2024-09-30
0001043961 us-~~
~~gaap:RestrictedStockMember 2024-07-01
2024-09-30 0001043961 us-~~
~~gaap:RestrictedStockMember 2024-01-01
2024-09-30 0001043961 us-~~
~~gaap:RestrictedStockMember 2023-07-01
2023-09-30 0001043961 us-~~
~~gaap:RestrictedStockMember 2023-01-01
2023-09-30 0001043961~~
~~srt:MaximumMember us-~~
~~gaap:EmployeeStockOptionMember 2024-
01-01 2024-09-30 0001043961~~

~~**prpo:ServiceRevenueNetMember us-
gaap:SelfPayMember 2024-07-01 2024-09-
30 0001043961**~~

~~**prpo:DiagnosticTestingMember us-
gaap:SelfPayMember 2024-07-01 2024-09-
30 0001043961**~~

~~**prpo:DiagnosticTestingMember
prpo:ServicesRevenueNetMember 2024-07-
01 2024-09-30 0001043961**~~

~~**prpo:DiagnosticTestingMember
prpo:PayerTypeThirdPartyPayerMember
2024-07-01 2024-09-30 0001043961**~~

~~**prpo:DiagnosticTestingMember
prpo:MedicareMember 2024-07-01 2024-
09-30 0001043961**~~

~~**prpo:DiagnosticTestingMember
prpo:MedicaidMember 2024-07-01 2024-
09-30 0001043961**~~

~~**prpo:ServiceRevenueNetMember
prpo:ContractDiagnosticServicesMember
2024-07-01 2024-09-30 0001043961**~~

~~**prpo:DiagnosticTestingMember
prpo:ContractDiagnosticServicesMember
2024-07-01 2024-09-30 0001043961**~~

~~**prpo:DiagnosticTestingMember us-
gaap:SelfPayMember 2024-01-01 2024-09-
30 0001043961**~~

~~**prpo:DiagnosticTestingMember
prpo:ServicesRevenueNetMember 2024-01-**~~

~~01-2024-09-30-0001043961
prpo:DiagnosticTestingMember
prpo:PayerTypeThirdPartyPayerMember
2024-01-01-2024-09-30-0001043961
prpo:DiagnosticTestingMember
prpo:MedicareMember-2024-01-01-2024-
09-30-0001043961
prpo:DiagnosticTestingMember
prpo:MedicaidMember-2024-01-01-2024-
09-30-0001043961
prpo:ServiceRevenueNetMember
prpo:ContractDiagnosticServicesMember
2024-01-01-2024-09-30-0001043961
prpo:DiagnosticTestingMember
prpo:ContractDiagnosticServicesMember
2024-01-01-2024-09-30-0001043961
prpo:DiagnosticTestingMember-us-
gaap:SelfPayMember-2023-07-01-2023-09-
30-0001043961
prpo:DiagnosticTestingMember
prpo:ServicesRevenueNetMember-2023-07-
01-2023-09-30-0001043961
prpo:DiagnosticTestingMember
prpo:PayerTypeThirdPartyPayerMember
2023-07-01-2023-09-30-0001043961
prpo:DiagnosticTestingMember
prpo:MedicareMember-2023-07-01-2023-
09-30-0001043961
prpo:DiagnosticTestingMember~~

~~prpo:MedicaidMember 2023-07-01 2023-09-30 0001043961~~

~~prpo:DiagnosticTestingMember us-~~

~~gaap:SelfPayMember 2023-01-01 2023-09-30 0001043961~~

~~prpo:DiagnosticTestingMember~~

~~prpo:ServicesRevenueNetMember 2023-01-01 2023-09-30 0001043961~~

~~prpo:DiagnosticTestingMember~~

~~prpo:PayerTypeThirdPartyPayerMember 2023-01-01 2023-09-30 0001043961~~

~~prpo:DiagnosticTestingMember~~

~~prpo:MedicareMember 2023-01-01 2023-09-30 0001043961~~

~~prpo:DiagnosticTestingMember~~

~~prpo:MedicaidMember 2023-01-01 2023-09-30 0001043961 us-~~

~~gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001043961 us-~~

~~gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001043961 us-~~

~~gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001043961 us-~~

~~gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001043961~~

~~prpo:Agp2023SalesAgreementMember 2024-07-01 2024-09-30 0001043961~~

~~prpo:Agp2023SalesAgreementMember 2024-01-01 2024-09-30 0001043961~~

~~**prpo:AtMarketOfferingMember**~~
~~**prpo:AllianceGlobalPartnersMember 2023-07-01 2023-09-30 0001043961**~~
~~**srt:MaximumMember**~~
~~**prpo:Agp2023SalesAgreementMember 2023-01-01 2023-09-30 0001043961**~~
~~**prpo:AtMarketOfferingMember**~~
~~**prpo:AllianceGlobalPartnersMember 2023-01-01 2023-09-30 0001043961 us-**~~
~~**gaap:PreferredClassBMember 2023-12-31 0001043961 us-**~~
~~**gaap:PreferredClassBMember 2017-08-28 0001043961**~~
~~**prpo:AtMarketOfferingMember**~~
~~**prpo:AllianceGlobalPartnersMember 2021-04-02 2024-09-30 0001043961**~~
~~**prpo:CPAGlobalMember 2017-02-06 2017-02-06 0001043961 prpo:CPAGlobalMember**~~
~~**srt:MaximumMember 2024-09-30 0001043961 prpo:CPAGlobalMember**~~
~~**srt:MaximumMember 2023-12-31 0001043961 prpo:LoanAgreementMember**~~
~~**2024-09-30 0001043961**~~
~~**prpo:LoanAgreementMember 2023-12-31 0001043961 srt:MinimumMember 2024-09-30 0001043961**~~
~~**prpo:HemeScreenReagentRentalMember 2024-07-01 2024-09-30 0001043961**~~
~~**prpo:HemeScreenReagentRentalMember**~~

~~2024-01-01-2024-09-30-0001043961
prpo:HemeScreenReagentRentalMember
2023-07-01-2023-09-30-0001043961
prpo:HemeScreenReagentRentalMember
2023-01-01-2023-09-30-0001043961
prpo:HemeScreenReagentRentalMember
2024-09-30-0001043961
prpo:HemeScreenReagentRentalMember
2023-12-31-0001043961
prpo:WarrantLiabilitiesMember 2024-07-01
2024-09-30-0001043961
prpo:WarrantLiabilitiesMember 2024-01-01
2024-09-30-0001043961
srt:MaximumMember
prpo:WarrantLiabilitiesMember 2023-07-01
2023-09-30-0001043961
srt:MaximumMember
prpo:WarrantLiabilitiesMember 2023-01-01
2023-09-30-0001043961
prpo:RdoCommonWarrantsMember us-
gaap:MeasurementInputSharePriceMember
prpo:RegisteredDirectOfferingMember
2023-06-08-0001043961
prpo:RdoCommonWarrantsMember us-
gaap:MeasurementInputRiskFreeInterestRa
prpo:RegisteredDirectOfferingMember
2023-06-08-0001043961
prpo:RdoCommonWarrantsMember us-
gaap:MeasurementInputPriceVolatilityMem~~

~~**prpo:RegisteredDirectOfferingMember
2023-06-08 0001043961**~~

~~**prpo:RdoCommonWarrantsMember us-
gaap:MeasurementInputExpectedTermMem**~~

~~**prpo:RegisteredDirectOfferingMember
2023-06-08 0001043961 us-**~~

~~**gaap:EmployeeStockOptionMember 2024-
09-30 0001043961 us-**~~

~~**gaap:EmployeeStockOptionMember 2024-
01-01 2024-09-30 0001043961**~~

~~**prpo:LoanAgreementMember 2024-05-01
2024-05-01 0001043961**~~

~~**prpo:DepartmentOfEconomicAndCommunit**~~

~~**prpo:TermLoanMember 2024-01-01 2024-
09-30 0001043961**~~

~~**prpo:DepartmentOfEconomicAndCommunit**~~

~~**prpo:TermLoanMember 2018-01-08 2018-
01-08 0001043961**~~

~~**prpo:DepartmentOfEconomicAndCommunit**~~

~~**prpo:TermLoanMember 2018-01-08**~~

~~**0001043961 prpo:LoanAgreementMember**~~

~~**prpo:DefaultFeesMember 2024-05-01
0001043961**~~

~~**prpo:FinancedInsuranceLoanMember
2024-07-31 0001043961**~~

~~**prpo:FinancedInsuranceLoanMember
2023-07-31 0001043961**~~

~~**prpo:LoanAgreementMember 2024-05-01
0001043961**~~

~~**prpo:FinancedInsuranceLoanMember
2024-09-30 0001043961**~~

~~**prpo:BusinessLoanAgreementMember
2024-09-30 0001043961**~~

~~**prpo:FinancedInsuranceLoanMember
2023-12-31 0001043961 us-**~~

~~**gaap:ProductMember 2024-07-01 2024-09-
30 0001043961 us-gaap:ProductMember**~~

~~**2024-01-01 2024-09-30 0001043961 us-**~~

~~**gaap:ProductMember 2023-07-01 2023-09-
30 0001043961 us-gaap:ProductMember**~~

~~**2023-01-01 2023-09-30 0001043961 us-**~~

~~**gaap:PreferredClassBMember 2024-07-01
2024-09-30 0001043961 us-**~~

~~**gaap:PreferredClassBMember 2024-01-01
2024-09-30 0001043961 us-**~~

~~**gaap:PreferredClassBMember 2023-07-01
2023-09-30 0001043961 us-**~~

~~**gaap:PreferredClassBMember 2023-01-01
2023-09-30 0001043961**~~

~~**prpo:CustomerCMember us-**~~

~~**gaap:SalesRevenueNetMember us-**~~

~~**gaap:CustomerConcentrationRiskMember
2024-07-01 2024-09-30 0001043961**~~

~~**prpo:CustomerCMember us-**~~

~~**gaap:SalesRevenueNetMember us-**~~

~~**gaap:CustomerConcentrationRiskMember
2024-01-01 2024-09-30 0001043961**~~

~~**prpo:CustomerCMember us-**~~

~~gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember
2024-01-01 2024-09-30 0001043961
prpo:CustomerMember us-
gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember
2023-07-01 2023-09-30 0001043961
prpo:CustomerDMember us-
gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember
2023-07-01 2023-09-30 0001043961
prpo:CustomerBMember us-
gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember
2023-01-01 2023-12-31 0001043961
prpo:CustomerMember us-
gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember
2023-01-01 2023-09-30 0001043961 2018-
12-20 0001043961 2018-12-19 0001043961
prpo:AtMarketOfferingMember
prpo:AllianceGlobalPartnersMember 2021-
04-02 0001043961
prpo:RegisteredDirectOfferingMember
2023-06-08 0001043961
prpo:PreFundedWarrantsMember
prpo:RegisteredDirectOfferingMember
2024-09-30 0001043961
prpo:RdoCommonWarrantsMember 2024-~~

~~09-30 0001043961~~

~~prpo:RdoCommonWarrantsMember 2023-06-30 0001043961~~

~~prpo:RdoCommonWarrantsMember~~

~~prpo:RegisteredDirectOfferingMember 2023-06-08 0001043961~~

~~prpo:PreFundedWarrantsMember~~

~~prpo:RegisteredDirectOfferingMember 2023-06-08 0001043961 2023-09-30~~

~~0001043961 2022-12-31 0001043961 us-~~

~~gaap:WarrantMember 2024-01-01 2024-09-30 0001043961 us-~~

~~gaap:PreferredStockMember 2024-01-01 2024-09-30 0001043961 us-~~

~~gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001043961 us-~~

~~gaap:WarrantMember 2023-01-01 2023-09-30 0001043961 us-~~

~~gaap:PreferredStockMember 2023-01-01 2023-09-30 0001043961 us-~~

~~gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001043961~~

~~srt:MaximumMember~~

~~prpo:DepartmentOfEconomicAndCommunit~~

~~prpo:TermLoanMember 2024-07-01 2024-09-30 0001043961 srt:MaximumMember~~

~~prpo:DepartmentOfEconomicAndCommunit~~

~~prpo:TermLoanMember 2024-01-01 2024-09-30 0001043961 srt:MaximumMember~~

~~prpo:DepartmentOfEconomicAndCommunit~~
~~prpo:TermLoanMember 2023-07-01 2023-~~
~~09-30 0001043961 srt:MaximumMember~~
~~prpo:DepartmentOfEconomicAndCommunit~~
~~prpo:TermLoanMember 2023-01-01 2023-~~
~~09-30 0001043961 us-gaap:ParentMember~~
~~2024-07-01 2024-09-30 0001043961 us-~~
~~gaap:AdditionalPaidInCapitalMember~~
~~2024-07-01 2024-09-30 0001043961 us-~~
~~gaap:ParentMember 2024-01-01 2024-09-~~
~~30 0001043961 us-~~
~~gaap:AdditionalPaidInCapitalMember~~
~~2024-01-01 2024-09-30 0001043961 us-~~
~~gaap:ParentMember 2023-07-01 2023-09-~~
~~30 0001043961 us-~~
~~gaap:AdditionalPaidInCapitalMember~~
~~2023-07-01 2023-09-30 0001043961 us-~~
~~gaap:ParentMember 2023-01-01 2023-09-~~
~~30 0001043961 us-~~
~~gaap:AdditionalPaidInCapitalMember~~
~~2023-01-01 2023-09-30 0001043961 us-~~
~~gaap:SelfPayMember 2024-09-30~~
~~0001043961~~
~~prpo:PayerTypeThirdPartyPayerMember~~
~~2024-09-30 0001043961~~
~~prpo:MedicareMember 2024-09-30~~
~~0001043961 prpo:MedicaidMember 2024-~~
~~09-30 0001043961~~
~~prpo:ContractDiagnosticServicesAndOtherM~~

~~2024-09-30 0001043961 us-
gaap:SelfPayMember 2023-12-31
0001043961
prpo:PayerTypeThirdPartyPayerMember
2023-12-31 0001043961
prpo:MedicareMember 2023-12-31
0001043961 prpo:MedicaidMember 2023-
12-31 0001043961
prpo:ContractDiagnosticServicesAndOtherM
2023-12-31 0001043961 us-
gaap:EmployeeStockOptionMember 2024-
08-30 2024-08-30 0001043961
prpo:RegisteredDirectOfferingMember
2024-09-30 0001043961
prpo:Agp2023SalesAgreementMember
2024-09-30 0001043961
prpo:Agp2023SalesAgreementMember
2024-04-08 0001043961 2024-04-08
0001043961 srt:MaximumMember
prpo:Agp2023SalesAgreementMember
2023-04-14 0001043961
prpo:Agp2023SalesAgreementMember
2023-04-14 0001043961
prpo:AtMarketOfferingMember
prpo:AllianceGlobalPartnersMember 2020-
04-13 0001043961
prpo:RdoCommonWarrantsMember
prpo:RegisteredDirectOfferingMember
2023-06-08 2023-06-08 0001043961~~

~~prpo:RegisteredDirectOfferingMember
2023-06-08 2023-06-08 0001043961~~
~~prpo:EquityIncentivePlan2017Member
2024-01-01 2024-09-30 0001043961~~
~~prpo:RegisteredDirectOfferingMember
2023-06-07 2023-06-07 0001043961~~
~~srt:MinimumMember 2024-01-01 2024-09-
30 0001043961 2023-12-31 0001043961~~
~~us-gaap:CommonStockMember 2023-07-01
2023-09-30 0001043961 us-~~
~~gaap:CommonStockMember 2023-01-01
2023-09-30 0001043961~~
~~srt:MaximumMember 2024-07-01 2024-09-
30 0001043961 srt:MaximumMember
2024-01-01 2024-09-30 0001043961~~
~~srt:MaximumMember 2023-07-01 2023-09-
30 0001043961 srt:MaximumMember
2023-01-01 2023-09-30 0001043961~~
~~prpo:DepartmentOfEconomicAndCommunit
2024-09-30 0001043961~~
~~prpo:DepartmentOfEconomicAndCommunit
2023-12-31 0001043961 us-~~
~~gaap:PreferredClassBMember 2024-09-30
0001043961~~
~~prpo:RdoCommonWarrantsMember 2023-
06-01 2023-06-30 0001043961 2023-09-01
2023-09-30 0001043961~~
~~prpo:Agp2023SalesAgreementMember
2023-04-14 2023-04-14 0001043961~~

~~**prpo:AtMarketOfferingMember**~~
~~**prpo:AllianceGlobalPartnersMember 2021-04-02 2021-04-02 0001043961**~~
~~**prpo:ServiceRevenueNetMember**~~
~~**prpo:PayerTypeThirdPartyPayerMember 2024-07-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember**~~
~~**prpo:MedicareMember 2024-07-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember**~~
~~**prpo:MedicaidMember 2024-07-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember 2024-07-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember us-gaap:SelfPayMember 2024-01-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember**~~
~~**prpo:PayerTypeThirdPartyPayerMember 2024-01-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember**~~
~~**prpo:MedicareMember 2024-01-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember**~~
~~**prpo:MedicaidMember 2024-01-01 2024-09-30 0001043961 us-gaap:SelfPayMember 2024-01-01 2024-09-30 0001043961**~~
~~**prpo:ServiceRevenueNetMember 2024-01-01 2024-09-30 0001043961**~~

~~prpo:PayerTypeThirdPartyPayerMember
2024-01-01 2024-09-30 0001043961
prpo:MedicareMember 2024-01-01 2024-
09-30 0001043961 prpo:MedicaidMember
2024-01-01 2024-09-30 0001043961
prpo:ServiceRevenueNetMember us-
gaap:SelfPayMember 2023-07-01 2023-09-
30 0001043961
prpo:ServiceRevenueNetMember
prpo:PayerTypeThirdPartyPayerMember
2023-07-01 2023-09-30 0001043961
prpo:ServiceRevenueNetMember
prpo:MedicareMember 2023-07-01 2023-
09-30 0001043961
prpo:ServiceRevenueNetMember
prpo:MedicaidMember 2023-07-01 2023-
09-30 0001043961
prpo:ServiceRevenueNetMember 2023-07-
01 2023-09-30 0001043961 2023-07-01
2023-09-30 0001043961
prpo:ServiceRevenueNetMember us-
gaap:SelfPayMember 2023-01-01 2023-09-
30 0001043961
prpo:ServiceRevenueNetMember
prpo:PayerTypeThirdPartyPayerMember
2023-01-01 2023-09-30 0001043961
prpo:ServiceRevenueNetMember
prpo:MedicareMember 2023-01-01 2023-
09-30 0001043961~~

~~prpo:ServiceRevenueNetMember
prpo:MedicaidMember 2023-01-01 2023-09-30 0001043961
prpo:ServiceRevenueNetMember 2023-01-01 2023-09-30 0001043961 2023-01-01 2023-09-30 0001043961 2024-09-30 0001043961 srt:MaximumMember 2024-09-30 0001043961 2024-07-01 2024-09-30 0001043961 2024-11-03 0001043961 2024-01-01 2024-09-30 shares iso4217:USD pure iso4217:USD shares prpo:item prpo:Y prpo:segment 47 47 1420125 1482133 6900 6900 0001043961 --12-31 2024 Q3 false 0.05 0.05 10-Q true 2024-09-30 false 001-36439 PRECIPPIO, INC. DE 91-1789357 4 Science Park New Haven CT 06511 203 787-7888 Common Stock, \$0.01 par value per share PRPO NASDAQ Yes Yes Non-accelerated Filer true false false 1482333 1053000 1502000 2755000 2572000 1021000 1301000 590000 384000 591000 495000 3255000 3682000 753000 739000 342000 174000 447000 612000 12106000 12818000 48000 76000 16951000 18101000 444000 235000 103000 132000 205000 218000 701000 622000 2743000 1824000 282000 110000 4478000 3141000 84000 106000 190000 18000 254000 407000 5006000 3672000 0.01 0.01~~

~~15000000 15000000 47 47 39000 0.01 0.01~~
~~150000000 150000000 1482133 1420125~~
~~15000 14000 114005000 112565000~~
~~-102075000 -98150000 11945000~~
~~14429000 16951000 18101000 4599000~~
~~3738000 11329000 8574000 681000~~
~~831000 1936000 2469000 5280000~~
~~4569000 13265000 11043000 71000 51000~~
~~183000 175000 5209000 4518000~~
~~13082000 10868000 2579000 2401000~~
~~7105000 6050000 353000 232000 1064000~~
~~813000 2932000 2633000 8169000~~
~~6863000 2277000 1885000 4913000~~
~~4005000 2874000 3333000 8793000~~
~~10771000 -597000 -1448000 -3880000~~
~~-6766000 -29000 -7000 -45000 -12000~~
~~-626000 -1455000 -3925000 -6778000~~
~~-626000 -1455000 -3925000 -6778000~~
~~-0.42 -0.42 -1.04 -1.04 -2.69 -2.69 -5.39~~
~~-5.39 1480217 1480217 1394596 1394596~~
~~1456653 1456653 1258633 1258633 47~~
~~1469540 14000 113550000 -101449000~~
~~12115000 12115000 -626000 -626000~~
~~-626000 12593 1000 57000 58000 58000~~
~~398000 398000 398000 47 1482133 15000~~
~~114005000 -102075000 11945000~~
~~11945000 47 1420125 14000 112565000~~
~~-98150000 14429000 14429000 -3925000~~
~~-3925000 -3925000 11822 78000 78000~~

~~78000 50186 1000 308000 309000 309000~~
~~1054000 1054000 1054000 47 1482133~~
~~15000 114005000 -102075000 11945000~~
~~11945000 47 1378115 14000 111632000~~
~~-97620000 14026000 65000 14091000~~
~~-1455000 -1455000 -1455000 2492 16000~~
~~16000 16000 52 350000 350000 350000 47~~
~~1380555 14000 111998000 -99075000~~
~~12937000 65000 13002000 47 1141013~~
~~11000 108588000 -92297000 16302000~~
~~65000 16367000 -6778000 -6778000~~
~~-6778000 206250 3000 1757000 1760000~~
~~1760000 30852 485000 485000 485000~~
~~2492 16000 16000 16000 52 1152000~~
~~1152000 1152000 47 1380555 14000~~
~~111998000 -99075000 12937000 65000~~
~~13002000 -3925000 -6778000 900000~~
~~931000 165000 153000 66000 63000 2000~~
~~2000 1054000 1168000 309000 183000~~
~~175000 -97000 622000 206000 -72000~~
~~-249000 -306000 55000 468000 -166000~~
~~-150000 172000 -90000 919000 629000~~
~~-126000 -3673000 179000 77000 -179000~~
~~-77000 62000 62000 28000 78000 2245000~~
~~250000 382000 316000 -144000 1867000~~
~~-449000 -1883000 1502000 3445000~~
~~1053000 1562000 54000 29000 24000~~
~~3000 317000 372000 58000 205000~~ <p
style="font-family: 'Times New

1. BUSINESS DESCRIPTION

Business

Description.

Inc., and its subsidiaries, (collectively,

“we”, “us”, “our”, the “Company” or

“Precipio”) is a healthcare biotechnology

company focused on cancer diagnostics.

Our mission is to address the pervasive

problem of cancer misdiagnoses by

developing solutions in the form of

diagnostic products and services.

~~products and services aim to deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. We develop innovative technologies in our laboratory where we design, test, validate, and use these products clinically. We believe these technologies improve diagnostic outcomes across various diseases within the hematologic field. We then commercialize these technologies as proprietary products that serve the global laboratory community in furtherance of our mission to eliminate or greatly reduce the prevalence of misdiagnosis. To deliver our strategy, we have structured our organization to develop diagnostic products, including our laboratory and research and development (“R&D”) facilities located in New Haven, Connecticut and Omaha, Nebraska, respectively, which house teams that collaborate on the development of new products and services. We operate clinical laboratory improvement amendment (“CLIA”) laboratories in both New Haven, Connecticut and Omaha, Nebraska where we provide essential blood cancer diagnostics to office-based oncologists in~~

~~many states nationwide. To deliver on our strategy of mitigating misdiagnoses we rely heavily on our CLIA laboratory to support R&D beta-testing of the products we develop, in a clinical environment.~~

~~development of laboratory products involves a qualified facility; highly skilled laboratory staff; and access to viable patient specimens to conduct development and testing. Our CLIA laboratory in New Haven, which is operated by our pathology services division, encapsulates these components, and also generates revenue for us which covers costs associated with operating this laboratory. This structure of utilizing our clinical lab to obtain samples and utilize the equipment and staffing to develop, test and validate our products, significantly reduces the development costs and timeline for our products. This also~~

~~enables us to accelerate the time to market of new product development and launch.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'~~

~~as a clinical laboratory, we are always the first user of every product we develop, which allows us to optimize important laboratory functions such as workflow, inventory management, regulatory and billing issues. As a vendor, this places us as a reputable user of our own products, and we believe gains us significant credibility with existing and prospective customers. Furthermore, because we use our products as part of our day-to-day operations, we are able to deliver a high level of hands-on, experienced support to customers, improving their experience with our products.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'~~

~~~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'Products Division commercial team generates direct sales and works with our key distributors. Global healthcare distributors, such as ThermoFisher, McKesson, and Cardinal Health, have partnered with us to form the backbone of our go-to-market strategy and enable us to access laboratories around the country that can benefit from using our diagnostic products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our operating structure promotes the harnessing of our proprietary technology and genetic diagnostic expertise to bring to market our robust pipeline of innovative solutions designed to address the root causes of misdiagnoses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Going Concern.</p><p style="font-family:'Times New~~

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America ("GAAP") applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business and do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. For the nine months ended September 30, 2024, the Company had a net loss of \$3.9 million and net cash used in operating activities of \$0.1 million.

As of September 30, 2024, the Company had an accumulated deficit of \$102.1 million and a working capital deficit of \$1.2 million. The Company's ability to continue as a going concern over the next twelve months from the date of issuance of

~~these condensed consolidated financial statements in this Quarterly Report on Form 10-Q is dependent upon a combination of achieving its business plan, including generating additional revenue and avoiding potential business disruption due to the macroeconomic environment and geopolitical instability, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.~~

~~To meet its current and future obligations the Company has taken the following steps to capitalize the business:~~

<del></del>	<del></del>	<del></del>

~~<td style="padding:0pt;">On April 14, 2023, the Company entered into a sales agreement with AGP, pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to \$5.8million, to or through AGP, as sales agent (the "AGP 2023 Sales Agreement"). The sale of our shares of common stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the registration statement (the "2023 Registration Statement") on Form S-3 (File No. 333-271277), filed by the Company with the U.S. Securities and Exchange Commission ("SEC") on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023.~~

~~On April 8, 2024, we filed a prospectus supplement to our prospectus dated April 25, 2023 registering the offer and sale of up to \$1,061, of shares of our common stock (the “April 2024 Prospectus Supplement”). As of the datethe condensed consolidated financial statements were issued, the Company has approximately <span style="font-~~

~~family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"/>\$3.7</s~~
~~million available for future sales pursuant to the 2023 Registration Statement, which includes approximately \$1.0</s~~
~~million of remaining availability pursuant to the April 2024 Prospectus Supplement.~~
~~See Note 7 Stockholders' Equity, AGP 2023 Sales Agreement, for further discussion.</td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:justify;margin:0pt 0pt 0pt 72pt;">
<span style="margin-
left:0pt;visibility:hidden;"></p><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;text-indent:36pt;margin:0pt
0pt 12pt 0pt;">Notwithstanding the
aforementioned circumstances, there
remains substantial doubt about the
Company's ability to continue as a going
concern for the next twelve months from
the date these condensed consolidated
financial statements were issued. There
can be no assurance that the Company will
be able to successfully achieve its
initiatives summarized above in order to
continue as a going concern over the next
twelve months from the date of issuance of
this Quarterly Report Form 10-Q.</p>
-3900000 -100000 -102100000 1200000
5800000 1061478000 3700000 1000000.0
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;font-
weight:bold;margin:0pt 0pt 12pt 0pt;">2.
SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</p><p style="font-family:'Times
New Roman','Times','serif';font-
size:10pt;font-style:italic;margin:0pt 0pt
12pt 0pt;">Basis of Presentation.</p><p~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to a 1-for-reverse stock split which was effected on September 21, 2023As of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated financial statements are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are necessary for a fair presentation of the*~~

~~financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 contained in our Annual Report on Form 10-K, filed with the SEC on March 29, 2024. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2024.~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt~~

~~0pt;">Recently Adopted Accounting Pronouncements.~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2022, the Financial Accounting Standards Board (the "FASB") issued ASU 2022-03, Fair Value Measurement (Topic 820) ("ASU 2022-03"). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not~~

~~considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures~~

~~The adoption of this standard was not material to our condensed consolidated financial statements.~~

~~In August 2020, the FASB issued ASU 2020-06 “*Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity*.” This ASU amends the guidance on convertible instruments and~~

~~the derivatives scope exception for contracts in an entity's own equity and improves and amends the related earnings per share ("EPS") guidance for both Subtopics. The Company adopted this guidance on January 1, 2024.~~

~~The adoption of this standard was not material to our condensed consolidated financial statements.~~

~~Recent Accounting Pronouncements Not Yet Adopted.~~

~~In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The~~

~~guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.~~

~~*In December 2023, the FASB issued ASU 2023-09—Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1)*~~

~~consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company's financial position, results of operations or cash flow.~~

~~Loss Per Share.~~

~~Basic loss per share is calculated based on the weighted-average number of common shares (including pre-~~

~~funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company's common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive due to the net loss.~~

~~*Times New Roman', 'Times', 'serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;*~~The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:

~~left:0pt;padding-right:0pt;width:100%;">~~
~~<tr style="height:1pt;"><td~~
~~style="vertical-~~
~~align:bottom;width:77.51%;margin:0pt;pada~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.77%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.77%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~

~~align:bottom;width:77.51%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt;"><span~~
~~style="font-size:8pt;visibility:hidden;">~~
~~</p></td><td colspan="3"~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:20.01%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;">September 30, </p>~~
~~</td></tr><tr><td style="vertical-~~
~~align:bottom;width:77.51%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;">—</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:8.77%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;">2024</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;">—</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:8.77%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;">2023</p></td></tr>~~
~~<tr><td style="vertical-~~
~~align:bottom;width:77.51%;background:#cc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">303,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">234,213</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-~~

Warrants
Preferred stock

~~align:bottom;white-
space:nowrap;width:2.46%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:8.77%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
5,875</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.46%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:8.77%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
5,875</p></td></tr><tr><td
style="vertical-
align:bottom;width:77.51%;margin:0pt;pada
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~753,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~705,976</p></td></tr></table><p style="font-family:'Times New~~

~~*Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt; " <span style="font-size: 1pt; visibility: hidden; " </p> <p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; margin: 0pt 0pt 12pt 0pt; " >Basis of Presentation. </p> <p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt; " >The accompanying condensed consolidated financial statements are presented in conformity with GAAP. As required under GAAP, pursuant to a 1-for- 20 reverse stock split which was effected on September 21, 2023 , unless otherwise indicated, the Company has adjusted all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements. As of*~~

~~September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated financial statements are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 contained in our Annual Report on Form 10-K, filed with the SEC on March 29, 2024. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2024.~~

~~Recently Adopted Accounting Pronouncements.~~

~~In June 2022, the Financial Accounting Standards Board~~

~~(the “FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures~~

~~*for equity securities subject to contractual sale restrictions. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.*~~

~~*In August 2020, the FASB issued ASU 2020-06 “Debt—Debt with Conversion*~~

~~and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity~~.” This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related earnings per share (“EPS”) guidance for both Subtopics. The Company adopted this guidance on January 1, 2024. The adoption of this standard was not material to our condensed consolidated financial statements.

~~Recent Accounting Pronouncements Not Yet Adopted.~~

~~In November 2023, the FASB issued ASU~~

~~2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily through enhanced disclosures of significant segment expenses. The guidance will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application to all periods presented upon adoption, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09—Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”) which is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU~~

~~2023-09 requires additional disaggregation of the reconciliation between the statutory and effective tax rate for an entity and of income taxes paid, both of which are disclosures required by current GAAP. The amendments improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in ASU 2023-09 apply to all entities that are subject to Topic 740, Income Taxes. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. ASU 2023-09 is effective for the Company beginning January 1, 2025. Adoption of ASU 2023-09 is expected to enhance the usefulness of income tax disclosures and is not expected to have a material impact on the Company's financial position, results of operations or cash flow.~~

~~12pt 0pt;">Loss Per Share.</p><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per share is calculated based on the weighted-average number of common shares (including pre-funded warrants) outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Shares of the Company's common stock underlying pre-funded warrants are included in the calculation of basic and diluted loss per share due to the negligible exercise price of the pre-funded warrants. Options, warrants and conversion rights pertaining to 753,752 and 705,976 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2024 and 2023, respectively, because the effect is anti-dilutive due to the net loss.</p><p style="font-~~

~~family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt~~

~~0pt 12pt 0pt;">The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<del><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<del><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:77.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt;"><span~~
~~style="font-size:8pt;visibility:hidden;">~~
~~</p></td><td colspan="3"~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:20.01%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;">September 30, </p>~~
~~</td></tr><tr><td style="vertical-~~

~~align:bottom;width:77.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:8.77%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;">2024</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~
~~weight:bold;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:8.77%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr>
<tr><td style="vertical-align:bottom;width:77.51%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
303,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">234,213</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">444,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~

~~465,888~~

Preferred stock	<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt;"></p></td><td style="vertical-align: bottom; white-space: nowrap; width: 8.77%; background: #cccccc; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt;"><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: right; margin: 0pt 3pt 0pt 0pt;">5,875</p></td><td style="vertical-align: bottom; white-space: nowrap; width: 2.46%; background: #cccccc"><p ><="" ><p<="" p="" p><="" style="vertical-align: bottom; white-space: nowrap; width: 8.77%; background: #cccccc; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt;" td><td=""></p></p>

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,875</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">753,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">753,752</p></td></tr></table>~~

~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~705,976</p></td></tr></table><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~753752 705976 <p style="font-~~
~~family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:justify;text-indent:36pt;margin:0pt~~
~~0pt 12pt 0pt;">The following table~~
~~summarizes the outstanding securities not~~
~~included in the computation of diluted net~~
~~loss per share:</p><table style="border-~~
~~collapse:collapse;font-~~
~~size:16pt;height:max-content;margin-~~
~~left:auto;margin-right:auto;padding-~~
~~left:0pt;padding-right:0pt;width:100%;">~~
~~<tr style="height:1pt;"><td~~
~~style="vertical-~~
~~align:bottom;width:77.51%;margin:0pt;pada~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~303,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~234,213</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.51%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~Warrants</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">444,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">465,888</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc~~
~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,875</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;pada<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">753,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">705,976</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>303433 234213 444444 465888 5875 5875 753752 705976 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.~~

~~LONG-TERM DEBT~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">~~

~~Long-term debt consists of the following:~~

~~</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;">~~

~~<tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;pada~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.44%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.34%;margin:0pt;pad~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;pad
<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.08%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~

~~***style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollars in Thousands</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">***~~

September 30, 2024

December 31, 2023

Connecticut Department of
Economic and Community Development
(DECD)

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#c</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">146</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">DECD debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;pad</p><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(12)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financed insurance loan</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.44%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.34%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~261</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#c0<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">207</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Business loan agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—*~~
~~*</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#ccc*~~
~~*<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term debt</p></td><td*~~
~~*style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc*~~
~~*<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*~~
~~**~~
~~*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ccc*~~
~~*<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*~~
~~*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ccc*~~
~~*<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~*528</p></td><td style="vertical-align:bottom;white-*~~

~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:11.93%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~341</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:68.93%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Current portion of long-term~~
~~debt</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(235)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cc<<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt, net of current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ccc~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:12.34%;background:#c
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
84</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.39%;background:#ccc
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:11.93%;background:#c0c0c0;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">106</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Department of Economic and Community Development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 8, 2018, the Company entered into an agreement with the Connecticut Department of Economic and Community Development ("DECD") by which the Company received a loan of \$300,000 secured by substantially all of the Company's assets (the "DECD 2018 Loan"). The DECD 2018 Loan is a ten-year loan due~~

~~on December 31, 2027 and includes interest paid monthly at 3.25%. The maturity date of the DECD 2018 Loan was extended to May 31, 2028 and the modification did not have a material impact on the Company's cash flows.~~

~~Amortization of the debt issuance costs were less than \$1 thousand for the three months ended September 30, 2024 and 2023, respectively and \$2 thousand for the nine months ended September 30, 2024 and 2023, respectively.~~

~~Financed Insurance Loan.~~

~~The Company finances certain of its insurance premiums (the "Financed Insurance Loans"). In July 2024, the Company financed \$0.3 million with a 9.99% interest rate and is obligated to make payments on a monthly basis through~~

~~June 2025. In July 2023, the Company financed \$0.4 million with a 9.99% interest rate and made payments on a monthly basis through June 2024. As of September 30, 2024 and December 31, 2023, the Financed Insurance Loan's outstanding balance of \$0.3 million and \$0.2 million, respectively, was included in current maturities of long-term debt in the Company's condensed consolidated balance sheets. A corresponding prepaid asset was included in other current assets.~~

~~*Business Loan Agreement.*~~

~~May 1, 2024, the Company entered into a Business Loan and Security Agreement (the "Loan Agreement") with Altbanq Lending LLC, pursuant to which the Company obtained a loan in the principal amount of \$250,000 (the "Secured Loan"). According to the Loan Agreement, the Company granted the lender a continuing security~~

~~interest in certain collateral (as defined in the Loan Agreement). Furthermore, the Company's Chief Executive Officer provided a personal guaranty for the Secured Loan. The Secured Loan has a term of one year and an interest rate of 20%, such that pursuant to the Loan Agreement, the Company is obligated to pay the Lender 52 payments of \$5,769 on a weekly basis and the total sum of the Secured Loan and interest (not including any fees) shall equal a total repayment amount of \$300,000. If the Company defaults on payments then a default fee of \$15,000 shall be payable to the lender.~~

~~the lender.~~

~~Company has the right, at its discretion, to request the lender to loan an additional amount of up to \$250,000 on the same terms and conditions as set forth in the Loan Agreement, provided that there has been no material change in the Company's finances.~~

~~*New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; background: #ffffff; margin: 0pt; ' </p> <p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; background: #ffffff; margin: 0pt; ' of September 30, 2024 and December 31, 2023, the outstanding balance of \$0.2 million and zero, respectively, under the Loan Agreement, was included in current maturities of long-term debt in the Company's condensed consolidated balance sheets. </p> <p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-weight: bold; margin: 0pt 0pt 12pt 0pt; " > Long-term debt consists of the following: </p> <table style="border-collapse: collapse; font-size: 16pt; height: max-content; margin-left: auto; margin-right: auto; padding-left: 0pt; padding-right: 0pt; width: 100%; " > <tr style="height: 1pt; " > <td style="vertical-align: bottom; width: 68.93%; margin: 0pt; pade </div style="height: 1pt; overflow: hidden; overflow-*~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

	
	

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Dollars in Thousands~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-~~
~~weight:bold;">December 31, 2023~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:68.93%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Connecticut Department of~~
~~Economic and Community Development~~
~~(DECD)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.44%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.34%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~123~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~	~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	<del></del>	<del></del>	~~</p>~~	~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ccc~~	~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~	~~0pt;">~~	~~\$~~	~~</p>~~	~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#c~~	~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~	~~146~~	~~</p>~~	~~</td>~~	~~</tr>~~	~~<tr>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:68.93%;margin:0pt;pada~~	~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~	~~0pt;">DECD debt issuance costs~~	~~</p>~~	~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~	~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:11.93%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(12)</p></td></tr><tr><td
style="vertical-
align:bottom;width:68.93%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Financed insurance loan</p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.44%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:12.34%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">207</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Business loan agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.39%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.93%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td></tr><tr><td style="vertical-
align:bottom;width:68.93%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Total long-term debt</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.44%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:12.34%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
528</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.39%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.93%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
341</p></td></tr><tr><td
style="vertical-
align:bottom;width:68.93%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Current portion of long-term
debt</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.44%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:12.34%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(235)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt, net of current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ccc bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#c bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cccccc;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cccccc;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">106</p></td></tr></table>123000146000 10000 12000 261000 207000154000 528000 341000 444000 23500084000 106000 300000 P10Y 2027-12-31 0.0325 2028-05-31 1000 1000 2000 2000300000 0.0999 400000 0.0999 300000300000 200000 250000 P1Y 0.20 5769300000 15000 250000 200000 0 <p style="font-family:'Times New~~

~~**Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">**~~

~~**<span style="font-**~~

~~**weight:normal;">4. ACCRUED**~~

~~**EXPENSES</p><p style="font-**~~

~~**family:'Times New**~~

~~**Roman','Times','serif';font-size:10pt;text-**~~

~~**align:justify;text-indent:36pt;margin:0pt**~~

~~**0pt 12pt 0pt;">Accrued expenses at**~~

~~**September 30, 2024 and December 31,**~~

~~**2023 are as follows:</p><table**~~

~~**style="border-collapse:collapse;font-**~~

~~**size:16pt;height:max-content;padding-**~~

~~**left:0pt;padding-right:0pt;width:100%;">**~~

~~**<tr style="height:1pt;"><td**~~

~~**style="vertical-**~~

~~**align:bottom;width:69%;margin:0pt;padding**~~

~~**<div**~~

~~**style="height:1pt;overflow:hidden;overflow-**~~

~~**wrap:break-word;position:relative;"><div**~~

~~**style="bottom:0pt;position:absolute;width:1**~~

~~**<p style="font-family:'Times New**~~

~~**Roman','Times','serif';font-**~~

~~**size:10pt;margin:0pt 0pt 0.05pt 0pt;">**~~

~~**<span style="font-**~~

~~**size:1pt;visibility:hidden;"></p>**~~

~~**</div></div></td><td style="vertical-**~~

~~**align:bottom;white-**~~

~~**space:nowrap;width:2.06%;margin:0pt;padd**~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;pad~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:11.92%;margin:0pt;padding:
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td></tr><tr><td
style="vertical-
align:bottom;width:69%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
(dollars in thousands)</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td colspan="2"
style="vertical-align:bottom;white-
space:nowrap;width:13.78%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September 30, 2024~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">December 31, 2023~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeef~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#c<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:11.92%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
764</p></td></tr><tr><td
style="vertical-
align:bottom;width:69%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Accrued compensation</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.45%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:12.33%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;paddi~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~754</p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeef~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~Accrued franchise, property and sales and use taxes</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.45%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.33%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~152</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.82%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.4%;background:#cccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#c
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
287</p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHC
temporary funding assistance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

[illegible]

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#c bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cccccc;border-bottom:1px solid black;border-left:1px solid black;border-right:1px solid black;border-top:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cccccc;border-bottom:1px solid black;border-left:1px solid black;border-right:1px solid black;border-top:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.92%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,824</p></td></tr></table><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;text-indent:36pt;margin:0pt
0pt 12pt 0pt;"><span
style="visibility:hidden;"></p><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;text-indent:36pt;margin:0pt
0pt 12pt 0pt;">The Company uses Change
Healthcare (“CHC”), a healthcare
technology company owned by
UnitedHealth Group, to process some of its
patient claims billings. In February 2024,
CHC announced that it had experienced a
cyberattack and as a result had to~~

~~temporarily shut down some of its information technology systems. This system shut down caused delays in billing and reimbursement processes to CHC's customers and, as a result, CHC established a Temporary Funding Assistance Program to help bridge the gap in short-term cash flow needs for customers affected by the disruption of its services due to the cyberattack. Funding distributed through this program is interest free and has no other fees or costs associated with it. As of September 30, 2024, CHC's systems have yet to be fully restored.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2024, the Company received approximately \$1.1 million through CHC's Temporary Assistance Program. On October 28, 2024, the Company received a notice from CHC stating that they have restored the connectivity of their systems and are requesting repayment of the funds the Company received through the Temporary Assistance Program. The repayment date contained in the notice is~~

~~space:nowrap;width:2.06%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.45%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.33%;margin:0pt;pad~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(dollars in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~**style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#cceeef"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc**~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#c
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">764</p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;pad
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">754</p></td></tr><tr><td style="vertical-align:bottom;width:69%;background:#ccccff"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued franchise, property and sales and use taxes</p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#c~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~287</p></td></tr><tr><td~~
~~style="vertical-align:bottom;width:69%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHC~~
~~temporary funding assistance</p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt 3pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
1,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt 3pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt 3pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt 3pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69%;background:#ccccff;">~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cccccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cccccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;width:69%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,824</p></td></tr></table> 586000 764000 929000 754000 152000 287000 1057000 19000 19000 2743000 1824000 1100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.~~

~~COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is involved in legal proceedings related to matters, which~~

~~are incidental to its business. Also, the Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. See below for a discussion on these matters.~~

~~**PURCHASE COMMITMENTS**~~

~~The Company has entered into purchase commitments for reagents from suppliers. These agreements started in 2011 and run through 2025. The Company and the suppliers will true up the amounts on an annual basis. The future minimum purchase commitments under these and other purchase agreements are approximately \$2.3 million at~~

~~September 30, 2024.~~

~~*LITIGATIONS*~~

~~CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owed approximately \$0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of less than \$0.1 million has been recorded and is reflected in accounts payable within the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023.~~

~~*LEGAL AND REGULATORY ENVIRONMENT*~~

Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.

~~Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.~~

~~2300000
200000 100000 100000~~

~~**Times New Roman', 'Times', 'serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;**~~

~~**LEASES**~~

~~The Company leases administrative facilities and laboratory equipment through operating lease agreements. In addition, we rent various equipment used in our diagnostic lab and in our administrative offices through finance lease arrangements. Our operating leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common area or other~~

~~maintenance costs). The facility leases include one or more options to renew, from 1 to 5 years or more. The exercise of lease renewal options is typically at our sole discretion, therefore, the renewals to extend the lease terms are not included in our right-of-use ("ROU") assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and, when they are reasonably certain of exercise, we include the renewal period in our lease term. As our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.~~

~~Operating leases result in the recognition of ROU assets and lease liabilities on the balance sheet. ROU assets represent our right to use the leased asset for the lease term and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at commencement~~

~~date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The primary leases we enter into with initial terms of 12 months or less are for equipment.~~

~~The Company also recognizes ROU assets from finance leases in connection with its HemeScreen Reagent Rental (“HSRR”) program. For certain customers in the HSRR program, the Company leases diagnostic testing equipment and then subleases the equipment to the customer. Finance lease ROU assets and finance lease liabilities are recognized at the lease commencement date, and at the sublease commencement date the finance lease ROU asset is derecognized and is recorded as cost of sales in the condensed consolidated statements of operations. There were no derecognized finance lease ROU assets for the three and nine months ended September 30, 2024 and 2023, respectively.~~

~~Where Precipio is the lessor, customers lease diagnostic testing equipment from the Company with the transfer of ownership to the customer at the end of the lease term at no additional cost. For these contracts, the Company accounts for the arrangements as sales-type leases. The lease asset for sales-type leases is the net investment in leased asset, which is recorded once the finance lease ROU asset is derecognized and a related gain or loss is noted. The net investment in leased assets was \$0.1 million as of September 30, 2024 and December 31, 2023, respectively, and is included in other current assets and other assets in our condensed consolidated balance sheets.~~

~~The~~

~~balance sheet presentation of our operating and finance leases is as follows:~~

~~<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;pad~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;pad~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p>	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p>
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p>	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p>

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Classification on the Condensed Consolidated Balance Sheet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September~~
~~30, 2024</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:11pt;visibility:hidden;"></p>~~
~~</td><td colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.58%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">December 31,~~
~~2023</p></td></tr><tr><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:55.4%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">Assets:</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.78%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#c<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use assets, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">612</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease right-of-use assets, net (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
174</p></td></tr><tr><td
style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;"><b
style="font-weight:bold;">Total lease
assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">786</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;"><span style="font-~~

~~size:9pt;visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-~~

space:nowrap;width:18.16%;margin:0pt;padding:0pt 0pt 0.05pt 0pt; <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">	

~~</p>
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Current maturities of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~205~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ ~~</p>~~ ~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>~~ ~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~ ~~218~~	
~~</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:6pt;">Current maturities of finance lease liabilities~~ ~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:6pt;">~~	

~~align:bottom;white-
space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:18.16%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
103</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.61%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
family:'Calibri','Helvetica','sans-serif';font-~~

~~size:9pt;visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
132</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities, less
current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:9pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~254</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~

</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">407</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease liabilities, less current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

~~</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#c0c0c0;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:18.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">775</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">As of September 30, 2024 and December 31, 2023, finance lease right-of-use assets included zero<span~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, respectively, of assets related to finance leases associated with the HSRR program.~~

~~</td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2024, the estimated future minimum lease payments, excluding non-lease components, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;width:15.86%;margin:0pt;padding~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.83%;margin:0pt;padding~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;width:15.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td></tr><tr><td
style="vertical-
align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i
style="font-style:italic;">(dollars in~~

thousands)	
Operating Leases	

~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Finance Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Total~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;paddi~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;width:15.86%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September
30,</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;width:15.84%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September 30,</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;width:15.86%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;width:15.86%;border-~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;width:15.84%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">~~

[illegible]

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~37</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:15.84%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~97</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:40.9%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">2025</p></td><td style="vertical-~~
~~align:bottom;width:1.64%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~224</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.83%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~134</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">358</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;width:1.64%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeft<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ca<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeft<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.84%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
309</p></td></tr><tr><td
style="vertical-
align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt
0pt;">2027</p></td><td style="vertical-
align:bottom;width:1.64%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~69</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">2028</p></td><td style="vertical-align:bottom;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2%;background:#cceeef~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.83%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~29</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;background:#c~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
29</p></td></tr><tr><td style="vertical-
align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total
lease obligations</p></td><td
style="vertical-
align:bottom;width:1.64%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~498~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p>~~	
~~<td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~	
~~0pt;">~~	
~~</p>~~	
~~<td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~	
~~364~~	
~~</p>~~	
~~<td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p>~~	
~~<td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~	

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~~~862</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cccccc">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;width:1.64%;background:#cccccc">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#c bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(110)</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;paddi~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Present value of net minimum lease obligations</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;pad<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~752</p></td></tr><tr><td~~

~~style="vertical-~~

~~align:bottom;width:40.9%;background:#ccc~~

~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-~~

~~size:9pt;margin:0pt 0pt 0.05pt 0pt;">Less,~~

~~current portion</p></td><td~~

~~style="vertical-~~

~~align:bottom;width:1.64%;background:#ccc~~

~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-~~

~~align:bottom;white-~~

~~space:nowrap;width:2%;background:#ccccff~~

~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New~~

~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-~~

~~space:nowrap;width:15.86%;background:#cc~~

~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(205)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(103)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(308)</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Long term portion</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;border-bottom:3px~~
~~double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~254</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.83%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;border-bottom:3px~~
~~double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:15.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">444</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other information as of September 30, 2024 and December 31, 2023 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;pad~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:100%;background-color:transparent;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

September 30,	
December 31,	

~~Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease
term (years):</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:20.93%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.86%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:57.96%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~6pt;">Operating leases</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:20.93%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2.8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;background:#c~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;background:#c~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2.8</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.86%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2.0</p></td></tr><tr><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:57.96%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Weighted-average discount rate:</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.93%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.23%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr></table>~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#c<~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.00%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;pad<~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;pad<~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13.77%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padd<~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;pad<~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.63%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2024 and 2023, operating cash flows from operating leases was \$0.2 million, respectively, and operating lease ROU assets obtained in exchange for operating lease liabilities was zero and \$0.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2024 and 2023, finance lease ROU assets obtained in exchange for finance lease liabilities was \$0.2 million and zero, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt"~~

Operating Lease Costs

Operating lease costs were approximately \$0.1 million during the three months ended September 30, 2024 and 2023, respectively, and \$0.2 million for the nine months ended September 30, 2024 and 2023, respectively. These costs are primarily related to long-term operating leases for the Company's facilities and laboratory equipment. Short-term and variable lease costs were less than \$0.1 million for the three and nine months ended September 30, 2024 and 2023, respectively.

Finance Lease Costs

Finance lease amortization and interest expenses are included in the condensed consolidated

~~statements of operations for the three and nine months ended September 30, 2024 and 2023. The balances within these accounts are less than \$0.1 million, respectively.~~

~~1 P1Y P5Y 0 0 0 0 100000 100000~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;pad~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:18.14%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td></tr><tr><td
style="vertical-align:bottom;white-
space:nowrap;width:55.4%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt 0pt;"><i
style="font-style:italic;">(dollars in
thousands)</i></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
family:'Calibri','Helvetica','sans-serif';font-
size:11pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:11pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:11pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:11pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt; Calibri', 'Helvetica', 'sans-serif'; font-size: 11pt; visibility: hidden;	
Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt; Calibri', 'Helvetica', 'sans-serif'; font-size: 11pt; visibility: hidden;	
Roman', 'Times', 'serif'; font-size: 8pt; text-align: center; margin: 0pt 0pt 0.05pt 0pt; Classification on the Condensed Consolidated Balance Sheet	
Roman', 'Times', 'serif'; font-	

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,~~

2023

Assets:	
	

~~</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td></tr><tr><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:55.4%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~6pt;">Operating lease right-of-use assets,~~
~~net </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.78%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:9pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~447</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
612</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt
6pt;">Finance lease right-of-use assets, net
(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:9pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~342</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~

~~size:9pt;visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">174</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt">~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-family:'Calibri','Helvetica','sans-serif';font-~~

~~size:9pt;visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">786</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities:~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.14%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td></tr><tr><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:55.4%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Current:</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.78%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:18.16%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.61%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
family:'Calibri','Helvetica','sans-serif';font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:18.14%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td></tr><tr><td style="vertical-
align:bottom;white-
space:nowrap;width:55.4%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt
6pt;">Current maturities of operating lease
liabilities</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.78%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.44%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
218</p></td></tr><tr><td
style="vertical-align:bottom;white-
space:nowrap;width:55.4%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt
6pt;">Current maturities of finance lease
liabilities</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:18.16%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:9pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~132</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:9pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;background:#c
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities, less
current maturities</p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-family:'Calibri','Helvetica','sans-serif';font-~~

~~size:9pt;visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
407</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease liabilities, less current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-~~

~~size:9pt;visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:18.16%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#ccc;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.44%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:9pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:18.14%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:9pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
18</p></td></tr><tr><td style="vertical-
align:bottom;white-
space:nowrap;width:55.4%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt 12pt;"><b
style="font-weight:bold;">Total lease
liabilities</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.78%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.44%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.16%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:9pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~752</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.61%;margin:0pt;padd.~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~family:'Calibri','Helvetica','sans-serif';font-~~
~~size:9pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">775</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New~~

As of September 30, 2024 and December 31, 2023, finance lease right-of-use assets included

zero

respectively, of assets related to finance leases associated with the HSRR program.

447000
612000
342000
174000
789000
786000
205000
218000
103000
132000
254000
407000
190000
18000
752000
775000
0
0

As of September 30, 2024, the estimated future minimum lease payments, excluding non-lease

components, are as follows:

~~style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr></table>~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;width:15.86%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.83%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;width:15.84%;margin:0pt;pada~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~

~~</div></div></td></tr><tr><td
style="vertical-
align:bottom;width:40.9%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i
style="font-style:italic;">(dollars in
thousands)</i></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">—</p>
</td><td colspan="2" style="vertical-
align:bottom;white-
space:nowrap;width:17.87%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Operating
Leases</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.83%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-~~

~~align:bottom;width:40.9%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~style:italic;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;width:15.86%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September~~
~~30,</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;width:15.86%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September
30,</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September 30,</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;margin:0pt;paddi~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;width:15.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;width:15.86%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td style="vertical-align:bottom;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">2024 (remaining)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeft<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ca<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeft<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.84%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
97</p></td></tr><tr><td style="vertical-
align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt
0pt;">2025</p></td><td style="vertical-
align:bottom;width:1.64%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
224</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
134</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~358</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:40.9%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">2026</p></td><td style="vertical-~~
~~align:bottom;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#ccccff~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ ~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ccc">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ccc">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ ~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ccc">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ccc">~~

~~align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.84%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
309</p></td></tr><tr><td
style="vertical-
align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt
0pt;">2027</p></td><td style="vertical-
align:bottom;width:1.64%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:15.86%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~69</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~69</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:40.9%;background:#cce~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">2028</p></td><td style="vertical-~~

~~align:bottom;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#ccccff~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.83%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~29</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;paddi~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total~~
~~lease obligations</p></td><td~~
~~style="vertical-align:bottom;width:1.64%;margin:0pt;paddi~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~862</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Less:~~
~~Amount representing interest</p></td><td style="vertical-align:bottom;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccee~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccee~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#c~~
~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(110)</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Present value of net minimum lease obligations</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~459~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~	
~~293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~	

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~~~752</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cccccc">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">~~~~Less, current portion</p></td><td style="vertical-align:bottom;width:1.64%;background:#cccccc">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(205)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(103)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#c bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(308)</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;paddi~~

[illegible]

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px~~

~~double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~444</p></td></tr></table><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:justify;text-indent:36pt;margin:0pt~~
~~0pt 12pt 0pt;">As of September 30, 2024,~~
~~the estimated future minimum lease~~
~~payments, excluding non-lease~~
~~components, are as follows:</p><table~~
~~style="border-collapse:collapse;font-~~
~~size:16pt;height:max-content;padding-~~
~~left:0pt;padding-right:0pt;width:100%;">~~
~~<tr style="height:1pt;"><td~~
~~style="vertical-~~
~~align:bottom;width:40.9%;margin:0pt;paddi~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding-left:0pt">
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;text-align:center">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding-left:0pt">
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;text-align:center">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding-left:0pt">~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;width:15.84%;margin:0pt;pada
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New~~

~~*Roman', 'Times', 'serif'; font-size: 8pt; margin: 0pt 0pt 0.05pt 0pt; "><i style="font-style: italic; ">(dollars in thousands)</i></p></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.64%; margin: 0pt; padding: 0pt 0pt 0.05pt 0pt; "><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 8pt; margin: 0pt 0pt 0.05pt 0pt; "><b style="font-weight: bold; "></p></td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; width: 17.87%; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt; "><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 8pt; text-align: center; margin: 0pt 0pt 0.05pt 0pt; "><b style="font-weight: bold; ">Operating Leases</p></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.83%; margin: 0pt; padding: 0pt 0pt 0.05pt 0pt; "></p></td><td colspan="2" style="vertical-align: bottom; white-*~~

~~space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;paddi<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;width:15.86%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September~~
~~30,</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;width:15.84%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September 30,</p></td></tr><tr><td~~
~~style="vertical-align:bottom;width:40.9%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px~~

~~solid #000000;margin:0pt;padding:0pt;">~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;width:15.86%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.83%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;width:15.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#ccccff">
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">2024
(remaining)</p></td><td style="vertical-align:bottom;width:1.64%;background:#ccccff">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ccccff">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
60</p></td><td style="vertical-align:bottom;white-*~~

~~space:nowrap;width:1.83%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.86%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~37</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#c
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">97</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
224</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.83%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
134</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~358</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:40.9%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">2026</p></td><td style="vertical-~~
~~align:bottom;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#ccceff~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:15.86%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
214</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.83%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;background:#c
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
95</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~309</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:40.9%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:9pt;margin:0pt 0pt 0.05pt~~
~~0pt;">2027</p></td><td style="vertical-~~
~~align:bottom;width:1.64%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~~~—~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~69~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ <del></del> <del></del> ~~</p>~~ ~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~ ~~0pt;">~~ ~~</p>~~ ~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;pad~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~ ~~69~~ ~~</p>~~ ~~</td>~~
~~</tr>~~	~~<tr>~~ ~~<td style="vertical-align:bottom;white-space:nowrap;width:40.9%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt~~ ~~0pt;">~~ ~~2028~~ ~~</p>~~ ~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeef;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr></table>~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;background:#c0c0c0;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;pad<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">862</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amount representing interest</p></td><td style="vertical-align:bottom;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccceft bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#ccccff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:15.86%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(71)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2%;background:#cceeef~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:15.84%;background:#c~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~

[illegible]

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:15.84%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
752</p></td></tr><tr><td
style="vertical-
align:bottom;width:40.9%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt 0pt;">Less,
current portion</p></td><td
style="vertical-
align:bottom;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;background:#ccceff
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;background:#c~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(205)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.83%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;background:#cceeef
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(103)</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2%;background:#cceeef
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;background:#cceeef
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.84%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(308)</p></td></tr><tr><td
style="vertical-
align:bottom;width:40.9%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:9pt;margin:0pt 0pt 0.05pt 0pt;">Long
term portion</p></td><td style="vertical-~~

~~align:bottom;width:1.64%;margin:0pt;padding:0pt~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2%;border-bottom:3px
double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:15.86%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
190</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2%;border-bottom:3px
double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">444</p></td></tr></table> 60000 37000 97000 224000 134000 358000 214000 95000 309000 69000 69000 29000 29000 498000 364000 862000 39000 71000 110000 459000 293000 752000 205000 103000 308000 254000 190000 444000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;pad<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.93%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.23%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt 0pt 0pt 0pt;<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;padding:0pt 0pt 0pt 0pt;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;padding:0pt 0pt 0pt 0pt;<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.23%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:9pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.86%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:9pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">December 31,~~
~~</p></td></tr><tr><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:57.96%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.93%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:9pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~

2023	
Weighted-average remaining lease term (years):	

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:18.86%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:57.96%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~6pt;">Operating leases</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:20.93%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2.2</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.23%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:18.86%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
2.8</p></td></tr><tr><td style="vertical-
align:bottom;white-
space:nowrap;width:57.96%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
6pt;">Finance leases</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:20.93%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
2.8</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.23%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#c
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
2.0</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate:</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

Operating leases	8.00%	
Operating leases	8.00%	

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.00%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.96%;margin:0pt;padding:0pt 0pt 0.05pt 6pt;">Finance leases</td><td style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">13.77%</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">10.63%</td></tr></table>~~

~~P2Y2M12D P2Y9M18D P2Y9M18D P2Y
0.0800 0.0800 0.1377 0.1063 200000
200000 0 100000 200000 0 100000 100000
200000 200000 100000 100000 100000
100000 100000 100000 100000 100000~~<p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;font-
weight:bold;margin:0pt 0pt 12pt 0pt;">
<span style="font-
weight:normal;">7.
STOCKHOLDERS' EQUITY</p><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;font-
style:italic;margin:0pt 0pt 12pt
0pt;">Common Stock.</p><p style="font-
family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;text-indent:36pt;margin:0pt
0pt 12pt 0pt;">Pursuant to our Third
Amended and Restated Certificate of
Incorporation, as amended, we currently
have 150,000,000 shares of common stock
authorized for issuance. On December 20,
2018, the Company's shareholders
approved the proposal to authorize the
Company's Board of Directors to, in its
discretion, amend the Company's Third
Amended and Restated Certificate of
Incorporation to increase the total number

~~of authorized shares of common stock from 150,000,000 shares to 250,000,000 shares. The Company has not yet implemented this increase.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">
During the three and nine months ended September 30, 2024, the Company issued
12,593
 and
50,186
 shares of its common stock, respectively, in connection with consulting services of approximately
\$0.1
 million and
\$0.3
 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">~~

~~At The Market Offering Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">AGP Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On April 2, 2021, the Company entered into a sales agreement with A.G.P./Alliance Global Partners ("AGP"), pursuant to which the Company was permitted to offer and sell its common stock, par value \$0.01 per share (the "Common Stock") (the "Shares"), having aggregate sales proceeds of up to~~

~~\$22.0 million. Shares can be sold either directly to or through AGP as a sales agent (the “AGP Sales Agreement”), from time to time, in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the Shares (the “2021 ATM Offering”). The Company is limited in the number of shares it can sell in the 2021 ATM Offering due to the offering limitations currently applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company’s public float as of the applicable date of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the AGP Sales Agreement.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">~~
~~~~
~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'~~
~~sale of our shares of Common Stock to or through AGP, will be made pursuant to the registration statement (the “Registration Statement”) on Form S-3 (File No. 333-~~

~~237445), which was declared effective by the SEC on April 13, 2020, for an aggregate offering price of up to \$50.0 million.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;~~

~~the AGP Sales Agreement, Shares were permitted to be sold by any method permitted by law deemed to be an “at the market offering.” AGP will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the AGP Sales Agreement, AGP was required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;~~

~~rules of The Nasdaq Capital Market to sell~~

~~the Shares from time to time based upon the Company's instructions, including any price, time or size limits specified by the Company. AGP is not under any obligation to purchase any of the Shares on a principal basis pursuant to the AGP Sales Agreement, except as otherwise agreed by AGP and the Company in writing and expressly set forth in a placement notice. AGP's obligations to sell the Shares under the AGP Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions. The Company is not obligated to make any sales of Shares under the AGP Sales Agreement and any determination by the Company to do so will be dependent, among other things, on market conditions and the Company's capital raising needs.~~

~~Company agreed to pay AGP a cash fee of 3.0% of the aggregate gross proceeds from the sale of the Shares on the Company's~~

~~behalf pursuant to the AGP Sales Agreement. The AGP Sales Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has provided AGP with customary indemnification and contribution rights. The Company also agreed to reimburse AGP for certain specified expenses, including the expenses of counsel to AGP.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2023, we received net proceeds of zero and \$0.5 million from the sale of zero~~

~~ and
<span
style="background:#ffffff;">30,827

shares of common stock through
the AGP Sales Agreement.<span
style="background:#ffffff;"> </p>
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;text-indent:36pt;margin:0pt;">
<span
style="visibility:hidden;background:#ffffff;"
</p><p style="font-family:'Times
New Roman','Times','serif';font-
size:10pt;text-align:justify;text-
indent:36pt;margin:0pt;">As of the date of
issuance of this Quarterly Report on Form
10-Q, we have received an aggregate of
\$15.6 million in net proceeds, after
issuance costs of approximately \$0.5
million, from the sale of 260,128 shares of
common stock pursuant to the AGP Sales
Agreement. The offering of the Shares
pursuant to the AGP Sales Agreement
terminated upon the expiration of the
Company's Registration Statement<span
style="background:#ffffff;"> on Form S-3
(File No. 333-237445).</p><p
style="font-family:'Times New~~

~~*Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;*~~
~~**~~
~~*</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;">*~~
~~*<i style="font-style: italic;">AGP 2023 Sales Agreement</i> </p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;">*~~
~~**~~
~~*</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;">*~~
~~*On April 14, 2023, the Company entered into the AGP 2023 Sales Agreement, in an “at the market offering” (as defined in Rule 415(a) (4) under the Securities Act of 1933, as amended) of the shares of Common Stock. AGP will be entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares of Common Stock pursuant to the AGP 2023 Sales Agreement.*~~
~~*</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;">*~~

~~
</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">~~

~~The sale of our shares of Common Stock to or through AGP, pursuant to the AGP 2023 Sales Agreement, will be made pursuant to the 2023 Registration Statement on Form S-3 (File No. 333-271277), filed by the Company with the SEC on April 14, 2023, as amended by Amendment No. 1 filed by the Company with the SEC on April 25, 2023, and declared effective on April 27, 2023, for an aggregate offering price of up to \$5.8 million.</p><p style="font-~~

~~family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">~~

~~
</p><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">~~

~~On April 8, 2024, we filed a prospectus supplement (the "April 2024 Prospectus Supplement") to our prospectus dated April 25, 2023 registering the offer and sale of up to <span~~

~~**\$1,061,478** of shares of our common stock~~

~~**During the three and nine months ended September 30, 2023, we received net proceeds of**~~

~~**zero** and less than~~

~~**\$1**~~

~~**thousand, respectively, from the sale of**~~

~~**zero** and~~

~~**25** shares of common stock, respectively, pursuant to the AGP 2023 Sales Agreement.~~

~~During the three and nine months ended September 30, 2024, we received net proceeds of zero and \$0.1 million, respectively, from the sale of zero and 11,822 shares of common stock, respectively, pursuant to the AGP 2023 Sales Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">have approximately \$1.0 million of remaining availability pursuant to the 2024 Prospectus Supplement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Registered Direct~~

~~Offering~~

~~family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;'">~~

~~visibility:hidden;">~~

~~font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'~~

~~June 8, 2023, the Company, entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the "Registered Direct Offering"), an aggregate of: (i) 206,250 shares (the "Shares") of its common stock, \$0.01 par value (the "Common Stock"), at a price of \$9.00 per share, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 15,972 shares of Common Stock, at a price of \$8.98 per Pre-Funded Warrant. The Company reviewed the provisions of the Pre-Funded Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to~~

remeasurement on each balance sheet

The Pre-Funded Warrants are immediately exercisable, have an exercise price of \$0.02 per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. All of the Pre-Funded Warrants were exercised during the year ended December 31, 2023 and no Pre-Funded Warrants were outstanding as of September 30, 2024.

a concurrent private placement (the “Private Placement” and together with the Registered Direct Offering, the “Offering”), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, for no additional consideration, warrants (the “RDO Common Warrants” and, together with the

~~**Shares and the Pre-Funded Warrants, the “Securities”) to purchase up to 444,444 shares of Common Stock. The Company reviewed the provisions of the RDO Common Warrants to determine the balance sheet classification and concluded that these warrants are to be classified as equity and are not subject to remeasurement on each balance sheet date. The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of \$12.60 per share, and will expire December 12, 2028. The fair value of the RDO Common Warrants of approximately \$3.5 million at the date of issuance was estimated using the Black-Scholes model which used the following inputs: term of 5 years; risk free rate of 3.89%; volatility of 143%; and share price of \$9.00 per share based on the trading price of the Company’s common stock. The Company allocated \$1.3 million of the issuance proceeds to the RDO Common Warrants based on the relative fair value of the RDO Common Warrants, Common Stock and Pre-Funded Warrants issued in the Offering. A holder of Pre-Funded Warrants may not exercise the warrant if the holder,**~~

~~together with its affiliates, would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company.~~

~~*Registered Direct Offering resulted in gross proceeds to the Company of approximately \$2.0 million. The net proceeds to the Company from the Registered Direct Offering are approximately \$1.8 million, excluding any proceeds that may be received upon the cash exercise of the RDO Common Warrants, after deducting the financial advisor's fees and estimated offering expenses payable by the Company. The*~~

~~Company intends to use the net proceeds from the Registered Direct Offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments and others.~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'*~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'*~~

~~Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions. Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements (the "Lock-Up Agreements"), agreed not to sell or transfer any of the Company securities which they hold, subject to~~

~~certain exceptions, during the 90-day period following the closing of the Registered Direct Offering. The Purchase Agreement also requires the Company to use commercially reasonable efforts to file a registration statement with the SEC to register the resale by the Purchasers of the shares of Common Stock issuable upon exercise of the RDO Common Warrants within thirty (30) days of the date of the Purchase Agreement. The Company filed this registration statement on Form S-1 (File No. 333-273172), which was declared effective by the SEC on July 19, 2023.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;' June 7, 2023, the Company also entered into a financial advisory agreement (the “Financial Advisor Agreement”) with A.G.P./Alliance Global Partners (the “Financial Advisor”). Pursuant to the terms of the Financial Advisor Agreement, the Financial Advisor agreed to use its~~

~~reasonable best efforts to arrange for the sale of the Securities. The Company paid the Financial Advisor a cash fee of \$140,000 generated from the sale of the Shares and Pre-Funded Warrants.~~

~~*Financial Advisor Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Financial Advisor, including for liabilities under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties, and termination provisions.*~~

~~*Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'to the Purchase Agreement, the Company has agreed that, subject to certain exceptions, (i) it will not issue any shares of common stock or securities exercisable or convertible into shares of common stock or to file any registration statement or amendment or supplement thereto for a period of ninety (90) days following the closing of the*~~

~~*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;and that (ii) it will not enter into a variable rate transaction for a period of one hundred eighty (180) days following the closing of the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'*~~

~~*<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'Registered Direct Offering was made pursuant to the 2023 Registration*~~

~~Statement, as supplemented by a prospectus supplement dated June 9, 2023. As a result of sales already made through the AGP 2023 Sales Agreement and the Registered Direct Offering, the Company has \$3.7 million of remaining availability under the 2023 Registration Statement.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preferred Stock.</p><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company's Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors.</p><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;font-~~

~~*style:italic;margin:0pt 0pt 12pt 0pt;">Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock ("Series B Preferred Stock") with the State of Delaware, which designates 6,900 shares of our preferred stock as Series B Preferred Stock. The Series B Preferred Stock has a stated value of \$1 thousand per share and a par value of \$0.01 per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering consisting of the Company's Series B Preferred Stock and warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The conversion price of the Series B Preferred Stock contains a down round feature. The Company will recognize*~~

~~the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation.~~

~~There were no conversions of Series B Preferred Stock during the three and nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and December 31, 2023, the Company had 6,900 shares of Series B Preferred Stock designated and issued and 47 shares of Series B Preferred Stock outstanding. Based on the stated value of \$1 thousand per share and a conversion price of \$8.00 per share, the outstanding shares of Series B Preferred Stock at September 30, 2024 were convertible into 5,875 shares of common stock.~~

~~Common Stock Warrants.~~

~~align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following represents a summary of the warrants outstanding as of September 30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.69%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<del><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<del><p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:13.57%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:21.59%;margin:0pt;padding:0pt~~

~~</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;">

~~</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;~~~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.69%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:13.57%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.59%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Underlying</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Exercise</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.69%;margin:0pt;pada~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:13.57%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-~~
~~weight:bold;">Issue Year</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:21.59%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-~~

~~weight:bold;">Expiration</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:14.91%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Shares ~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:16.23%;border-~~
~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</p></td></tr><tr><td style="vertical-align:bottom;width:16.69%;background:#cc<<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrants</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#ccc<<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#c<<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr></table>~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.59%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding:0pt
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1)
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.69%;margin:0pt;padding:0pt~~

~~align:bottom;white-
space:nowrap;width:4.24%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:13.57%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt
0pt;">2023</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:4.24%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:21.59%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt
0pt;">December 2028</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:4.24%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
444,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
12.60</p></td></tr></table><div~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%,<div style="background-color:#000000;height:1pt;position:relative;transform:translate(-50%,0 0);"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1)These warrants were issued in connection with the 2023 registered direct offering and concurrent private placement and are the RDO common warrants discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">During the three and nine~~

~~months ended September 30, 2023, 5,593 and 13,012 warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2018.~~

~~During the three and nine months ended September 30, 2024, zero and 15,091 warrants expired, respectively. The warrants had been issued in connection with transactions that were completed in 2019.~~

~~RDO Common Warrants. In connection~~

~~with the Registered Direct Offering and concurrent private placement in June 2023, the Company issued 444,444 RDO Common Warrants to purchase up to 444,444 shares of Common Stock.~~

~~The RDO Common Warrants are exercisable beginning six months after the date of issuance, have an exercise price of \$12.60 per share, and will expire December 12, 2028.~~

150000000	150000000	250000000	12593	50186	100000	300000	0.01	22000000.0	50000000.0	0.030	0	500000	0	30827	15600000	500000	260128	0.030	5800000	1061478	0	1000	0	25	0	100000	0	11822	1000000.0	206250	0.01	9.00	15972	8.98	0.02	0	444444	P6M	12.60	3500000	5	0.0389	1.43	9.00	1300000	0.0499	0.0999	0.1999	P61D	2000000.0	1800000	P90D	P30D	140000	P90D	P180D	3700000	15000000	6900	1000	0.01	0	0	0	0	0	6900	6900	47	47	1000	8.00	5875

~~The following represents a summary of the warrants outstanding as of~~

~~September 30, 2024:~~

Times New Roman, Times, serif; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt; font-size: 1pt; visibility: hidden;	Times New Roman, Times, serif; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt; font-size: 1pt; visibility: hidden;

		

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;pad~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;pad~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">—</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt~~
~~0pt;">~~~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:21.59%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt~~
~~0pt;">~~~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:14.91%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~

Underlying	Exercise

Issue Year	Expiration

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Shares ~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Price~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:16.69%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i~~
~~style="font-style:italic;text-decoration-~~
~~color:#000000;text-decoration-~~
~~line:underline;text-decoration-~~
~~style:solid;">Warrants</i></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:4.24%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:13.57%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:4.24%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.59%;background:#c~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;background:#c~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:4.24%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.67%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:13.55%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:16.69%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1)~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:4.24%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.59%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.91%;margin:0pt;padding:444,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:444,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:444,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:444,444</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-~~

~~height:1.19em;position:relative;width:100%,
<div style="background-
color:#000000;height:1pt;position:relative;t
auto 0 0;"></div></div><p style="font-
family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;margin:0pt;"><span
style="display:inline-block;text-
align:left;text-indent:0pt;width:36pt;">
<span style="font-family:'Times New
Roman','Times','serif';font-size:10pt;font-
style:normal;font-weight:normal;">(1)
These warrants were
issued in connection with the 2023
registered direct offering and concurrent
private placement and are the RDO
common warrants discussed below.</p>
444444 12.60 5593 13012 0 15091 444444
444444 P6M 12.60 <p style="font-
family:'Times New
Roman','Times','serif';font-size:10pt;font-
weight:bold;margin:0pt 0pt 12pt 0pt;">
<span style="font-
weight:normal;">8. FAIR
VALUE</p><p style="font-family:'Times
New Roman','Times','serif';font-
size:10pt;text-align:justify;text-
indent:36pt;margin:0pt 0pt 12pt
0pt;">FASB guidance on fair value~~

~~measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.~~

~~FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:~~

~~Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;~~

~~Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and~~

~~liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and~~

~~Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.~~

~~Common Stock Warrant Liabilities.~~

~~Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated statements of operations.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">~~

~~Bridge Note Warrant Liabilities</p><p style="font-~~

~~family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During 2018 and 2019, the Company issued warrants in connection with the issuance of convertible notes. All of these warrants issuances were classified as warrant liabilities (the "Bridge Note Warrant Liabilities"). </p><p style="font-~~

~~family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black Scholes model. During the nine months ended September 30, 2024, the last remaining warrants related to Bridge Note Warrant Liabilities expired and thus at September 30, 2024 there were no warrant liabilities to be valued. As of December 31,~~

~~2023, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 0.4 years; volatility rate of 71% to 77%; and risk free rate of 5.33% to 5.40%. During the three and nine months ended September 30, 2024, the changes in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were zero. During the three and nine months ended September 30, 2023, the changes in the fair value of the warrant liabilities were less than \$1 thousand, respectively.~~

~~0~~	~~0.3~~	~~0.4~~	~~0.71~~	~~0.77~~	~~0.0533~~	~~0.0540~~	~~0~~	~~0~~	~~-1000~~	~~-1000~~

~~9. EQUITY INCENTIVE PLAN~~

~~*Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt; ">The Company currently issues stock awards under its 2017 Stock Option and Incentive Plan, as amended (the "2017 Plan") which will expire on June 5, 2027. The shares authorized for issuance under the 2017 Plan were 320,699 at September 30, 2024, of which 14,705 were available for future grant. The shares authorized under the 2017 Plan are subject to annual increases on January 1 by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares determined by the Company's Board of Directors or Compensation Committee. During the nine months ended September 30, 2024, the shares authorized for issuance increased by 71,006 shares.*~~

~~*</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; margin: 0pt 0pt 12pt 0pt; ">Stock Options.*~~

~~*</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt; ">The Company accounts for*~~

~~all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the condensed consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate.~~

~~During the nine months ended September 30, 2024, the Company granted stock options to~~

~~purchase up to 75,862 shares of common stock at a weighted average exercise price of \$4.99 per share. These awards have vesting periods of up to four years and had a weighted average grant date fair value of \$4.54. The fair value calculation of options granted during the nine months ended September 30, 2024 used the following assumptions: risk free interest rate of 3.94% to 4.26%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 133% to 139% based on historical volatility of the Company's common stock over a time that is consistent with the expected life of the option.~~

~~family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'~~

~~On August 30, 2024, the Company's board of directors (the "Board") approved a one-time stock option repricing (the "Option Repricing"), effective August 31, 2024 (the "Effective Date"). The repricing was undertaken in accordance with, and as permitted by the 2017 Plan. The Option Repricing applies to all Relevant Options (as defined below)~~

~~granted pursuant to the 2017 Plan that were held by employees, including executive officers and non-employee directors of the Board, to the extent such options had an exercise price in excess of~~
~~\$6.56, the closing price per share of the Company's Common Stock as reported on The Nasdaq Stock Market on August 30, 2024. "Relevant Options" means all outstanding eligible stock options granted to eligible employees, service providers and non-employee directors of the board of the Company before and including December 31, 2022. As of the Effective Date, all such options were repriced such that the exercise price per share was reduced to~~
~~\$6.56, provided that the original exercise price will apply to stock option exercises during a~~
~~one year retention period. Under the terms of the Option Repricing, if prior to the first anniversary of the~~

~~Effective Date (except following a change of control), a Relevant Option is exercised or employment/services are terminated by the Company with cause or voluntarily by the option holder, the option holder will be required to pay the original exercise price of the Relevant Option. If the employment/services of an option holder is terminated by the Company without cause prior to the first anniversary of the Effective Date, the option holder will retain the benefit of the reduced exercise price~~

~~The Option Repricing does not change the number of shares, the vesting schedule, or the expiration date of the Relevant Options.~~

~~Out of the Company's approximately 304,000 total~~

~~outstanding options on the Effective Date, approximately 177,000 were repriced. The Board approved the Option Repricing after careful consideration of various alternatives and the recommendation of the compensation committee of the Board that the repricing was fair, just, and reasonable to the Company and its stockholders.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'>~~
~~~~
~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'>~~
~~determined that the Option Repricing represents a modification of the impacted awards and calculated incremental compensation cost of approximately \$0.5 million resulting from the modification. The incremental expense will be recognized over 1.4 years.~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:justify;text-indent:36pt;background:#ffffff;margin:0pt;'

</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity under our plans during the nine months ended September 30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padd
<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.56%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.62%;margin:0pt;pad
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td></tr><tr><td
style="vertical-~~

~~align:bottom;width:72.21%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.05%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.48%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-~~
~~weight:bold;">Number of</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.06%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td colspan="2"~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:13.18%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Weighted-Average</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Options</p></td></tr></table>~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;background:#cc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">232,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">46.56</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.21%;margin:0pt;pada~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">75,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:11.62%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
4.99</p></td></tr><tr><td
style="vertical-
align:bottom;width:72.21%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
6pt;">Forfeited</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.05%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:10.48%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(5,173)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;background:#ccc
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#ccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#ccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18.26</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~~~303,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
7.19</p></td></tr><tr><td
style="vertical-
align:bottom;width:72.21%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Exercisable at
September 30, 2024</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.05%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:10.48%;background:#cc
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
187,554</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cccccc;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cccccc;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.52</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt~~

~~Opt 12pt 0pt;">As of September 30, 2024, there were 274,463 options that were vested or expected to vest with aggregate intrinsic value of \$0.1 million and a remaining weighted average contractual life of 6.8 years.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt~~

~~Opt;">Restricted Stock Awards.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt~~

~~Opt 12pt 0pt;">Restricted stock awards are subject to vesting restrictions. If a~~

~~grantee's service with the Company is terminated prior to vesting of the~~

~~restricted stock, all unvested shares shall be forfeited and returned to the Company.~~

~~Upon vesting, the restricted stock award shall no longer be deemed restricted.~~

~~</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt~~

~~Opt 12pt 0pt;">As of September 30, 2024, there were 2,492 and zero restricted stock~~

~~awards that were vested and unvested, respectively.~~

~~</p><p style="font-family:'Times New~~

~~*Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt; ">There were no restricted stock awards granted during the three and nine months ended September 30, 2024. There were 2,492 restricted stock awards granted during the three and nine months ended September 30, 2023, respectively.*~~

~~*</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 0pt; margin: 0pt 0pt 12pt 0pt; "><i style="font-style: italic; ">Stock Compensation.</i></p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt; ">For the three and nine months ended September 30, 2024, we recorded non-cash stock-based compensation expense for all stock awards of \$0.4 million and \$1.1 million, respectively, within operating expense in the accompanying statements of operations.For the three and nine months ended September 30, 2023, we recorded non-cash stock-based compensation expense for all stock awards of<span*~~

~~\$0.4 million and \$1.2 million, respectively, within operating expense in the accompanying statements of operations.~~ As of September 30, 2024, the unrecognized compensation expense related to unvested stock awards and the Option repricing was \$1.9 million, which is expected to be recognized over a weighted-average period of 1.7 years.

~~2027-06-05 320699 14705 0.05 71006
75862 4.99 4.99 P4Y 4.54 0.0394 0.0426
P6Y 1.33 1.39 6.56 6.56 P1Y 304000
177000 500000 P1Y4M24D~~

~~The following table summarizes stock option activity under our plans during the nine months ended September 30, 2024:

--	~~

~~style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr></table>~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.56%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;height:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td></tr></table>~~

~~align:bottom;white-
space:nowrap;width:10.48%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-
weight:bold;">Number of</p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td colspan="2"
style="vertical-align:bottom;white-
space:nowrap;width:13.18%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Weighted-
Average</p></td></tr><tr><td
style="vertical-
align:bottom;width:72.21%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:8pt;visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2.05%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.48%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Options~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:8pt;visibility:hidden;"></p>~~
~~</td><td colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:13.18%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~

~~**Roman', 'Times', 'serif'; font-size: 8pt; text-align: center; margin: 0pt 0pt 0.05pt 0pt; ">**~~
~~**<b style="font-weight: bold;">Exercise Price</p>**~~
~~**</td></tr><tr><td style="vertical-align: bottom; width: 72.21%; background: #ccc**~~
~~**<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt;">Outstanding at January 1, 2024</p>**~~
~~**</td><td style="vertical-align: bottom; white-space: nowrap; width: 2.05%; background: #ccc**~~
~~**<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt;">**~~
~~**</p></td><td style="vertical-align: bottom; white-space: nowrap; width: 10.48%; background: #ccc**~~
~~**<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-align: right; margin: 0pt 3pt 0.05pt 0pt;">**~~
~~**232,744</p></td><td style="vertical-align: bottom; white-space: nowrap; width: 2.06%; background: #ccc**~~
~~**<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin: 0pt 0pt 0.05pt 0pt;">**~~
~~****~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#c~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">46.56</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
75,862</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.56%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.62%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
4.99</p></td></tr><tr><td
style="vertical-
align:bottom;width:72.21%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
6pt;">Forfeited</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.05%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~~~(5,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cccccc">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cccccc">~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
18.26</p></td></tr><tr><td
style="vertical-
align:bottom;width:72.21%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Outstanding at
September 30, 2024</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.05%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:10.48%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
303,433</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.19</p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;background:#cc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at September 30, 2024</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.05%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.48%;background:#c~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~187,554</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.56%;background:#ccc~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:11.62%;background:#c~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~7.52</p></td></tr></table> 232744 46.56~~
~~75862 4.99 5173 18.26 303433 7.19~~
~~187554 7.52 274463 100000 P6Y9M18D~~
~~2492 0 0 0 2492 2492 400000 1100000~~
~~400000 1200000 1900000 P1Y8M12D<p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;font-~~
~~weight:bold;margin:0pt 0pt 12pt 0pt;">10.~~
~~SALES SERVICE REVENUE, NET AND~~
~~ACCOUNTS RECEIVABLE</p><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;font-~~
~~style:italic;margin:0pt 0pt 12pt 0pt;"><i~~
~~style="text-decoration-color:#000000;text-~~
~~decoration-line:underline;text-decoration-~~
~~style:solid;">ASC Topic 606, "Revenue from~~
~~contracts with customers"</i></p><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:justify;text-~~
~~indent:36pt;margin:0pt;">The Company~~
~~follows the guidance of ASC 606 for the~~
~~recognition of revenue from contracts with~~

~~customers to transfer goods and services. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model:~~

~~</p><p style="font-family:'EYInterstate';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Step 1:~~

~~Identification of the contract with the customer. Sub-steps include determining the customer in a contract, initial contract identification and determining if multiple contracts should be combined and accounted for as a single transaction.~~

~~Step 2: Identify the performance obligation in the contract.~~

~~Sub-steps include identifying the promised goods and services in the contract and~~

~~identifying which performance obligations within the contract are distinct.~~

~~Step 3: Determine the transaction price. Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer.~~

~~Step 4: Allocate transaction price. Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer.~~

~~Step 5:~~

~~*Satisfaction of performance obligations. Sub-steps include ascertaining the point in time when an asset is transferred to the customer and when the customer obtains control of the asset upon which time the Company recognizes revenue.*~~

~~*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Nature of Contracts and Customers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The Company's contracts and related performance obligations are similar for its customers and the sales process for all customers starts upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research. Payment terms for the services provided are 30 days, unless separately negotiated.</p><p*~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Diagnostic testing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient's laboratory report, per the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt;"></p></del>*~~

~~*indent:22.3pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Clinical research grants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.3pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Control of the clinical research services are transferred to the customer over time. The Company will recognize revenue utilizing the “effort based” method, measuring its progress toward complete satisfaction of the performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Biomarker testing and*~~

clinical project services

Control of the biomarker testing and clinical project services are transferred to the customer over time. The Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results.

The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers

and clinical research grants funded by both bio-pharma customers and government health programs.

Reagents and other diagnostic products

Control of reagents and other diagnostic products are transferred to the customer at a point in time and, as such, the Company recognizes these revenues at a point in time based on the delivery method. These revenues include revenues from reagent sets for our HSRR program and other product sales and are included in product revenue in our condensed consolidated statements of operations.

Disaggregation of Revenues by Transaction Type

~~0pt 12pt 0pt;">We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Service revenue, net for the three and nine months ended September 30, 2024 and 2023 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<del><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:3.39%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.64%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

For the Three Months Ended September 30,

(dollars in thousands)

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Diagnostic Testing</p>~~
~~</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding:~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">~~
~~</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:3.39%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;"></p>
</td><td colspan="2" style="vertical-
align:bottom;white-
space:nowrap;width:11.78%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td></tr><tr><td style="vertical-
align:bottom;width:69.62%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Medicaid</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:3.39%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~8</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~10~~

~~Medicare~~	<del></del>
<del></del>	~~1,819~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,691</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-~~
~~pay</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~39~~

~~Third party payers~~	~~2,743~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,998</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Contract diagnostics and other</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.14%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.64%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
28</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:3.39%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.14%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt"~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,738</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="5" style="vertical-align:bottom;width:26.97%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">For the Nine Months Ended September 30, </p>~~
~~</td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">~~
~~(dollars in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Diagnostic Testing</p>~~

~~</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td></tr></table>~~

~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">—</p>
</td><td colspan="2" style="vertical-
align:bottom;white-
space:nowrap;width:11.78%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td></tr><tr><td style="vertical-
align:bottom;width:69.62%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Medicaid</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:3.39%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.14%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~3,736</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-~~
~~pay</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">155</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~6,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
4,661</p></td></tr><tr><td
style="vertical-
align:bottom;width:69.62%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Contract diagnostics and other</p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:3.39%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.14%;background:#ccc
bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:9.64%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:69.62%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Service revenue, net</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
11,329</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:3.39%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.14%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.64%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
8,574</p></td></tr></table><p~~

~~*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">

</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue from the Medicare and Medicaid programs account for a portion of the Company's patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity*~~

~~*expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. The Company derives its revenues from the following types of transactions: diagnostic testing ("Diagnostic"), revenues from the Company's ICP technology and bio-pharma projects encompassing genetic diagnostics (collectively "Biomarker"),*~~
~~*revenues from clinical research grants from state and federal research programs and diagnostic product sales, including revenues from equipment leases and reagent sales associated with our HSRR program.*~~

~~*Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; text-indent: 36pt; margin: 0pt 0pt 12pt*~~

Deferred revenue

Deferred revenue, refers to advance payments for products or services that are to be delivered in the future. The Company records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or services that are owed to a customer. As the product or service is delivered over time, the Company recognizes the appropriate amount of revenue from deferred revenue. For the periods ended September 30, 2024 and December 31, 2023, the deferred revenue was \$0.3 million and \$0.1 million, respectively.

Contractual Allowances and Adjustments

We are reimbursed by

~~payers for services we provide. Payments for services covered by payers average less than billed charges. We monitor revenue and receivables from payers and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payers. Accordingly, the total revenue and receivables reported in our condensed consolidated financial statements are recorded at the amounts expected to be received from these payers. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts~~. The following table presents our revenues initially recognized for each associated payer class

~~during the three and nine months ended
September 30, 2024 and 2023~~.

~~<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;min-
height:0.0pt;margin:0pt;"><span
style="font-size:0pt;visibility:hidden;">
</p><table style="border-
collapse:collapse;font-
size:16pt;height:max-content;padding-
left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;"><td
style="vertical-
align:bottom;width:37.99%;margin:0pt;pada
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.28%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:37.99%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="17"~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:60.35%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">For the Three~~
~~Months Ended September 30, </p>~~
~~</td></tr><tr><td style="vertical-~~
~~align:bottom;width:37.99%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">~~
~~(dollars in thousands)</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:16.67%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Contractual Allowances and
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Revenues, net of Contractual~~

<p style="font-family:'Times New Roman','Times','serif'; font-size:10pt; margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom; white-space:nowrap; width:1.64%; margin:0pt; padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif'; font-size:10pt; margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom; white-space:nowrap; width:16.67%; border-bottom:1px solid #000000; margin:0pt; padding:0pt;"><p style="font-family:'Times New Roman','Times','serif'; font-size:8pt; text-align:center; margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">Gross Revenues</p></td><td style="vertical-align:bottom; white-space:nowrap; width:1.64%; margin:0pt; padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif'; font-size:10pt; margin:0pt 0pt 0.05pt 0pt;"> </p></td>

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">adjustments</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~<b style="font-weight:bold;">Allowances and adjustments</del>~~

~~</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr></table>~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">—</p>~~
~~</td><td colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.16%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2023~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:37.99%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Medicaid</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.89%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,819</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.28%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,691</p></td></tr><tr><td
style="vertical-
align:bottom;width:37.99%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:6.16%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~39</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.71%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~39</p></td></tr><tr><td style="vertical-~~

~~align:bottom;width:37.99%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Third party payers</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:6.79%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~9,356</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(6,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;paddi
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(4,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,998</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract diagnostics and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.7%;background:#cccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.29%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
11,212</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:6.16%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~8,698</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(6,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(4,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,738</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:6.79%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
681</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:6.16%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~831~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ <del></del> <del></del> ~~</p>~~ ~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc~~ ~~bottom:1px solid~~ ~~#000000;margin:0pt;padding:0pt;">~~ ~~<p~~ ~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~ ~~0pt;">~~ ~~</p>~~ ~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc~~ ~~bottom:1px solid~~ ~~#000000;margin:0pt;padding:0pt;">~~ ~~<p~~ ~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~ ~~</p>~~ ~~</td>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
831</p></td></tr><tr><td
style="vertical-
align:bottom;width:37.99%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~9,529~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double~~	
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~	
~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double~~	
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~	
~~(6,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(4,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
4,569</p></td></tr></table><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:justify;text-indent:36pt;margin:0pt;">
<span style="margin-
bottom:12pt;visibility:hidden;">
</p><table style="border-
collapse:collapse;font-
size:16pt;height:max-content;padding-
left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;"><td
style="vertical-
align:bottom;width:37.35%;margin:0pt;pada
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:7.71%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.01%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.89%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.28%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td></tr><tr><td
style="vertical-
align:bottom;width:37.35%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span style="font-
size:8pt;font-
weight:bold;visibility:hidden;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~
~~</p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30,~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.3%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Allowances and<~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~

[illegible]

~~align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allowances and adjustments</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;"><b style="font-
weight:bold;">2024</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt;"><b style="font-
weight:bold;">—</p></td><td
colspan="2" style="vertical-
align:bottom;white-
space:nowrap;width:7.83%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;"><b style="font-
weight:bold;">2023</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt;"><b style="font-
weight:bold;">—</p></td><td
colspan="2" style="vertical-
align:bottom;white-~~

[illegible]

~~align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr>~~
~~<tr><td style="vertical-align:bottom;width:37.35%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicaid</p></td>~~
~~<td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:6.79%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~33</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-***~~

~~align:right;margin:0pt 3pt 0pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.35%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
4,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-***~~

~~align:right;margin:0pt 3pt 0pt 0pt;">3,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,736</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.7%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.89%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~33</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~</p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~155</p></td></tr><tr><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:37.35%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~Third party
~~payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~<span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
23,285</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
16,233</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,489)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,572)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~4,661</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:37.35%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">Contract~~
~~diagnostics</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
32</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc
bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc
bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cccccc;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cccccc;border-bottom:1px solid black;color:#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New***~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:0pt 3pt 0pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~27,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;">~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"> (16,489)</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"> (11,574)</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~11,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~

~~8,574~~

~~style="vertical-align:bottom;width:37.35%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~ <del></del> <del></del> ~~</p>~~
~~</td>~~ ~~<td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc~~ ~~bottom:1px solid #000000;margin:0pt;padding:0pt;">~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~	~~</p>~~ ~~</td>~~ ~~<td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc~~ ~~bottom:1px solid #000000;margin:0pt;padding:0pt;">~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~ ~~1,936~~
~~</td>~~ ~~<td style="vertical-align:bottom;white-~~	

~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:6.79%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~2,469</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.26%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.71%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.01%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.7%;background:#cccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.89%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~1,936</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.06%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.28%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.88%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
2,469</p></td></tr><tr><td
style="vertical-
align:bottom;width:37.35%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
29,754</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.03%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
22,617</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.26%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,489)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,574)</p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,043</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Allowance for Credit Losses</p><p style="font-family:'Times~~

The Company provides for a general allowance for collectability of services when recording net sales. The Company has adopted the policy of recognizing net sales to the extent it expects to collect that amount. Reference is made to FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Credit Loss, and the Allowance for Credit Losses. The change in the allowance for credit losses is directly related to the increase in patient service revenues. The following table presents our reported revenues net of the collection allowance and adjustments for the three and nine months ended September 30, 2024 and 2023.

~~style="vertical-align:bottom; width:33.49%; margin:0pt; padding:0pt;"~~

~~<div style="height:1pt; overflow:hidden; overflow-wrap:break-word; position:relative;"><div style="bottom:0pt; position:absolute; width:100%; height:1pt;"><p style="font-family:'Times New Roman','Times','serif'; font-size:10pt; margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom; white-space:nowrap; width:1.98%; margin:0pt; padding:0pt;"><div style="height:1pt; overflow:hidden; overflow-wrap:break-word; position:relative;"><div style="bottom:0pt; position:absolute; width:100%; height:1pt;"><p style="font-family:'Times New Roman','Times','serif'; font-size:10pt; margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom; white-space:nowrap; width:1.25%; margin:0pt; padding:0pt;"><div style="height:1pt; overflow:hidden; overflow-wrap:break-word; position:relative;"><div style="bottom:0pt; position:absolute; width:100%; height:1pt;"><p style="font-family:'Times New Roman','Times','serif'; font-size:10pt; margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr></table>~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="17"~~
~~style="vertical-align:bottom;white-space:nowrap;width:64.51%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">For the Three Months Ended September 30, </p>~~
~~</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.98%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-
align:bottom;white-
space:nowrap;width:20.17%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Revenues,
net of</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-
align:bottom;white-
space:nowrap;width:20.17%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.21%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;"></p>
</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(dollars in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Contractual Allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Allowances for credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.21%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;"></p>
</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~***style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">***~~

~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-~~

~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd.~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">—</p>~~
~~</td><td colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.09%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2023~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd.~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">—</p>~~

2024	2023
2023	

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~10</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~

~~(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~

~~(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6</p></td></tr><tr><td style="vertical-~~

~~align:bottom;width:33.49%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Medicare</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,819</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,671</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~39</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">36</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
2,743</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,998</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(41)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~

~~(24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,974</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract diagnostics and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
28</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
4,599</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
3,738</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(71)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(51)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,528</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,687</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
681</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
831</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~681</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">831</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
5,280</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(71)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(51)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~5,209</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;border-~~
~~bottom:3px double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,518</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.88%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="17"~~
~~style="vertical-align:bottom;white-space:nowrap;width:64.51%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">For the Nine Months Ended September 30, </p>~~
~~</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~

[illegible]

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.21%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;"> </p>~~
~~</td></tr><tr><td style="vertical-~~
~~align:bottom;width:33.49%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">(dollars in~~
~~thousands)</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.17%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Contractual~~
~~Allowances</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.17%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Allowances~~
~~for credit</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.21%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;"></p>
</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">and adjustments</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.17%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">losses~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.21%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Total~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">—</p>~~
~~</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding~~

2022	2023
2024	

	
2023	
	

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">—</p>
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~22</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(12)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,435</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~3,693</p></td></tr><tr><td~~
~~style="vertical-align:bottom;width:33.49%;background:#cc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
155</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(3)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(15)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~30</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.88%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~140~~

~~style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;"~~ ~~Third party payers~~	~~style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"~~ <del></del>	~~style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"~~ <del></del>	~~style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"~~ ~~6,796~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
4,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(102)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(107)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
6,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,554</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:33.49%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Contract diagnostics and other</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.98%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
32</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~11,329~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~	
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~	
~~8,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~	
<del></del>	
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~	

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(175)</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
11,146</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,399</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,936</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.88%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
2,469</p></td></tr><tr><td
style="vertical-
align:bottom;width:33.49%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.98%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
13,082</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,868</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs to Obtain or Fulfill a Customer Contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales commissions are expensed when incurred because the amortization period would have been~~

~~one year or less. These costs are recorded in operating expenses in the condensed consolidated statements of operations.~~

~~Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the condensed consolidated statements of operations.~~

~~Accounts Receivable~~

~~The Company has provided an allowance for potential credit losses, which has been determined based on management's industry experience. The Company grants credit without collateral to its patients, most of who are insured under~~

~~third party payer agreements.~~

~~The following summarizes the mix of receivables outstanding related to payer categories:~~

~~The following summarizes the mix of receivables outstanding related to payer categories:~~	~~The following summarizes the mix of receivables outstanding related to payer categories:~~

~~space:nowrap;width:1.63%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.47%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.31%;margin:0pt;pad~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;pad~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.6%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt;"><b style="font-~~
~~weight:bold;">(dollars in thousands)~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.63%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt;"><span style="font-~~
~~family:'Calibri','Helvetica','sans-~~
~~serif';"></p></td><td~~
~~colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:13.78%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt;"><b style="font-~~

~~weight:bold;">September 30, 2024~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">~~~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">~~~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">~~~~<b style="font-weight:bold;">December 31, 2023~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicaid</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~</p>~~
~~</td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.47%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:12.31%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~10</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.52%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:11.79%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~25</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:69.6%;margin:0pt;paddi~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicare</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:11.79%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~1,561</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.6%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">Self-pay</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.63%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.47%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:12.31%;background:#c~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">229</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.63%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.47%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:12.31%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~1,508</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
1,641</p></td></tr><tr><td
style="vertical-align:bottom;width:69.6%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract diagnostic services, product and other</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cccccc;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">417</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;margin:0pt;paddi~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,873</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;background:#cccccc;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less allowance for credit losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cccccc;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cccccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#ccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#ccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,572)</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0pt 0pt;">1,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,301</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the roll-forward of the allowance for credit losses for the nine months ended September 30, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New~~

~~Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~

~~</div></div></td></tr><tr><td
style="vertical-
align:bottom;width:73.79%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span style="font-
size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt;"><b style="font-
weight:bold;">—</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.59%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span style="font-
size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.22%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt;"><span
style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allowance for</p></td>
</tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Credit</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~~~~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~~~~~</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,572)</p>
</td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for credit losses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr>~~
~~<tr><td style="vertical-align:bottom;width:73.79%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicaid</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicare</p></td>~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.59%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"> (66)</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.48%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">~~~~</p></td></tr>~~
~~<tr><td style="vertical-align:bottom;width:73.79%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Self-pay</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3)</p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p>~~
~~</td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:9.22%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"></p></td></tr>
<tr><td style="vertical-
align:bottom;width:73.79%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.33%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.59%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:9.22%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt;">(183)</p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:2.33%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.48%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:9.22%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"></p></td></tr>
<tr><td style="vertical-
align:bottom;width:73.79%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">Credit loss
expense</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td***~~

~~style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">~~~~</p></td></tr>~~
~~<tr><td style="vertical-align:bottom;width:73.79%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total charges</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">~~~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.48%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:9.22%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"> (183)</p></td>~~
~~</tr><tr><td style="vertical-~~
~~align:bottom;width:73.79%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">Balance,~~
~~September 30, 2024</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,755)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Customer Revenue and Accounts Receivable Concentration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our customers are oncologists, hospitals, reference laboratories, physician-office laboratories, and pharma and biotech companies. Customers that accounted for 10% or greater of our net sales or accounts receivable for the identified periods is as~~

~~follows:~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">~~

~~</p>~~

~~<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;">~~

~~<tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;pad~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td></tr><tr><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="3" style="vertical-align:bottom;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Net sales~~
~~</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~

~~align:bottom;width:1.41%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="3" style="vertical-align:bottom;width:19.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Net sales~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~weight:bold;visibility:hidden;">
</p></td><td colspan="3" style="vertical-align:bottom;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts receivable, as of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;pad<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;pad<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td colspan="3" style="vertical-align:bottom;width:19.15%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">

</p></td><td colspan="3" style="vertical-align:bottom;width:19.44%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Nine Months Ended </p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="3" style="vertical-~~
~~align:bottom;width:25.13%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td></tr><tr><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:23.09%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.68%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-
align:bottom;width:19.15%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September
30,</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.54%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.41%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-
align:bottom;width:19.44%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September
30,</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.55%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:11.77%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">September~~
~~30,</p></td><td style="vertical-~~
~~align:bottom;width:2.42%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.94%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">December 31,~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd.<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padd.<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.54%;margin:0pt;padd.
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-
align:bottom;white-
space:nowrap;width:23.09%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.68%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.41%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cc~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.41%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.23%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt
0pt;">13</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.54%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">%
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.41%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.51%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd~~

~~align:bottom;white-
space:nowrap;width:11.77%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:10.94%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.54%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-
align:bottom;white-
space:nowrap;width:23.09%;background:#c<
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.54%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.41%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.51%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.41%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.52%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0pt 0.05pt 6pt;">Customer C</td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">%
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">%
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
</p></td></tr></table>~~

~~align:bottom;white-
space:nowrap;width:23.09%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
6pt;">Customer D</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.68%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.51%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.41%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.23%;background:#ccc
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc~~

~~align:bottom;white-
space:nowrap;width:8.52%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.55%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.77%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.55%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.77%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

space:nowrap;width:10.94%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cccccc"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">* represents less than 10%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cccccc"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cccccc"> <p style="font-family:'Times New

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">~~
~~~~
~~</p> 1 1 1 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">~~
~~</p>~~
~~<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;">~~
~~<tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;pada~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;width:26.97%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">For the Three~~
~~Months Ended September 30, </p>~~
~~</td></tr><tr><td style="vertical-~~
~~align:bottom;width:69.62%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">~~
~~(dollars in thousands)</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~

~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Diagnostic Testing</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">1,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,691</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">39</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
2,743</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:3.39%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,998</p></td></tr><tr><td
style="vertical-
align:bottom;width:69.62%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Contract diagnostics and other</p>
</td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~28</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.14%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:9.64%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td></tr><tr><td style="vertical-
align:bottom;width:69.62%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Service revenue, net</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:3.39%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,738</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<del><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd
<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.62%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td colspan="5" style="vertical-align:bottom;width:26.97%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">For the Nine
Months Ended September 30, </p>
</td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">
(dollars in thousands)</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.97%;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Diagnostic Testing</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.62%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

	2024
Medicaid	

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~3,736</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">155</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">6,796</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:3.39%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,661</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:69.62%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Contract diagnostics and other</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.64%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~32</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:3.39%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.14%;background:#ccc~~
~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cccccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-~~

~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~8,574</p></td></tr></table><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:justify;text-indent:36pt;margin:0pt;">~~
~~<span style="margin-~~
~~bottom:12pt;visibility:hidden;">~~
~~</p> 8000 10000 1819000 1691000 1000~~
~~39000 2743000 1998000 28000 4599000~~
~~3738000 33000 22000 4435000 3736000~~
~~33000 155000 6796000 4661000 32000~~
~~11329000 8574000 300000 100000 <p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;min-~~
~~height:0.0pt;margin:0pt;"><span~~
~~style="font-size:0pt;visibility:hidden;">~~
~~</p><table style="border-~~
~~collapse:collapse;font-~~
~~size:16pt;height:max-content;padding-~~
~~left:0pt;padding-right:0pt;width:100%;">~~
~~<tr style="height:1pt;"><td~~
~~style="vertical-~~
~~align:bottom;width:37.99%;margin:0pt;pada~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.01%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.7%;margin:0pt;paddi
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd.~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;margin:0pt;padd.~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd
<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td colspan="17"
style="vertical-align:bottom;white-
space:nowrap;width:60.35%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">For the Three
Months Ended September 30, </p>
</td></tr><tr><td style="vertical-
align:bottom;width:37.99%;margin:0pt;pada
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">
(dollars in thousands)</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Contractual Allowances and
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Revenues, net of Contractual~~
~~</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">adjustments</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.42%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-~~
~~weight:bold;">Allowances and adjustments<~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:37.99%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~

2024	2023

~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
8</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:6.16%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~10</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ $\$$ ~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~***align:right;margin:0pt 3pt 0.05pt 0pt;">1,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">***~~
~~***</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">***~~
~~***</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">***~~
~~***</p></td><td style="vertical-align:bottom;white-***~~

~~space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~

~~(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,691</p></td></tr><tr><td~~
~~style="vertical-align:bottom;width:37.99%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">~~~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:6.79%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:6.16%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
39</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.71%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:7.7%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.89%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
39</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.99%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,956</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(6,613)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

(4,958)	2,743

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
1,998</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;background:#cc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract diagnostics and other</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p~~

~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.01%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.7%;background:#cccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.29%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.89%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
28</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.99%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~11,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(6,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.7%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(4,960)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.29%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.89%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
4,599</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.28%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
3,738</p></td></tr><tr><td
style="vertical-
align:bottom;width:37.99%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Product</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.64%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.03%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:6.16%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
831</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.26%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">831</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;pada<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(6,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(4,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,569</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;">~~

~~<tr style="height:1pt;"><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.89%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:37.35%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="17"~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:60.99%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~

For the Nine Months Ended September 30,				
(dollars in thousands)				
				
				

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Allowances and</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenues, net of Contractual</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.35%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~

~~weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">adjustments</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allowances and adjustments
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.35%;margin:0pt;padd
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;"><b style="font-
weight:bold;">2023</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt;"><b style="font-
weight:bold;">—</p></td><td
colspan="2" style="vertical-
align:bottom;white-
space:nowrap;width:8.98%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;"><b style="font-
weight:bold;">2024</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:2.01%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt;"><b style="font-
weight:bold;">—</p></td><td
colspan="2" style="vertical-
align:bottom;white-~~

~~space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~

~~align:bottom;white-
space:nowrap;width:9.16%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;"><b style="font-
weight:bold;">2023</p></td></tr>
<tr><td style="vertical-
align:bottom;width:37.35%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">Medicaid</p></td>
<td style="vertical-align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0pt 0pt;">
33</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
22</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.26%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.88%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~22</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:37.35%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">Medicare</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~4,435</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;">(2)</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.29%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.89%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
4,435</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.28%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
3,736</p></td></tr><tr><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:37.35%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Self-pay</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~16,233</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.26%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.71%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"> (16,489)</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:2.01%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.7%;margin:0pt;paddi~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"> (11,572)</p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~6,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~4,661</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.35%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract~~

~~diagnostics~~

	</p>	32	

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.71%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.01%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.7%;background:#cccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.29%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.89%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~32</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.06%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>***~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~
~~27,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~

~~20,148~~

~~<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~ <del></del> <del></del> ~~</p>~~	~~<td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~ ~~</p>~~ ~~</td>~~ ~~<td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">~~ ~~(16,489)~~ ~~</p>~~ ~~</td>~~ ~~<td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~ <del></del> <del></del> ~~</p>~~ ~~</td>~~ ~~<td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~ ~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(11,574)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt 0pt 0pt 0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,574</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
1,936</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.03%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:6.79%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
2,469</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.26%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.71%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2.01%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:7.7%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.29%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.89%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
1,936</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.06%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.28%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.88%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~2,469</p></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:37.35%;margin:0pt;pada~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.03%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~
~~style="vertical-align:bottom;white-~~

~~space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,617</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.26%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.71%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;">(16,489)</p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.01%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:7.7%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;">(11,574)</p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.29%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">\$</p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">~~

~~11,043~~

~~8000~~	~~10000~~

~~8000 10000 1819000 1693000 2000~~

~~1819000 1691000 1000 39000 1000 39000~~

~~9356000 6956000 6613000 4958000~~

~~2743000 1998000 28000 28000 11212000~~

~~8698000 6613000 4960000 4599000~~

~~3738000 681000 831000 681000 831000~~

~~11893000 9529000 6613000 4960000~~

~~5280000 4569000 33000 22000 33000~~

~~22000 4435000 3738000 2000 4435000~~

~~3736000 33000 155000 33000 155000~~

~~23285000 16233000 16489000 11572000~~

~~6796000 4661000 32000 32000 27818000~~

~~20148000 16489000 11574000 11329000~~

~~8574000 1936000 2469000 1936000~~

~~2469000 29754000 22617000 16489000~~

~~11574000 13265000 11043000~~

~~</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>~~

~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="17"~~
~~style="vertical-align:bottom;white-space:nowrap;width:64.51%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">For the Three Months Ended September 30, </p>~~
~~</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Revenues, net of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.21%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;"></p>~~
~~</td></tr><tr><td style="vertical-~~
~~align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;">(dollars in~~
~~thousands)</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:20.17%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Contractual~~
~~Allowances</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.17%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Allowances~~
~~for credit</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~

~~align:bottom;white-
space:nowrap;width:20.21%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;"></p>
</td></tr><tr><td style="vertical-
align:bottom;width:33.49%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.98%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-
align:bottom;white-
space:nowrap;width:20.17%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~<b style="font-weight:bold;">and
adjustments</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-
align:bottom;white-
space:nowrap;width:20.17%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">losses
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td colspan="5" style="vertical-
align:bottom;white-
space:nowrap;width:20.21%;border-~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Total
</p></td></tr><tr><td style="vertical-
align:bottom;width:33.49%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-
weight:bold;visibility:hidden;">
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.98%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b
style="font-weight:bold;">—</p>
</td><td colspan="2" style="vertical-
align:bottom;white-
space:nowrap;width:9.09%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">~~
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-~~

~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd.~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b~~
~~style="font-weight:bold;"></p>~~
~~</td><td colspan="2" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.13%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2023~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:33.49%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Medicaid</p></td><td~~
~~style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.98%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~8</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ $\$$ ~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,691</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~

~~(27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,671</p></td></tr><tr><td~~

~~style="vertical-align:bottom;width:33.49%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~39</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(3)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">36</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt;">Third party payers</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,743</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,998</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~2,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~1,974</p></td></tr><tr><td~~
~~style="vertical-align:bottom;width:33.49%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">Contract diagnostics and other</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
28</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.88%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~3,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(71)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~***align:right;margin:0pt 0pt 0.05pt 0pt;">***~~
~~***(51)</p></td><td style="vertical-***~~
~~***align:bottom;white-***~~
~~***space:nowrap;width:1.97%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New***~~
~~***Roman','Times','serif';font-***~~
~~***size:10pt;margin:0pt 0pt 0.05pt 0pt;">***~~
~~******~~
~~***</p></td><td style="vertical-***~~
~~***align:bottom;white-***~~
~~***space:nowrap;width:1.25%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New***~~
~~***Roman','Times','serif';font-***~~
~~***size:10pt;margin:0pt 0pt 0.05pt***~~
~~***0pt;"> </p></td><td style="vertical-***~~
~~***align:bottom;white-***~~
~~***space:nowrap;width:7.84%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New***~~
~~***Roman','Times','serif';font-size:10pt;text-***~~
~~***align:right;margin:0pt 3pt 0.05pt 0pt;">***~~
~~***4,528</p></td><td style="vertical-***~~
~~***align:bottom;white-***~~
~~***space:nowrap;width:1.97%;margin:0pt;padd***~~
~~***<p style="font-family:'Times New***~~
~~***Roman','Times','serif';font-***~~
~~***size:10pt;margin:0pt 0pt 0.05pt 0pt;">***~~
~~******~~
~~***</p></td><td style="vertical-***~~
~~***align:bottom;white-***~~

space:nowrap;width:1.25%;margin:0pt;padd <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,687</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.98%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
681</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">831</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(71)</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(51)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,518</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<div~~

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.88%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td></tr><tr><td~~
~~style="vertical-~~
~~align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td colspan="17"
style="vertical-align:bottom;white-space:nowrap;width:64.51%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">For the Nine Months Ended September 30, </p>
</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="5" style="vertical-align:bottom;white-~~

~~space:nowrap;width:20.17%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Revenues,~~
~~net of</p></td><td style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="5" style="vertical-align:bottom;white-~~
~~space:nowrap;width:20.17%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~

(dollars in thousands)

Contractual Allowances

~~style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Allowances for credit</p></td><td~~
~~style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.21%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;"></p>~~

~~</td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and adjustments</p></td></tr></table>~~

~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.17%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">losses~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="5" style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:20.21%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Total~~

~~</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~<b style="font-weight:bold;">—</p>
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2023
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">—</p>
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

2022	2023
2024	

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Medicaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
33</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(10)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;">\$</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~21~~

~~vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ <del></del> <del></del> ~~</p>~~	~~vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ ~~\$~~ ~~</p>~~	~~vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~ ~~12~~		
		~~</td></tr><tr>~~ <td>~~vertical-align:bottom;width:33.49%;margin:0pt;padding~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~Medicare~~</p>~~</td> <td>~~vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-~~</td>	~~vertical-align:bottom;width:33.49%;margin:0pt;padding~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ Medicare ~~</p>~~	~~vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">
4,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~3,736</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(66)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,693</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#cc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Self-pay</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.98%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
33</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3)</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"> </p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(15)</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">140</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~

~~6,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~4,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
6,694</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">4,554</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract diagnostics and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
32</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.88%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">—~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;width:33.49%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~11,329</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.97%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">~~
~~8,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~

~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt~~
~~0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">~~
~~(175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padd~~

~~align:bottom;white-
space:nowrap;width:7.88%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
8,399</p></td></tr><tr><td
style="vertical-
align:bottom;width:33.49%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">Product</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.98%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc~~

~~bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
1,936</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
2,469</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">—
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#ccc <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ccc bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#ccc bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,469</p></td></tr><tr><td style="vertical-align:bottom;width:33.49%;margin:0pt;pada~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-~~

~~bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
13,265</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">
11,043</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.25%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt
0pt;">\$</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:7.84%;border-
bottom:3px double
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;">
(183)</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.97%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:3px double~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,868</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p>8000 10000 3000 4000 5000 6000 1819000 1691000 27000 20000 1792000 1671000 1000 39000 3000 1000 36000 2743000 1998000 41000 24000 2702000 1974000 28000 28000 4599000 3738000 71000 51000 4528000 3687000 681000 831000 681000 831000 5280000 4569000 71000 51000 5209000 4518000 33000 22000 12000 10000 21000 12000 4435000 3736000 66000 43000 4369000 3693000 33000 155000 3000 15000 30000 140000 6796000 4661000 102000 107000 6694000 4554000 32000 32000 11329000 8574000 183000 175000 11146000 8399000~~

~~1936000 2469000 1936000 2469000~~
~~13265000 11043000 183000 175000~~
~~13082000 10868000~~ <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.6%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.47%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:12.31%;margin:0pt;pad~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.52%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:11.79%;margin:0pt;pad~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.6%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">~~	
~~</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">~~	
~~<b style="font-weight:bold;">December 31, 2023~~	
~~</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;background:#cccccc">~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicaid</p></td>~~	
~~<td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cccccc">~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">~~	
~~</p>~~	
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cccccc">~~	
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td~~	

~~style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;margin:0pt;padding:0pt"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medicare</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.63%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.47%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:12.31%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0pt 0pt;">~~
~~1,850</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~

~~style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
1,561</p></td></tr><tr><td
style="vertical-align:bottom;white-space:nowrap;width:69.6%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Self-pay</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">
191</p></td></tr></table>~~

~~align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.52%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:11.79%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">
229</p></td></tr><tr><td
style="vertical-
align:bottom;width:69.6%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">Third party
payers</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.63%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-***~~

~~align:right;margin:0pt 3pt 0pt 0pt;">
1,641</p></td></tr><tr><td
style="vertical-
align:bottom;width:69.6%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;">Contract diagnostic
services, product and other</p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:1.63%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.47%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:12.31%;background:#c
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0pt 0pt;">~~

~~217~~

~~vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccc~~ ~~font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;~~ 	~~vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ccc~~ ~~bottom:1px solid #000000;margin:0pt;padding:0pt;~~ ~~font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;~~	~~vertical-align:bottom;white-space:nowrap;width:11.79%;background:#ccc~~ ~~bottom:1px solid #000000;margin:0pt;padding:0pt;~~ ~~font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;~~
~~vertical-align:bottom;white-space:nowrap;width:69.6%;margin:0pt;padding:0pt;~~ ~~font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;~~ 		

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;pad~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,873</p></td></tr><tr><td style="vertical-align:bottom;width:69.6%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less allowance for credit losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cccccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cccccc;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:12.31%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"> (2,755)</p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.64%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.52%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-
space:nowrap;width:11.79%;background:#ccc
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"> (2,572)</p>
</td></tr><tr><td style="vertical-~~

Accounts receivable, net			\$	1,021	

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,301</p></td></tr></table> 10000 25000 1850000 1561000 191000 229000 1508000 1641000 217000 417000 3776000 3873000 2755000 2572000 1021000 1301000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the roll-forward of the allowance for credit losses for the nine months ended~~

~~September 30, 2024.~~

Times New Roman 	Times New Roman

~~space:nowrap;width:1.59%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:9.22%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.33%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allowance for</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Credit</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~	~~</td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">~~	~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~	~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc">~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc">~~	~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,572)</p>~~
~~</td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;pada~~	

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for credit losses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.48%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"></p></td></tr>~~
~~<tr><td style="vertical-~~
~~align:bottom;width:73.79%;background:#cc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">Medicaid</p></td>~~
~~<td style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"><span
style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr>
<tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;">Medicare</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"><span~~

~~***style="visibility:hidden;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr>***~~

~~<tr><td style="vertical-align:bottom;width:73.79%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Self-pay</p></td>~~
~~<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span~~

~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p>~~
~~</td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt;"></p></td></tr>
<tr><td style="vertical-align:bottom;width:73.79%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(183)</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit loss expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid~~

#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">\$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padd <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padd <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padd <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr>

~~<tr><td style="vertical-align:bottom;width:73.79%;background:#cc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total charges</p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~
~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p>~~

~~</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#ccc;bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (183)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.59%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:9.22%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt;"></p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.33%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;"><span~~
~~style="visibility:hidden;"></p>~~
~~</td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.48%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt;">\$</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:9.22%;border-~~
~~bottom:3px double~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt;">(2,755)</p>
</td></tr></table> 2572000 12000 66000
3000 102000 183000 183000 2755000 <p
style="font-family:'Times New
Roman','Times','serif';font-size:10pt;min-
height:0.0pt;margin:0pt;"><span
style="font-size:0pt;visibility:hidden;">
</p><table style="border-
collapse:collapse;font-
size:16pt;height:max-content;margin-
left:auto;margin-right:auto;padding-
left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;"><td
style="vertical-align:bottom;white-
space:nowrap;width:23.09%;margin:0pt;pad
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.68%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-~~

~~wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padd~~

~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~</p>~~
~~</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~
~~<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd
<div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p>
</div></div></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:2.42%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.77%;margin:0pt;pad
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:1
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-
size:1pt;visibility:hidden;"></p>
</div></div></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;margin:0pt;padd
<div
style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"><div~~

~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.94%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~
~~size:1pt;visibility:hidden;"></p>~~
~~</div></div></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;margin:0pt;padd~~
~~<div~~
~~style="height:1pt;overflow:hidden;overflow-~~
~~wrap:break-word;position:relative;"><div~~
~~style="bottom:0pt;position:absolute;width:1~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-~~

~~size:1pt;visibility:hidden;"></p>
</div></div></td></tr><tr><td
style="vertical-align:bottom;white-
space:nowrap;width:23.09%;margin:0pt;pad
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.68%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-
align:bottom;width:19.15%;border-
bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Net sales
</p></td><td style="vertical-
align:bottom;width:2.54%;margin:0pt;paddi
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="font-size:8pt;font-~~

~~weight:bold;visibility:hidden;">
</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-align:bottom;width:19.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td colspan="3" style="vertical-~~
~~align:bottom;width:25.13%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">Accounts~~
~~receivable, as of</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:2.54%;margin:0pt;padd.~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:23.09%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.68%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-align:bottom;width:19.15%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Three
Months Ended </p></td><td
style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-align:bottom;width:19.44%;margin:0pt;padding:
<p style="font-family:'Times New
Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">Nine Months~~

~~Ended~~

~~vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ <del></del> <del></del> ~~</p>~~	~~vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~ <del></del> <del></del> ~~</p>~~	~~vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~ <del></del> <del></del> ~~</p>~~			~~vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd~~ ~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">

</p></td><td colspan="3" style="vertical-align:bottom;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td colspan="3" style="vertical-align:bottom;width:19.44%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-~~

[illegible]

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">
<b style="font-weight:bold;">2024
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt 0.05pt 0pt 0pt;">
<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:8.23%;border-bottom:1px solid~~

~~#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">~~

~~<b style="font-weight:bold;">2023~~

~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.54%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:1.41%;margin:0pt;padd~~

~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~~~

~~</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:11.77%;border-~~
~~bottom:1px solid~~
~~#000000;margin:0pt;padding:0pt;"><p~~
~~style="font-family:'Times New~~
~~Roman','Times','serif';font-size:8pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<b style="font-weight:bold;">2024~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:center;margin:0pt 0pt 0.05pt 0pt;">~~
~~<span style="font-size:8pt;font-~~
~~weight:bold;visibility:hidden;">~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

[illegible]

~~align:bottom;white-
space:nowrap;width:1.41%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.51%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.41%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.52%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-~~

~~space:nowrap;width:2.55%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:11.77%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.94%;background:#c~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.23%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt~~
~~0pt;">13</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">%~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:8.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt~~
~~0pt;">14</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">%~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt;">
</p></td></tr><tr><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:23.09%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt~~
~~6pt;">Customer B</p></td><td~~
~~style="vertical-align:bottom;white-~~
~~space:nowrap;width:1.68%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~

~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~

~~align:bottom;white-
space:nowrap;width:8.52%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.55%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:11.77%;background:#cc
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New~~

Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#ccc"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt 6pt;">Customer C</td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 6pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt 6pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr></table>

~~align:bottom;white-
space:nowrap;width:8.51%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt
0pt;">24</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.41%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">%
</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:8.23%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:2.54%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-
align:bottom;white-
space:nowrap;width:1.41%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt~~
~~0pt;">14</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">%~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.55%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~

~~space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:11.77%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt~~
~~0pt;">20</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.42%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">%~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.94%;margin:0pt;pad~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Customer D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:8.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt~~
~~0pt;">12</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">%~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:2.42%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:10.94%;background:#c~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-size:10pt;text-~~
~~align:right;margin:0pt 3pt 0.05pt 0pt;">*~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td></tr><tr><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:23.09%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.68%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padd
<p style="font-family:'Times New
Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.51%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.52%;margin:0pt;padd~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~

~~
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;pad
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padd
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
~~

~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt 0.05pt 0pt 0.05pt 0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">*
represents less than 10%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cccccc">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-~~

~~space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:8.23%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:2.54%;background:#ccc~~
~~<p style="font-family:'Times New~~
~~Roman','Times','serif';font-~~
~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-~~
~~align:bottom;white-~~
~~space:nowrap;width:1.41%;background:#ccc~~

~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#ccc~~
~~<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">~~
~~~~
~~</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#ccc~~
~~<p style="font-family:'Times New~~

~~Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#c<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#ccc<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#c<p style="font-family:'Times New Roman','Times','serif';font-~~

~~size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#ccc
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">

</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">

</p> 0.13 0.14 0.13 0.24 0.14 0.20 0.12 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">11.
SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">
Company has evaluated events and transactions subsequent to September 30, 2024 through the date of this Quarterly Report on Form 10-Q, and there are no~~

~~other events to report other than what has been disclosed in the condensed consolidated financial statements.~~

false false false false